<SEC-DOCUMENT>0001193125-15-307396.txt : 20151016
<SEC-HEADER>0001193125-15-307396.hdr.sgml : 20151016

<ACCEPTANCE-DATETIME>20150831060510

<PRIVATE-TO-PUBLIC>

ACCESSION NUMBER:		0001193125-15-307396

CONFORMED SUBMISSION TYPE:	S-1/A

PUBLIC DOCUMENT COUNT:		20

FILED AS OF DATE:		20150831

DATE AS OF CHANGE:		20150917


FILER:


	COMPANY DATA:	

		COMPANY CONFORMED NAME:			Penumbra Inc

		CENTRAL INDEX KEY:			0001321732

		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]

		IRS NUMBER:				000000000

		STATE OF INCORPORATION:			DE

		FISCAL YEAR END:			1231



	FILING VALUES:

		FORM TYPE:		S-1/A

		SEC ACT:		1933 Act

		SEC FILE NUMBER:	333-206412

		FILM NUMBER:		151083439



	BUSINESS ADDRESS:	

		STREET 1:		1351 HARBOR BAY PARKWAY

		CITY:			ALAMEDA

		STATE:			CA

		ZIP:			94502

		BUSINESS PHONE:		(510) 748-3251



	MAIL ADDRESS:	

		STREET 1:		1351 HARBOR BAY PARKWAY

		CITY:			ALAMEDA

		STATE:			CA

		ZIP:			94502



</SEC-HEADER>

<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d923792ds1a.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 1 to Form S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on August 31, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-206412 </B></P>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT
NO. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM S-1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION
STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Penumbra, Inc.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>3841</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>05-0605598</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>One Penumbra Place </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1351
Harbor Bay Parkway </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Alameda, California 94502 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(510) 748-3200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address,
Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Adam Elsesser
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Chairman, Chief Executive Officer and President </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Penumbra, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>One
Penumbra Place </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1351 Harbor Bay Parkway </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Alameda, California 94502 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(510) 748-3200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name,
Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to:
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Alan F. Denenberg</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Davis Polk &amp; Wardwell LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1600 El Camino Real</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Menlo
Park, California 94025</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(650) 752-2000</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Robert D. Evans</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Executive&nbsp;Vice&nbsp;President&nbsp;and&nbsp;General&nbsp;Counsel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Penumbra, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>One Penumbra
Place</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1351 Harbor Bay Parkway</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Alameda, California 94502</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(510) 748-3200</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Rezwan D. Pavri</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Richard A. Kline</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin
Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>135 Commonwealth Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, California 94025</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(650) 752-3100</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public</B>: As soon as practicable after the effective date of this
Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this form is filed to register
additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall
file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on
such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><FONT COLOR="#cc062a"><B>The information in this prospectus is not complete and may be changed. We may not sell these
securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any state where the
offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="center"><FONT COLOR="#cc062a"><B>Subject to
completion, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>Preliminary Prospectus </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g923792g60a08.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:arial" ALIGN="center"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This is the initial public offering of
common stock of Penumbra, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. Prior to this
offering, there has been no public market for our common stock. We anticipate that the initial public offering price will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have applied to list our common stock on the New York Stock Exchange under the symbol &#147;PEN.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds to Penumbra before expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section titled &#147;Underwriting&#148; for additional disclosure regarding underwriter compensation and offering expenses. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have granted the underwriters the right to purchase an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
from us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company&#148; as defined under the federal securities laws, and as such, we have elected to comply with reduced reporting requirements
for this prospectus and may elect to do so in future filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Investing in our common stock involves a high degree of risk. See the section titled &#147;<A HREF="#toc923792_2">Risk
 Factors</A>&#148; beginning on page 10. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of
these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters expect to
deliver the shares of common stock to purchasers on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:arial; font-size:16pt">
<TD VALIGN="top"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>BofA Merrill Lynch</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:arial; font-size:12pt">
<TD VALIGN="top"><B>Wells Fargo Securities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Canaccord Genuity</B></TD></TR>
</TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:1%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_6">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_8">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:2%; width:48%;padding-right:1%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_12">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_13">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_15">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_16">Material U.S. Federal Income and Estate Tax Consequences for Non-U.S. Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_18">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_21">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc923792_22">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  </DIV><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In this prospectus,
&#147;Penumbra,&#148; &#147;Penumbra, Inc.,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Penumbra, Inc. and its consolidated subsidiaries. We and the underwriters have not authorized anyone to provide
any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability
of, any other information that others may provide you. We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate
only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">This prospectus
includes industry and market data that we obtained from industry publications, internal estimates and other third-party sources. These sources may include government and industry sources. Industry publications and surveys generally state that the
information contained therein has been obtained from sources believed to be reliable. Although we believe the industry and market data to be reliable as of the date of this prospectus, this information could prove to be inaccurate. Industry and
market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature
of the data gathering process and other limitations and uncertainties. In addition, we do not know all of the assumptions regarding general economic conditions or growth that were used in preparing the forecasts from the sources relied upon or cited
herein. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We also refer to certain studies in this prospectus. In certain cases, we may sponsor, fund and/or control the conduct of these
studies, or may have other relationships with certain of the authors of such studies. Specifically, we sponsored, funded and controlled the THERAPY and Penumbra Pivotal studies, and provided a modest grant, together with a number of other industry
participants, relating to the MR CLEAN study, but did not control such study. We may also have or have had consulting relationships with or have provided grants to physicians who authored or co-authored some of such studies for matters unrelated to
such studies, including the MR CLEAN, ESCAPE, SWIFT PRIME, REVASCAT, Kass-Hout T, et al., Humphries W, et al., ADAPT FAST, Mascitelli, Patel, et al. and Milburn, et al. studies cited in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><B>Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus), all dealers that
buy, sell or trade our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to
their unsold allotments or subscriptions. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>This summary highlights information contained elsewhere in this prospectus. This summary may not contain all of the information that you should
consider before deciding to invest in our common stock. You should read this entire prospectus carefully, including the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results
of Operations&#148; and the consolidated financial statements and the notes to those statements contained elsewhere in this prospectus. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Penumbra is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. We have a broad
portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. The conditions that our products address include, among others, ischemic stroke and
hemorrhagic stroke, which involve blockage or rupture of blood vessels in the brain, and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures, which involve the use of medical devices to remove
or treat blockages or ruptures of blood vessels. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are an established company focused on the neuro market, and we recently expanded our
business to include the peripheral vascular market. We sell our products to hospitals, primarily through our salesforce, as well as through distributors in select international markets. We focus on developing, manufacturing and marketing products
for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. We design our products to provide these specialist physicians with a means
to drive improved clinical outcomes through faster and safer procedures. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We attribute our success to our culture built on cooperation, our
highly efficient product innovation process, our disciplined approach to product and commercial development, our deep understanding of our target end markets and our relationships with specialist physicians. We believe these factors have enabled us
to rapidly innovate in a highly capital-efficient manner. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Since our founding in 2004, we have had a strong track record of organic product
development and commercial expansion that has established the foundation of our global organization. Some of our key accomplishments include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching our first product, for neurovascular access, in the United States in 2007; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing our direct neuro salesforce in the United States and Europe in 2008; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching the first 510(k)-cleared, aspiration-based product for the treatment of ischemic stroke patients in 2008, and launching four subsequent generations of that product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching our first neurovascular coil for the treatment of brain aneurysms in 2011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching our first peripheral vascular product in 2013; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing our direct peripheral vascular salesforce in the United States and Europe in 2014. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of
June 30, 2015, we had approximately 1,000 employees worldwide. We sell our products to hospitals primarily through our direct sales organization in the United States, most of Europe, Canada and Australia, as well as through distributors in select
international markets. For the year ended December&nbsp;31, 2014, we generated revenue of $125.5 million, which represents a 41.3% increase over 2013, and $3.0 million in operating income as compared to an operating loss of $1.1 million in 2013. For
the six months ended June 30, 2015, we generated revenue of $81.3 million, which represents a 41.0% increase over the six months ended June 30, 2014, and $0.2 million in operating income as compared to operating income of $2.4 million for the six
months ended June 30, 2014. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We estimate that the market for our current neuro and peripheral vascular products in the United States and Europe combined was approximately $1.3
billion in 2014, which we estimate represents growth of approximately 3.2%&nbsp;per year from 2012. While reliable third-party data is not available for markets outside the United States and Europe, we believe that there is a substantial additional
market for our neuro and peripheral vascular products in the rest of the world. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">According to the American Heart Association (AHA), the worldwide
incidence of all forms of stroke was 33 million in 2010. Furthermore, according to a paper published in the journal <I>The Lancet</I>, 202&nbsp;million people globally were living with peripheral artery disease in 2010. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe the market for our products remains substantially under-penetrated today, and that this market will experience significant growth as we and
our competitors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generate additional clinical evidence supporting endovascular treatment of vascular disease; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improve existing technologies to enable physicians to treat vascular disease faster and more safely than previously possible; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">support and educate the growing number of specialist physicians who treat vascular disease in the use of endovascular treatment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grow the number of hospitals where endovascular treatment of vascular disease is available; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">raise patient awareness of endovascular treatment of vascular disease. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Industry Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Vascular disease refers to any condition that affects the circulatory system and typically manifests as a blockage or rupture of an artery or a vein. It
may occur in any part of the body, and is a condition that leads most often to blood vessel narrowing and obstruction, but can also lead to expansion of the blood vessel wall and blood vessel wall weakening and rupture. Vascular disease can cause a
range of conditions, from pain to functional impairment, and it can require the amputation of a limb or result in death. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">When the treatment for
vascular disease is performed from within a vessel, it is referred to as an endovascular procedure. Endovascular device markets are conventionally classified according to the anatomic location of the disorder. We currently focus our efforts on the
neuro and peripheral vascular markets. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Neuro products.</I></B> Our neuro products are used to treat patients with vascular disease and disorders in the brain, including patients with strokes caused by either vascular occlusion or rupture or weakening
of the vessel walls. Our neuro products are generally catheter-based technologies that are administered by an interventional neuroradiologist, a neurosurgeon or an interventional neurologist. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Peripheral products.</I></B> Our peripheral products are used to treat patients with vascular disease in all vasculature other than that which exists in the brain or the heart, including the upper and lower
extremities, kidneys, neck and lungs. Our products that address peripheral vascular disorders are catheter-based technologies that are typically administered by an interventional radiologist or a vascular surgeon. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Our Strengths </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As we have grown as an organization, we have
been able to scale our business from development stage in 2004 to a company with approximately 1,000 employees focused on multiple product categories in two target end markets. We believe the following strengths have enabled us to develop our broad
and differentiated product portfolio and have been, and will continue to be, significant factors in our continued success and growth: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our culture built on cooperation, which we have institutionalized through our unique organizational structure; </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our highly efficient product innovation process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our disciplined approach to clinical and commercial development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our deep understanding of our target end markets; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our relationships with specialist physicians. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Our Products </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Since our founding in 2004, we have invested in expanding our product development and marketing capabilities. These investments have included engineering
and materials science capabilities, pre-clinical and bench-testing infrastructure and in-house clinical and regulatory infrastructure. Our fully-integrated organization has enabled us to launch 14 product brands for access, thrombectomy and
embolization since 2007 to service our two target end markets. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table summarizes our product offerings in each of our target end
markets: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g923792g22q56.jpg" ALT="LOGO">
 </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Our Growth Strategies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe the following strategies will continue to play a critical role in our future growth: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expanding the penetration of our products in our target end markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">growing the acceptance of our innovative products as the standard of care in their targeted clinical applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continuing to leverage our development capabilities to drive efficient, rapid product development; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scaling our organizational culture of cooperative product development and commercial execution. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Risks Associated
With Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our business is subject to numerous risks, as more fully described in the section titled &#147;Risk Factors&#148; immediately
following this prospectus summary. These risks include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we have a limited operating history and may not be able to sustain or grow our profitability or generate positive cash flows from operations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our existing products may be rendered obsolete and we may be unable to effectively introduce and market new products or may fail to keep pace with advances in technology; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in product introductions could adversely affect our business, results of operations, financial condition or cash flows; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we face significant competition, and if we are unable to compete effectively, we may not be able to achieve or maintain significant market penetration or improve our results of operations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our future growth depends, in part, on our ability to further penetrate our current customer base and increase the frequency of use of our products by our customers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our future growth depends, in part, on significantly expanding our user base to include additional specialist physicians in both our existing and future target end markets; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the marketing and sales of our products require a significant amount of time and expense and we may not have the resources to successfully market and sell our products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third-party reimbursement may not be available or adequate for the procedures in which our products are used; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we are subject to stringent domestic and foreign medical device regulation, which may impede the approval or clearance process for our products, hinder our development activities and manufacturing processes and, in some
cases, result in the recall or seizure of previously approved or cleared products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we rely on a variety of intellectual property rights, and if we are unable to maintain or protect our intellectual property, our business and results of operations will be harmed; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may become involved in lawsuits or other proceedings to protect or enforce our patents or other intellectual property rights or to defend against accusations of infringement, which could be expensive, time consuming
and unsuccessful. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We were incorporated in 2004 as a Delaware corporation under the name Penumbra, Inc. Our principal executive offices are located at One Penumbra Place,
1351 Harbor Bay Parkway, Alameda, California 94502, and our telephone number is (510)&nbsp;748-3200. Our website address is www.penumbrainc.com. The information on, or that can be accessed through, our website is not part of this prospectus. We have
included our website address as an inactive textual reference only. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We use &#147;Penumbra System<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,&#148;
&#147;ACE&#153;,&#148; &#147;Penumbra Coil 400&#153;,&#148; &#147;Penumbra SMART COIL&#153;,&#148; &#147;LIBERTY&#153; Stent,&#148; &#147;Apollo&#153; System,&#148; &#147;Ruby<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Coil,&#148;
&#147;Indigo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> System&#148; and other marks as trademarks in the United States and other countries. This prospectus contains references to our trademarks and service marks and to those
belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or
&#153; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not
intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Implications of Being an Emerging Growth Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are an
&#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earlier of (1)&nbsp;December&nbsp;31, 2020 (the last day of the fiscal year following the fifth
anniversary of our initial public offering), (2)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.0 billion, (3)&nbsp;the last day of the fiscal year in which we are deemed to be a large accelerated
filer, which means the market value of our common stock that is held by non-affiliates is equal to or exceeds $700 million as of the prior June&nbsp;30th, and (4)&nbsp;the date on which we have issued more than $1.0 billion in non-convertible debt
during the prior three-year period. We refer to the Jumpstart Our Business Startups Act of 2012 herein as the &#147;JOBS Act,&#148; and any reference herein to &#147;emerging growth company&#148; has the meaning ascribed to it in the JOBS Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">An emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions
include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to present only two years of audited financial statements and only two years of related &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in this
prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements, including in this prospectus; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have elected to take advantage of certain of the reduced disclosure obligations in this prospectus and may elect to take advantage of other reduced
reporting requirements in our future filings with the U.S. Securities and Exchange Commission (the SEC). As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies
in which you hold equity interests. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The JOBS Act also provides that an emerging growth company can take advantage of an extended transition period
for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not
emerging growth companies. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">Common stock to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">Option to purchase additional shares of our common stock from us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise
their option to purchase additional shares in full, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (which is the midpoint of the estimated initial public offering price range set forth on the
cover page of this prospectus), after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The principal purposes of this offering are to increase our capitalization and financial flexibility, create a public market for our common stock and enable access to the public equity markets for us and our
stockholders. We intend to use the net proceeds from this offering for product development, including research and development and clinical trials, expansion of our salesforce and working capital and general corporate purposes. From time to time, we
may consider the acquisition of complementary technologies or businesses, though we have no agreements or understandings with respect to any such acquisitions at this time. Pending the use of the net proceeds from this offering, we intend to invest
the net proceeds in investment grade, interest bearing securities. See the section titled &#147;Use of Proceeds&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">Proposed NYSE stock symbol </P></TD>
<TD>&#147;PEN&#148; </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The number of shares of common stock to be outstanding after this offering is based upon 26,038,637 shares
outstanding (including preferred stock on an as-converted basis) as of June 30, 2015, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,460,574 shares of common stock issuable upon the exercise of options to purchase shares of our common stock outstanding as of June 30, 2015, at a weighted average exercise price of $5.27 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,713,634 shares of common stock reserved for future grant or issuance under our 2014 Equity Incentive Plan as of June 30, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">871,250 shares of common stock issuable upon the exercise of options to purchase shares of our common stock at an exercise price of $22.04 per share and 11,000 shares of restricted stock, which were granted in August
2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">450,000 shares of common stock issuable upon the exercise of options to purchase shares of our common stock to be granted to our Chief Executive Officer at an exercise price equal to our initial public offering price,
which options will vest over a period of four years from the date of this prospectus; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,000,000 shares of common stock initially reserved for future issuance under our Amended and Restated 2014 Equity Incentive Plan, which will become effective immediately prior to the completion of this offering, as
well as any automatic increases in the number of shares of our common stock reserved for future issuance pursuant to this plan; and </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">600,000 shares of common stock initially reserved for issuance under our 2015 Employee Stock Purchase Plan, or our ESPP, as well as any automatic increases in the number of shares of our common stock reserved for future
issuance pursuant to this plan. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Unless otherwise indicated, this prospectus reflects and assumes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outstanding shares include 24,818 shares of common stock issued upon early exercise of stock options and subject to repurchase; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outstanding shares include 755,771 shares of unvested restricted stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of options outstanding as of June 30, 2015, or subsequently issued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all of our outstanding shares of preferred stock into an aggregate of 19,510,410 shares of common stock immediately upon the completion of this offering, assuming a one-to-one conversion
ratio of our outstanding shares of preferred stock into common stock; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise by the underwriters of their option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock from us; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the filing and effectiveness of our amended and restated certificate of incorporation in Delaware and the adoption and effectiveness of our amended and restated bylaws immediately upon the completion of this offering.
</TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following tables summarize our consolidated financial data. We have derived the summary consolidated statement of operations data for the years ended
December&nbsp;31, 2013 and 2014, from our audited consolidated financial statements included elsewhere in this prospectus. We have derived the summary consolidated statement of operations data for the year ended December&nbsp;31, 2012, from our
audited consolidated financial statements not included in this prospectus. We have derived the summary consolidated statement of operations data for the six months ended June 30, 2014 and 2015, and our balance sheet data as of June 30, 2015, from
our unaudited interim consolidated financial statements included elsewhere in this prospectus. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and reflect,
in our opinion, all adjustments of a normal, recurring nature that are necessary for a fair statement of the unaudited interim consolidated financial statements. Our historical results are not necessarily indicative of the results that may be
expected in the future and the results for the six months ended June 30, 2015 are not necessarily indicative of results to be expected for the full year or any other period. The following summary consolidated financial data should be read in
conjunction with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and related notes included elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" NOWRAP ALIGN="center"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">19,489</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7,538</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">28,240</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,376</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(474</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="top">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Income (loss) before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,657 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Net income (loss) attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt"> 355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Net income (loss) per share attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">0.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(0.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt"> 0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">0.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(0.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt"> 0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Weighted average shares used to compute net income (loss) per share attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,153,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,304,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,609,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,520,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,886,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,500,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,609,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,743,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Pro forma net income (loss) per share &#151; Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Pro forma net income (loss) per share &#151; Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Weighted average shares used to compute the pro forma net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">&#151;Basic (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,680,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,510,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">&#151;Diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,037,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,510,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June 30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma column reflects (i)&nbsp;the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 19,510,410 shares of our common stock, which conversion will occur immediately upon
the completion of this offering, as if such conversion had occurred on June 30, 2015, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted column gives effect to (a)&nbsp;the pro forma adjustments set forth in (1)&nbsp;above and (b)&nbsp;the sale and issuance by us of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of
the estimated initial public offering price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated initial public offering price range set
forth on the cover page of this prospectus, would increase or decrease, as applicable, the amount of our cash and cash equivalents, total assets, working capital and stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting underwriting discounts and commissions payable by us. An increase or decrease of 1.0&nbsp;million shares
in the number of shares offered by us would increase or decrease, as applicable, the amount of our cash and cash equivalents, total assets, working capital and stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million,
assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, after deducting
underwriting discounts and commissions payable by us. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>You should carefully consider the risks described below before making an investment decision. Additional risks not presently known to us or that we
currently deem immaterial may also impair our business. Our business could be harmed by any of these risks. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing
these risks, you should also refer to the other information contained in this prospectus, including the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated
financial statements and related notes, before making a decision to invest in our common stock. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Business Risks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have a limited operating history and may not be able to sustain or grow our profitability or generate positive cash flows from operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We were founded in 2004 and did not generate any revenue until 2007. Moreover, while we have successfully developed, obtained regulatory clearance or
approval for, and introduced a number of products in the neuro market since 2007, we first introduced products in the peripheral vascular and neurosurgical markets in 2013 and 2014, respectively. Accordingly, we only have a limited operating history
upon which investors can evaluate our business and prospects, and this limited operating history may not be indicative of our future results. Since 2009, we have been generally profitable on an annual basis; however, we incurred operating losses in
2013, and we are not currently <FONT STYLE="white-space:nowrap">cash-flow</FONT> positive. We can give no assurance that we will be profitable or <FONT STYLE="white-space:nowrap">cash-flow</FONT> positive in the future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We expect that our general and administrative and sales and marketing expenses will increase to support our anticipated growth as well as the additional
operational and reporting costs associated with being a public company. We have also expended significant amounts on research and development to develop and fund clinical testing of our products, and we expect to continue to do so. We also expend
significant amounts on maintaining inventory levels of raw materials, components and finished products to meet anticipated customer demand. In addition, our coil products are sold on a consignment basis, which requires us to expend significant
amounts on inventory that is placed at many customer locations. Our ability to sustain our growth and profitability and become cash-flow positive may be influenced by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to achieve and maintain market acceptance of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated problems and additional costs relating to the development and testing of new products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to introduce, manufacture at scale and commercialize new products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to produce sufficient quantities of our products to meet demand and to smoothly transition to new products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of competition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and impact of market and regulatory developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to expand into new markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing pressure from competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability and adequacy of third-party reimbursement for procedures in which our products are used; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain adequate intellectual property protection for our products and technologies. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If we encounter difficulties with any of the foregoing or unexpected expenses, it could materially adversely affect our business, results of operations,
financial condition or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our existing products may be rendered obsolete and we may be unable to effectively introduce and market new products
or may fail to keep pace with advances in technology. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The medical device market is characterized by rapidly advancing technology. Our
success depends, in part, on our ability to anticipate technological advancements and competitive innovations and introduce new products to adapt to these advancements and innovations. To compete in the marketplace, we have made, and we must
continue to make, substantial investments in new product development, whether internally through research and development or externally through licensing or acquisitions. We can give no assurance that we will be successful in identifying, developing
or acquiring, and marketing new products or enhancing our existing products. In addition, we can give no assurance that new products or alternative treatment techniques developed by competitors will not render our current or future products obsolete
or inferior, technologically or economically. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The success of any new products that we develop or acquire depends on achieving and maintaining market
acceptance. Market acceptance for our current and new products could be affected by a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to market and distribute our products effectively; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability, perceived efficacy and pricing of alternative products from our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the development of new products or alternative treatments by others that render our products and technologies obsolete; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price, quality, effectiveness and reliability of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our customer service and reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to convince specialist physicians to use our products on their patients; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market entry of new products or alternative treatments. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our competition may respond more
quickly to new or emerging technologies or a changing clinical landscape, undertake more extensive marketing campaigns, have greater financial, marketing and other resources than us or be more successful in attracting potential customers and
strategic partners. Given these factors, we cannot assure you that we will be able to continue or increase our level of success. Our failure to introduce new and innovative products in a timely manner, and our inability to maintain or grow the
market acceptance of our existing products, could result in permanent write-downs or write-offs of our inventory and otherwise have a material and adverse effect on our business, results of operations, financial condition or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Delays in product introductions could adversely affect our business, results of operations, financial condition or cash flows. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The medical device market is highly competitive and designs change often to adjust to shifting market preferences and other factors. Therefore, product
life cycles are relatively short. As a result, any delays in our product launches may significantly impede our ability to enter or compete in a given market and may reduce the sales that we are able to generate from these products. We may experience
delays in any phase of a product launch, including during research and development, clinical trials, regulatory review, manufacturing and marketing. Delays in product introductions could materially adversely affect our business, results of
operations, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We face significant competition, and if we are unable to compete effectively, we may not be able to achieve or
maintain significant market penetration or improve our results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The medical device industry is intensely competitive, subject
to rapid change and significantly affected by new product introductions and other market activities of industry participants. We compete with a number of manufacturers and distributors of neuro and peripheral vascular devices. Our most notable
competitors are Boston Scientific, Johnson&nbsp;&amp; Johnson, Medtronic, Stryker and Terumo. All of these competitors are large, well-capitalized companies with longer operating histories and significantly greater resources than us. We also
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
compete with a number of smaller medical device companies that have a single product or a limited range of products. Our competitors may be able to spend more on product development, marketing,
sales and other product initiatives, or be more focused in their spending and activities, than we can. Some of our competitors have: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significantly greater name recognition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">broader or deeper relations with healthcare professionals, customers and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">more established distribution networks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional lines of products and the ability to offer rebates or bundle products to offer greater discounts or other incentives to gain a competitive advantage; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">greater experience in conducting research and development, manufacturing, clinical trials, marketing and obtaining regulatory clearance or approval for products; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">greater financial and human resources for product development, sales and marketing and patent litigation. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We compete primarily on the basis that our products are able to treat patients with neurovascular and peripheral vascular diseases and disorders safely
and effectively. Our continued success depends on our ability to: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop innovative, proprietary products that can cost-effectively address significant clinical needs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to innovate and develop scientifically advanced technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain and maintain regulatory clearances or approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrate efficacy in Penumbra-sponsored and third-party clinical trials and studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">apply technology across product lines and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract and retain skilled research and development and sales personnel; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effectively manufacture and successfully market and sell products. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We cannot assure you that we
will be able to compete effectively on the basis of these factors. Additionally, our competitors with greater financial resources could acquire or develop new technologies or products that effectively compete with our existing or future products. If
we are unable to effectively compete, it would materially adversely affect our business, results of operations, financial condition and cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our
future growth depends, in part, on our ability to further penetrate our current customer base and increase the frequency of use of our products by our customers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We will need to continue to make specialist physicians and other hospital staff aware of the benefits of our products to generate increased demand and
frequency of use, and thus increase sales to our hospital customers. Although we are attempting to increase the number of patients treated with procedures that use our products through our established relationships and focused sales efforts, we
cannot provide assurance that our efforts will increase the use of our products. If we are unable to increase the frequency of use of our products by specialist physicians, this could materially adversely affect our business, results of operations,
financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our future growth depends, in part, on significantly expanding our user base to include additional specialist physicians
in both our existing and future target end markets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Currently, the primary users of our neuro products are neuro interventionalists who
perform endovascular neuro interventions. We also began selling in the peripheral vascular market in 2013 with the introduction of our Ruby Coil and the neurosurgery market in 2014 with the introduction of our Apollo System, and we may enter new
target end markets in the future. Our revenue growth will depend in part on our ability to convince </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
specialist physicians in our existing and future target end markets of our products&#146; efficacy, to educate them in the proper use of our products and to sell our products to their affiliated
hospitals. Convincing specialist physicians to use new products and to dedicate the time and energy necessary for adequate education in the use of our products is challenging, especially in new markets where treatments using our products are not
established. Expanding our customer base in existing or new target end markets may require, among other things, additional clinical evidence supporting patient benefits, training in a manner to which we are not accustomed, or other resources that we
do not readily have available or are not cost effective for us to provide. If we are unable to convert specialist physicians in existing or new target end markets to the use of our products, our sales growth will be limited, which could materially
adversely affect our business, results of operations, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The marketing and sales of our products require a significant amount
of time and expense and we may not have the resources to successfully market and sell our products, which would adversely affect our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The marketing and sales of our products requires us to invest in training and education and employ a salesforce that is large enough to interact with the
specialist physicians who use our products. Entering new markets also requires a significant amount of time and expense in order to identify and establish relationships with key opinion leaders among the specialist physicians who may use our
products in those markets. We may not have adequate resources to market and sell our products successfully against larger competitors. For example, when we began selling in the peripheral vascular market in 2013, we did not have a dedicated direct
peripheral vascular sales team and our neuro sales team was required to dedicate a portion of its efforts to the sales of our peripheral vascular products. We subsequently expended significant sums to develop a direct salesforce focused on
peripheral vascular product sales. If we do not have adequate resources to market and sell our products effectively, or cannot otherwise market and sell our products successfully, it could materially adversely affect our business, results of
operations, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Third-party reimbursement may not be available or adequate for the procedures in which our products are used.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our ability to commercialize new products successfully in both the United States and international markets depends in part on the
availability of, and hospitals&#146; ability to obtain, adequate levels of third-party reimbursement for the procedures in which our products are used. In the United States, the cost of medical care is funded, in substantial part, by government
insurance programs, such as Medicare and Medicaid, and private and corporate health insurance plans. Third-party payors may deny reimbursement if they determine that a device used in a procedure has not received appropriate FDA or other governmental
regulatory clearances or approvals, is not used in accordance with cost-effective treatment methods as determined by the payor, or is experimental, unnecessary or inappropriate. Our ability to commercialize our products successfully will depend, in
large part, on the extent to which adequate reimbursement levels for the cost of their use are obtained from government authorities, private health insurers and other organizations, such as health maintenance organizations. Further, healthcare in
the United States and international markets is also being affected by economic pressure to contain reimbursement levels and costs. Changing reimbursement models could materially adversely affect our business, results of operations, financial
condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have generated a significant portion of our revenue from products that are used in connection with the treatment of neurovascular
diseases, and our revenue and business prospects would be adversely affected if our neuro product sales were to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have generated
most of our revenue from our neurovascular products, including our Penumbra System, Penumbra Coil 400 and Neuron products. If any one or more of these products, or any successor products, were no longer available for sale in any key market because
of regulatory, third-party reimbursement or intellectual property issues or any other reason, or if one of our competitors introduced one or more products that specialist physicians believe are superior to our products, our revenue from these
products would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
decline. A significant decline in our sales of neurovascular products could also negatively impact our financial condition and our ability to conduct product development activities, and therefore
negatively impact our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We must maintain and further develop relationships with specialist physicians. If specialist physicians do not
recommend and endorse, or use, our products or if our relationships with specialist physicians deteriorate, our products may not be accepted or maintain acceptance in the marketplace, which would adversely affect our business and results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our products are sold to hospitals for use by specialist physicians practicing at their facilities. In order for us to sell our
products, specialist physicians must recommend and endorse them for the hospital to purchase them, and must use them in treating their patients to generate follow-on sales. We may not obtain the necessary recommendations or endorsements for new
products from specialist physicians, nor may we be able to maintain the current or future level of acceptance and usage of our products. Acceptance of our products depends on educating the medical community as to the distinctive characteristics,
perceived benefits, safety, clinical efficacy and cost-effectiveness of our products compared to products of our competitors or treatments that do not use our products, and on training specialist physicians in the proper application and use of our
products. We invest in significant training and education of our sales representatives and specialist physicians to achieve market acceptance of our products, with no assurance of success. If we are not successful in obtaining and maintaining the
recommendations or endorsements of specialist physicians for our products, if specialist physicians prefer our competitors&#146; products or other alternative treatments that do not use our products, or if our products otherwise do not gain or
maintain market acceptance, our business could be adversely affected. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, the research, development, marketing and sales of our products
are dependent, in part, upon our working relationships with specialist physicians. We rely on them to provide us with knowledge and feedback regarding our products and the marketing of our products. If we are unable to develop or maintain strong
relationships with specialist physicians and receive their advice and input, the development and marketing of our products could suffer, which could materially adversely affect our business, results of operations, financial condition or cash flows.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not be able to achieve or maintain satisfactory pricing and margins for our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Manufacturers of medical devices have a history of price competition, and we can give no assurance that we will be able to achieve satisfactory prices
for our products or maintain prices at the levels we have historically achieved. If we are unable to achieve or maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices, our margins could
erode and we may be unable to maintain profitable operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We cannot be certain that we will be able to manufacture our products in high volumes at
commercially reasonable costs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We currently maintain our manufacturing operations in buildings located at our campus in Alameda, California.
We currently produce substantially all of our products at this facility, and we do not have redundant facilities. We may need to expend significant capital resources and increase the size of our manufacturing capabilities as we grow our business. We
could, however, encounter problems related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">capacity constraints; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production yields; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">quality control; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equipment availability; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shortages of qualified personnel. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our continuous product innovation limits our ability to identify and implement manufacturing efficiencies.
Failure to do so may reduce our ability to manufacture our products at commercially reasonable costs. If we are unable to manufacture our products in high volumes at commercially reasonable costs, it could materially affect our ability to adequately
increase production of our products and fulfill customer orders on a timely basis, which could have a material adverse effect on our business, results of operations, financial condition or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are required to maintain high levels of inventory, which consume a significant amount of our working capital and could lead to permanent write-downs or
write-offs of our inventory. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We maintain a significant inventory of raw materials, components and finished goods, which subjects us to a
number of risks and challenges. Our hospital customers typically maintain only small quantities of our products at their facilities, so as products are used, they order replacements that typically require prompt delivery. As a result, we must
maintain sufficient levels of finished goods to permit rapid shipment of products following receipt of a customer order. In turn, we must also maintain a sufficient supply of raw materials and components inventory to permit rapid manufacturing and
re-stocking of finished goods. Furthermore, our coil inventory is supplied to hospital customers on a consignment basis, which means that it is classified as part of our inventory for financial reporting purposes but is maintained at the hospital
location until it is used. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Maintaining a significant inventory of raw materials, components and finished goods consumes a significant amount of our
working capital. This working capital could be used for other purposes, such as research and development or sales and marketing activities. As we grow our business, we may need substantial additional capital to fund higher levels of inventory, which
may materially adversely affect our liquidity or result in dilution to our stockholders if we sell additional equity securities or leverage if we raise debt capital to finance our working capital requirements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Maintaining a significant inventory of raw materials, components and finished goods also subjects us to the risk of inventory excess and obsolescence,
which may lead to a permanent write-down or write-off of our inventory. While in inventory, our components and finished goods may become obsolete, and we may over-estimate the amount of inventory needed, which may lead to excessive inventory. In
these circumstances, we would write-down or write-off our inventory, and we may be required to expend additional resources or be constrained in the amount of end product that we can produce. Furthermore, our products have a limited shelf life due to
sterilization requirements, and part or all of a given product or component may expire, resulting in a decrease in value and potentially a permanent write-down of our inventory. For example, we recorded write downs of $0.9 million and $1.9 million
for excess and obsolete inventory in 2013 and 2014, respectively. In the event that a substantial portion of our inventory becomes excess or obsolete, it could materially adversely affect our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Defects or failures associated with our products could lead to recalls, safety alerts or litigation, as well as significant costs and negative publicity.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Manufacturing flaws, component failures, design defects, off-label uses or inadequate disclosure of product-related information could result
in an unsafe condition or the injury or death of a patient. These problems could lead to a recall of, or issuance of a safety alert relating to, our products and result in significant costs, negative publicity and adverse competitive pressure. While
we have had product recalls, they have all been voluntary, based on our own internal safety and quality monitoring and testing data, and none of our past product recalls has been material. The circumstances giving rise to recalls are, however,
unpredictable, and any future recalls of existing or future products could materially adversely affect our business, results of operations, financial condition or cash flows. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The medical device industry has historically been subject to extensive litigation over product liability claims. There are high rates of mortality and
other complications associated with some of the medical conditions suffered by the patients whom specialist physicians use our devices to treat, and we may be subject to product liability claims if our products cause, or merely appear to have
caused, an injury or death. In addition, an injury or death that is caused by the activities of our suppliers, such as those that provide us with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
components and raw materials, or by an aspect of a treatment used in combination with our products, such as a complementary drug or anesthesia, may be the basis for a claim against us by
patients, hospitals, health-care providers or others purchasing or using our products, even if our products were not the actual cause of such injury or death. An adverse outcome involving one of our products could result in reduced market acceptance
and demand for all of our products, and could harm our reputation and our ability to market our products in the future. In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could
result in the suspension or delay of regulatory reviews of our premarket notifications or applications for marketing. Any of the foregoing problems could disrupt our business and have a material adverse effect on our business, results of operation,
financial condition or cash flows. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Although we carry product liability insurance in the United States and in other countries in which we conduct
business, including for clinical trials and product marketing, we can give no assurance that such coverage will be available or adequate to satisfy any claims. Product liability insurance is expensive, subject to significant deductibles and
exclusions, and may not be available on acceptable terms, if at all. If we are unable to obtain or maintain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability
claims, we could be exposed to significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could materially adversely affect our business, financial
condition and results of operations. Defending a suit, regardless of its merit or eventual outcome, could be costly, could divert management&#146;s attention from our business and might result in adverse publicity, which could result in reduced
acceptance of our products in the market, product recalls or market withdrawals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our products are continually the subject of clinical trials conducted by us,
our competitors, or other third parties, the results of which may be unfavorable, or perceived as unfavorable, and which could materially adversely affect our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As a part of the regulatory process of obtaining marketing clearance or approval for new products and new indications for existing products, as well as
to provide specialist physicians with ongoing information regarding the efficacy of our products, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations and trial endpoints. Our competitors and
third parties also conduct clinical trials of our products without our participation. Unfavorable or inconsistent clinical data from existing or future clinical trials conducted by us, our competitors or third parties, or the market&#146;s or
regulators&#146; perception of clinical data, could materially adversely affect our business, results of operations, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our
future success depends in part upon establishing an interventional stroke care pathway in the United States that integrates the use of endovascular thrombectomy into the treatment of ischemic stroke. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The stroke care pathway in the United States generally begins with emergency responders who are responsible for transporting the patient to a hospital
facility. With a small number of exceptions (such as for trauma), emergency responders in the United States generally operate under a protocol that transports patients to the nearest hospital, which decreases the likelihood that the patient will be
transported to a stroke center that has a developed stroke team and an interventional approach to the treatment of stroke. Further, there is no agreed upon standard of care among physicians or hospitals regarding the treatment of ischemic stroke
patients, and treatment protocols vary according to the particular hospital, often resulting in significant delays and gaps in patients being assessed for and receiving interventional treatment. The absence of a uniform protocol among hospitals and
among physicians within the same hospital means that we have to educate each hospital and stroke center about protocols that integrate our products for the treatment of stroke. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe that the stroke care system in the United States has not been historically geared towards interventional treatment of stroke due to the
absence of clinical evidence that interventional techniques were effective. Our and our competitors&#146; ability to alter the existing stroke care pathway may depend on whether we and our competitors are successful in using recent positive clinical
studies to convince specialist physicians that intervention yields superior clinical results relative to cases where intervention is not used. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Establishing an interventional stroke pathway that integrates the use of interventional treatments,
including our products, will depend upon many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continuing to educate hospitals and specialist physicians about the clinical evidence supporting intervention, as well as the use, benefits and cost-effectiveness of our products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improving the speed with which patients are assessed for and receive interventional treatments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the likelihood that patients are transported to a hospital or stroke center where interventional treatments are available. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Even if these efforts are successful, it may be years before existing systems and care pathways are changed. These factors may make it difficult to grow
our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Any data that is gathered in the course of clinical trials may be significantly more favorable than the typical results achieved by practicing
specialist physicians, which could negatively impact rates of adoption of our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Even if the data collected from clinical trials
indicates positive results, each specialist physician&#146;s actual experience with our products will vary. Clinical trials often involve procedures performed by specialist physicians who are technically proficient and high volume users.
Consequently, the results reported in clinical trials may be significantly more favorable than typical results of other users. If specialist physicians&#146; experiences indicate, or they otherwise believe, that our products are not as safe or
effective as other treatment options with which they are more familiar, or clinical trial data indicates the same, adoption of our products may suffer, which could materially adversely affect our business, results of operations, financial condition
or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Negative publicity regarding our products or marketing tactics by competitors could reduce demand for our products, which would adversely
affect sales and our financial performance. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We may experience, from time to time, negative exposure in clinical publications or in marketing
campaigns of our competitors. Such publications or campaigns may present negative individual physician experience regarding the safety or effectiveness of our products or may suggest our competitors&#146; products are superior to ours, based on
studies or clinical trials conducted or funded by competitors or that involved competitive products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our reputation and competitive position may
also be harmed by other publicly available information suggesting that our products are not safe. For example, we file adverse event reports under Medical Device Reporting, or MDR, obligations with the FDA that are publicly available on the
FDA&#146;s website. We are required to file MDRs if our products may have caused or contributed to a serious injury or death or malfunctioned in a way that could likely cause or contribute to a serious injury or death if it were to recur. Any such
MDR that reports a significant adverse event could result in negative publicity and could harm our reputation and future sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our dependence on key
suppliers puts us at risk of interruptions in the availability of our products, which could reduce our revenue and adversely affect our results of operations. In addition, increases in prices for raw materials and components used in our products
could adversely affect our results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We require the timely delivery of sufficient amounts of components and materials to
manufacture our products. For reasons of quality assurance, cost effectiveness or availability, we procure certain raw materials and components from a single or limited number of suppliers. We generally acquire such raw materials and components
through purchase orders placed in the ordinary course of business, and as a result we may not have a significant inventory of these materials and components and generally do not have any guaranteed or contractual supply arrangements with many of
these suppliers. Our reliance on these suppliers subjects us to risks that could harm our business, including, but not limited to, difficulty locating and qualifying alternative suppliers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our dependence on third-party suppliers involves several other risks, including limited control over
pricing, availability, quality and delivery schedules. Suppliers of raw materials and components may decide, or be required, for reasons beyond our control, to cease supplying raw materials and components to us or to raise their prices. Shortages of
raw materials, quality control problems, production capacity constraints or delays by our suppliers could negatively affect our ability to meet our production requirements and result in increased prices for affected materials or components. We may
also face delays, yield issues and quality control problems if we are required to locate and secure new sources of supply. While we have not experienced any to date, any material shortage, constraint or delay may result in delays in shipments of our
products, which could materially adversely affect our results of operations. Increases in prices for raw materials and components used in our products could also materially adversely affect our results of operations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, the FDA and regulators outside of the United States may require additional testing of any raw materials or components from new suppliers
prior to our use of these materials or components. In the case of a device with clearance under section 510(k) of the U.S. Federal Food, Drug, and Cosmetic Act, referred to as a 510(k), we may be required to submit a new 510(k) if a change in a raw
material or component supplier results in a change in a material or component supplied that is not within the 510(k) cleared device specifications. If we need to establish additional or replacement suppliers for some of these materials or
components, our access to the materials or components might be delayed while we qualify such suppliers and obtain any necessary FDA approvals or clearances. Our suppliers may also be subject to regulatory inspection and scrutiny. Any adverse
regulatory finding or action against those suppliers could impact their ability to supply us with raw materials and components for our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our
corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovative approach, creativity, and teamwork fostered by our culture, and our business may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe that a critical contributor to our success has been our corporate culture, which we believe fosters innovation, teamwork, and a focus on
execution, as well as facilitating critical knowledge transfer and knowledge sharing. As we grow, we may find it difficult to maintain these important aspects of our corporate culture, which could limit our ability to innovate and operate
effectively. Any failure to preserve our culture could also negatively affect our ability to retain and recruit personnel or execute on our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If our facilities were to become inoperable, we would be unable to continue to develop and manufacture our products until we were able to restore full research,
manufacturing and administrative capabilities at our facilities or secure a new facility, and as a result, our business would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We
currently maintain our research and development, manufacturing and administrative operations in buildings located at our campus in Alameda, California, and we do not have redundant facilities. Alameda is situated on or near earthquake fault lines,
and our facilities are built on filled land, which could be prone to liquefaction in a major earthquake. Should one or more of our buildings be significantly damaged or destroyed by natural or man-made disasters, such as earthquakes, fires or other
events, it could take months to relocate or rebuild, during which time our employees may seek other positions, our research, development and manufacturing would cease or be delayed and our products may be unavailable. Moreover, because of the time
required to approve and license a manufacturing facility under FDA and non-U.S. regulatory requirements, we may not be able to resume production on a timely basis even if we are able to replace production capacity in the event we lose manufacturing
capacity. While we maintain property and business interruption insurance, such insurance has limits and would only cover the cost of rebuilding and relocating and lost profits, but not losses we may suffer due to our products being replaced by
competitors&#146; products. The inability to perform our research, development and manufacturing activities, combined with our limited inventory of raw materials and components and manufactured products, may cause specialist physicians to
discontinue using our products or harm our reputation, and we may be unable to reestablish relationships with those specialist physicians in the future. Consequently, a catastrophic event at our facility could materially adversely affect our
business, results of operations, financial condition or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>To successfully market and sell our products internationally, we must address a number of unique challenges
applicable to international markets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">For 2014 and the six months ended June 30, 2015, we derived 34% and 34%, respectively, of our revenue
from international sales. International sales are subject to a number of risks and challenges, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reliance on distributors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">varying coverage and reimbursement policies, processes and procedures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in staffing and managing international operations from which sales are conducted; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in penetrating markets in which our competitors&#146; products or alternative procedures that do not use our products are more established; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced protection for intellectual property rights in some countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">export licensing requirements or restrictions, trade regulations and foreign tax laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuating foreign currency exchange rates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign certification, regulatory requirements and legal requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lengthy payment cycles and difficulty in collecting accounts receivable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">customs clearance and shipping delays; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing pressure in international markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">political and economic instability; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preference for locally produced products. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If we are unable to successfully address these challenges, we
may not be able to grow our international sales and our results of operations may suffer as a result. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Over the long term, we intend to grow our
business internationally and to do so, we will need to either spend substantial sums to expand or develop direct sales capabilities in existing and new geographic areas or generate additional sales through existing distributors or attract additional
distributors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As a result of our international operations, we are required to comply with tax requirements in multiple jurisdictions, the scope and
impact of which may be unclear. Moreover, tax authorities in jurisdictions in which we do business could disagree with tax positions that we take, including, for example, our inter-company pricing policies, or could assert that we owe more taxes
than we currently pay due to the level and nature of our activities in such jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We rely on our distributors to market and sell our products in
certain international markets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have established a direct sales capability in the United States, most of Europe, Canada and Australia,
which we have complemented with distributors in Japan and certain other international markets. Sales to distributors represented 17.7% and 17.7% of our revenue in 2014 and the six months ended June 30, 2015, respectively. In addition, sales to our
Japanese distributor, Medico&#146;s Hirata Inc., represented approximately 11.7% of our revenue in 2014. Our success outside of the United States, most of Europe, Canada and Australia depends largely upon marketing arrangements with distributors, in
particular their sales expertise and their relationships with specialist physicians and affiliated hospitals in their geographic areas. Distributors may terminate their relationship with us, sell competitive products or devote insufficient sales
efforts or other resources to our products. We do not control our distributors, and they may not be successful in implementing our marketing plans. In addition, many of our distributors initially obtain and maintain foreign regulatory approval for
the sale of our products in their respective countries, and their efforts in obtaining and maintaining regulatory approval may not be as robust as we desire or expect. Our failure to maintain our existing relationships with our distributors, or our
failure to recruit and retain additional skilled distributors in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
existing or new international markets, could have an adverse effect on our operations. If current or future distributors do not perform adequately, or if we lose a significant distributor, such
as our Japanese distributor, we may not be able to maintain existing levels of international revenue or realize expected long term international revenue growth. We have also experienced turnover with some of our distributors in the past that has
adversely affected sales in the countries in which those distributors operate. Similar occurrences could happen in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Most of our customer
relationships outside of the United States are with governmental entities, and we could be materially adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws in non-U.S. jurisdictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The FCPA and similar anti-bribery laws in non-U.S. jurisdictions generally prohibit companies and their intermediaries from making improper payments to
non-U.S. officials for the purpose of obtaining or retaining business. Because of the predominance of government-sponsored healthcare systems around the world, most of our customer relationships outside of the United States are with governmental
entities, and physicians practicing in those systems are considered &#147;government officials;&#148; our sale to these entities are therefore subject to such anti-bribery laws. Our policies mandate compliance with these anti-bribery laws. We
operate in many parts of the world that have experienced governmental corruption, and in certain circumstances strict compliance with anti-bribery laws may be at variance with local customs and practices. Despite our training and compliance
programs, our internal control policies and procedures may not always protect us from reckless or criminal acts committed by our employees, distributors or agents. Violations of the FCPA or other anti-bribery laws, or allegations of such violations,
could disrupt our business and materially adversely affect our business, results of operations, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Foreign currency exchange
rates may adversely affect our results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are exposed to the effects of changes in foreign currency exchange rates, and we have not
historically hedged our foreign currency exposure. Approximately 34% and 34% of our revenue for 2014 and the six months ended June 30, 2015, respectively, were derived from sales in non-U.S. markets, and we expect sales from non-U.S. markets to
continue to represent a significant portion of our revenue. For direct sales in our international markets, we are paid by our customers in their local currency, which is primarily euros. For sales to distributors in our international markets, we are
paid in either U.S. dollars, euros or Japanese yen. Therefore, when the U.S. dollar strengthens relative to the euro, yen or other local currency, as it has in recent periods, our U.S. dollar reported revenue from non-U.S. dollar denominated sales
will decrease, or we will need to increase our non-U.S. dollar denominated prices, which may not be commercially practical. Conversely, when the U.S. dollar weakens relative to the euro, yen or other local currency, our U.S. dollar reported expenses
from non-U.S. dollar denominated operating costs will increase. Changes in the relative values of currencies occur regularly and, in some instances, could materially adversely affect our business, results of operations, financial condition or cash
flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have experienced rapid growth in recent periods, and if we fail to manage our growth effectively, our business and results of operations may
suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have significantly expanded our overall business, research and development, customer base, product portfolio, employee headcount
and operations in recent periods. We have also established new operations in other countries. We have increased our total number of full-time employees from 468 as of December&nbsp;31, 2013, to approximately 1,000 as of June 30, 2015. Our expansion
has placed, and our expected future growth will continue to place, a significant strain on our managerial, operational, product development, sales and marketing, administrative, financial and other resources. More systems, facilities, processes and
management employees are needed to allow us to continue to grow successfully. We also plan to continue to increase our salesforce. Our experience has been that it takes at least six months, and often longer, before new sales personnel generate
enough sales to cover their costs, resulting in increased costs without offsetting revenue during periods in which we are increasing the size of our salesforce. To meet anticipated demand for our products, we will also have to obtain additional
space, buy additional equipment and hire additional research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and development and manufacturing employees, including quality control personnel and other personnel involved in the production process. If we are unable to manage our growth successfully, it
could have a material and adverse effect on our business, results of operations, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We depend on key personnel to operate our
business and develop our products, and if we are unable to retain, attract and integrate qualified personnel, our ability to develop and successfully grow our business could be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe that our future success is highly dependent on the contributions of our executive officers, particularly our chief executive officer, as well
as our ability to attract and retain highly skilled and experienced sales and marketing, technical and other personnel in the United States and in international markets. Each of these persons&#146; efforts will be critical to us as we continue to
develop our products and business. If we were to lose one or more of our key employees, including to competitors, we may experience difficulties in competing effectively, developing our products and implementing our business strategies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our research and development and sales and marketing programs depend on our ability to attract and retain highly skilled technicians, engineers and
salespeople. We may not be able to attract or retain qualified employees in the future due to the intense competition for qualified personnel among life science businesses, particularly in the San Francisco Bay Area, where our corporate
headquarters, research and development and manufacturing facilities are located. If we are not able to identify, recruit and retain highly qualified personnel, we may experience constraints that will adversely affect our ability to support our
research, development, manufacturing and sales programs, and ultimately our ability to compete. If we are unable to identify, recruit and retain qualified salespeople, there could be a delay or decline in the adoption of our products. If key
personnel were to leave Penumbra, either to join our competitors or otherwise, we may not be able to attract and retain equally qualified personnel to replace them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We depend on information technology systems to operate our business and a cyber-attack or other breach of these systems could have a material adverse effect on
our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We rely on information technology systems to process, transmit and store electronic information in our day-to-day operations.
Our information technology systems are vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption. Any such successful attacks could result in the theft of intellectual property or
other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyber-attacks are becoming more sophisticated and frequent, and our systems could be the target of malware and other
cyber-attacks. We have invested in our systems and the protection of our data to reduce the risk of an intrusion or interruption, and we monitor our systems on an ongoing basis for any current or potential threats. We can give no assurances that
these measures and efforts will prevent interruptions or breakdowns. If we fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to these
systems, our competitive position could be harmed, we could lose existing customers, have difficulty preventing, detecting, and controlling fraud, have disputes with customers, specialist physicians and other health care professionals, have
regulatory sanctions or penalties imposed, incur expenses or lose revenues as a result of a data privacy breach or theft of intellectual property or suffer other adverse consequences, any of which could have a material adverse effect on our
business, results of operations, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cost-containment efforts of our customers, purchasing groups and governmental
organizations could have a material adverse effect on our sales and profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In an effort to reduce costs, many hospitals within the
United States have become members of Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs). GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors and offer the negotiated prices to
affiliated hospitals and other members. GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process. Bids are generally solicited from multiple providers with the intention of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
driving down pricing or reducing the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain or maintain contract positions
with major GPOs and IDNs. Furthermore, the increasing leverage of organized buying groups may reduce market prices for our products, thereby reducing our profitability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can
offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN
generally are free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90 days&#146; notice. Accordingly, although we have multiple contracts with many major GPOs
and IDNs, the members of such groups may choose to purchase from our competitors due to the price or quality offered by such competitors, which could result in a decline in our sales and profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The successful use of our products depends, in part, on our ability to educate specialist physicians in the proper use of our products, which may be more complex
than competitive products or alternative treatments that do not use our products. If we are unable to educate specialist physicians in the proper use of our products, we may experience a high risk of product liability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The successful use of our products depends, in part, on our ability to educate specialist physicians in the proper use of our products, which may be more
complex than competitive products or alternative treatments that do not use our products. We educate specialist physicians on the proper techniques in using our products to achieve the intended outcome. However, our products may be more complicated
to operate than competitive products or alternative treatments that do not use our products. In the event that specialist physicians perceive that our products are complex relative to alternative products or established treatments that do not use
our products, we may have difficulty gaining or increasing adoption of our products. Further, we may be unable to provide adequate education on the use of our products to specialist physicians, and some specialist physicians may not be willing to
invest the time required to become properly educated on the use of our products. If we are unable to educate specialist physicians to properly use our products, this may lead to inadequate demand for our products and materially adversely affect our
business, results of operations, financial condition or cash flows. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If we do not adequately educate specialist physicians on the use of our
products, and our products are used incorrectly during procedures, we may also be subject to claims against us by such specialist physicians, their hospitals or their patients. Our business, including our reputation, may consequently be adversely
affected by any litigation that may occur based on error in the use of our products, and such litigation could also materially adversely affect our results of operations, financial condition or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Regulatory Risks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to stringent domestic and foreign
medical device regulation, which may impede the approval or clearance process for our products, hinder our development activities and manufacturing processes and, in some cases, result in the recall or seizure of previously approved or cleared
products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our products, development activities and manufacturing processes are subject to extensive and rigorous regulation by the U.S. Food
and Drug Administration (FDA) and by comparable agencies in foreign countries and by other regulatory agencies and governing bodies. Manufacturers of medical devices such as us must comply with certain regulations that cover the composition,
labeling, testing, clinical study, manufacturing, packaging and distribution of medical devices. In addition, medical devices must receive FDA clearance or approval before they can be commercially marketed in the United States. The FDA may require
testing and surveillance programs to monitor the effects of cleared or approved products that have been commercialized and can prevent or limit further marketing of a product based on the results of these post-marketing programs. Furthermore, most
major markets for medical devices outside the United States require clearance, approval or compliance with certain standards and requirements before a product can be commercially marketed. The process of obtaining marketing approval or clearance
from the FDA and foreign regulatory agencies for new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
products could take a significant period of time, require the expenditure of substantial resources, involve rigorous pre-clinical and clinical testing, require changes to our products and result
in limitations on the indicated uses of our products. We cannot provide assurance that we will receive the required approval or clearance from the FDA and foreign regulatory agencies for future products on a timely basis. Results from pre-clinical
studies and early clinical trials may not allow us to predict results in later-stage testing. We cannot be certain that our future clinical trials will demonstrate the safety and effectiveness of any of our future products or will result in
clearance or approval to market any of these products. The failure to receive approval or clearance for significant new products on a timely basis could have a material adverse effect on our business, results of operation, financial condition or
cash flows. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The FDA also conducts periodic inspections of our facilities to determine compliance with both the FDA&#146;s Quality System Regulation
(QSR) requirements and/or MDR regulations. Product approvals or clearances by the FDA can be withdrawn, and new product approvals or clearances by the FDA and foreign regulatory bodies can be delayed, due to failure to comply with regulatory
requirements or the occurrence of unforeseen problems following initial approval or clearance of a product. The failure to comply with regulatory requirements or the discovery of previously unknown problems with a product or manufacturer could
result in fines, delays or suspensions of regulatory approvals or clearances, seizures or recalls of products (with the attendant expenses and adverse competitive impact), the banning of a particular device, an order to replace or refund the cost of
any device previously manufactured or distributed, operating restrictions and criminal prosecution, as well as decreased sales as a result of negative publicity and product liability claims, all of which could have a material adverse effect on our
business, results of operation, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The implementation of healthcare reform in the United States could have a material adverse
effect on our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act of 2010 (the Affordable Care Act) was enacted into law in the United States. The Affordable Care Act includes provisions that, among other things, reduce and/or limit Medicare reimbursement, require all individuals to have health
insurance (with limited exceptions) and impose new and/or increased taxes. Specifically, the law imposes a 2.3% excise tax on the sale in the United States of certain medical devices by a manufacturer, producer or importer of such devices starting
after December&nbsp;31, 2012. The Affordable Care Act also reduces Medicare and Medicaid payments to hospitals and clinical laboratories, which could reduce medical procedure volumes and impact the demand for our products or the prices at which we
sell them. While this legislation is intended to expand health insurance coverage to uninsured persons in the United States, the impact of any overall increase in access to healthcare on sales of our products remains uncertain. Various healthcare
reform proposals have also emerged at the state level. The impact of the Affordable Care Act and these proposals could have a material adverse effect on our business, results of operation, financial condition or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we modify our FDA cleared products, we may need to seek and obtain new clearances, which, if not granted, would prevent us from selling our modified products
or require us to redesign our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">A component of our strategy is to continue to modify and upgrade our products that have been cleared
by the FDA. The FDA requires device manufacturers to make a determination of whether or not a modification requires a clearance; however, the FDA can review a manufacturer&#146;s decision not to submit for additional clearances. Any modifications to
an FDA cleared device that would significantly affect its safety or effectiveness or that would constitute a major change in its intended use would require a new 510(k) clearance or possibly a premarket approval. We may not be able to obtain
additional 510(k) clearances or premarket approvals for new products or for modifications to, or additional indications for, our existing products in a timely fashion, or at all. We also cannot provide any assurance that the FDA will agree with our
decisions not to seek clearances for particular device modifications. Delays in obtaining future clearances would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our revenue and future
profitability. We have made modifications to our products in the past and may make additional modifications in the future that we believe do not or will not require additional clearances. If the FDA disagrees, and requires new clearances or
approvals for any modifications, and we fail to obtain such approvals or clearances or fail to secure approvals or clearances in a timely </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
manner, we may be required to recall and to stop the manufacturing and marketing of the modified device until we obtain FDA approval or clearance, and we may be subject to significant regulatory
fines or penalties, all of which could harm our results of operations and require us to redesign our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not receive necessary foreign
regulatory approvals or clearances or otherwise comply with foreign regulations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In 2014 and for the six months ended June 30, 2015, sales
outside the United States accounted for approximately 34% and 34%, respectively, of our total sales, and we expect this percentage to increase in future years. Foreign regulatory bodies have established varying regulations. Specifically, the
European Union has promulgated rules that require that medical device products receive the right to affix the CE mark, an international symbol of adherence to quality assurance standards and compliance with applicable European medical device
directives. Although we have received CE markings for all of the products we currently sell in the European Union, we can give no assurance that we will be able to obtain European Union approval for any of our future products. Our inability or
failure, or the inability or failure of our international distributors, to comply with varying foreign regulations or the imposition of new regulations could restrict or, in certain countries, result in the prohibition of the sale of our products,
and thereby adversely affect our business, financial condition and results of operations. In addition, our profitability from our international operations may be limited by risks and uncertainties related to economic conditions in these regions,
foreign currency fluctuations, regulatory and reimbursement approvals, competitive offerings, infrastructure development, rights to intellectual property and our ability to implement our overall business strategy. Any significant changes in the
competitive, political, legal, regulatory, reimbursement or economic environment where we conduct international operations may have a material adverse effect on our business, results of operation, financial condition or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not be able to meet regulatory quality requirements applicable to our manufacturing process. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are required to register with the FDA as a device manufacturer and as a result, we are subject to periodic inspection by the FDA for compliance with
the FDA&#146;s QSR requirements, which require manufacturers of medical devices to adhere to certain regulations, including testing, quality control and documentation procedures. In addition, the federal MDR regulations require us to provide
information to the FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury, or has malfunctioned, and if the malfunction were to recur, it would be likely to cause or
contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is rigorously monitored through periodic inspections by the FDA. In the European Community, we are required to maintain
certain International Organization for Standardization (ISO) certifications in order to sell products and we undergo periodic inspections by notified bodies to obtain and maintain these certifications. Some foreign countries, most notably Japan and
Brazil, have similar requirements or may require inspections of our manufacturing facilities before approving a product for sale in their country. Some of our suppliers are subject to the same or similar scrutiny. If we or our suppliers fail to
adhere to QSR, ISO or similar requirements, this could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances or approvals, recalls or other consequences, which could in turn have a material adverse
effect on our business, results of operation, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to periodic inspections by the FDA and other regulatory
bodies related to regulatory requirements that apply to medical devices designed and manufactured, and clinical trials sponsored, by us. We recently received notices of inspectional observations or deficiencies from the FDA, which require us to
undertake corrective and preventive actions or other actions in order to address the FDA&#146;s concerns, which could be expensive and time-consuming to complete and could impose additional burdens and expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are subject to periodic inspections by the FDA and other regulatory bodies. If we receive a notice of inspectional observations or deficiencies from
the FDA following an inspection, we may be required to undertake corrective and preventive actions or other actions in order to address the FDA&#146;s concerns, which could be expensive and time-consuming to complete and could impose additional
burdens and expenses. Failure to adequately address the FDA&#146;s concerns could expose us to enforcement and administrative actions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">For example, from June 24, 2015 to July 15, 2015 the FDA conducted an inspection of our records relating to
certain investigational sites for two different clinical trials and from July 30, 2015 to August 4, 2015, the FDA conducted an inspection of our quality system. At the conclusion of the first inspection, a Form FDA 483 was issued with one
observation. The 483 observation pertained to the failure to ensure proper monitoring at five of the investigational sites reviewed. Specifically, the observation noted that protocols relating to performing onsite&nbsp;monitoring visits at
appropriate intervals and providing documentation to clearly address any repeated data problems and resolutions of noted deficiencies in written reports after each onsite visit&nbsp;were not properly followed. At the conclusion of the second
inspection, a Form FDA 483 was also issued with one observation relating to our procedures for Corrective and Preventative Action (CAPA). Specifically, the observation noted our CAPA procedures do not require an effectiveness check in all cases.
</P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We responded to the first Form FDA 483 on August 4, 2015, and we have begun to take preventive actions to address the observation in that Form
FDA 483. We continue to review and enhance our investigational site monitoring to ensure compliance with regulatory requirements. We opened a CAPA to address the observation in the second Form FDA 483 and responded to the second Form FDA 483 on
August&nbsp;24, 2015. However, the FDA may conclude that we have not adequately responded to its observations, and could take action against us without further notice. Action by the FDA against us could result in monetary fines or require us to take
further corrective actions, which could be expensive and time-consuming to complete and could impose additional burdens and expenses, and could even require us to discontinue our investigational studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to healthcare fraud and abuse regulations that could result in significant liability, require us to change our business practices and restrict our
operations in the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are subject to various federal, state and local laws targeting fraud and abuse in the healthcare industry,
including anti-kickback and false claims laws. Violations of these laws are punishable by criminal or civil sanctions, including substantial fines, imprisonment and exclusion from participation in healthcare programs such as Medicare and Medicaid.
These laws and regulations are wide ranging and subject to changing interpretation and application, which could restrict our sales or marketing practices. Furthermore, since many of our customers rely on reimbursement from Medicare, Medicaid and
other governmental programs to cover a substantial portion of their expenditures, our exclusion from such programs as a result of a violation of these laws could have a material adverse effect on our business, results of operation, financial
condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about medical devices. If we are
found to have improperly promoted our products for off-label uses, we may become subject to significant fines and other liability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The FDA
and other regulatory agencies strictly regulate the promotional claims that may be made about medical devices. For example, devices cleared under section 510(k) cannot be marketed for any intended use that is outside of the FDA&#146;s substantial
equivalence determination for such devices. Physicians nevertheless may use our products on their patients in a manner that is inconsistent with the intended use cleared by the FDA. If we are found to have promoted such &#147;off-label&#148; uses,
we may become subject to significant government fines and other related liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in
off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our operations are subject to environmental, health and safety laws and regulations, with which compliance may be costly. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our business is subject to federal, state, and local laws and regulations relating to the protection of the environment, worker health and safety and the
use, management, storage, and disposal of hazardous substances and wastes. Failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. In addition, environmental laws and regulations could require
us to pay for environmental remediation and response costs, or subject us to third party claims for personal injury, natural </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
resource or property damage, relating to environmental contamination. Liability may be imposed whether or not we knew of, or were responsible for, such environmental contamination. The cost of
defending against environmental claims, of compliance with environmental, health and safety regulatory requirements or of remediating contamination could materially adversely affect our business, assets or results of operations and, consequently,
amounts available for distribution to our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We rely on a variety of intellectual property rights, and if we are unable to maintain or protect our intellectual property, our business and results of operations
will be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our commercial success will depend, in part, on our ability to obtain and maintain intellectual property protection for our
products and related technologies both in the United States and elsewhere, successfully defend our intellectual property rights against third-party challenges and successfully enforce our intellectual property rights to prevent third-party
infringement. While we rely primarily upon a combination of patents, trademarks and trade secret protection, as well as nondisclosure, confidentiality and other contractual agreements to protect the intellectual property related to our brands,
products and other proprietary technologies, protection derived from patents is relatively limited. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The process of obtaining patent protection is
expensive and time-consuming, and we may not be able to prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may choose not to seek patent protection for certain innovations or products and may
choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any event, any patent protection we obtain may
be limited. As a result, some of our products are not, and in the future may not be, protected by patents. We generally apply for patents in those countries where we intend to make, have made, use or sell products and where we assess the risk of
infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we sell products and we may not accurately predict all the countries where patent protection would ultimately be desirable. If
we fail to timely file a patent application in any such country or major market, we may be precluded from doing so at a later date. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their
own products and, further, may export otherwise infringing products to territories in which we have patent protection that may not be sufficient to terminate infringing activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Furthermore, we cannot guarantee that any patents will be issued from any pending or future owned or licensed patent applications, or if any current or
future patents will provide us with any meaningful protection or competitive advantage. Even if issued, existing or future patents may be challenged, including with respect to ownership, narrowed, invalidated, held unenforceable or circumvented, any
of which could limit our ability to prevent competitors and other third parties from developing and marketing similar products or limit the length of terms of patent protection we may have for our products and technologies. Other companies may also
design around technologies we have patented, licensed or developed. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our
products or practicing our own patented technology. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The patent positions of medical device companies can be highly uncertain and involve complex
legal, scientific and factual questions for which important legal principles remain unresolved. The standards that the United States Patent and Trademark Office (USPTO) and its foreign counterparts use to grant patents are not always applied
predictably or uniformly. Changes in either the patent laws, implementing regulations or the interpretation of patent laws may diminish the value of our rights. The legal systems of certain countries do not protect intellectual property rights to
the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Because patent applications in the United States, Europe and many other jurisdictions are typically not published until 18 months after filing, or in
some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or applications. We can give
no assurance that all of the potentially relevant art relating to our patents and patent applications has been found; overlooked prior art could be used by a third party to challenge the validity, enforceability and scope of our patents or prevent a
patent from issuing from a pending patent application. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the validity, enforceability and scope of our patents in the United States, Europe and in
other countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against our competitors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Third parties may challenge any existing patent or future patent we own or license through adversarial proceedings in the issuing offices or in court
proceedings, including as a response to any assertion of our patents against them. In any of these proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable, or even if valid and enforceable, insufficient to
provide protection against competing products and services sufficient to achieve our business objectives. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or reexamination by the USPTO if a third party asserts a
substantial question of patentability against any claim of a U.S. patent we own or license. The adoption of the Leahy-Smith America Invents Act (Leahy-Smith Act) in September 2011 established additional opportunities for third parties to invalidate
U.S. patent claims, including <I>inter partes</I> review and post-grant review proceedings. Outside of the United States, patents we own or license may become subject to patent opposition or similar proceedings, which may result in loss of scope of
some claims or the entire patent. In addition, such proceedings are very complex and expensive, and may divert our management&#146;s attention from our core business. If any of our patents are challenged, invalidated, circumvented by third parties
or otherwise limited or expire prior to the commercialization of our product candidates, and if we do not own or have exclusive rights to other enforceable patents protecting our products or other technologies, competitors and other third parties
could market products and use processes that are substantially similar to, or superior to, ours and our business would suffer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The degree of future
protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep a competitive advantage. For example: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to develop products that are similar to, or better than, ours in a way that is not covered by the claims of our patents; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might not have been the first to make the inventions covered by our patents or pending patent applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might not have been the first to file patent applications for these inventions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not develop additional proprietary technologies that are patentable. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may file lawsuits or initiate
other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file
infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a
patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#146;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds
that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business
position, business prospects and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our commercial success depends significantly on our ability to operate without infringing upon the intellectual
property rights of third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The medical device industry is subject to rapid technological change and substantial litigation regarding
patent and other intellectual property rights. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have
applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our products. Numerous third party patents exist in the fields relating to our
products, and it is difficult for industry participants, including us, to identify all third-party patent rights relevant to our products and technologies. Moreover, because some patent applications are maintained as confidential for a certain
period of time, we cannot be certain that third parties have not filed patent applications that cover our products and technologies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Patents could
be issued to third parties that we may ultimately be found to infringe. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to
obtain or maintain a license to any technology that we require may materially harm our business, financial condition and results of operations. Furthermore, we would be exposed to a threat of litigation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">From time to time, we may be party to, or threatened with, litigation or other proceedings with third parties, including non-practicing entities, who
allege that our products, components of our products and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. The types of situations in which we may become a party to such litigation or
proceedings include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not
infringe those third parties&#146; patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our collaborators may participate at substantial cost in International Trade Commission proceedings to abate importation of products that would compete unfairly with our products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, derivation or opposition proceedings to
determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if third parties initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or
patents licensed to us, we will need to defend against such proceedings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to ownership disputes relating to intellectual property, including disputes arising from conflicting obligations of consultants or others who are involved in developing our products; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that
we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">These lawsuits and proceedings, regardless of merit, are time-consuming and expensive to initiate, maintain, defend or settle, and could divert the time
and attention of managerial and technical personnel, which could materially adversely affect our business. Any such claim could also force use to do one or more of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur substantial monetary liability for infringement or other violations of intellectual property rights, which we may have to pay if a court decides that the product or technology at issue infringes or violates the
third party&#146;s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the third party&#146;s attorneys&#146; fees; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay substantial damages to our customers or end users to discontinue use or replace infringing technology with non-infringing technology; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">stop manufacturing, selling, using, exporting or licensing the product or technology incorporating the allegedly infringing technology or stop incorporating the allegedly infringing technology into such product or
technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain from the owner of the infringed intellectual property right a license, which may require us to pay substantial upfront fees or royalties to sell or use the relevant technology and which may not be available on
commercially reasonable terms, or at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">redesign our products and technology so they do not infringe or violate the third party&#146;s intellectual property rights, which may not be possible or may require substantial monetary expenditures and time;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into cross-licenses with our competitors, which could weaken our overall intellectual property position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lose the opportunity to license our technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual property against others; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">find alternative suppliers for non-infringing products and technologies, which could be costly and create significant delay; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relinquish rights associated with one or more of our patent claims, if our claims are held invalid or otherwise unenforceable. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have
substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing,
marketing or otherwise commercializing our products and technology. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a
material adverse effect on our business, results of operation, financial condition or cash flows. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, we may indemnify our customers and
distributors against claims relating to the infringement of intellectual property rights of third parties related to our products. Third parties may assert infringement claims against our customers or distributors. These claims may require us to
initiate or defend protracted and costly litigation on behalf of our customers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers, suppliers or
distributors, or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of
our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or
investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. The occurrence of any of these events may have a material adverse effect on our business, results of operation, financial
condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and
future products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents. On September&nbsp;16, 2011, the Leahy-Smith Act was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that
affect the way patent applications are prosecuted, redefine prior art, and may also affect patent litigation. The USPTO developed new regulations and procedures to govern </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
administration of the Leahy-Smith Act, including switching the United States patent system from a &#147;first-to-invent&#148; system to a &#147;first-to-file&#148; system. Under a
&#147;first-to-file&#148; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the
invention earlier. Many of the substantive changes to patent law associated with the Leahy-Smith Act, in particular, the first-to-file provisions, only became effective recently. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act
will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of
which could have a material adverse effect on our business, results of operation, financial condition or cash flows. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, patent reform
legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the U.S. Supreme Court and the U.S. Court of
Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws
in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may
materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Obtaining and maintaining patent
protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these
requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and
other similar provisions. In addition, periodic maintenance fees on our owned and in-licensed patents are due to be paid to governmental patent agencies over the lifetime of the patents. Future maintenance fees will also need to be paid on other
patents that may be issued to us. We have systems in place to remind us to pay these fees, and we employ outside firms to remind us or our licensor to pay annuity fees due to patent agencies on our patents and pending patent applications. In certain
cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business, results of
operation, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We currently own eight trademarks, related to our company
name, logo, products and technology, that are registered with the USPTO as well as six trademarks registered in Europe and Japan. Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic
or determined to be infringing on other marks or names. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential customers in our markets of interest. There is no
guarantee we will be able to secure registration for any of our pending trademark applications with the USPTO or comparable foreign authorities. In addition, third parties have registered trademarks similar and identical to our trademarks, and may
in the future file for registration of such trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these
trademarks to market our products in those countries where such third parties have registered such trademarks or obtained such common law rights. In any case, if we are unable to establish name recognition based on our trademarks and trade names,
then we may not be able to compete effectively and our business may be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, we may be involved in litigation or other proceedings to protect our trademark rights
associated with our company name or the names used with our products. For example, the United States application for registration of our Apollo trademark is currently subject to an opposition proceeding before the Trademark Trial and Appeal Board.
An adverse decision in such proceeding could require us to establish an alternative name for our Apollo product line. Any objections we receive from the USPTO, foreign trademark authorities or third parties relating to our pending applications could
require us to incur significant expense in defending the objections or establishing alternative names. Names used with our products may be claimed to infringe names held by others or to be ineligible for proprietary protection. If we have to change
the name of our company or any product, we may experience a loss in goodwill associated with our brand name, customer confusion or a loss of sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are
unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition to patent protection, we also rely on confidential proprietary information, including trade secrets and know-how, to develop and maintain our
competitive position. We seek to protect our confidential proprietary information, in part, by entering into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us.
These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#146;s relationship with us be kept confidential. Our agreements with employees and our
personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we
have these agreements may not comply with their terms. Thus, despite such agreements, such inventions may become assigned to third parties. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know
whether the steps we have taken to protect our intellectual property will be effective. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful
protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and
those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment
or a license to that intellectual property from that individual, or a third party or from that individual&#146;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would
impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to
maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no
protection against such independent discovery. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We may also employ individuals who were previously or concurrently employed at research institutions
and/or other medical device companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of
their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our products, are rightfully owned by their former or concurrent employer. Litigation may be
necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Risks Related to Our Finances and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>It is difficult to forecast future performance, which may cause our financial results to fluctuate unpredictably. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">A number of factors over which we have limited or no control may contribute to fluctuations in our financial results, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in revenue due to the unavailability of specialist physicians who use our products during certain times of the year, such as those periods when there are major conferences on conditions they treat or those
periods when high volume users of our products take time off of work; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">positive or negative media coverage of our products or the procedures or products of our competitors or our industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publication of clinical trial results or studies by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our sales process due to industry changes, such as changes in the stroke care pathway; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in receipt of anticipated purchase orders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in customers receiving products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of our independent distributors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain further regulatory clearances or approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of product development and clinical trial activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in, or failure of, product and component deliveries by our suppliers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in reimbursement policies or levels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">customer response to the introduction of new products or alternative treatments, and the degree to we which we are effective in transitioning customers to our products; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in foreign currency. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In the event our actual revenue and results of operations do not meet
our or others&#146; forecasts for a particular period, the market price of our common stock may decline substantially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may require additional financing in
the future and may not be able to obtain such financing on favorable terms, if at all, which could force us to delay, reduce or eliminate our research and development activities or otherwise harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">To date, we have financed our operations primarily through our operations, private placements of our equity securities and borrowings under a line of
credit with a financial institution. We are unable to predict the extent of any future operating cash flows or whether we will be able to maintain or grow our profitability. If we require additional financing to continue or expand our operations,
for research and development, for acquisitions or for other purposes, we may determine to engage in equity or debt financings or incur other indebtedness. We may not be able to timely secure additional debt or equity financing on favorable terms, or
at all. If we raise additional funds through the issuance of equity or convertible debt or other equity-linked securities, our existing stockholders could suffer significant dilution. Any debt financing obtained by us in the future could involve
restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential
acquisitions. If needed funds are not available in adequate amounts or on acceptable terms from additional financing sources, our business will be materially adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we engage in any acquisitions, we will incur a variety of costs and may potentially face numerous risks that could
adversely affect our business and operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If appropriate opportunities become available, we may seek to acquire additional businesses,
assets, technologies or products to enhance our business. In connection with any acquisitions, we could issue additional equity securities or convertible debt or equity-linked securities, which would dilute our stockholders, cause us to incur
substantial debt to fund the acquisitions, or assume significant liabilities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Acquisitions involve numerous risks, including problems integrating
the purchased operations, technologies or products, unanticipated costs and other liabilities, diversion of management&#146;s attention from our core businesses, adverse effects on existing business relationships with current and/or prospective
customers and/or suppliers, risks associated with entering markets in which we have no or limited prior experience and potential loss of key employees. Acquisitions may also require us to record goodwill and non-amortizable intangible assets that
will be subject to impairment testing on a regular basis and potential periodic impairment charges, incur amortization expenses related to certain intangible assets, and incur write offs and restructuring and other related expenses, any of which
could harm our results of operations and financial condition. If we fail in our integration efforts with respect to any of our acquisitions and are unable to efficiently operate as a combined organization, our business and financial condition may be
adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Risks Relating to Securities Markets and Investment in Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>A viable trading market for our common stock may not develop or be sustained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Prior to this offering, there has been no public market for shares of our common stock. Although we have applied to list our common stock on the New York
Stock Exchange (&#147;NYSE&#148;), an active trading market for our shares may never develop or be sustained following this offering. We and the underwriters will determine the initial public offering price of our common stock through negotiation.
This price will not necessarily reflect the price at which investors in the market will be willing to buy and sell our shares following this offering. The initial public offering price may vary from the market price of our common stock after the
offering. In addition, the trading volume of companies such as ours is often very low, and thus your ability to resell your shares may be severely constrained. As a result of these and other factors, you may be unable to resell your shares of our
common stock at or above the initial public offering price. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The price of our common stock may be volatile, and you could lose all or part of your
investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Stock markets have experienced extreme volatility that has often been unrelated to the operating performance of particular
companies. These broad market fluctuations may adversely affect the trading price of our common stock. In addition, limited trading volume of our stock may contribute to its future volatility. Price declines in our common stock could result from
general market and economic conditions, some of which are beyond our control, and a variety of other factors, including any of the risk factors described in this prospectus. These broad market and industry factors may harm the market price of our
common stock, regardless of our operating performance, and could cause you to lose all or part of your investment in our common stock since you might be unable to sell your shares at or above the price you paid in this offering. Factors that could
cause fluctuations in the market price of our common stock include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">price and volume fluctuations in the overall stock market from time to time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">volatility in the market prices and trading volumes of medical device company stocks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in operating performance and stock market valuations of other medical device companies generally, or those in our industry in particular; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of shares of our common stock by us or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow our company, or our failure to meet these estimates or the expectations of investors;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the financial projections we may provide to the public, any changes in those projections or our failure to meet those projections; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of new products or services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the public&#146;s reaction to our press releases, other public announcements and filings with the SEC; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rumors and market speculation involving us or other companies in our industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in our results of operations or fluctuations in our results of operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated developments in our business, our competitors&#146; businesses or the competitive landscape generally; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning our intellectual property or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announced or completed acquisitions of businesses or technologies by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">new laws or regulations or new interpretations of existing laws or regulations applicable to our business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in accounting standards, policies, guidelines, interpretations or principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any significant change in our management; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic conditions and slow or negative growth of our markets. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, in the past,
following periods of volatility in the overall market and the market price of a particular company&#146;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us,
could result in substantial costs and a diversion of our management&#146;s attention and resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Purchasers in this offering will experience immediate and
substantial dilution in the book value of their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The initial public offering price of our common stock is substantially higher
than the net tangible book value per share of our outstanding common stock immediately prior to this offering. Therefore, if you purchase our common stock in this offering, you will incur an immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in net tangible book value per share from the price you paid, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (which is the midpoint
of the estimated initial public offering price range set forth on the cover page of this prospectus). In addition, purchasers who bought shares from us in this offering will have contributed &nbsp;&nbsp;&nbsp;&nbsp;% of the total consideration paid
to us by our stockholders to purchase shares of our common stock, in exchange for acquiring approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding shares of our capital stock as of June 30, 2015 after giving effect to this offering. The exercise
of outstanding options will result in further dilution. For a further description of the dilution that you will experience immediately after this offering, see the section titled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If our executive officers, directors and largest stockholders choose to act together, they may be able to significantly influence our management and operations,
acting in their own best interests and not necessarily those of other stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of June 30, 2015, our executive officers, directors
and holders of 5% or more of our outstanding stock and their affiliates beneficially owned approximately 36.1% of our voting stock in the aggregate, and we expect that immediately following the completion of this offering the same group will
continue to hold at least &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting stock, based on the number of shares outstanding as of June 30, 2015. As a result, these stockholders, acting together, would be able to significantly influence all
matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of this group of stockholders may not always coincide with the interests of
other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
stockholders, and they may act in a manner that advances their best interests and not necessarily those of other stockholders. This concentration of ownership may have the effect of delaying,
preventing or deterring a change in control of our company, could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company and might ultimately affect the market price of our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>A significant portion of our outstanding shares of common stock is restricted from immediate resale but may be sold into the market in the near
future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Sales of a
substantial number of shares of our common stock in the public market could occur at any time, subject to the 180-day lock-up periods under the lock-up agreements described in the section of this prospectus titled &#147;Underwriting.&#148; These
sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. As of June 30, 2015, our directors, executive officers and holders of 5% or
more of our outstanding stock beneficially owned approximately 36.1% of our outstanding stock in the aggregate. If one or more of them were to sell a substantial portion of the shares they hold, it could cause our stock price to decline. Futhermore,
the lock-up agreements mentioned above may be waived by the underwriters at any time which could lead to these shares being sold in the market prior to the expiration of this 180-day lock-up period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, as of June 30, 2015, there were 2,460,574 shares subject to outstanding options that will become eligible for sale in the public market upon
exercise of such options to the extent permitted by any applicable vesting requirements, the lock-up agreements and Rules 144 and 701 under the Securities Act of 1933, as amended (Securities Act). Moreover, after this offering, holders of an
aggregate of 21,617,845 shares of our common stock will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves
or other stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We also intend to register all &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock
that we may issue under our Amended and Restated 2014 Equity Incentive Plan. Once we register these shares, they can be freely sold in the public market upon issuance and once vested and exercised, as applicable, subject to the 180-day lock-up
periods under the lock-up agreements described in the section of this prospectus titled &#147;Underwriting.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Sales of our common stock as
restrictions end or pursuant to registration rights may make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. These sales also could cause the price of our common stock to fall and
make it more difficult for you to sell shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our amended and restated certificate of incorporation, our amended and restated bylaws and
Delaware law contain provisions that could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Provisions of Delaware law (where we are incorporated), our amended and restated certificate of incorporation and amended and restated bylaws may
discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. In addition, these provisions may frustrate or prevent any attempts
by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace or remove our board of directors. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorizing the issuance of &#147;blank check&#148; preferred stock without any need for action by stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requiring supermajority stockholder voting to effect certain amendments to our amended and restated certificate of incorporation and amended and restated bylaws; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminating the ability of stockholders to call and bring business before special meetings of stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibiting stockholder action by written consent; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dividing our board of directors into three classes so that only one third of our directors will be up for election in any given year; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing that our directors may be removed by our stockholders only for cause. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, we are
subject to Section&nbsp;203 of the Delaware General Corporation Law, which may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, including discouraging takeover attempts that could have
resulted in a premium over the market price for shares of our common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">These provisions apply even if a takeover offer may be considered
beneficial by some stockholders and could delay or prevent an acquisition that our board of directors determines is not in our and our stockholders&#146; best interests and could also affect the price that some investors are willing to pay for our
common stock. See the section titled &#147;Description of Capital Stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our amended and restated certificate of incorporation will provide that the
Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our
directors, officers or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of
Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our
amended and restated certificate of incorporation or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. The choice of forum provision may limit a stockholder&#146;s ability
to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. If a court were to find
the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which
could harm our business and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>As a public company, our expenses and administrative burden will increase. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, our
administrative staff will be required to perform additional tasks. For example, in anticipation of becoming a public company, we will need to adopt additional internal controls and disclosure controls and procedures and bear all of the internal and
external costs of preparing and distributing periodic public reports in compliance with our obligations under applicable securities laws. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In
addition, laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 and related regulations implemented by the SEC and the NYSE, have increased legal and financial compliance
costs and made some regulatory and compliance activities more time consuming. We are currently evaluating and monitoring developments with respect to new and proposed rules and cannot predict or estimate the amount of additional costs we may incur
or the timing of such costs. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is
provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply
with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#146;s time and attention from revenue-generating activities to compliance activities. We
also expect that being a public company, and being subject to these new rules and regulations, will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur
substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and attract and retain qualified executive officers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The increased costs associated with operating as a public company may decrease our net income or increase any future net loss and may cause us to reduce
costs in other areas of our business or increase the prices of our products to offset the effect of such increased costs. Additionally, if these requirements divert our management&#146;s attention from other business concerns, they could have a
material adverse effect on our business, results of operation, financial condition or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are an &#147;emerging growth company,&#148; and we
cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take
advantage of exemptions from various reporting requirements that are applicable to other public companies but not to &#147;emerging growth companies,&#148; including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations&#148; disclosure; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting under Section&nbsp;404 of the Sarbanes-Oxley Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
additional information about the audit and the financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the
completion of this offering, (b)&nbsp;in which we have total annual gross revenue of at least $1 billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by
non-affiliates exceeds $700 million as of the prior June&nbsp;30th, and (2)&nbsp;the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period. We cannot predict if investors will find our common
stock less attractive if we choose to rely on these exemptions. If some investors find our common stock less attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for our common stock and the
price of our common stock may be more volatile. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting
standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised
accounting standards as other public companies that are not emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail to maintain an effective system of disclosure controls and
internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the Exchange Act), the
Sarbanes-Oxley Act, and the listing standards of the NYSE. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time
consuming and costly, and place significant strain on our personnel, systems and resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and
procedures and internal control over financial reporting. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we will
file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our
principal executive and financial officers. We are also continuing to improve our internal control over financial reporting. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over
financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our current controls and any new controls that we develop may become inadequate because of changes in our business. Further, weaknesses in our disclosure
controls or our internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls, or any difficulties encountered in their implementation or improvement, could harm our operating
results or cause us to fail to meet our reporting obligations and may result in errors in our financial statements or a restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal control over
financial reporting also could adversely affect the results of management evaluations and independent registered public accounting firm audits of our internal control over financial reporting that we will eventually be required to include in our
periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would
likely have a negative effect on the trading price of our common stock. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on the NYSE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are not currently required to comply with the SEC rules that implement Section 404 of the Sarbanes-Oxley Act, and are therefore not required to make a
formal assessment of the effectiveness of our internal control over financial reporting for that purpose. As a public company, we will be required to provide an annual management report on the effectiveness of our internal control over financial
reporting commencing with our second annual report on Form 10-K. Our independent registered public accounting firm is not required to audit the effectiveness of our internal control over financial reporting until after we are no longer an
&#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied
with the level at which our internal control over financial reporting is documented, designed or operating. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Any failure to maintain effective
disclosure controls and internal control over financial reporting could have a material and adverse effect on our business and results of operations, and cause a decline in the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We will have broad discretion in the use of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of
operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development and commercialization of our products and cause the price of our common
stock to decline. Until the net proceeds are used, they may be placed in investments that do not produce significant income or that may lose value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If
securities or industry analysts do not publish or cease publishing research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our
business. We may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who cover us downgrade our stock or publish inaccurate or
unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our
stock price and trading volume to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any
return on their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our
common stock, which may never occur, would provide a return to stockholders. Investors seeking cash dividends should not invest in our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Impairment of our deferred tax assets could require a charge to earnings, which could result in a negative impact on our results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Primarily as a result of net operating losses, stock based compensation, various accruals and reserves, and tax credits, we maintain a deferred tax asset
(an asset recognized to reflect an expected benefit to be realized in the future) that may be used to reduce the amount of tax that we would otherwise be required to pay in future periods. Deferred tax assets are reduced by a valuation allowance
when it is more likely than not that the future realization of all or some of the deferred tax assets will not be achieved. Valuation allowances related to deferred tax assets can be affected by changes to tax laws, statutory tax rates, future
taxable income levels and input from our tax advisors or regulatory authorities. At June 30, 2015, our net deferred tax asset was $6.8 million, after reduction of a&nbsp;valuation&nbsp;allowance&nbsp;of $2.9 million. If our management was to
determine that we would not be able to realize all or a portion of our net deferred tax assets in the future, a valuation allowance and a related charge to earnings would be reflected in that period, which could have a material adverse impact on our
financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have made statements under the sections titled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations,&#148; &#147;Business&#148; and in other sections of this prospectus that are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as
&#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or
&#147;continue,&#148; the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance,
our anticipated growth strategies and anticipated trends in our business. Forward-looking statements contained in this prospectus include, but are not limited to statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to design, develop, manufacture and market innovative products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expected future growth, including growth in international sales; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and growth potential of the markets for our products, and our ability to address those markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the market acceptance of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the performance of our salesforce and distributors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments in the United States and other markets in which we sell our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to scale our organizational culture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our use of the proceeds from this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our results of operations and capital requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause
our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed in the
section titled &#147;Risk Factors.&#148; You should specifically consider the numerous risks outlined in the section titled &#147;Risk Factors.&#148; Although we believe the expectations reflected in the forward-looking statements are reasonable, we
cannot guarantee future results, level of activity, performance or achievements. We undertake no obligation to update any forward-looking statements made in this prospectus to reflect events or circumstances after the date of this prospectus or to
reflect new information or the occurrence of unanticipated events, except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We estimate that the net proceeds to us from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their option to purchase additional shares from us in full, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and
estimated offering expenses payable by us. Each $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated initial public offering
price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, our net proceeds from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by
us, as set forth on the cover page of this prospectus, remains the same, after deducting underwriting discounts and commissions payable by us. An increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us would increase or
decrease, as applicable, our net proceeds from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the
midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions payable by us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The principal purposes of this offering are to increase our capitalization and financial flexibility, create a public market for our common stock and
enable access to the public equity markets for us and our stockholders. We intend to use the net proceeds from this offering for product development, including research and development and clinical trials, expansion of our salesforce and for working
capital and general corporate purposes. From time to time, we may consider the acquisition of complementary technologies or businesses, though we have no agreements or understandings with respect to any such acquisitions at this time. We currently
have no specific plans for the use of the net proceeds that we receive from this offering. Accordingly, we will have broad discretion in using these proceeds. Pending the use of the net proceeds from this offering, we intend to invest the net
proceeds in investment grade, interest bearing securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds for use in the operation and
expansion of our business, and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors, subject to applicable laws, and will
depend on a number of factors, including our financial condition, results of operations, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors may deem relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets forth our cash and cash equivalents and capitalization as of June 30, 2015: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma basis, giving effect to (i)&nbsp;the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 19,510,410 shares of our common stock, which conversion will occur
immediately upon the completion of this offering, as if such conversion had occurred on June&nbsp;30, 2015, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma as adjusted basis, giving effect to the pro forma adjustments set forth above, and the sale and issuance by us of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common
stock in this offering, at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this
prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">This table
should be read in conjunction with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and the consolidated financial statements and notes thereto appearing elsewhere in this
prospectus. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June 30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share<BR>and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents and marketable investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock, $0.001 par value per share, 25,000,000 shares authorized, 19,510,410 shares issued and outstanding, actual; no shares
authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock, $0.001 par value per share, no shares authorized, issued or outstanding, actual; 5,000,000 shares authorized, no shares issued
or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Common stock, $0.001 par value per share, 40,000,000 shares authorized, 5,747,638 shares issued and outstanding, actual; 300,000,000 authorized,
25,258,048 shares issued and outstanding, pro forma; 300,000,000 authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Notes receivable from stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:arial; font-size:9pt">Each $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the
midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the amount of our pro forma as adjusted cash and cash equivalents, additional paid-in capital,
total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains
the same, after deducting underwriting </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
discounts and commissions payable by us. An increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us would increase or decrease, as applicable, the amount of our pro
forma as adjusted cash and cash equivalents, additional paid-in capital, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming an initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions
payable by us. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The actual column in the table above is based on 5,747,638 shares of our common stock issued and outstanding and
excludes 24,818 shares of common stock issued upon early exercise of stock options and subject to repurchase and 755,771 shares of unvested restricted stock. See Notes 10 and 12 to our Consolidated Financial Statements. The pro forma and pro forma
as adjusted columns in the table above are based on 25,258,048&nbsp;shares of our common stock (including preferred stock on an as-converted basis) outstanding as of June 30, 2015, and exclude the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,460,574 shares of common stock issuable upon the exercise of options to purchase shares of our common stock outstanding as of June 30, 2015, at a weighted average exercise price of $5.27 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,713,634 shares of common stock reserved for future grant or issuance under our 2014 Equity Incentive Plan as of June 30, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">871,250 shares of common stock issuable upon the exercise of options to purchase shares of our common stock at an exercise price of $22.04 per share and 11,000 shares of restricted stock, which were granted in August
2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">450,000 shares of common stock issuable upon the exercise of options to purchase shares of our common stock to be granted to our Chief Executive Officer at an exercise price equal to our initial public offering price,
which options will vest over a period of four years from the date of this prospectus; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">24,818 shares of common stock issued upon early exercise of stock options and subject to repurchase; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">755,771 shares of unvested restricted stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,000,000 shares of common stock initially reserved for future issuance under our Amended and Restated 2014 Equity Incentive Plan, which will become effective immediately prior to the completion of this offering, as
well as any automatic increases in the number of shares of our common stock reserved for future issuance pursuant to this plan; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">600,000 shares of common stock initially reserved for issuance under our ESPP, as well as any automatic increases in the number of shares of our common stock reserved for future issuance pursuant to this plan.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_7"></A>DILUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our pro forma net tangible book value as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of
common stock. Pro forma net tangible book value per share represents tangible assets, less liabilities, divided by the aggregate number of shares of common stock outstanding, after giving effect to the automatic conversion of all outstanding shares
of our preferred stock into an aggregate of 19,510,410 shares of our common stock, which conversion will occur immediately upon the completion of this offering. After giving effect to the sale by us of the
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering, at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of
the estimated initial public offering price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book
value as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015, would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in pro forma net tangible book value to existing stockholders of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and an immediate dilution
to new investors of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. The following table illustrates this per share dilution: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Assumed initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net tangible book value per share as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase in pro forma net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma as adjusted net tangible book value per share after offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, our pro forma as
adjusted net tangible book value per share to new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and would increase or decrease, as applicable, dilution per share to new investors in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and
commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us would increase or decrease, as applicable, our pro forma as adjusted net tangible book
value by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and increase or decrease, as applicable, the dilution to new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming the assumed initial
public offering price remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If
the underwriters&#146; option to purchase additional shares is exercised in full, the pro forma as adjusted net tangible book value per share of our common stock, as adjusted to give effect to this offering, would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and the dilution in pro forma net tangible book value per share to new investors in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets forth, on a pro forma as adjusted basis, as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015, the number of shares of common stock purchased from us, the total consideration paid, or to be paid, and the average
price per share paid, or to be paid, by existing stockholders and by the new investors, at an assumed initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated initial public
offering range set forth on the cover page of this prospectus, before deducting underwriting discounts and commissions and estimated offering expenses payable by us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Average&nbsp;Price<BR>Per Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:26.85pt; font-size:8pt; font-family:arial"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the total
consideration paid by new investors and total consideration paid by all stockholders by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of this
prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The number of
shares of common stock to be outstanding after this offering is based upon 26,038,637&nbsp;shares outstanding (including preferred stock on an as-converted basis) as of June 30, 2015, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,460,574 shares of common stock issuable upon the exercise of options to purchase shares of our common stock outstanding as of June 30, 2015, at a weighted average exercise price of $5.27 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,713,634 shares of common stock reserved for future grant or issuance under our 2014 Equity Incentive Plan as of June 30, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">871,250 shares of common stock issuable upon the exercise of options to purchase shares of our common stock at an exercise price of $22.04 per share and 11,000 shares of restricted stock, which were granted in August
2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">450,000 shares of common stock issuable upon the exercise of options to purchase shares of our common stock to be granted to our Chief Executive Officer at an exercise price equal to our initial public offering price,
which options will vest over a period of four years from the date of this prospectus; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,000,000 shares of common stock initially reserved for future issuance under our Amended and Restated 2014 Equity Incentive Plan, which will become effective immediately prior to the completion of this offering, as
well as any automatic increases in the number of shares of our common stock reserved for future issuance pursuant to this plan; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">600,000 shares of common stock initially reserved for issuance under our ESPP, as well as any automatic increases in the number of shares of our common stock reserved for future issuance pursuant to this plan.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">To the extent options are exercised, there will be further dilution to new investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_8"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following selected consolidated financial data of Penumbra, Inc. should be read in conjunction with, and are qualified by reference to, the section
titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and the consolidated financial statements and notes thereto included elsewhere in this prospectus. The consolidated statement of operations
data for the years ended December&nbsp;31, 2013 and 2014, and the consolidated balance sheet data as of December&nbsp;31, 2013 and 2014, are derived from, and qualified by reference to, our audited consolidated financial statements included
elsewhere in this prospectus and should be read in conjunction with those consolidated financial statements and notes thereto. The consolidated statement of operations data for the year ended December&nbsp;31, 2012, are derived from our audited
consolidated financial statements not included in this prospectus. The consolidated statement of operations data for the six month periods ended June&nbsp;30, 2014 and 2015, and the consolidated balance sheet data as of June 30, 2015, are derived
from our unaudited consolidated financial statements included elsewhere in this prospectus which, in our opinion, have been prepared on the same basis as the audited consolidated financial statements and reflect all adjustments, consisting only of
normal recurring adjustments, necessary for a fair presentation of our results of operations and financial position. Our historical results are not necessarily indicative of the results that may be expected in the future and the results for the six
months ended June 30, 2015 are not necessarily indicative of results to be expected for the full year or any other period. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">73,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">88,848</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">125,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">57,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">81,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">24,178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">30,972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">42,668</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">19,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">27,160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">48,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">57,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">82,842</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">38,154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">54,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">12,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">14,084</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">15,575</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">7,538</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">7,983</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">32,987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">44,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">64,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">28,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">45,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">45,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">59,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">79,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">35,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">53,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">3,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(1,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">3,009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">2,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">177</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(474</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(498</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Income (loss) before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">3,892</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(1,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">3,139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">2,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">1,934</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(5,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">233</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">1,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">4,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">2,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">1,657</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(169</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Net income (loss) attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Net income (loss) per share attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">0.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(0.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">0.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(0.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8.5pt">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Weighted average shares used to compute net income (loss) per share attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,153,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,304,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,609,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,520,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,886,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,500,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,609,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,743,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Pro forma net income (loss) per share&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Pro forma net income (loss) per share&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">Weighted average shares used to compute the pro forma net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">&#151;Basic (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,680,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,510,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:8.5pt; font-family:arial">&#151;Diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,037,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,510,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results may differ
materially from those discussed in the forward-looking statements as a result of various factors, including those set forth in the sections titled &#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements.&#148; The
following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements included elsewhere in this prospectus, as well as the information presented under the section titled
&#147;Selected Consolidated Financial Data.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Penumbra is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. We have a broad
portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. The conditions that our products address include, among others, ischemic stroke, hemorrhagic
stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are an established
company focused on the neuro market, and we recently expanded our business to include the peripheral vascular market. We focus on developing, manufacturing and marketing products for use by specialist physicians, including interventional
neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. We design our products to provide these specialist physicians with a means to drive improved clinical outcomes through faster and safer
procedures. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Since our founding in 2004, we have invested heavily in our product development capabilities in our two key markets: neuro and
peripheral vascular. We launched our first neurovascular product in 2007, our first peripheral vascular product in 2013 and our first neurosurgical product in 2014. To date, we have launched 14 product brands, and we expect to continue to develop
and build our portfolio of products based on our thrombectomy, embolization and access technologies. Generally, when we introduce a next generation product or a new product designed to replace a current product, sales of the earlier generation
product or the product replaced decline. Our research and development activities are centered around the development of new products and clinical activities designed to support our regulatory submissions and demonstrate the effectiveness of our
products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We manufacture substantially all of our products at our campus in Alameda, California and stock inventory of raw materials, components and
finished goods at that location. We rely on a single or limited number of suppliers for certain raw materials and components, and we generally have no long-term supply arrangements with our suppliers, as we order on a purchase order basis. We ship
all of our products from Alameda to our hospital customers and distributors worldwide pursuant to purchase orders. We typically recognize revenue when products are delivered to our hospital customers or distributors, other than our coils, which we
ship to our hospital customers on a consignment basis, and for which we recognize revenue when the hospital customers utilize products in a procedure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Hospitals purchase our products for use in procedures performed by their specialist physicians, generally seeking reimbursement from third party payors
for procedures performed. We believe that the cost-effectiveness of our products is attractive to our hospital customers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In 2014, 34% of our
revenue was generated from customers located outside of the United States. Our sales outside of the United States are denominated principally in the euro and Japanese yen. As a result, we have foreign exchange exposure, but do not currently engage
in hedging. In 2014, no single hospital and only one distributor accounted for more than 10% of our sales. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of June 30, 2015, we had approximately
1,000 employees worldwide. We sell our products to hospitals primarily through our direct sales organization in the United States, most of Europe, Canada and Australia, as well as through distributors in select international markets. In 2014, we
generated revenue of $125.5 million, which represents a 41.3% increase over 2013, and $3.0 million in operating income as compared to an operating loss of $1.1 million in 2013. For the six months ended June 30, 2015, we generated revenue of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
$81.3&nbsp;million, which represents a 41.0% increase over the six months ended June 30, 2014, and $0.2 million in operating income as compared to operating income of $2.4 million for the six
months ended June 30, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Factors Affecting Our Performance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">There are a number of factors that have impacted, and we believe will continue to impact, our results of operations and growth. These factors include:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The rate at which we grow our salesforce and the speed at which newly hired salespeople become fully effective can impact our revenue growth or our costs incurred in anticipation of such growth. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our industry is intensely competitive and, in particular, we compete with a number of large, well-capitalized companies. We must continue to successfully compete in light of our competitors&#146; existing and future
products and their resources to successfully market to the specialist physicians who use our products. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We must continue to successfully introduce new products that gain acceptance with specialist physicians and successfully transition from existing products to new products, ensuring adequate supply while avoiding excess
inventory of older products and resulting inventory write-downs or write-offs. In addition, as we introduce new products, we generally build our inventory of components and finished goods in advance of sales, which may cause quarterly fluctuations
in our results of operations. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Publications of clinical results by us, our competitors and other third parties can have a significant influence on whether, and the degree to which, our products are used by specialist physicians and the procedures and
treatments those physicians choose to administer for a given condition. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The specialist physicians who use our products may not perform procedures during certain times of the year, such as those periods when they are at major medical conferences or are away from their practices for other
reasons, the timing of which occurs irregularly during the year and from year to year. </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, we have experienced and expect
to continue to experience meaningful variability in our quarterly revenue and gross profit as a result of a number of factors, including, but not limited to: the number of available selling days, which can be impacted by holidays; the mix of
products sold; the geographic mix of where products are sold; the demand for our products and the products of our competitors; the timing of or failure to obtain regulatory approvals or clearances for products; increased competition; the timing of
customer orders; inventory write-offs and write-downs; costs, benefits and timing of new product introductions; the availability and cost of components and raw materials; and fluctuations in foreign currency exchange rates. We experience quarters in
which we have significant revenue growth sequentially followed by quarters of moderate or no revenue growth. Additionally, we experience quarters in which operating expenses, in particular research and development expenses, fluctuate depending on
the stage and timing of product development. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Revenue.</I></B> We sell our products directly to hospitals and through distributors for use in procedures performed by specialist physicians to treat patients in
two key markets: neuro and peripheral vascular disease. We sell our products through purchase orders, and we do not have long term purchase commitments from our customers. We typically recognize revenue when products are delivered to our hospital
customers or distributors. However, with respect to products that we consign to hospitals, which primarily consist of coils, we recognize revenue at the time hospitals utilize products in a procedure. Revenue also includes shipping and handling
costs that we charge to customers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cost of Revenue.</I></B> Cost of revenue consists primarily of the cost of raw materials and components, personnel costs,
including stock-based compensation, inbound freight charges, receiving costs, inspection and testing costs, warehousing costs, royalty expense, shipping and handling costs and other labor and overhead costs incurred in the manufacturing of products.
We manufacture substantially all of our products in our manufacturing facility at our campus in Alameda, California. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Research and Development.</I> Research and development expenses include product development, clinical and regulatory expenses, materials, depreciation and other costs
associated with the development of our products. Research and development expenses also include salaries, benefits and other related costs, including stock-based compensation, for personnel and consultants. We expense research and development costs
as they are incurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We expect to incur additional research and development costs as we continue to innovate and develop new products and engage in
ongoing clinical research. These costs will generally increase in absolute terms as we continue to expand our product pipeline and add personnel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Sales, General
and Administrative.</I> Sales, general and administrative expenses primarily consist of salaries, benefits and other related costs, including stock-based compensation, for personnel and consultants engaged in sales, marketing, finance, legal,
compliance, administrative, information technology, medical education and training and human resource activities. Our sales, general and administrative expenses also include commissions, generally based on a percentage of sales, to direct sales
representatives and the medical device excise tax, which is approximately 2.3% of U.S. sales. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We expect our sales, general and administrative
expenses to continue to increase in absolute terms as we expand our salesforce and operations. Additionally, we expect to incur increased expenses related to headcount, professional service fees, systems and other infrastructure related to operating
as a public company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Income Tax Expense.</I></B> We are taxed at the rates applicable within each jurisdiction where we sell products. The composite income
tax rate, tax provisions, deferred tax assets and deferred tax liabilities will vary according to the jurisdiction in which profits arise. Tax laws are complex and subject to different interpretations by management and the respective governmental
taxing authorities, and require us to exercise judgment in determining our income tax provision, our deferred tax assets and liabilities and the potential valuation allowance recorded against our net deferred tax assets. Deferred tax assets and
liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not that the future realization of all or some of
the deferred tax assets will not be achieved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets forth the components of our consolidated statements of operations in dollars and as a percentage of revenue for the periods
presented: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sales, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(474</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income (loss) before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Six Months Ended June 30, 2015 Compared to Six Months Ended June 30, 2014 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Revenue </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Neuro</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Peripheral Vascular</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Revenue increased $23.6 million, or 41.0%, to $81.3 million in the six months ended June 30, 2015, from $57.6 million in
the six months ended June 30, 2014. Our revenue growth was due to expansion of our salesforce headcount by 42.5%, further market penetration of our existing products and sales of new products. Increased sales of Penumbra System products accounted
for more than half of the revenue increase in the six months ended June 30, 2015. Additionally, approximately 10.4% of the increase in revenue for the six months ended June 30, 2015 came from the sale of new products, including our Indigo peripheral
thrombectomy product, our Apollo System and our Benchmark neuro access product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Revenue from sales in the United States increased $17.0 million, or
46.0%, to $54.0 million in the six months ended June 30, 2015, from $37.0 million in the six months ended June 30, 2014. Revenue from sales in international markets increased $6.6 million, or 32.1%, to $27.3 million in the six months ended June 30,
2015, from $20.7 million in the six months ended June 30, 2014. Revenue from international sales represented 34% and 36% of our total revenue for the six months ended June 30, 2015 and 2014, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Revenue from our neuro products increased $16.0 million, or 31.9%, to $66.1 million in the six months
ended June 30, 2015, from $50.1 million in the six months ended June 30, 2014. Our neuro product sales experienced strong momentum due to further market penetration and growth in the market following the presentation and publication of trial results
in the fourth quarter of 2014, and the presentation and publication of additional trial results in the first quarter of 2015, each of which support endovascular treatment of stroke. We believe that these published trial results led to increases in
the number of procedures performed by specialist physicians using our products. Increased sales of Penumbra System products accounted for most of the revenue increase in the six months ended June 30, 2015. Further, while our introduction of
Benchmark in the fourth quarter 2014 was designed as a potential replacement for our Neuron access products, sales of our Neuron access products have increased slightly since Benchmark was introduced. The increase in revenue from our neuro products
was partially offset by a 20% period over period decrease in sales of our neuro embolization products. This decrease was due to reduced demand for our Penumbra Coil 400 product as well as a shift in our focus towards the anticipated launch of our
SMART Coil in the second half of 2015. Prices for our neuro products remained substantially flat during the period. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Revenue from our peripheral
vascular products increased $7.6 million, or 100.8%, to $15.2 million in the six months ended June 30, 2015, from $7.6 million in the six months ended June 30, 2014. Our peripheral embolization and peripheral thrombectomy products experienced strong
volume growth in the period, primarily due to the focused efforts of our dedicated peripheral vascular salesforce, which was established in the second half of 2014, and further market penetration of our products. Prices for our peripheral vascular
products remained substantially flat during the period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Gross Profit and Gross Margin </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross margin %</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Gross profit increased $15.9 million, or 41.8%, to $54.1 million in the six months ended June 30, 2015, from $38.2
million in the six months ended June 30, 2014. The increase in gross profit was primarily due to an increase in revenue from sales of our neuro and peripheral vascular products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Gross margin increased 0.4 percentage points to 66.6% in the six months ended June 30, 2015, from 66.2% in the six months ended June 30, 2014. The
increase in gross margin was primarily due to geographic and product mix. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and Development (R&amp;D) </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>R&amp;D as a percentage of revenue</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I></I><I></I><I></I>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>13.1</I><I></I><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I>%</I><I></I><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><I></I><I></I>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I></I><I>9.8</I><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I></I><I>%</I><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">R&amp;D expenses increased by $0.5 million, or 5.9%, to $8.0 million in the six months ended June 30, 2015, from $7.5
million in the six months ended June 30, 2014. The $0.5 million increase in R&amp;D expenses was primarily due to a $0.9 million increase in compensation expense resulting from increased headcount to support continued investment in our products, a
$0.2 million increase in travel related expenses and a $0.2 million increase in expenses related to demo products, partially offset by $0.8 million reduced R&amp;D spend due to the stage and timing of development activities on our projects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sales, General and Administrative (SG&amp;A) </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">SG&amp;A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">SG&amp;A <I>as a percentage of revenue</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I></I><I></I>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>49.0</I><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I>%</I><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><I></I>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>56.5</I><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I>%</I><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">SG&amp;A expenses increased by $17.7 million, or 62.7% to $45.9 million in the six months ended June 30, 2015, from $28.2
million in the six months ended June 30, 2014. Our sales and administrative headcount in the six months ended June 30, 2015 increased by 61.8%, which led to a $11.5 million increase in compensation expense. Additionally, SG&amp;A expenses were
impacted by a $2.5 million increase due to expanded marketing programs, a $1.7 million increase in legal, professional and consulting expenses and a $1.0 million increase in travel-related expenses of our salesforce to support our sales activities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provision for Income Taxes </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">nm</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Effective tax rate</I> <I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I></I><I></I>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>28.7</I><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I>%</I><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I></I><I></I>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>364.1</I><I></I></TD>
<TD NOWRAP VALIGN="bottom"><I>%</I><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our provision for income taxes decreased $0.4 million, to $0.2 million in the six months ended June 30, 2015, from $0.7
million in the six months ended June 30, 2014. Our effective tax rate increased to 364.1% for the six months ended June 30, 2015, compared to 28.7% for the six months ended June 30, 2014. The effective tax rate is based on a projection of our full
year results. The higher effective tax rate for the six months ended June 30, 2015 was primarily due to the change in mix of jurisdictional profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Year Ended
December&nbsp;31, 2014 Compared to Year Ended December&nbsp;31, 2013 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Revenue </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Neuro</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Peripheral Vascular</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Revenue increased $36.7 million, or 41.3%, to $125.5 million in 2014, from $88.8 million in 2013. Our revenue growth was
primarily due to expansion of our salesforce headcount by 55.8%, further market penetration of our existing products and sales of new products. Increased sales of Penumbra System products accounted for approximately half of the revenue increase in
2014. With respect to the impact of the introduction of new products, 12.1% of the increase in 2014 revenues came from the sale of new products, including our Indigo peripheral thrombectomy product, our Apollo System and our Benchmark neuro access
product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Revenue from sales in the United States increased $24.7 million, or 42.3%, to $83.0 million in 2014, from $58.3 million in 2013. Revenue
from sales in international markets increased $12.0 million, or 39.3%, to $42.5&nbsp;million in 2014, from $30.5 million in 2013. Revenue from international sales represented 34% and 34% of our total revenue for 2014 and 2013, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Revenue from our neuro products increased $24.9 million, or 30.6%, to $106.2&nbsp;million in 2014, from $81.3&nbsp;million in 2013. Our neuro product
sales experienced strong momentum due to further market penetration and growth in the market following presentation of trial results in October 2014, which support endovascular treatment of stroke. Additionally, our neuro product sales benefited
from the launch of our ACE Reperfusion Catheter in July 2013. Prices for our neuro products remained substantially flat during the period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Revenue from our peripheral vascular products increased $11.8 million, or 156.7%, to $19.3&nbsp;million in
2014, from $7.5&nbsp;million in 2013. Peripheral vascular product sales volume growth benefited from the focused efforts of our dedicated peripheral vascular salesforce, which was established in the second half of 2014, further market penetration
and sales from our recently launched Indigo product. Prices for our peripheral vascular products remained substantially flat during the period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Gross Profit
and Gross Margin </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Gross margin %</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>65.1</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>66.0</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Gross profit increased $25.0 million, or 43.1%, to $82.8 million in 2014, from $57.9 million in 2013. The increase in
gross profit was primarily driven by an increase in revenue from sales of our neuro and peripheral vascular products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Gross margin increased 0.9
percentage points, to 66.0% in 2014, from 65.1% in 2013. The increase in gross margin is attributable to geographic and product mix and improved manufacturing efficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and Development (R&amp;D) Expenses </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>R&amp;D as a percentage of revenue</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>15.9</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>12.4</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">R&amp;D expenses increased $1.5 million, or 10.6%, to $15.6 million in 2014, from $14.1 million in 2013. The $1.5 million
increase was primarily due to a $1.2 million increase in compensation expense resulting from increased headcount to support continued research and development in our products and a $0.3 million increase in consulting costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sales, General and Administrative (SG&amp;A) Expenses </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">SG&amp;A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>SG&amp;A as a percentage of revenue</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>50.6</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>51.2</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">SG&amp;A expenses increased by $19.3 million, or 43.1%, to $64.3 million in 2014, from $44.9 million in 2013. The $19.3
million increase was primarily due to a $10.9 million increase in compensation expense resulting from increased headcount, a $2.1 million increase in legal, professional and consulting fees, a $2.1 million increase in marketing expenses due to
expanded marketing programs and a $1.5 million increase in travel-related expenses for our salesforce to support our sales activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provision for Income
Taxes </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">nm</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Effective tax rate</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>nm</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>28.5</I></TD>
<TD NOWRAP VALIGN="bottom"><I>%&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our provision for income taxes was $0.9 million in 2014 compared to a tax benefit of $5.4 million in 2013.
The higher tax provision in 2014 was due to the release of a valuation allowance of $5.0 million against net deferred tax assets in 2013 and the reduced availability of net operating loss carryforwards in 2014. Our effective tax rate was 28.5% in
2014. The effective tax rate in 2014 was lower than the U.S. federal statutory rate due to the impact of federal income tax credits. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Prior to 2013,
we recorded a valuation allowance in the full amount of our net deferred tax assets, as we had assessed our cumulative loss position and determined that the future benefits were not more likely than not to be realized. As of December&nbsp;31, 2013,
we determined that it is more likely than not that a portion of the net deferred tax assets will be realized for federal and state income tax purposes in the U.S., except in California, and released $5.0 million of the valuation allowance. We
continue to record a valuation allowance in the full amount of the net deferred tax assets attributable to California and certain foreign jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Quarterly Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets forth unaudited
quarterly consolidated statement of operations data for each of the six quarters ended June&nbsp;30, 2015. The information for each of these quarters has been prepared on a basis consistent with our audited annual consolidated financial statements
appearing elsewhere in this prospectus, and includes, in our opinion, all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the financial information contained herein. The following quarterly data
should be read together with our consolidated financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the future. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quarter Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FY2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FY2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Mar. 31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Sept. 30,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Dec. 31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Mar. 31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Income before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net income (loss) attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net income (loss) per share attributable to common stockholders&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net income (loss) per share attributable to common stockholders&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Weighted average shares used to compute net income (loss) per share attributable to common stockholders&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,430,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,608,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,688,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,701,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,903,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,096,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Weighted average shares used to compute net income (loss) per share attributable to common stockholders&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,705,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,868,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,688,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,102,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,193,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,096,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our revenue and gross profit increased sequentially for all quarters presented. However, we may have quarters
for which we experience significant revenue and gross profit growth followed by quarters with limited revenue and gross profit growth. For example, in the three months ended September&nbsp;30, 2014, we experienced limited sequential revenue and
gross profit growth due to a number of factors, including mix of products sold, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
limited growth in demand and the effects of hiring and integrating new sales people and their transition into existing sales territories. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Other factors affecting our revenue and gross profit growth include acceptance of new products by specialist physicians and successfully transitioning
these physicians to new products from existing products, buildup of inventory of new products and write downs or write offs of inventory of older products, introduction of new products by competitors, publication of clinical results that may
influence specialist physicians and the fact that the specialist physicians who use our products may not perform procedures during certain times of the year due to their attendance at major medical conferences or for other reasons, the time of which
occurs irregularly during the year and from year to year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Additionally, in the third quarter of 2014, we repurchased an aggregate of 629,663 shares
of our Series B, Series C, Series D and Series E Preferred Stock from certain of our shareholders and recorded a distribution of $6.3 million to such shareholders which impacted our earnings per share computation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Since our inception, we have
financed our operations through private placements of preferred stock. As of June 30, 2015, we had $91.3 million in working capital, which included $36.8 million in cash and cash equivalents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition to our existing cash and cash equivalents and marketable investment balances, our principal source of liquidity is our accounts receivable.
We believe these sources will provide sufficient liquidity for us to meet our liquidity requirements for at least the next 12 months. Our principal liquidity requirements are to fund our operations, including our research and development, and
capital expenditures. To facilitate our expansion, we may also lease or purchase additional facilities. We expect to continue to make investments as we launch new products, expand our manufacturing operations and further expand into international
markets. We may, however, require or elect to secure additional financing as we continue to execute our business strategy. If we require additional funds, we may seek to raise capital through equity or debt financing, which may not be available on
acceptable terms, could result in dilution to our stockholders and could require us to agree to covenants that limit our operating flexibility. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>June 30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marketable investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Working capital consists of total current assets less total current liabilities. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets forth, for the periods indicated, our beginning balance of cash and cash equivalents, net cash flows provided by (used in)
operating, investing and financing activities and our ending balance of cash and cash equivalents: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,001</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net Cash Provided by (Used in) Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Cash provided by (used in) operating activities consists primarily of net income adjusted for certain non-cash items (including depreciation and
amortization, inventory write downs, stock-based compensation expense, provision for doubtful accounts, provision for sales returns, loss on minority investment, loss on disposal of property and equipment, provision for product warranty), and the
effect of changes in working capital and other activities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Net cash used in operating activities was $8.3 million during the six months ended June
30, 2015 and consisted of net loss of $0.2 million and net changes in operating assets and liabilities of $13.8 million, partially offset by non-cash items of $5.6 million. The change in operating assets and liabilities include the increase in
inventories of $11.3 million to support our revenue growth, an increase in accounts receivable of $4.9 million, an increase in prepaid expenses and other current and non-current assets of $2.8 million, partially offset by an increase in accrued
expenses and other non-current liabilities of $4.7 million and accounts payable of $0.5&nbsp;million, as a result of the growth in our business activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Net cash provided by operating activities was $2.0 million during the six months ended June 30, 2014, and consisted of net income of $1.7 million and
non-cash items of $1.7 million, partially offset by net changes in operating assets and liabilities of $1.3 million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Net cash used by operating
activities was $6.4&nbsp;million in 2014 and consisted of net income of $2.2 million and non-cash items of $3.5&nbsp;million, offset by net changes in operating assets and liabilities of $12.1&nbsp;million. The change in operating assets and
liabilities include an increase in inventories of $9.4&nbsp;million to support our revenue growth and a corresponding increase in accounts receivable of $7.4&nbsp;million and an increase in prepaid expenses and other current and non-current assets
of $1.9&nbsp;million partially offset by an increase in accrued expenses and other non current liabilities of $5.4 million and accounts payable of $1.3 million as a result of the growth in our business activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Net cash used by operating activities was $3.4&nbsp;million in 2013 and consisted of net income of $4.1&nbsp;million, and a change in non-cash items of
$2.5&nbsp;million, which includes a release of a valuation allowance of $5.0 million and a change in deferred tax benefits of $0.3&nbsp;million, partially offset by net changes in operating assets and liabilities of $5.0&nbsp;million. The
significant items in the change in operating assets and liabilities include increases in inventories and accounts receivable of $3.8 million and $1.6 million, respectively, partially offset by increase in accrued expenses and other non-current
liabilities of $1.7 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net Cash Provided by (Used in) Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Cash provided by (used in) investing activities relates primarily to divestures or purchases of marketable investments and capital expenditures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Net cash provided by investing activities was $45.0 million during the six months ended June 30, 2015 and consisted of net proceeds from sales of
marketable investments of $48.1 million partially offset by capital expenditures of $3.1 million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Net cash used in investing activities was $0.9
million during the six months ended June 30, 2014 and consisted of capital expenditures of $0.8 million and net purchase of marketable investments of $0.1 million. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Net cash used in investing activities was $37.0 million in 2014 and consisted of net purchase of marketable investments of $33.1 million and capital
expenditures of $3.9 million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Net cash used in investing activities was $1.3 million during in 2013 and consisted of capital expenditures of $0.8
million and net purchase of marketable investments of $0.5 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net Cash Provided by (Used in) Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Cash from financing activities primarily relates to capital raising activities through equity or debt financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Financing activities in the six months ended June 30, 2015 used cash of $3.0 million and consisted of
payment of employee taxes related to vested common and restricted stock of $2.5 million and payments of deferred issuance costs of $1.0&nbsp;million, partially offset by proceeds from exercises of stock options of $0.5&nbsp;million. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Financing activities in the six months ended June 30, 2014 provided $50.5 million and consisted of proceeds from the issuance of Series F Preferred Stock
of $57.1 million, net of issuance costs and proceeds from exercises of stock options of $0.3 million. These proceeds were offset in part by the repayment of amounts outstanding under our credit facility of $6.0 million upon its termination in May
2014 and repurchases of common stock and stock options of $0.9 million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Financing activities in 2014 provided $42.9 million and consisted of
proceeds from issuance of Series&nbsp;F Preferred Stock of $57.2 million, net of issuance costs and proceeds from exercises of stock options of $1.0 million. These proceeds were partially offset by repurchases of preferred stock, common stock and
stock options of $9.4 million and the repayment of amounts outstanding under our credit facility of $6.0 million upon its termination in May 2014. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Financing activities in 2013 provided $2.2 million and consisted of proceeds from our credit facility of $2.0 million and proceeds from exercises of
stock options of $0.2 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Indebtedness </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In May
2012, we entered into a $15.0 million revolving credit facility with Wells Fargo Bank, National Association. The credit facility was collateralized by our investment balances. The interest on the credit facility was based on the daily one-month
London Inter-Bank Offered Rate (LIBOR), plus 1.75% and was payable monthly. The outstanding balance on the credit facility was due in full on June&nbsp;1, 2015. The credit facility contained customary covenants for credit facilities of this type,
including limitations on disposition of assets and changes in control. In May 2014, in conjunction with our Series F Preferred Stock financing, we paid the then outstanding balance on the credit facility and terminated the credit facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Contractual Obligations and Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table
summarizes our contractual obligations as of December&nbsp;31, 2014: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less&nbsp;Than<BR>One Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1-3&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>3-5&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>More&nbsp;than<BR>Five&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Rent obligations<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Equipment lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Purchase commitments<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We lease our corporate headquarters and a manufacturing facility at our campus in Alameda, California pursuant to lease agreements that expire in November 2029. Additionally, we lease offices in Germany, Australia and
Brazil. In June 2015, a lease for additional space at our campus in Alameda, California commenced upon our landlord&#146;s substantial completion of tenant improvements. This lease expires in November 2029 and, as of June 30, 2015, represented a
contractual obligation of $13.9 million. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We lease equipment and automobiles under operating leases. These leases expire at various dates through 2018. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Purchase commitments consist of contracts with suppliers to purchase raw materials to be used to manufacture products. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The amounts in the table above exclude $0.6 million of income tax liabilities included in current liabilities as we are unable to
reasonably&nbsp;estimate the timing of settlement. See Note 15 to our Consolidated Financial Statements. In addition, the table above does not reflect royalty obligations under a license agreement as amounts due thereunder fluctuate depending on
sales levels. See Note 7 to our Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We do not have any off-balance sheet arrangements or any holdings in variable interest entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Quantitative and Qualitative Disclosure about Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We
are exposed to various market risks, which may result in potential losses arising from adverse changes in market rates, such as interest rates and foreign exchange rates. We do not enter into derivatives or other financial instruments for trading or
speculative purposes and do not believe we are exposed to material market risk with respect to our cash and cash equivalents and/or our marketable investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interest Rate Risk.</I></B> We had cash and cash equivalents of $3.3 million and $36.8 million as of December&nbsp;31, 2014 and June 30, 2015, respectively, which
consisted of cash and highly liquid money market funds. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Foreign Exchange Risk Management.</I></B> We operate in countries other than the United States, and,
therefore, we are exposed to foreign currency risks. We bill most sales outside of the United States in local currencies, primarily the euro and Japanese yen. We expect that the percentage of our sales denominated in foreign currencies will increase
in the foreseeable future as we continue to expand into international markets. When sales or expenses are not denominated in U.S. dollars, a fluctuation in exchange rates could affect our net income. We do not believe an immediate 10% adverse change
in foreign exchange rates would have a material effect on our results of operations. We do not currently hedge our exposure to foreign currency exchange rate fluctuations; however, we may choose to hedge our exposure in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Related-Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">For a description of our
related-party transactions, see the section titled &#147;Certain Relationships and Related-Party Transactions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Critical Accounting Policies and Estimates
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The
preparation of our consolidated financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the applicable periods. Management bases its estimates, assumptions and judgments on historical experience and on various other factors that it believes to be
reasonable under the circumstances. Different assumptions and judgments would change the estimates used in the preparation of our consolidated financial statements, which, in turn, could materially change our results from those reported. Management
evaluates its estimates, assumptions and judgments on an ongoing basis. Historically, our critical accounting estimates have not differed materially from actual results. However, if our assumptions change, we may need to revise our estimates, or
take other corrective actions, either of which may also have a material adverse effect on our consolidated statements of operations, liquidity and financial condition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe the following critical accounting policies involve significant areas where management applies judgments and estimates in the preparation of
our consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Segments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have
determined our operating segment on the same basis that we use to evaluate our performance internally. We have one business activity: the design, development, manufacturing and marketing of innovative medical devices, and we operate as one operating
segment. Our chief operating decision-maker, our Chief Executive Officer, reviews our operating results for the purpose of allocating resources and evaluating financial performance. We determine revenue by geographic area, based on the destination
to which we ship our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Revenue Recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Revenue is comprised of product revenue net of returns, discounts and administration fees. We recognize revenue when persuasive evidence of an
arrangement exists, delivery has occurred, the sales price is fixed or determinable and collectability is reasonably assured. Evidence of an arrangement consists of customer orders, and we typically consider delivery to have occurred once title and
risk of loss has been transferred and the product has been delivered to our customers. We typically recognize revenue when products are delivered to our hospital customers or distributors. However, with respect to products that we consign to
hospitals, which primarily consist of coils, we recognize revenue at the time hospitals utilize our products used in a procedure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We defer revenue
for amounts that we have already invoiced our customers for and are ultimately expected to be recognized as revenue, but for which not all revenue recognition criteria have been met. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our terms and conditions permit product returns and exchanges, and we record returns reserves in the period when revenue is recognized. Estimates are
based on actual historical returns over the prior three years and are recorded as reductions in revenue at the time of sale. Upon recognition, we reduce revenue and cost of revenue for the estimated return. Return rates can fluctuate over time, but
are sufficiently predictable to allow us to estimate expected future product returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Accounts Receivable </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Accounts receivable are stated at invoice value less estimated allowances for returns and doubtful accounts. We continually monitor customer payments and
maintain a reserve for estimated losses resulting from our customers&#146; inability to make required payments. We consider factors such as historical experience, credit quality, age of the accounts receivable balances, geographic related risks and
economic conditions that may affect a customer&#146;s ability to pay. In cases where there are circumstances that may impair a specific customer&#146;s ability to meet its financial obligations, a specific allowance is recorded against amounts due,
and thereby reduces the net recognized receivable to the amount reasonably believed to be collectible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Inventories </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Inventories are stated at the lower of cost (determined under the first-in first-out method) or market. Write-downs are provided for finished goods
expected to become nonsaleable and provisions are specifically made for excessive, slow-moving or obsolete items. Market value is determined as the lower of replacement cost or net realizable value. We regularly review inventory quantities in
consideration of actual loss experiences, projected future demand, and remaining shelf life to record a provision for excess and obsolete inventory when appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The estimate of excess quantities is subjective and primarily dependent on our estimate of future demand for a particular product. If the estimate of
future demand is inaccurate based on actual sales, we may increase the write down for excess inventory for that component and record a charge to inventory impairment in the accompanying consolidated statements of operations and comprehensive income.
We periodically evaluate the carrying value of inventory on hand for potential excess amount over demand using the same lower of cost or market approach as that has been used to value the inventory. We also periodically evaluate inventory quantities
in consideration of actual loss experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Cost of Revenue </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Cost of revenue includes direct and indirect costs associated with the manufacture of our products. Direct costs include material and labor, while
indirect costs include, but are not limited to, inbound freight charges, receiving costs, inspection and testing costs, warehousing costs, royalty expense and other labor and overhead costs incurred in the manufacturing of products. Cost of revenue
also includes stock-based compensation, warranty replacement costs, cost of revenue related to product return reserves, and excess and obsolete inventory write-downs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Research and Development (R&amp;D) Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">R&amp;D costs include personnel-related costs, including stock-based compensation, regulatory, supplies, services, depreciation, allocated facilities and
information services, clinical trial and related clinical manufacturing expenses, fees paid to investigative sites and other indirect costs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our
clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites. We estimate preclinical and clinical trial expenses based on the services performed pursuant to contracts with research
institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time period over which services will be performed and the level of patient
enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made to third parties under these arrangements in
advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Stock-based compensation costs related to stock options granted to employees are measured at the date of grant based on the estimated fair value of the
award, net of estimated forfeitures. We estimate the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model on a straight-line basis over the requisite service period of the award,
which is generally the vesting term of four years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Black-Scholes option-pricing model requires the use of highly subjective assumptions which
determine the fair value of stock-based awards. The assumptions used in our option-pricing model represent management&#146;s best estimates. These estimates are complex, involve a number of variables, uncertainties and assumptions and the
application of management&#146;s judgment, so that they are inherently subjective. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. These assumptions are
estimated as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I></I><B><I>Fair Value of Common Stock.</I></B><I></I> Because our stock is not publicly traded, we must estimate its fair
value, as discussed in &#147;Common Stock Valuations&#148; below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I></I><B><I>Risk-Free Interest Rate.</I></B><I> </I>We base the risk-free
interest rate used in the Black-Scholes valuation model on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term of the options for each option group. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I></I><B><I>Expected Term.</I></B><I></I> The expected term represents the period that our stock-based awards are expected to be outstanding. Because of
the limitations on the sale or transfer or our common stock as a privately held company, we do not believe our historical exercise pattern is indicative of the pattern we will experience as a publicly traded company. We have consequently used the
Staff Accounting Bulletin, or SAB, 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period. We plan to continue to use the SAB&nbsp;110 simplified method until we have sufficient trading
history as a publicly traded company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><B><I>Volatility.</I></B> We determine the price volatility factor based on the historical volatilities of our
peer group as we do not have a trading history for our common stock. Industry peers consist of several public companies in the medical device technology industry with comparable characteristics including enterprise value, risk profiles and position
within the industry. We intend to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our own common stock share price becomes
available, or unless circumstances change such that the identified companies are no longer similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><B><I>Dividend Yield.</I></B> The expected dividend assumption is based on our current expectations about our anticipated dividend policy. We currently
do not expect to issue any dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition to assumptions used in the Black-Scholes option-pricing model, we must also estimate a
forfeiture rate to calculate the stock-based compensation for our awards. We will continue to use judgment in evaluating the assumptions related to our stock-based compensation on a prospective basis. As we continue to accumulate additional data, we
may have refinements to our estimates, which could materially impact our future stock-based compensation expense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We used the following assumptions
in our Black-Scholes option pricing model to determine the fair value of employee stock options: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June 30,</B></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center"><B>(unaudited)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6.25</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">45%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">45%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">45%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">45%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">0.63%&nbsp;-&nbsp;0.90%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">1.76%&nbsp;-&nbsp;2.02%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">1.76%&nbsp;-&nbsp;2.02%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">1.56%&nbsp;-&nbsp;1.78%</FONT></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets forth the stock-based compensation expense included in the consolidated statements of operations
(in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sales, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of June 30, 2015, we had approximately $11.4 million of total unrecognized compensation expense, net of related
forfeiture estimates, which we expect to recognize over a weighted average period of approximately 3.5 years. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The intrinsic value of all
outstanding options as of June&nbsp;30, 2015 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million based on the estimated fair value of our common stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share,
which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Common Stock Valuations
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The fair value of the shares of common stock underlying our stock options has historically been determined by our board of directors.
Because there has been no public market for our common stock and in the absence of recent arm&#146;s-length cash sales transactions of our common stock with independent third parties, our board of directors has determined the fair value of our
common stock by considering at the time of grant a number of objective and subjective factors. Our board of directors intends all options granted to be exercisable at a price per share not less than the per share fair value of our common stock
underlying those options on the date of grant. The estimated fair value of our common stock was determined at each valuation date in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid,
Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Our board of directors, with the assistance of management, developed these valuations using significant judgment and taking into account numerous factors, including the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">independent third-party valuations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">progress of research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our operating and financial performance, including our levels of available capital resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rights and preferences of our common stock compared to the rights and preferences of our other outstanding equity securities; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equity market conditions affecting comparable public companies, as reflected in comparable companies&#146; market multiples, IPO valuations and other metrics; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the achievement of enterprise milestones, including our progress in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of achieving a liquidity event for the shares of common stock, such as an IPO given prevailing market and medical device sector conditions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our preferred stock in arms-length transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the illiquidity of our securities by virtue of being a private company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business risks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">management and board experience. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We considered the following approaches in the preparation of our
valuations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Market Approach</I>.&nbsp;The market approach values a business by reference to guideline companies, for which enterprise values are known. This approach has two principal methodologies. The guideline public company
methodology derives valuation multiples from the operating data and share prices of similar publicly traded companies. The guideline acquisition methodology focuses on comparisons between the subject company and guideline acquired public or private
companies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Option-Pricing Method Backsolve, or OPM backsolve</I>. The OPM backsolve method derives the implied equity value for a company from a recent transaction involving the company&#146;s own securities issued on an
arms-length basis. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Probability Weighted Expected Return Method</I>.&nbsp;Using the probability weighted expected return, or PWERM, method, the value of a company&#146;s common stock is estimated based upon the analysis of future values
for the company assuming various possible future liquidity events like an initial public offering, sale or merger. Share value is based upon the probability-weighted present value of expected future net cash flows, considering each of the possible
future events, as well as the rights and preferences of each share class. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, we also considered an enterprise value
allocation method: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Option-Pricing Method, or OPM</I>.&nbsp;Under this method, each class of stock is modeled as a call option with a distinct claim on the enterprise value of the company. The option&#146;s exercise prices would be
based on a comparison with the enterprise value. The method assumes that a formula, such as the Black-Scholes model, would calculate the fair value when provided with certain values, including share price, expiration date, volatility and the risk
free interest rate. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The per share common stock value was estimated by allocating our enterprise value using the OPM method in
October&nbsp;1, 2013 , May&nbsp;16, 2014, and September&nbsp;30, 2014, which determined the common stock value to be $7.75, $9.06 and $10.92, respectively. The per share common stock value was estimated in December&nbsp;31, 2014, March&nbsp;31, 2015
and June 30, 2015, which utilized the PWERM method, which determined the common stock value to be $12.36, $14.46 and $20.51, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In
determining the estimated fair value of our common stock, our board of directors also considered the fact that our stockholders could not freely trade our common stock in the public markets. Accordingly, we applied discounts to reflect the lack of
marketability of our common stock based on the expected time to liquidity. The estimated fair value of our common stock at each grant date reflected a non-marketability discount partially based on the anticipated likelihood and timing of a future
liquidity event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The key subjective factors and assumptions used in our valuations primarily consisted of: (i)&nbsp;the selection of the appropriate
market comparable transactions, (ii)&nbsp;the selection of the appropriate comparable publicly traded companies, (iii)&nbsp;the financial forecasts utilized to determine future cash balances and necessary capital requirements, (iv)&nbsp;the
probability and timing of the various possible liquidity events, (v)&nbsp;the estimated weighted average cost of capital and (vi)&nbsp;the discount for lack of marketability of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">At each grant date the board of directors reviewed any recent events and their potential impact on the
estimated fair value per share of the common stock. As is provided for in Internal Revenue Code Section&nbsp;409A, we generally rely on our valuations for up to twelve months unless we have experienced a material event that would have affected the
estimated fair value per common share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We
account for income taxes using the asset and liability method, whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities, and are measured
using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We provide a valuation allowance to reduce the net deferred tax assets to their estimated realizable value. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">At December&nbsp;31, 2014, we had approximately $17.8&nbsp;million and $2.0&nbsp;million of state and foreign net operating loss carryforwards,
respectively, available to offset future taxable income. The state net operating loss carryforwards will begin to expire in 2017. At December&nbsp;31, 2014, we had research credits available to offset federal and state tax liabilities in the amount
of $0.7&nbsp;million and $2.8&nbsp;million, respectively. Federal credits will begin to expire in 2027 and California state tax credits have no expiration. As of December&nbsp;31, 2014, we had fully used $22.6&nbsp;million of federal net operating
losses, which we had accumulated in our first six years of operations, from 2004 through 2009. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The calculation of our current provision for income
taxes involves the use of estimates, assumptions and judgments while taking into account current tax laws, interpretation of current tax laws and possible outcomes of future tax audits. We have established reserves to address potential exposures
related to tax positions that could be challenged by tax authorities. Although we believe our estimates, assumptions and judgments to be reasonable, any changes in tax law or its interpretation of tax laws and the resolutions of potential tax audits
could significantly impact the amounts provided for income taxes in our consolidated financial statements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">At June 30, 2015, our net deferred tax
asset was $6.8 million, after reduction of a&nbsp;valuation&nbsp;allowance&nbsp;of $2.9 million. The calculation of our deferred tax asset balance involves the use of estimates, assumptions and judgments while taking into account estimates of the
amounts and type of future taxable income. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that the future realization of all or some of the deferred tax assets will not be achieved. Valuation allowances
related to deferred tax assets can be affected by changes to tax laws, statutory tax rates, future taxable income levels and input from our tax advisors or regulatory authorities. If our management was to determine that we would not be able to
realize all or a portion of our net deferred tax assets in the future, a valuation allowance related charge to earnings would be reflected in that period, which could have a material adverse impact on our financial condition and results of
operations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have adopted ASC 740-10 &#147;Accounting for Uncertainty in Income Taxes&#148; that prescribes a recognition threshold and
measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in our income tax return, and also provides guidance on derecognition, classification, interest and penalties,
accounting in interim periods, disclosure and transition. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We include interest and penalties related to unrecognized tax benefits within income tax
expense in the accompanying consolidated statements of operations. We have not incurred any interest or penalties related to unrecognized tax benefits in any of the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Recently Issued Accounting Standards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In May 2014, the FASB
issued ASU No.&nbsp;2014-09, <I>Revenue from Contracts with Customers</I>, which outlines a comprehensive new revenue recognition model designed to depict the transfer of promised goods or services to customers in an amount that reflects the
consideration to which the entity expects to be entitled in exchange for those goods or services. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after
December&nbsp;15, 2016. Early adoption is not permitted. We are currently evaluating the impact of this accounting standard. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In July 2015, the FASB voted to defer the effective date by one year to December&nbsp;15, 2017 for annual
reporting periods beginning after that date. The FASB also voted to permit early adoption of the standard, but not before the original effective date of December&nbsp;15, 2016. The final accounting standard formally amending the effective date is
expected to be issued by the FASB by the end of the third quarter of 2015. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In November 2014, the FASB issued ASU No.&nbsp;2014-17, <I>Pushdown
Accounting</I>, which provides an acquired entity to elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs and allows the acquired entity to determine whether to elect to apply pushdown
accounting for each individual change-in-control event in which the acquirer obtains control of the acquired entity. This accounting standard is effective as of November&nbsp;18, 2014 and we will apply the guidance to future change-in control
events. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In July 2015, the FASB issued ASU No. 2015-11, <I>Simplifying the Measurement of Inventory</I>, which requires an entity to measure most
inventory at the lower of cost and net realizable value, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. The accounting standard is effective prospectively for annual periods
beginning after December 15, 2016 and interim periods therein. Early adoption is permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of this accounting standard. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Penumbra is a global interventional therapies
company that designs, develops, manufactures and markets innovative medical devices. We have a broad portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral
vascular. The conditions that our products address include, among others, ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are an established company focused on the neuro market, and we recently expanded our business to include the peripheral vascular market. We sell our
products to hospitals, primarily through our salesforce, as well as through distributors in select international markets. We focus on developing, manufacturing and marketing products for use by specialist physicians, including interventional
neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. We design our products to provide these specialist physicians with a means to drive improved clinical outcomes through faster and safer
procedures. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We attribute our success to our culture built on cooperation, our highly efficient product innovation process, our disciplined
approach to product and commercial development, our deep understanding of our target end markets and our relationships with specialist physicians. We believe these factors have enabled us to rapidly innovate in a highly capital-efficient manner.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Since our founding in 2004, we have had a strong track record of organic product development and commercial expansion that has established the
foundation of our global organization. Some of our key accomplishments include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching our first product, for neurovascular access, in the United States in 2007; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing our direct neuro salesforce in the United States and Europe in 2008; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching the first 510(k)-cleared, aspiration-based product for the treatment of ischemic stroke patients in 2008, and launching four subsequent generations of that product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching our first neurovascular coil for the treatment of brain aneurysms in 2011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching our first peripheral vascular product in 2013; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing our direct peripheral vascular salesforce in the United States and Europe in 2014. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of
June 30, 2015, we had approximately 1,000 employees worldwide. We sell our products to hospitals primarily through our direct sales organization in the United States, most of Europe, Canada and Australia, as well as through distributors in select
international markets. For the year ended December&nbsp;31, 2014, we generated revenue of $125.5 million, which represents a 41.3% increase over 2013, and $3.0&nbsp;million in operating income as compared to an operating loss of $1.1&nbsp;million in
2013. For the six months ended June 30, 2015, we generated revenue of $81.3 million, which represents a 41.0% increase over the six months ended June 30, 2014, and $0.2 million in operating income as compared to operating income of $2.4 million for
the six months ended June 30, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We estimate that the market for our current neuro and peripheral vascular products in the United States and Europe combined was approximately $1.3
billion in 2014, which we estimate represents growth of approximately 3.2%&nbsp;per year from 2012. While reliable third-party data is not available for markets outside the United States and Europe, we believe that there is a substantial additional
market for our neuro and peripheral vascular products in the rest of the world. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe the market for our products remains substantially underpenetrated today, and that this market
will experience significant growth as we and our competitors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generate additional clinical evidence supporting endovascular treatment of vascular disease; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improve existing technologies to enable physicians to treat vascular disease faster and more safely than previously possible; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">support and educate the growing number of specialist physicians who treat vascular disease in the use of endovascular treatment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grow the number of hospitals where endovascular treatment of vascular disease is available; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">raise patient awareness of endovascular treatment of vascular disease. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We estimate that the market for
our neuro products in the United States and Europe combined was over $500 million in 2014. According to the American Heart Association (AHA), the worldwide incidence of all forms of stroke was 33&nbsp;million in 2010. We believe the recent
publication of several major clinical trials demonstrating the benefit of endovascular treatment of ischemic stroke patients over the standard medical therapy will significantly expand the neuro market and support increased future growth. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We estimate that the market for our peripheral vascular products in the United States and Europe combined was over $750 million in 2014. Furthermore,
according to a paper published in the journal <I>The Lancet</I>, 202&nbsp;million people globally were living with peripheral artery disease in 2010. We believe that expanded adoption of new technologies developed to treat peripheral vascular
disease will drive continued growth in this market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Industry Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B></B><B><I>Vascular Disease</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Vascular disease refers
to any condition that affects the circulatory system and typically manifests as a blockage or rupture of an artery or a vein. It may occur in any part of the body and is a condition that leads most often to blood vessel narrowing and obstruction,
but can also lead to expansion of the blood vessel wall and blood vessel wall weakening and rupture. Vascular disease can cause a range of conditions, from pain to functional impairment, and it can require the amputation of a limb or result in
death. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">When the treatment for vascular disease is performed from within a vessel, it is referred to as an endovascular procedure. Endovascular
procedures are minimally invasive means of treating the two major vascular problems that can develop within blood vessels: an occlusion, where the vessel is blocked or narrowed, and an aneurysm, or weakening of the vessel wall that forms a
balloon-like pouch that fills with blood. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Endovascular procedures are performed by utilizing an accessible artery to reach an occlusion or aneurysm.
During most endovascular procedures, a catheter is placed into the femoral artery in the groin, and X-ray imaging or fluoroscopy is used to help the physician visually navigate the catheter to the area to be treated. Endovascular procedures are less
invasive and require a smaller incision than conventional open surgery, and we believe they are safer procedures for patients, reduce hospital stays and recovery times, and are more cost effective to the healthcare system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Endovascular device markets are conventionally classified according to the anatomic location of the disorder. We currently focus our efforts on the neuro
and peripheral vascular markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Neurovascular Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Neurovascular diseases are vascular diseases and disorders in the brain. A devastating complication of neurovascular disease is stroke. A stroke is
caused by either an occlusion or rupture of an artery or vein. According to the AHA, the worldwide incidence of all forms of stroke was 33&nbsp;million in 2010, and stroke was the second leading cause of death globally. The AHA estimates that there
are approximately 795,000 strokes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
annually in the United States, making stroke the fourth leading cause of death, and the leading cause of long-term disability. The AHA estimates that stroke results in total direct and indirect
costs of approximately $33 billion in the United States annually. There are two principal forms of stroke: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ischemic strokes, which are caused by the blockage of an artery to the brain and affect approximately 690,000 patients annually in the United States; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hemorrhagic strokes, which are caused by a sudden rupture of a brain artery that leads to bleeding into or around the brain and affect approximately 105,000 patients annually in the United States. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Both forms of stroke may result in permanent brain damage or death. Patients who survive a stroke are often left with disabilities, including paralysis,
coma, impaired cognition, decreased coordination, loss of visual acuity, loss of speech, loss of sensation or some combination of these conditions. The devastating effects of stroke are one of the greatest costs to the healthcare system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Ischemic Stroke </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Ischemic strokes can be caused by several
kinds of disease and can be characterized as either thrombotic or embolic. A thrombotic stroke is the most common and occurs when arteries in the brain become blocked by the formation of a clot within the brain. An embolic stroke occurs when a clot
or small piece of plaque formed in one of the arteries leading to the brain travels through the bloodstream where it lodges in narrower arteries in the brain and blocks blood flow. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Treatment for patients with a blocked blood vessel in the brain that has caused an ischemic stroke consists of two basic methodologies to restore blood
flow to the brain: intravenous (IV) lysis of the clot with administration of tissue plasminogen activator (tPA), the standard medical therapy, and more recently, endovascular removal of the clot with catheter based devices, or thrombectomy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">tPA is a clot dissolving drug that is administered to patients presenting with ischemic stroke symptoms within 3 hours, in most patients, and up to 4.5
hours in certain eligible patients. However, a large percentage of stroke patients do not arrive at a hospital in time for tPA treatment, and a significant percentage of patients treated with tPA do not immediately experience improved blood flow, or
perfusion, to the brain. Such delays in perfusion can lead to prolonging or exacerbating the symptoms of ischemic stroke. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Currently, thrombectomy
products are 510(k) cleared by the FDA for use within eight hours of stroke onset to restore blood flow in patients experiencing an ischemic stroke. Thrombectomy is performed by advancing a catheter to the site of the blocked blood vessel in the
brain and then aspirating the clot into an aspiration catheter at the site of the clot, deploying a stent-like device and retracting it through the cerebral vasculature into a large catheter in the neck, or a combination of the two approaches.
Ischemic stroke patients with large vessel occlusions and those with sufficient salvageable tissue are candidates for endovascular thrombectomy. According to a paper published in the journal <I>Stroke</I>, only 0.6% of stroke patients in the United
States in 2009 underwent such a procedure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In the past year, several major clinical trials have produced clinical data demonstrating the benefit of
endovascular treatment of stroke patients over standard medical therapy. The MR CLEAN study, published in <I>The New England Journal of Medicine</I> in January 2015, demonstrated the benefit of endovascular thrombectomy plus standard medical therapy
over standard medical therapy alone. The MR CLEAN study demonstrated the benefit of endovascular treatment across the range of clinical outcomes at 90 days, judged by the modified Rankin Scale (mRS), which is a commonly used scale measuring the
degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. In the MR CLEAN study, where patients received endovascular treatment for stroke, there was a significant
increase in the number achieving functional independence at 90 days, with 32.6% of the endovascular treatment group achieving a 0 to 2 on the mRS, which indicates no symptoms or only slight disability, compared to 19.1% of the control group. The
results of this study have now been independently confirmed by several additional clinical trials: ESCAPE (2015), SWIFT PRIME (2015), EXTEND IA (2015), REVASCAT (2015), THRACE (2015) and our own THERAPY (2015) study. These studies support
endovascular stroke treatment (as compared to standard medical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">therapy) across a range of different products and patient selection criteria. With the exception of our own
THERAPY study, we do not have access to the raw data underlying the published results of these trials, and so we cannot state with certainty whether any of our products was used in any of the trials. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">With the recent clinical data supporting the benefits of endovascular thrombectomy, the Society of NeuroInterventional Surgery (SNIS) has stated
endovascular thrombectomy is a new standard of care for stroke patients who qualify for the procedure. SNIS published the Report of its Standard and Guidelines Committee in the <I>Journal of NeuroInterventional Surgery</I> in May 2015, including the
following specific language: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:arial">&#147;For patients with anterior circulation stroke and documented E[mergent] L[arge] V[essel]
O[cclusion] affecting the ICA or M1 segment of the MCA and a corresponding clinical deficit, the addition of endovascular embolectomy results in superior clinical outcomes compared with best medical therapy alone. Embolectomy needs to be performed
as rapidly as possible for the greatest clinical benefit, and is best when performed within 6 h[ours] from onset of symptoms (AHA Class I, level of evidence A.).&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ICA or M1 Segment of the MCA refers to the specific anatomical location of the occlusion in the vasculature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, on June 29, 2015, the American Heart Association/American Stroke Association (AHA/ASA) issued its updated guidance on endovascular
treatment of acute ischemic stroke&#151;the 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment. It was published in <I>Stroke</I>, the medical journal
of the AHA/ASA. The AHA/ASA guidelines focus on the use of stent retrievers as the primary method of endovascular treatment of acute ischemic stroke but also allow for the use of other devices. Recommendation 10 specifically states: &#147;Use of
stent retrievers is indicated in preference to the MERCI device. The use of mechanical thrombectomy devices other than stent retrievers may be reasonable in some circumstances.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Given the recent clinical data supporting endovascular treatment of ischemic stroke patients and the substantial clinical need and economic burden of
ischemic stroke, we believe that the market for endovascular treatment of ischemic stroke is in its early stages of development and will continue to expand significantly over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Hemorrhagic Stroke </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Hemorrhagic strokes are caused by a
sudden rupture of a brain artery leading to bleeding into or around the brain. A cerebral aneurysm is usually located along the major arteries deep within brain structures. A major cause of hemorrhagic stroke is the rupture of a cerebral aneurysm.
Aneurysms can vary in shape and size, typically grow over time and, due to pressure placed on the wall of the aneurysm, are prone to rupture. Ruptured aneurysms can cause death as a result of massive intracranial bleeding and loss of perfusion to
the brain in the area affected by the aneurysm rupture. If an aneurysm ruptures, it leaks blood into the space around the brain. This is called a subarachnoid hemorrhage. If the hemorrhage bleeds into the brain itself, causing damage to the brain
directly, this results in a hemorrhagic stroke. According to the AHA, once an aneurysm bleeds, there is an approximately 30% to 40% likelihood of death and an approximately 20% to 35% likelihood of moderate to severe brain damage, even if the
aneurysm is successfully treated. If the aneurysm is not treated quickly, additional bleeding may occur from the already ruptured aneurysm. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The
optimal treatment for an aneurysm depends upon many factors, including whether the aneurysm has ruptured or not. If an aneurysm has not ruptured, the optimal treatment will depend upon its size, location and shape and the patient&#146;s symptoms.
Small, unruptured aneurysms that are not creating any symptoms may not need treatment unless they grow, trigger symptoms, or rupture. A ruptured aneurysm usually requires immediate treatment because the re-bleeding rate remains quite high. However,
the treatment time and options for treatment depend upon the size, location and shape of the aneurysm, as well as the patient&#146;s overall medical condition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Depending on an individual&#146;s risk factors, surgical clipping of an aneurysm had been traditionally recommended. In this open surgical procedure,
patients are placed under general anesthesia, an opening is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
made in the skull, the brain tissue is spread apart, and the aneurysm is surgically exposed. The neurosurgeon then places a clip around the aneurysm&#146;s base. The clip seals off the aneurysm
so that blood cannot enter. Possible complications from surgical clipping include infection at the incision site, rupturing of the aneurysm during surgery, damage to the artery and bleeding into the brain which could result in brain damage. As with
other open surgical procedures, there are risks associated with the use of anesthesia during the procedure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The primary endovascular procedure for
treating both unruptured and ruptured aneurysms uses a repair technique called embolization. The objective of embolization is to induce a blood clot, or thrombus, in the diseased vasculature to limit blood flow through the diseased vascular anatomy,
thereby reducing blood pressure and flow to a ruptured area or the likelihood of rupture in an unruptured area. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The endovascular embolization of
cerebral aneurysms usually involves the deployment of small platinum coils into the aneurysm. During such an embolic coiling procedure, the physician accesses the femoral artery to allow the introduction of a catheter which is inserted and guided
towards the brain. A microcatheter is then introduced through the larger catheter and used to deliver coils through the neck and into the sac of the aneurysm. They are individually placed and often detached by a small electric current or mechanical
detachment. This process is generally repeated until the aneurysm is filled with many coils, generally in progressively smaller sizes. Coiling may be done under local or general anesthesia. Possible complications include rupture of the aneurysm
during treatment and damage to the artery and bleeding into the brain that could result in brain damage or death, as well as risks from the anesthesia. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Following the release of results from the International Subarachnoid Aneurysm Trial (ISAT) which were published in the journal <I>The Lancet</I> in 2002
and did not involve our products, the treatment of aneurysms shifted from open surgical techniques, such as surgical clipping, to minimally invasive, endovascular techniques, such as embolic coiling. The ISAT was a clinical trial involving 2,143
patients in Europe, North America and Australia that compared aneurysm clipping with embolic coiling as a method of treating cerebral aneurysms. The trial concluded that endovascular intervention with detachable platinum coils resulted in a 23%
relative and 7% absolute reduction in the risk of major brain injury or death at one-year follow up compared with surgical clipping of the aneurysm. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">According to the American Association of Neurological Surgeons, up to 6% of the general population in the United States may be living with an unruptured
aneurysm. In addition, an estimated 30,000 people per year in the United States suffer from a ruptured cerebral aneurysm. According to the AHA, annually, 0.5% to 3.0% of people with a brain aneurysm may suffer from bleeding. If a patient has one
aneurysm, there is a 15% to 20% likelihood that the patient has at least one or more additional aneurysms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Peripheral Vascular Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Peripheral vascular disease is defined as vascular disease occurring in vessels outside of the brain or heart. Peripheral vascular disease is
characterized by the narrowing or occlusion of blood vessels and can cause pain or loss of function and lead to amputation and death. Mortality from peripheral vascular disease can occur as a result of stroke, kidney failure or diabetes-related
vascular complications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">According to a paper published in the journal <I>The Lancet</I>, the worldwide prevalence of peripheral artery disease was
202&nbsp;million in 2010. Within the United States, the AHA estimates that approximately 8&nbsp;million adults have peripheral artery disease. Patients with peripheral artery disease have a nearly threefold increase in the risk of suffering a heart
attack or stroke. Over half of the population with peripheral artery disease does not display classic symptoms of the disease, leading to substantial underdiagnosis. Massachusetts General Hospital estimates that only approximately 25% of patients
with peripheral artery disease in the United States undergo treatment for the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">More particularly, in <I>Deep Vein Thrombosis</I>, Dr.
Camerota estimated that approximately 1 million people in the United States are diagnosed with deep vein thrombosis (DVT) each year. Approximately 300,000 people die of a venous thromboembolism complication, which exceeds that of acute myocardial
infarction or acute stroke. In addition, according to <I>The New England Journal of Medicine</I>, acute limb ischemia, a sudden decrease in limb perfusion that threatens the viability of the limb, is found in approximately 1.5 out of 10,000 people
per year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Peripheral thrombectomy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">When blood is unable to flow smoothly through a vessel, it can begin to coagulate, turning from a free-flowing liquid to a semisolid gel, a process known
as blood clotting. A blood clot, or thrombus, that forms within a blood vessel may continue to grow, blocking off the blood supply to certain parts of the body and causing damage to tissues and organs. In some patients, blood clots come from other
sources and dislodge in relatively small vessels, thereby causing a blockage or embolization. If left untreated, a vascular blockage can lead to limb ischemia, a potentially lethal clinical event. Limb ischemia is a sudden decrease in blood supply
to the limb that threatens the viability of the limb. The rapid onset of this condition reduces or prevents the delivery of nutrients to the metabolically active tissues of the limb, including skin, muscle, and nerves. Symptoms of limb ischemia
include pain, pulselessness, pale color, perishing cold feeling and paraesthetic feeling, such as burning or tingling, and paralysis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Thrombotic
occlusion is the most common cause of limb ischemia. Immediate surgical or endovascular removal of the clot is recommended in order to restore blood flow to the limb and prevent amputation. In these situations, thrombectomy and thrombolysis are
often performed as a less invasive alternative to bypass surgery, where clot removal is imperative for the patient&#146;s survival. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Minimally
invasive endovascular procedures for the treatment of blood clots in the peripheral vasculature consist primarily of thrombolytic drug infusion, syringe aspiration or mechanical removal. In thrombolytic drug infusion, a catheter with holes allowing
for drug infusion is inserted into the blocked or narrowed part of the artery over a previously positioned guidewire that directs the catheter to the affected area. A thrombolytic drug, such as tPA, is then infused at a set infusion rate for a
period of 18 to 48 hours, during which time, these patients are closely monitored in an Intensive Care Unit (ICU) to ensure there are no complications associated with infusion of the drug. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Clot removal using syringe aspiration is accomplished through the use of a catheter delivered to the clot, and then a syringe is hooked to the end of the
catheter. This syringe creates an initial vacuum, and hence can remove very short, soft segments of the clot in small vessels. As clot segments get longer, and more fibrous in nature, these syringe aspiration techniques are no longer effective, and
a more robust mode of endovascular treatment is required. Some new techniques are evolving, where there is now the ability to maintain a continuous vacuum using a mechanical pump, and the addition of another wire-based tool along with the catheter
to help keep the catheter option for the duration of the procedure. This is proving to be able to handle longer segments of the clot, as well as a clot that has been in place for a longer period of time. Other techniques involve the combination of
the tPA drug along with a mechanical component, with the risk of bleeding, albeit lower, as well as added procedural cost. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Percutaneous thrombectomy
devices are increasingly used to remove clots from peripheral and coronary vessels because they offer a faster treatment option than the traditional standard of care, systemic thrombolysis. The advantages of thrombectomy over thrombolytic drug
administration alone can include rapid reperfusion of ischemic limbs, reduced procedural times, potentially shorter hospital stays, and lower recurrence of thrombosis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">With proper endovascular or surgical care, acute limb ischemia is a highly treatable condition; however, delayed treatment beyond six to 12 hours can
result in permanent disability, amputation and death. Despite currently available treatments, according to <I>The New England Journal of Medicine</I>, it is estimated that acute limb ischemia has an associated one-year mortality rate of between 15%
and 20% and an in-hospital amputation rate of between 10% and 15%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Peripheral embolization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Aneurysms are another potential result of peripheral vascular disease. Peripheral aneurysms vary in size, shape and location. Peripheral vascular
aneurysms occur in the renal arteries, the lower extremities and the visceral arteries, which are located in the abdomen and feed several important organs, such as the liver and spleen. Ruptured aneurysms can result in death as a result of massive
bleeding and loss of perfusion to the organ that the vessel feeds. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Internal hemorrhaging can be difficult to control, and interventional
radiologists will often perform an embolization to occlude the bleeding vessel. Leading causes of internal hemorrhaging where embolization is used </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
include trauma (generally major organ or gastrointestinal), pre- and post-surgical organ removal, hemoptysis (respiratory tract bleeding resulting in the excessive coughing up of blood),
epistaxis (excessive and uncontrollable nosebleed), pseudoaneurysm hemorrhage and pulmonary AVM (arterial venous malformation) hemorrhage. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">A
peripheral aneurysm requires surgical or endovascular repair because of the risk of rupture. If the aneurysm is small and there are no symptoms, the physician will monitor its size to determine when repair is needed. Endovascular repair makes use of
a catheter to place embolization coils that occlude the aneurysm and prevent blood flow to the area, thereby preventing further growth of the aneurysm. Open surgical repair of a peripheral aneurysm may be recommended if the aneurysm anatomy does not
allow for endovascular repair. In this procedure, the damaged vasculature is removed and replaced with a graft or surgically ligated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Minimally
invasive endovascular procedures for the treatment of peripheral aneurysms or blood vessel sacrifice involve the placement of a catheter at the targeted location. The interventional radiologist then delivers metallic occlusion devices such as
embolization coils or plugs to the target location to obstruct the aneurysm or vessel. Coils can be either pushable or detachable. Pushable coils are pushed out of the catheter without exact control of placement and delivery. Detachable coils offer
precise physician control and can be carefully positioned until the physician is satisfied with the coil placement at the desired location. At this point, the physician uses a trigger mechanism, which can be mechanical or electrolytic, to detach the
coil and release it into the target vessel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Peripheral vascular embolization coils (PV coils) are used in a variety of clinical applications.
Detachable PV coils are becoming more popular among interventional radiologists due to their clinical benefits relative to pushable coils, their ease of use and their predictability. Clinical applications involving the use of coils include: active
extravasations; selective embolization in patients with visceral aneurysms; exclusion of branches prior to chemoembolization and radioembolization; embolization in patients with gastrointestinal bleeding; embolization of branches prior to stent
graft procedures; procedures after stent grafting in patients with persistent type II endoleaks and sac enlargement; treatment of patients with varicocele and pelvic congestion syndrome; high flow AVM; post trans intrahepatic shunt placement;
balloon retrograde transvenous obliteration; and exclusion of hepatic branches prior to liver resection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Our Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe the following strengths have enabled us to develop our broad and differentiated product portfolio and will continue to be significant factors
in our success and growth. We plan to continue investing in our organization to preserve these strengths as we grow our business. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Our culture built on cooperation, which we have institutionalized through our unique organizational structure.</I></B> From our inception, we structured Penumbra in a unique way, designed to optimize the level of
cooperation and communication between functional areas of the organization. This structure is highlighted by the application of distinctive methodologies to almost every important aspect of management, including research and development (R&amp;D)
project selection, budgeting, hiring and compensation. We believe our success in maintaining this structure over the past ten years demonstrates that our corporate structure and approach to culture and cooperation should be scalable as we continue
to grow. We also seek to ensure maximum control of our development, manufacturing and commercialization processes, and accordingly, we currently conduct substantially all of our own product development, manufacture substantially all of our own
products and, where cost effective, sell our own products through our direct sales organization. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Our highly efficient product innovation process.</I></B> Our differentiated products have been a significant factor in our commercial success. We believe our ability to rapidly develop innovative products is in
large part attributable to the fully integrated product innovation process that we have implemented and the management philosophy behind that process. From project initiation, we staff projects with a development team that includes our R&amp;D
engineers, personnel with manufacturing and quality control competencies, as well as employees focused on clinical, regulatory and marketing. This enables us to have a broad perspective on the design, manufacturing and clinical needs for the
product, and ensures that members of the team share in the ownership of any given project. In addition, we rotate our project team leaders from our various functional areas to ensure cooperation and communication. We empower each project team to
foster and encourage long-term innovative success by discouraging the fear of failure. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Our disciplined approach to product and commercial development.</I></B> One of the benefits of our organizational structure and product innovation process is our ability to approach our development and
commercialization in a disciplined manner. In our product development, this discipline includes incorporating the feedback of our cross-functional teams to optimize the materials selection or physician ease-of-use objectives early in the process,
which enables us to accelerate the development process. Of equal importance, this also enables us to eliminate a project more expeditiously should it not meet the requirements for success defined by one of our functional teams. In our commercial
development, we believe that we have applied the same discipline to our selection of target end markets and our identification of new sales and marketing talent. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Our deep understanding of our target end markets.</I></B> We have assembled a team with in-depth knowledge of both of the target end markets in which we currently compete. We entered the neuro market in 2007, and
we have a highly experienced team with extensive expertise and long tenure in this market. We believe our experience and expertise in this market has enabled us to effectively address specific clinical challenges with innovative products and
technologies. In our peripheral vascular business, we have built a team with vast experience in peripheral vascular disease. We have also sought expertise and gained insight from many of the physician thought leaders in the interventional and
vascular surgery community. The combination of internal expertise and access to external expertise has enabled us to engage in focused product development. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Our relationships with specialist physicians.</I></B> Many of the specialist physicians who use our products have been responsible for developing clinical treatments in the neuro and peripheral vascular markets.
Given our deep understanding of the clinical challenges in these markets, we have been able to develop very strong relationships with many of the leading specialist physicians. These physicians range from those in the specialist residency programs
in endovascular treatment of stroke to influential thought leaders who are developing some of the most innovative research and techniques in the field. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Our Growth Strategies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe the following strategies
will continue to play a critical role in our future growth: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Expanding the penetration of our products in our target end markets.</I></B> In order to grow our business, we plan to continue to establish and strengthen our presence in our target end markets of neuro and
peripheral vascular disease. We sell our products through our direct sales organization in the United States, most of Europe, Canada and Australia and through distributors in select international markets. We plan to expand the reach and penetration
of our products by growing our direct sales organization and establishing new relationships with specialist physicians who have not used our products. We also plan to establish deeper relationships with hospital customers for whom we believe the
cost effectiveness of our products is very attractive relative to alternatives. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Growing the acceptance of our innovative products as the standard of care in their targeted clinical applications.</I></B> We develop innovative products to improve the clinical outcomes in our targeted
applications in a cost effective manner. Improving a clinical outcome can have many implications, ranging from improving post-procedure reperfusion in ischemic stroke or limb ischemia to generating rapid occlusion in hemorrhagic stroke patients and
reducing procedure times. We have evaluated some of our products in clinical studies to obtain U.S. regulatory clearance, and many of our products have been studied post-marketing in either Penumbra or third-party sponsored clinical trials. We
believe that our strategy of continuing to invest in clinical studies for our products will help us differentiate our products for specialist physicians, hospital customers and patients. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Continuing to leverage our product development capabilities to drive efficient, rapid product development.</I></B> We believe our highly efficient product development process has been a significant factor in our
success to date. We plan to continue investing in product development, applying our integrated development approach and core technology expertise, to drive efficient, rapid product development in our target end markets. We expect to maintain our
disciplined approach to product development in markets where we believe we can improve clinical outcomes in a cost-effective manner. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Scaling our culture of cooperative product development and commercial execution.</I></B> We believe that our organizational structure has been an important differentiating factor because it has enabled us to
innovate and commercialize our products in a capital efficient manner. As we have grown as an organization, we have been able to scale our business from development stage in 2004 to a company with approximately 1,000 employees currently focused on
multiple product categories in two target end markets. We believe our experience in maintaining our unique structure while scaling our business will help us considerably as we grow our business going forward. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Our Products </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Since our founding in 2004, we have invested in expanding our product development and marketing capabilities. These investments have included engineering
and materials science capabilities, pre-clinical and bench-testing infrastructure and in-house clinical and regulatory infrastructure. Our fully-integrated organization has enabled us to launch 14 product brands for access, thrombectomy and
embolization since 2007 to service our two target end markets. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table summarizes our product offerings in each of our target end
markets: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g923792g99m70.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>OUR NEURO PRODUCTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neurovascular Access </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Accessing the brain through the tortuous
neurovasculature has been a substantial challenge for physicians treating vascular disorders in the brain. Companies developing products for neurovascular applications have historically leveraged technologies developed for use in coronary or
peripheral vascular interventions. This approach created challenges given the vastly different anatomy, structure and sizing of the neurovascular vessels. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our portfolio of neurovascular access products includes our Neuron Access System catheters, BENCHMARK Intracranial Access System catheters and a variety
of microcatheters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Neuron Access System </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We
recognized the challenges posed by existing access technologies and focused our initial efforts on developing a guide catheter system designed specifically for neurointerventional procedures. Our Neuron delivery catheter is a variable stiffness
guide catheter with increased support in the aortic arch, which enables trackability to access the intracranial vasculature. The design of Neuron enables physicians to position the catheter much higher in the anatomy than conventional guide
catheters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe the Neuron family of guide catheters and the Penumbra distal delivery catheters that we subsequently introduced have enabled
many neuro-endovascular procedures that previously had not been possible in the tortuous anatomy of the neurovasculature. We have continued our development and currently offer a wide range of catheters that enable delivery of the different
therapeutic catheters that are required for ischemic and hemorrhagic stroke interventions. Our Neuron products include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>The Neuron Intracranial Access System</I> is indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature. The system is a two-catheter system comprised of the Neuron
Delivery Catheter and the Select Catheter. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>The Neuron Delivery Catheter</I> is a variable stiffness, large lumen catheter that combines proximal arch support with a microcatheter-like distal segment that is designed to access the intracranial anatomy. The
Neuron can be used individually with a 0.038 inch guidewire, or together with the Neuron Select Catheter, to access the desired location. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>The Select Catheter</I> is a single lumen, braid-reinforced, torquable catheter with a radiopaque distal end and a hub on the proximal end. The Select Catheter enables primary access with the Neuron Delivery
Catheters, obviating the need for an extra guide catheter. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>The Neuron MAX System</I> is an additional configuration to the currently available Neuron Intracranial Access System. The Neuron MAX System is a long sheath catheter with a flexible distal tip for neurovascular use
and provides a larger lumen to enable a wide range of device compatibility in neurovascular procedures. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>BENCHMARK Intracranial Access System
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Advances in our catheter technology, driven largely by our advances in ischemic stroke therapy, have enabled us to further develop our
intracranial access category of products. Our latest development in this category is the BENCHMARK catheter, which features additional improvements in ease-of-use, trackability, and aortic arch support that we believe will further enhance our
position in the neurovascular access market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The BENCHMARK catheter technology achieves these improvements by combining our advanced tracking
technology with the original Neuron intracranial access concept. In addition to improved proximal support in the arch through multi-geometry metal reinforcement, the distal tip is softer and more trackable, while maintaining complete distal shaft
radiopacity for improved visualization. The BENCHMARK also is available pre-packaged with a Select catheter to obviate the need for a neurovascular guide catheter exchange, which reduces the number of devices needed per procedure and shortens
procedure times. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Ischemic Stroke </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Penumbra
System </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We developed our aspiration-based Penumbra System family of products to enable specialist physicians to revascularize blood
vessels that are blocked by clots in the intracranial vasculature. We launched our first Penumbra System product in 2008 in the United States. We believe ACE, launched in June 2013, and ACE 64, launched in May 2015, represent significant
advancements over prior generations of the Penumbra System. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:arial"><I>Overview of the Penumbra System </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our Penumbra System family of products is comprised of several principal components, which include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Penumbra Reperfusion Catheters</I> are the cornerstone of the Penumbra System and are manufactured using a variety of proprietary processes and materials science innovations. We have launched five successive
generations of Reperfusion Catheters since 2008. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:arial">The latest generation of our Reperfusion Catheters, the ACE family of catheters,
represents our most powerful and trackable Reperfusion Catheters launched to date. Its design enables specialist physicians to track these large bore aspiration catheters to the distal locations of occluded vessels. Once at the site of the
occlusion, ACE provides significantly greater aspiration power than our prior Reperfusion Catheters, which we believe contributes to improved clinical outcomes and reduced procedure times. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:arial">ACE 64, our latest generation of ACE catheter, is designed to offer enhanced aspiration power relative to prior generations of the product, while
maintaining trackability. ACE 64 launched in the United States in late May 2015. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Penumbra Separators</I> are a component of the earlier generations of the Penumbra System and enable a physician to remove an aspirated clot that has aggregated in the Reperfusion Catheter during the procedure. The
Separators were an important component of our earlier Penumbra System due to the smaller diameter of our original Reperfusion Catheters, which resulted in frequent obstruction of the catheter. With the launch of our larger diameter ACE, Separators
are less frequently used by physicians. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>3D</I> is a stent retriever component of the Penumbra System that allows a physician to combine direct aspiration with stent retriever technology in a procedure commonly called &#147;Solumbra.&#148; 3D is currently
being evaluated in a clinical study pursuant to an Investigational Device Exemption (IDE) to obtain 510(k) clearance. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Penumbra Aspiration Pumps</I> are attached to our Reperfusion Catheters and provide the aspirating suction force. Our second generation MAX Aspiration Pump features increased aspiration capabilities and an improved,
easier to use design. We have standardized the MAX Aspiration Pump to work with all generations of our Reperfusion Catheters. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:arial"><I>Evolution of Penumbra System&#146;s Reperfusion Catheters </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Penumbra System Reperfusion Catheters are the foundation of the Penumbra System. The principal generations of our Reperfusion Catheters include the
original Penumbra System, Penumbra System MAX, Penumbra System ACE and Penumbra System ACE 64. We have introduced five successive generations of these catheters since early 2008. Each subsequent generation of our Reperfusion Catheters has
incorporated significant performance enhancements relative to prior generations with regard to trackability and aspiration power. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>The Generations of the Penumbra System </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g923792g69x68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:arial"><I>The Original Penumbra System </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our original Penumbra System was CE&#150;marked in September 2006 and 510(k) cleared by the FDA in December 2007. The Penumbra System is intended for use
in the revascularization of patients with ischemic stroke within eight hours of symptom onset. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our original Penumbra System was evaluated in the
Penumbra Pivotal study, a 125 patient clinical study to assess the safety and effectiveness of the Penumbra System in the revascularization of patients presenting with ischemic stroke. This study was sponsored by Penumbra to support and obtain
regulatory clearance for the original Penumbra System. The Penumbra Pivotal study demonstrated an 81.6% success rate in achieving successful revascularization. The study was completed in 2007 and the results were published in the journal
<I>Stroke</I> in 2009. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We had commissioned and subsequently evaluated the Penumbra System in our THERAPY study, a clinical study comparing the
clinical outcomes in the medical management of stroke patients with IV recombinant tPA (rtPA) to stroke patients treated with a combination of IV rtPA and the Penumbra System. The THERAPY study was commenced in March 2012, and was designed to enroll
up to 692 patients, but was stopped early in October 2014, because the positive results of the MR CLEAN study made it unethical to continue to treat the control group in the THERAPY study with medical management rather than with endovascular
treatment. The MR CLEAN study demonstrated the superiority of endovascular treatment of stroke over medical management. As a result, the steering committee for THERAPY recommended stopping enrollment for the trial. The THERAPY study results, after
the randomization of 108 patients, were presented in April 2015 at the European Stroke Organization Conference and the manuscript is being prepared for submission to a peer-reviewed journal. Despite the early termination of the study, the
pre-specified per protocol analysis demonstrated a significant benefit of combined treatment with IV rtPA and the Penumbra System over IV rtPA alone. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:arial"><I>Penumbra System MAX </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Penumbra System MAX applies our advanced tracking technology and improved aspiration power to the Penumbra System&#146;s aspiration platform.
Launched in 2011, the 3MAX and 4MAX Systems feature MAX Tracking Technology that allows access over a solo guidewire for an even faster, easier procedure than with our original Penumbra System. The proximal shaft of these specialized catheters
incorporates tapering, larger diameters, enabling increased aspiration power. In August 2012, we launched the 5MAX, which added our MAX Tracking Technology to an even larger dimension Reperfusion Catheter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:arial"><I>ACE </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Almost a decade of research and product
development culminated in the introduction of our first ACE Reperfusion Catheter in July 2013. ACE features a unique tapered design, large lumen diameter and other developments that result in significantly greater aspiration power and improved
trackability compared to our earlier original Penumbra System and Penumbra MAX products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Given its improved aspiration power and larger lumen size,
our ACE Reperfusion Catheter can enable the extraction of a fibrous thrombus without fragmentation and often in one solid piece. This leaves the longitudinal fibrin strands in the clot intact, allowing the thrombus to retain its integrity. We
believe this is evidenced in our post-launch clinical experience, in which clinicians have seen high rates of TICI 3 revascularization, representing complete recanalization of the affected area, using our ACE catheters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our ACE 64 Reperfusion Catheter was launched in the United States in May 2015. It is built on our ACE platform and offers an increased lumen diameter,
which leads to further increased aspiration power and which we believe will aid in the removal of clot from the neurovasculature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>ACE Reperfusion
Catheter </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g923792g52i76.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:arial"><I>Penumbra System Clinical Experience </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">There have been a number of clinical studies that have confirmed that mechanical thrombectomy results in generally better clinical outcomes than
non-interventional treatments. Generations of our Penumbra System have been evaluated in several post-market clinical studies that demonstrate improved clinical outcomes. The following table summarizes certain key findings from certain clinical
studies involving the Penumbra System and competitive technologies for treatment of ischemic stroke. While most of these studies were not designed to provide statistically significant comparisons of the various devices, these studies are highlighted
as representative examples of the continuing evolution of mechanical thrombectomy in which clinical results are improving over time from original generation to subsequent generations across different products (including Penumbra products and
competitor products). Within this context, these clinical studies indicate that the original Penumbra System performed less well in some of the metrics set forth below as compared to current competitive devices and current generations of the
Penumbra System (including 5MAX and ACE). </P>  <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR BGCOLOR="#051e68" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt"><FONT COLOR="#ffffff"><B>Product</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT COLOR="#ffffff"><B>MERCI<FONT COLOR="#ffffff"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></FONT></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT COLOR="#ffffff"><B>Original<BR>Penumbra<BR>System</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT COLOR="#ffffff"><B>Stent<BR>Retriever</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT COLOR="#ffffff"><B>&#147;Solumbra&#148;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT COLOR="#ffffff"><B>5MAX</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT COLOR="#ffffff"><B>ACE</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:8pt">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B>Author</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Kass-Hout<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(JNIS 2014)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Humphries<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(JNIS</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>2014)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Turk<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>(JNIS&nbsp;2014)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">&nbsp;</TD></TR>


<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Number of patients</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">TICI 2b/3</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:arial"><I>(Successful revascularization (includes partial and complete revascularization))</I></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">70%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">78%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">86%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">88%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">96%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">98%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">TICI 3</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:arial"><I>(Complete revascularization)</I></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">14%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">9%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">37%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">44%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">41%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">61%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Puncture to
revascularization</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:arial"><I>(Time from groin puncture to successful revascularization)</I></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">91&nbsp;min</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">75&nbsp;min</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">79&nbsp;min</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">57&nbsp;min</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">38&nbsp;min</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">36&nbsp;min</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">sICH</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:arial"><I>(Symptomatic intracranial hemorrhage)</I></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">7%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">6%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">7%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">5%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">mRS <FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT></FONT> 2 at 90 days</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:arial"><I>(Modified Rankin scale)</I></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">25%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">41%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">36%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">44%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">34%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">50%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>(1)</TD>
<TD ALIGN="left" VALIGN="top">Merci is the marketing name for the &#147;corkscrew&#148; retriever device developed by Concentric Medical, Inc. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Kass-Hout T, Kass-Hout O, Sun C-H J, et al. (2014) Clinical, angiographic and radiographic outcome differences among mechanical thrombectomy devices: initial experience of a large-volume center. <I>J NeuroIntervent
Surg</I>. Advance online publication doi:10.1136/neurintsurg-2013-011037. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Humphries W, Hoit D, Doss VT, et al. (2014) Distal aspiration with retrievable stent assisted thrombectomy for the treatment of ischemic stroke. <I>J NeuroIntervent Surg</I>. Advance online publication
doi:10.1136/neurintsurg-2013-010986. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Turk AS, Frei D, Fiorella D, et al. (2014) ADAPT FAST study: a direct aspiration first pass technique for stroke thrombectomy. <I>J NeuroIntervent Surg</I>. Advance online publication
doi:10.1136/neurintsurg-2014-011125. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe the advancements offered by the Penumbra System, and in particular the ACE Reperfusion
Catheter, have changed and will continue to change the way specialist physicians treat ischemic stroke. Some of the principal benefits include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Improved trackability:</I> The ACE Reperfusion Catheter&#146;s design features significant improvements in trackability, enabling greater ease-of-use in accessing the middle cerebral artery in a highly reproducible
manner. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:arial; font-size:10pt"><I>Reduced procedure times:</I> We believe the improved trackability and the significantly greater aspiration power, which can be applied directly to the site
of the clot, can enable clinicians using ACE to achieve revascularization faster than has been possible historically. Once our catheter has been navigated to the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:arial; font-size:10pt">
clot site, aspiration is typically rapid and the clot removed, often intact. The ADAPT FAST study demonstrated that ACE procedures averaged revascularization in 36 minutes from groin access.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Reduced need for general anesthesia:</I> We believe ACE also may offer clinicians the ability to reduce the need for general anesthesia during the procedure. In some cases, ACE procedures can be performed without
general anesthesia. It has been demonstrated that performing thrombectomy procedures without general anesthesia has been associated with better clinical outcomes for the patient. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Significant cost advantage:</I> We designed ACE to offer significant economic advantages to our hospital customers relative to prior generations of the Penumbra System and our competitors&#146; offerings. These cost
savings relative to competitive revascularization products are driven by lower total direct product costs as well as reduced procedure times. Based on current list prices, ACE procedures can be performed more cost effectively than procedures using
stent retrievers based on device costs alone. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>3D </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">3D is a stent retriever that is designed to be used in conjunction with our Penumbra System. We believe that it will be useful in treating a small
percentage of very difficult to treat ischemic clots that may not be removed with our catheters and aspiration pumps alone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>3D </B></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g923792g47d02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>(side view of deployed 3D stent retriever) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are currently evaluating 3D in a clinical trial pursuant to an Investigational Device Exemption (IDE) study to obtain 510(k) clearance. The 230
patient clinical study compares the safety and effectiveness of 3D as part of the Penumbra System with that of the standard Penumbra System alone. This study is actively enrolling patients. As of June 30, 2015, we have recruited 46 centers in the
United States to participate in the trial and have enrolled 183 patients. We expect to complete enrollment of the study in 2016 and anticipate being in a position to file for 510(k) clearance by the end of 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neurovascular Embolization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Given the minimal product
differentiation among the existing coils on the market, we concluded that to initially penetrate this market successfully we would have to develop a coil that was materially easier to deliver, and provided a procedural economic advantage. We also
identified a segment of aneurysms that traditional neurovascular coils could not effectively treat on a cost effective basis. These included larger aneurysms and other larger, more complex lesions. We estimate that these aneurysms and lesions
currently represent less than 10% of the addressable aneurysms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The Penumbra Coil 400 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We developed our Penumbra Coil 400 to offer an improved alternative for the treatment of larger aneurysms and other larger, more complex lesions. We
implemented several proprietary design innovations to enable the coil to maintain shape while achieving biomechanically stable occlusion. Our coil system is composed of a platinum embolization coil complemented by a nitinol inner structure and
stretch resistant nitinol wire. It is attached to a composite delivery pusher with a radiopaque positioning marker. The Penumbra Detachment Handle offers instant mechanical detachment of the coil and can be controlled by the physician in the sterile
field. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We received 510(k) clearance for the Penumbra Coil 400 in 2011. The Penumbra Coil system is FDA cleared for
endovascular embolization of intracranial aneurysms and other neurovascular abnormalities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra Coil 400 Design Relative to Traditional Coils
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g923792g09m51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:arial"><I>Review of Penumbra Coil 400 Clinical Performance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Given the size and handling of the Penumbra Coil 400, it is able to achieve higher packing density with fewer coils compared to competitive coiling
systems. These findings have been confirmed in numerous physician sponsored post-marketing studies. Collectively, the clinical studies have shown that use of the Penumbra Coil 400 resulted in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">less retreatments or worsening occlusions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">larger aneurysm treatment capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">higher packing density; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fewer coils per aneurysm. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Certain single center clinical studies evaluating the Penumbra Coil 400 have
shown the clinical and economic benefit of using the large volume Penumbra Coil 400. Some of the principle conclusions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In their 2014 study of 75 patients, Mascitelli, Patel, et al. reported their single-center experience with the Penumbra Coil 400 and compared it to their results with conventional coils. They concluded that the Penumbra
Coil 400 is more efficient in the embolization of cerebral aneurysms, achieves greater packing density with fewer coils, and the related procedure takes less time to perform without compromising safety. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In their 2012 study of 58 patients, Milburn et al. reported their single-center experience with the Penumbra Coil 400 and compared it to their results with conventional coils. In consecutive cases, they reported a
greater than 90% rate of stable occlusion on average follow-up time of 8.6 months. They evaluated and compared the number and total length of coils used per unit volume of aneurysm and experienced a 67% cost savings using the Penumbra Coil 400.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Penumbra SMART Coil </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Leveraging our
initial experience treating larger aneurysms and more complex lesions with the Penumbra Coil 400, we turned our efforts to developing a standard sized coil to compete in the traditional, smaller neurovascular coil market. While the market has seen
significant growth over the last 15 years, there has been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
very little innovation in the last several years with regard to coil design, material science and performance. As a result, neurovascular coils built on the traditional, smaller-coil platform
offer very little differentiation in terms of materials, ease-of-use and trackability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In light of these dynamics, we focused our development
efforts on a coil that would improve ease of delivery, or &#147;feel&#148; of the coil compared to the leading established coils. In order to accomplish this, our engineering team developed a highly sophisticated coil that dramatically changes its
softness profile within the span of a single individual coil. This progressive softness feature enables physicians to pack the coil into a delicate lesion and mitigate catheter kick-back at the end of delivery, which can preclude the successful
complete embolization of the lesion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Penumbra SMART Coil is designed to treat patients with a wide range of neurovascular lesions, including the
small and medium sized aneurysms that comprise the majority of the neurovascular coiling market. Alternative products available to physicians in this market are offered in single levels of softness &#150; standard, soft or extra soft. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The three principal levels of softness that competitors offer are derived from using smaller platinum filaments to increase the level of softness.
However, this methodology does not allow for changes to the softness level within an individual coil. The design of the Penumbra SMART Coil allows the level of softness to be determined not only by the diameter of the platinum filament, but also by
a structural component inside the coil itself. This development enables the Penumbra SMART Coil to become progressively softer within the span of an individual coil. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We anticipate launching our SMART Coil in the second half of 2015. We believe that it will provide us with another important opportunity to offer
specialist physicians a broader suite of products to address their neurovascular coiling needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>LIBERTY Stent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As the market for neurovascular coils grew over the past 15 years, the need arose to optimize coil performance using additional structural support
devices. Neurovascular stents were initially developed as a means to complement these coil embolization procedures by enabling the treatment of wide-necked aneurysms that could not be treated with coils alone. These stents have historically had
several shortcomings, which include lack of complete coverage of the neck of the aneurysm, challenging stent delivery through neurovascular tortuosity and limited vessel wall opposition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">To expand our presence in the market for the treatment of aneurysms, we began developing a next generation aneurysm stent that could overcome the
limitations of existing stents. The objectives were to develop a stent that could: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide enhanced coverage of the neck of the aneurysm and increased flow diversion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improve ease-of-use and stent delivery; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide improved opposition to the vessel wall through a self-expanding stent with excellent conformability. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The LIBERTY stent is Penumbra&#146;s product for stent-assisted coil embolization. The product incorporates a self-expanding nitinol stent technology
developed from a laser-cut hypotube processed to create high coverage with many thin struts supported by a larger structure. This laser-cut nitinol design, complete with thin stent struts, address many of the limitations of other products in the
market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Unlike currently marketed flow-diverting stents, the LIBERTY stent allows the physician to penetrate the stent with a microcatheter and
place coils for immediate protection from the possibility of aneurysm rupture, while establishing a scaffold for healing across the aneurysm neck. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>LIBERTY Stent System </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g923792g52x14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are currently evaluating LIBERTY in a 120 patient international clinical study, the results of which, if positive,
will be submitted to support our premarket approval application, or PMA. As of June 30, 2015, we had enrolled 113&nbsp;patients in the study. We expect to complete enrollment of the study by the end of 2015 and anticipate being in a position to file
for PMA approval by the FDA upon completion of the last patient&#146;s 12-month follow-up. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neurosurgical Tools </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The Apollo System </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We received 510(k) clearance from
the FDA for our first neurosurgical product, the Apollo System, in 2014. The Apollo system leverages our expertise in thrombectomy and access to offer a minimally invasive approach to surgical removal of fluid and tissue from the ventricles in the
brain. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Apollo system is comprised of two primary components: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Apollo wand that is inserted into the brain through an endoscope, which, in turn, is inserted through a small burr hole into the skull; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a reusable hardware device that delivers vacuum, irrigation and vibrational energy along the disposable wand to the site of the hemorrhage. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Apollo System</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Apollo Wand</B></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g923792g57t30.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt" ALIGN="center">


<IMG SRC="g923792g36f76.jpg" ALT="LOGO">
&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>OUR PERIPHERAL VASCULAR PRODUCTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">After initially focusing our business on our neuro products, we identified the peripheral vascular market as an ideal opportunity to leverage our neuro
experience and our core expertise in thrombectomy, embolization and access technologies to develop new products that could address significant clinical needs cost effectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The peripheral vasculature suffers from disorders that are very similar to those experienced in the neurovasculature that our products already
successfully address. For example, weakening of the vascular walls can result in aneurysms, and blockages can form as the result of embolism or advanced atherosclerosis. Just as the disruption of blood flow to the brain has high mortality and
morbidity, disruptions in the peripheral vasculature can also have serious adverse consequences. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The peripheral vasculature also presents unique
challenges that do not apply to interventional efforts in the brain. Many peripheral arteries and veins are significantly larger than those found in the brain and therefore have higher blood flow rates. More importantly, they must be able to
accommodate larger pressure gradients and sustain structural integrity despite substantial movement and flexing of the organs and musculature that surround them. Imaging can also be more challenging as physicians have to view their equipment through
many more layers of organs and tissue than in the brain. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In 2012, we began investing further in research and development to evaluate and identify
potential solutions to address significant clinical needs in the peripheral vasculature. Our products for the treatment of peripheral vascular disease focus on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">peripheral vascular embolization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vessel occlusion; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">peripheral vascular thrombectomy. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Peripheral Embolization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ruby Coil System </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">After completing research and
development focusing on the specific requirements of the peripheral embolization market, we launched our Ruby Coil System for use in the peripheral vascular market in 2013. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Ruby Coil System consists of detachable coils that are specifically designed for peripheral applications. The Ruby coils have a controlled mechanical detachment mechanism that permits the
physician to deliver and reposition the coil until the final satisfactory position is reached before detachment. Compared to pushable coils, this minimizes costly complications like embolizing unintended vessels. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Ruby Coil System is used in a variety of clinical applications, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">active extravasations, or the escape of blood into surrounding tissue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selective embolization in patients with visceral aneurysms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exclusion of branches prior to chemoembolization and radioembolization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">embolization in patients with gastrointestinal bleeding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">embolization of branches prior to stent graft procedures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">procedures after stent grafting in patients with persistent type II endoleaks and sac enlargement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">treatment of patients with varicocele and pelvic congestion syndrome; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">high flow arterial venous malformations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">post trans intrahepatic shunt placement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">balloon retrograde transvenous obliteration; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exclusion of hepatic branches prior to liver resection. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe our Ruby Coil System offers
specialist physicians a differentiated, cost-effective solution in the treatment of peripheral embolization patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>POD (Penumbra Occlusion Device)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We developed POD, our peripheral vascular occlusion device, to address a specific need in the peripheral embolization market to rapidly and
precisely occlude a target vessel. Current options for vessel occlusion in the periphery are limited, either requiring multiple devices or difficult to deliver vascular plugs. Microcatheter deliverable devices, such as coils, are not ideally suited
for vessel embolization due to their tendency to migrate with antegrade flow and generally require the deployment of several devices to achieve occlusion. Vascular plug technology for larger peripheral vessels requires access with large diagnostic
catheters or even larger bore sheaths. Additionally, these devices often require the placement of adjunctive devices, such as coils, to achieve complete occlusion. Our POD device utilizes technology that delivers both variable sizing and variable
softness to provide a single device solution for rapid and precise embolization of the target vessel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Unlike conventional vascular plugs, our POD
technology enables the occlusive device to be delivered through a microcatheter. Additionally, a single POD can occlude a range of vessel diameters, reducing the need for sophisticated measurement prior to embolization. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our POD technology leverages the key features of a dedicated vessel embolization device to improve ease-of-use. These include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">microcatheter deliverability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">instant detachment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">immediate and precise anchoring; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a single device to treat a range of vessel diameters; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dense occlusion in a short segment. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The technology achieves this range of features through the design of
a distal anchoring segment, thereby immediately anchoring the device in a range of vessel diameters. The proximal segment of the POD achieves </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
dense occlusion by packing a softer, smaller diameter segment tightly behind the anchored portion. Once POD is deployed, it can be detached instantly with the sterile detachment handle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>POD technology deployment </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g923792g84m45.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g923792g65f54.jpg" ALT="LOGO">
&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><I>Step 1: Anchor</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B><I>Step 2: Pack</I></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Peripheral Thrombectomy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Indigo System
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our Indigo System, which we launched in 2014, was designed for continuous aspiration mechanical thrombectomy (CAT), leveraging the success
of the Penumbra System in ischemic stroke. The Indigo System is designed to remove clots in the peripheral arteries, including in patients with limb ischemia. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our Indigo System family of products and accessories is an easy to use thrombectomy system that is powerful, highly trackable, and suited to a wide range
of clot morphology. The principal components include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Continuous Aspiration Mechanical Thrombectomy Catheters</I> are the foundation of the system and are ideally suited to reach anatomy below the knee. Much like our MAX and ACE catheters, the CAT catheters are robust,
durable, trackable and suited for the peripheral anatomy. The initial launch of the Indigo System included our CAT5 catheter and the device made for more distal access, CAT3, which is able to reach the distal peripheral vessels of the upper and
lower extremities. On May 26, 2015, we received FDA clearance for two larger sizes of the Indigo System, as well as to market the Indigo System for use in the vessels of both the peripheral arterial and venous systems. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Indigo Separator</I> enables the peripheral interventionalist to remove a difficult to aspirate clot from the CAT catheter. In the peripheral vessels, clots often form in long segments, and are more resistant to
traditional aspiration techniques. The Indigo System with the Separator enables a wide range of clot morphology to be removed from the body. In clinical settings, we have demonstrated that the Indigo System with the Separator removes clots that were
resistant to hours of revascularization attempts with other technologies and thrombolytic agents. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Penumbra Aspiration Pump</I> is the power source that provides the aspirating suction force to remove waste, such as blood and clots. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our initial clinical experience with the Indigo System has demonstrated high rates of revascularization and reduced procedure times in a range of case
applications including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">revascularization of visceral vessels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upper extremity revascularization in the brachial, radial, ulnar and digital arteries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">above and below the knee revascularization of arteries such as the superficial femoral, popliteal, peroneal, tibial and pedal arteries; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rescue revascularization following failed revascularization or embolic showering during angioplasty/stenting, complete total occlusion (CTO) procedures, atherectomy, mechanical thrombectomy and thrombolytic infusion.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Procedure times with current treatment options often range from several hours up to 24 to 72 hours when
thrombolytic therapy is administered. Procedures using the Indigo Systems can generally achieve revascularization in times similar to the neuro experience with the Penumbra System in ischemic stroke. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="26%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>CAT 5 &amp; SEP 5, CAT 3 &amp; SEP 3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Indigo Pump</B></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g923792g98k18.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt" ALIGN="center">


<IMG SRC="g923792g07k32.jpg" ALT="LOGO">
&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Research and Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We
direct our research efforts towards the development of clinical therapies that expand the therapeutic alternatives available to specialist physicians and improve upon our existing product offerings. Our research and development team has a track
record of product innovation and significant product improvements. Since inception, we have introduced 14 products brands in either the United States, international markets, or both. Our research and development expenses totaled $15.6 million and
$14.1 million for the years ended December&nbsp;31, 2014 and 2013, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe our ability to rapidly develop innovative products is in
large part attributable to the fully integrated product innovation process that we have implemented, and the management philosophy behind that process. In addition, we have recruited and retained engineers with both significant experience in the
development of medical devices as well as engineers directly from undergraduate and graduate programs that have become immediately productive within our development process. We have a pipeline of products in various stages of development that are
expected to provide additional commercial opportunities. All of our research and development efforts are based at our campus in Alameda, California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We currently maintain one manufacturing
facility at our campus in Alameda, California, which, together with our research and development space, totals 180,000 square feet. The manufacturing facilities run two eight-hour shifts per weekday. In addition, we have capacity to increase
production, and can expand adjacent to our current facilities. We currently produce substantially all of our products in house. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our rigorous quality
control management programs have earned us a number of quality-related manufacturing designations. Our manufacturing facilities are EN ISO 13485 compliant with ISO 13485-2003 certification achieved in 2005. In 2007, we achieved compliance with MDD
standards, allowing our products to be CE marked. We use annual internal audits, combined with external audits by regulatory agencies to help ensure strong quality control practices. An internal, on-going staff training and education program
contributes to our quality assurance program; training is documented and considered part of the employee evaluation process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have dedicated substantial resources to establish a direct sales capability in the United States, most of Europe, Canada and Australia, which we have
complemented with distributors in Japan and certain other international markets. We have regulatory clearance to sell our neurovascular access, ischemic stroke, neurovascular embolization, peripheral embolization and peripheral thrombectomy products
in two of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
three major markets, the United States and Europe, except that neither DDC nor Apollo System has been cleared in Europe and 3D has been cleared in Europe but not the United States. In our third
major market, Japan, we have regulatory clearance to sell our ischemic stroke, neurovascular embolization and peripheral embolization products. The only access product that has received regulatory clearance in Japan is PXSLIM. 3D, Penumbra SMART
Coil, Ruby Coil, POD and Indigo System have not received regulatory clearance in Japan. Our Coil 400 products are also used for peripheral embolization in Japan, and have received regulatory clearance for that use in that market. Liberty Stent has
not yet received regulatory clearance anywhere. We believe our global presence enables us to capitalize on the markets for neuro and peripheral vascular devices that exist outside of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We currently sell our products to hospitals in the United States through our dedicated salesforce in two target end markets, neuro and peripheral
vascular. Our sales representatives and sales managers generally have substantial medical device experience and market our products directly to a variety of specialist physicians engaged in the treatment of neurovascular and peripheral vascular
disorders, who are the end users of our products and significantly influence hospital buying decisions relating to medical devices. We are focused on developing strong relationships with specialist physicians and devote significant resources to
training and educating physicians in the use and benefits of our products. The principal specialist physicians in our two target end markets include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Neuro:</I></B> Interventional neuroradiologists, neurosurgeons and interventional neurologists. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Peripheral vascular:</I></B> Interventional radiologists and vascular surgeons. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition to our
direct sales organizations, we work with distributors in certain geographies where we have determined that selling through distributors is likely to be more effective. The largest market where we sell our products through a distributor,
Medico&#146;s Hirata Inc., is Japan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our direct sales have been, and we anticipate will continue to represent, a majority of our revenues. In 2014,
direct sales accounted for approximately 82.3% of our revenue, with the balance generated by independent distributors that sell our products outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Backlog </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We typically accept and ship orders on the day
purchase orders are received or the next business day. Furthermore, if requested, we generally permit customers to cancel or reschedule without penalty. As a result, we do not believe that our backlog at any particular time is material, nor is it a
reliable indication of future revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Reimbursement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In
the United States, hospitals are the purchasers of our products. Hospitals in turn bill various third-party payors, such as Medicare, Medicaid and private health insurance plans, for the total healthcare services required to treat the patient.
Government agencies, private insurers and other payors determine whether to provide coverage for a particular procedure and to reimburse hospitals for inpatient treatment at a fixed rate based on the diagnosis-related group (DRG) as determined by
the U.S. Centers for Medicare and Medicaid Services (CMS). The fixed rate of reimbursement is based on the procedure performed, and is unrelated to the specific medical device used in that procedure. Medicare rates for the same or similar procedures
vary due to geographic location, nature of facility in which the procedure is performed (i.e., teaching or community hospital) and other factors. While private payors vary in their coverage and payment policies, most look to coverage and payment by
Medicare as a benchmark by which to make their own decisions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Some payors may deny reimbursement if they determine that the device used in a
treatment was unnecessary, not cost-effective, or used for a non-approved indication. We cannot assure you that government or private third-party payors will cover and reimburse the procedures using our products in whole or in part in the future or
that payment rates will be adequate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Outside the United States, market acceptance of medical devices depends partly upon the availability of
reimbursement within the prevailing healthcare payment system. Reimbursement levels vary significantly by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
country, and by region within some countries. Reimbursement is obtained from a variety of sources, including government-sponsored and private health insurance plans, and combinations of both. A
small number of countries may require us to gather additional clinical data before recognizing coverage and reimbursement for our products. It is our intent to complete the requisite clinical studies and obtain coverage and reimbursement approval in
countries where it makes economic sense to do so. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The increased emphasis on managed healthcare in the United States and on country and regional
pricing and reimbursement controls in international markets will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our product sales and results of operations. These pressures can arise from rules and
practices of insurers and managed care organizations, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, medical device reimbursement policies and pricing in general. Our ability to achieve
market acceptance or significant sales volume will depend in large part on the availability of coverage and the level of reimbursement for procedures performed using our products under healthcare payment systems in such markets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">All third-party reimbursement programs, whether government funded or insured commercially, whether in the United States or internationally, are
developing increasingly sophisticated methods of controlling health care costs through prospective reimbursement and capitation programs, group purchasing, redesign of benefits, second opinions required prior to major surgery, careful review of
bills, encouragement of healthier lifestyles and exploration of more cost-effective methods of delivering health care. These types of programs and legislative or regulatory changes to reimbursement policies could potentially limit the amount which
healthcare providers may be willing to pay for medical devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market
activities of industry participants. We compete with a number of manufacturers and distributors of neurovascular and peripheral vascular medical devices. Our most notable competitors are Boston Scientific, Johnson&nbsp;&amp; Johnson, Medtronic,
Stryker and Terumo. All of these competitors are large, well-capitalized companies with significantly more market share and resources than we have. As a consequence, they are able to spend more on product development, marketing, sales and other
product initiatives than we can. We also compete with a number of smaller medical device companies that have single products or a limited range of products. Some of our competitors have: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significantly greater name recognition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">broader or deeper relations with healthcare professionals, customers and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">more established distribution networks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional lines of products and the ability to offer rebates or bundle products to offer greater discounts or other incentives to gain a competitive advantage; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">greater experience in conducting research and development, manufacturing, clinical trials, marketing and obtaining regulatory clearance or approval for products; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">greater financial and human resources for product development, sales and marketing and patent litigation. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We compete primarily on the basis that our products are able to treat patients with neurovascular and peripheral vascular diseases and disorders safely
and effectively. Our continued success depends on our ability to: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop innovative, proprietary products that can cost-effectively address significant clinical needs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to innovate and develop scientifically advanced technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain and maintain regulatory clearances or approvals; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrate efficacy in Penumbra-sponsored and third-party clinical trials and studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">apply technology across product lines and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract and retain skilled research and development and sales personnel; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effectively manufacture and successfully market and sell products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our success depends in part on our ability to protect our proprietary technology and intellectual property and operate without infringing the patents and
other proprietary rights of third parties. We rely on a combination of patent, trademark, trade secret, copyright and other intellectual property rights and measures to protect our intellectual property rights that we consider important to our
business. We also rely on know-how and continuing technological innovation to develop and maintain our competitive position. We do not have any material licenses to any technology or intellectual property rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of June 30, 2015, we owned 18 issued patents globally, of which seven were U.S. patents. As of June 30, 2015, we owned 31 pending patent applications,
of which 14 were patent applications pending in the United States. Subject to payment of required maintenance fees, annuities and other charges, eight of our issued patents are currently expected to expire between 2024 and 2025; five of these
patents relate to components of the Penumbra System and the Indigo System and one of these patents relates to methods performed by the Apollo System. An additional four of our issued patents, which relate to components of devices that have not been
commercialized, are expected to expire between 2026 and 2027. The remaining six of our issued patents, which relate to the components of the Penumbra Coil and Ruby Coil, are currently expected to expire after 2027. Our issued patents relate to the
following main areas: mechanical thrombectomy, coil embolization, treatment of aneurysm and treatment of intracranial hemorrhage. Our pending patent applications relate primarily to the following five main areas: mechanical thrombectomy, coil
embolization, coronary atherectomy, blood filtration and treatment of patients with intracranial hemorrhage. Some of our pending patent applications pertain to components and methods of use associated with currently commercialized products. Our
pending patent applications may not result in issued patents and we can give no assurance that any patents that have issued or might issue in the future will protect our current or future products or provide us with any competitive advantage. See
the section titled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property&#148; for additional information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Additionally, we own or have
rights to trademarks or trade names that are used in our business and in conjunction with the sale of our products, including eight U.S. trademark registrations and six foreign trademark registrations as of June 30, 2015. Included in the registered
trademarks is a mark with our company name and logo. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We also seek to protect our proprietary rights through a variety of methods, including
confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to our proprietary information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>United States </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our products are medical devices subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act),
and its implementing regulations, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries under other statutes and regulations. The laws and regulations govern, among other things,
product design and development, pre-clinical and clinical testing, manufacturing, packaging, labeling, storage, recordkeeping and reporting, clearance or approval, marketing, distribution, promotion, import and export, and post-marketing
surveillance. Failure to comply with applicable requirements may subject a device and/or its manufacturer to a variety of administrative sanctions, such as issuance of Warning letters, import detentions, civil monetary penalties, and/or judicial
sanctions, such as product seizures, injunctions and criminal prosecution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>FDA&#146;s Premarket Clearance and Approval Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Each medical device we seek to commercially distribute in the United States will require either a prior 510(k) clearance, unless it is exempt, or a
premarket approval from the FDA. Medical devices are classified into one of three classes&#151;Class I, Class II or Class III&#151;depending on the degree of risk associated with each medical device and the extent of control needed to provide
reasonable assurance of safety and effectiveness. Class I devices are deemed to be low risk and are subject to the general controls of the FD&amp;C Act, such as provisions that relate to adulteration; misbranding; registration and listing;
notification, including repair, replacement, or refund; records and reports; and good manufacturing practices. Most Class I devices are classified as exempt from premarket notification under section 510(k) of the FD&amp;C Act, and therefore may be
commercially distributed without obtaining 510(k) clearance from the FDA., Class II devices are subject to both general controls and special controls to provide reasonable assurance of safety and effectiveness. Special controls include performance
standards, postmarket surveillance, patient registries, and guidance documents. A manufacturer may be required to submit to the FDA a premarket notification requesting permission to commercially distribute some Class II devices. Devices deemed by
the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k) device, are placed in Class III. A Class III device cannot be marketed
in the United States unless the FDA approves the device after submission of a premarket approval application, or PMA. However, there are some Class III devices for which FDA has not yet called for a PMA. For these devices, the manufacturer must
submit a premarket notification and obtain 510(k) clearance in orders to commercially distribute these devices. The FDA can also impose sales, marketing or other restrictions on devices in order to assure that they are used in a safe and effective
manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>510(k) Clearance Pathway </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">When a 510(k)
clearance is required, we must submit a premarket notification to the FDA demonstrating that our proposed device is substantially equivalent to a predicate device, which is a previously cleared and legally marketed 510(k) device or a device that was
in commercial distribution before May&nbsp;28, 1976. By regulation, a premarket notification must be submitted to the FDA at least 90 days before we intend to distribute a device. As a practical matter, clearance often takes significantly longer. To
demonstrate substantial equivalence, the manufacturer must show that the proposed device has the same intended use as the predicate device, and it either has the same technological characteristics, or different technological characteristics and the
information in the premarket notification demonstrates that the device is equally safe and effective and does not raise different questions of safety and effectiveness. The FDA may require further information, including clinical data, to make a
determination regarding substantial equivalence. If the FDA determines that the device, or its intended use, is not substantially equivalent to a previously cleared device or use, the FDA will place the device into Class III. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">There are three types of 510(k)s: traditional, special and abbreviated. Special 510(k)s are for devices that are modified and the modification needs a
new 510(k) but does not affect the intended use or alter the fundamental scientific technology of the device. Abbreviated 510(k)s are for devices that conform to a recognized standard. The special and abbreviated 510(k)s are intended to streamline
review, and the FDA intends to process special 510(k)s within 30 days of receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Premarket Approval Pathway </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">A premarket approval application must be submitted to the FDA for Class III devices for which the FDA has required a PMA. The premarket approval
application process is much more demanding than the 510(k) premarket notification process. A premarket approval application must be supported by extensive data, including but not limited to technical, preclinical, clinical trials, manufacturing and
labeling to demonstrate to the FDA&#146;s satisfaction reasonable evidence of safety and effectiveness of the device. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">After a premarket approval
application is submitted, the FDA has 45 days to determine whether the application is sufficiently complete to permit a substantive review and thus whether the FDA will file the application for review. The FDA has 180 days to review a filed
premarket approval application, although the review of an application generally occurs over a significantly longer period of time and can take up to several years. During this review period, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the FDA may request additional information or clarification of the information already provided. Also, an advisory panel of experts from outside the FDA may be convened to review and evaluate the
application and provide recommendations to the FDA as to the approvability of the device. Although the FDA is not bound by the advisory panel decision, the panel&#146;s recommendations are important to the FDA&#146;s overall decision making process.
In addition, the FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the Quality System Regulation or QSR. The agency also may inspect one or more clinical sites to assure compliance with FDA&#146;s
regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Upon completion of the PMA review, the FDA may: (i)&nbsp;approve the PMA which authorizes commercial marketing with specific
prescribing information for one or more indications, which can be more limited than those originally sought; (ii)&nbsp;issue an approvable letter which indicates the FDA&#146;s belief that the PMA is approvable and states what additional information
the FDA requires, or the post-approval commitments that must be agreed to prior to approval; (iii)&nbsp;issue a not approvable letter which outlines steps required for approval, but which are typically more onerous than those in an approvable
letter, and may require additional clinical trials that are often expensive and time consuming and can delay approval for months or even years; or (iv)&nbsp;deny the application. If the FDA issues an approvable or not approvable letter, the
applicant has 180 days to respond, after which the FDA&#146;s review clock is reset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Clinical Trials </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Clinical trials are almost always required to support premarket approval and are sometimes required for 510(k) clearance. In the United States, for
significant risk devices, these trials require submission of an application for an Investigational Device Exemption, or IDE, to the FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing results,
showing it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE must be approved in advance by the FDA for a specific number of patients at specified study sites. During the trial, the sponsor must
comply with the FDA&#146;s IDE requirements for investigator selection, trial monitoring, reporting, and recordkeeping. The investigators must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control
the disposition of investigational devices, and comply with all reporting and recordkeeping requirements. Clinical trials for significant risk devices may not begin until the IDE application is approved by the FDA and the appropriate institutional
review boards, or IRBs, at the clinical trial sites. An IRB is an appropriately constituted group that has been formally designated to review and monitor medical research involving subjects and which has the authority to approve, require
modifications in, or disapprove research to protect the rights, safety and welfare of human research subjects. A nonsignificant risk device does not require FDA approval of an IDE; however, the clinical trial must still be conducted in compliance
with various requirements of FDA&#146;s IDE regulations and be approved by an IRB at the clinical trials sites. We, the FDA or the IRB at each site at which a clinical trial is being performed may withdraw approval of a clinical trial at any time
for various reasons, including a belief that the risks to study subjects outweigh the benefits or a failure to comply with FDA or IRB requirements. Even if a trial is completed, the results of clinical testing may not demonstrate the safety and
effectiveness of the device, may be equivocal or may otherwise not be sufficient to obtain approval or clearance of the product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Sponsors of
clinical trials of devices are required to register with clinicaltrials.gov, a public database of clinical trial information. Information related to the device, patient population, phase of investigation, study sites and investigators, and other
aspects of the clinical trial is made public as part of the registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Ongoing Regulation by the FDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Even after a device receives clearance or approval and is placed on the market, numerous regulatory requirements apply. These include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment registration and device listing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation, and other quality assurance procedures during all aspects of the manufacturing
process; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">labeling regulations and the FDA prohibitions against the promotion of products for un-cleared, unapproved or &#147;off-label&#148; uses, and other requirements related to promotional activities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">medical device reporting regulations, which require that manufactures report to the FDA if their device may have caused or contributed to a death or serious injury or if their device malfunctioned and the device or a
similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">corrections and removal reporting regulations, which require that manufactures report to the FDA field corrections or removals if undertaken to reduce a risk to health posed by a device or to remedy a violation of the
Federal Food, Drug, and Cosmetic Act that may present a risk to health; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">post market surveillance regulations, which apply to certain class II or III devices when necessary to protect the public health or to provide additional safety and effectiveness data for the device. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major
change in its intended use, will require a new clearance or possibly a premarket approval. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacturer&#146;s
determination. If the FDA disagrees with our determination not to seek a new 510(k) clearance, the FDA may retroactively require us to seek 510(k) clearance or possibly a premarket approval. The FDA could also require us to cease marketing and
distribution and/or recall the modified device until 510(k) clearance or premarket approval is obtained. Also, in these circumstances, we may be subject to significant regulatory fines and penalties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Some changes to an approved PMA device, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA
approval of a new PMA or PMA supplement, as appropriate, before the change can be implemented. Supplements to a PMA often require the submission of the same type of information required for an original PMA, except that the supplement is generally
limited to that information needed to support the proposed change from the device covered by the original PMA. The FDA uses the same procedures and actions in reviewing PMA supplements as it does in reviewing original PMAs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">FDA regulations require us to register as a medical device manufacturer with the FDA. Additionally, the California Department of Health Services, or
CDHS, requires us to register as a medical device manufacturer within the state. Because of this, the FDA and the CDHS inspect us on a routine basis for compliance with the QSR. These regulations require that we manufacture our products and maintain
related documentation in a prescribed manner with respect to manufacturing, testing and control activities. We have undergone and expect to continue to undergo regular QSR inspections in connection with the manufacture of our products at our
facilities. Further, the FDA requires us to comply with various FDA regulations regarding labeling. Failure by us or by our suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or state authorities,
which may include any of the following sanctions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning or untitled letters, fines, injunctions, consent decrees and civil penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">customer notifications, voluntary or mandatory recall or seizure of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">operating restrictions, partial suspension or total shutdown of production; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay in processing submissions or applications for new products or modifications to existing products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawing approvals that have already been granted; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">criminal prosecution. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Medical Device Reporting laws and regulations require us to provide
information to the FDA when we receive or otherwise become aware of information that reasonably suggests our device may have caused or contributed to a death or serious injury as well as a device malfunction that likely would cause or contribute to
death or serious injury if the malfunction were to recur. In addition, the FDA prohibits an approved device from being marketed for off-label use. The FDA and other agencies actively enforce the laws and regulations
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including substantial monetary
penalties and criminal prosecution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Newly discovered or developed safety or effectiveness data may require changes to a product&#146;s labeling,
including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the
FDA&#146;s policies may change, which could delay or prevent regulatory clearance or approval of our products under development. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are also subject
to other federal, state and local laws, and regulations relating to safe working conditions, laboratory, and manufacturing practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Regulatory Inspections
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are subject to periodic inspections by the FDA and other regulatory bodies related to the regulatory requirements that apply to medical
devices designed and manufactured, and clinical trials sponsored, by us. When the FDA conducts an inspection, the inspectors will identify any deficiencies they believe exist in the form of a notice of inspectional observations, or Form FDA 483. If
we receive a notice of inspectional observations or deficiencies from the FDA following an inspection, we likely will be required to respond in writing, and may be required to undertake corrective and preventive actions or other actions in order to
address the FDA&#146;s concerns. Failure to address the FDA&#146;s concerns may result in the issuance of a warning letter or other enforcement or administrative actions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">From June&nbsp;24, 2015 to July&nbsp;15, 2015 the FDA conducted an inspection of our records relating to certain investigational sites for two different
clinical trials and from July 30, 2015 to August 4, 2015, the FDA conducted an inspection of our Quality System. At the conclusion of the first inspection, a Form FDA 483 was issued with one observation. The 483 observation pertained to the failure
to ensure proper monitoring at five of the investigational sites reviewed. Specifically, the observation noted that protocols relating to performing onsite monitoring visits at appropriate intervals and providing documentation to clearly address any
repeated data problems and resolutions of noted deficiencies in written reports after each onsite monitoring visit were not properly followed. At the conclusion of the second inspection, a Form FDA 483 was also issued with one observation relating
to our procedures for Corrective and Preventative Action (CAPA). Specifically, the observation noted our CAPA procedures do not require an effectiveness check in all cases. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We responded to the first Form FDA 483 on August 4, 2015, and we have begun to take preventive actions to address the observation in that Form FDA 483.
We continue to review and enhance our investigational site monitoring to ensure compliance with regulatory requirements. We opened a CAPA to address the observation in the second Form FDA 483 and responded to the second Form FDA 483 on
August&nbsp;24, 2015. However, the FDA may conclude in subsequent inspections that we have not adequately responded to its observations, and could take action against us without further notice. Action by the FDA against us could result in monetary
fines or require us to take further corrective actions, which could be expensive and time-consuming to complete and could impose additional burdens and expenses, and could even require us to discontinue our investigational studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>European Union </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our products are regulated in the
European Union as medical devices per the European Union Directive (93/42/EEC), also known as the Medical Device Directive. An authorized third party, Notified Body, must approve products for CE marking. The CE mark is contingent upon continued
compliance to the applicable regulations and the quality system requirements of the ISO 13485 standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Other Regions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Most major markets have different levels of regulatory requirements for medical devices. Modifications to the cleared or approved products may require a
new regulatory submission in all major markets. The regulatory requirements, and the review time, vary significantly from country to country. Products can also be marketed in other countries that have minimal requirements for medical devices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fraud and Abuse and Other Healthcare Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Anti-Kickback Statute </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are subject to various federal and
state healthcare laws, including, but not limited to, anti-kickback laws. In particular, the federal Anti-Kickback Statute prohibits persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration,
directly or indirectly, overtly or covertly, in cash or in kind, in exchange for or to induce either the referral of an individual for the furnishing or arranging for a good or service, or for the purchasing, leasing, ordering, or arranging for or
recommending any good, facility, service or item for which payment may be made in whole or in part under federal healthcare programs, such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is broad and prohibits many
arrangements and practices that are lawful in businesses outside of the healthcare industry. The term &#147;remuneration&#148; expressly includes kickbacks, bribes, or rebates and also has been broadly interpreted to include anything of value,
including, for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">There are a number of statutory exceptions and regulatory safe harbors protecting certain business arrangements from prosecution under the federal
Anti-Kickback Statute. These statutory exceptions and safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they may not be prosecuted under the federal
Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more applicable statutory exceptions or safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct
and business arrangements that do not fully satisfy all requirements of an applicable safe harbor may result in increased scrutiny by government enforcement authorities and will be evaluated on a case-by-case basis based on a cumulative review of
all of its facts and circumstances. Additionally, the intent standard under the federal Anti-Kickback Statute was amended under the Affordable Care Act, to a stricter standard such that a person or entity no longer needs to have actual knowledge of
the statute or specific intent to violate it in order to have committed a violation. The Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act which is discussed below. Penalties for violations of the anti-kickback statute include, but are not limited to, criminal, civil and/or administrative
penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from Medicare, Medicaid and other federal healthcare programs, and the curtailment or restructuring of operations. Various states have adopted laws similar to the
federal Anti-Kickback Statute, and some of these state laws may be broader in scope in that some of these state laws extend to all payors and may not contain safe harbors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Federal Civil False Claims Act.</I> The federal civil False Claims Act prohibits, among other things, persons or entities from knowingly presenting
or causing to be presented a false or fraudulent claim to, or the knowing use of false statements to obtain payment from or approval by, the federal government. Suits filed under the federal civil False Claims Act, known as &#147;<I>qui
tam</I>&#148; actions, can be brought by any individual on behalf of the government. These individuals, sometimes known as &#147;relators&#148; or, more commonly, as &#147;whistleblowers,&#148; may share in any amounts paid by the entity to the
government in fines or settlement. The number of filings of <I>qui tam</I> actions has increased significantly in recent years, causing more healthcare companies to have to defend a case brought under the federal civil False Claim Act. If an entity
is determined to have violated the federal civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Various states have adopted laws
similar to the federal civil False Claims Act, and many of these state laws are broader in scope and apply to all payors, and therefore, are not limited to only those claims submitted to the federal government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Federal Civil Monetary Penalties Statute.</I> The federal Civil Monetary Penalties Statute, among other things, imposes fines against any person who
is determined to have presented, or caused to be presented, claims to a federal healthcare program that the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Sunshine Act.</I> The Affordable Care Act also included a provision, commonly referred to as the
Sunshine Act. This provision requires that any manufacturer of a covered device that provides payment or other transfer of value to a physician or teaching hospital, or to a third party at the request of a physician or teaching hospital, must submit
to the Centers for Medicare and Medicaid Services information about the payment or other transfer of value annually, with the reported information to be made public on a searchable website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Health Insurance Portability and Accountability Act of 1996.</I> The federal Health Insurance Portability and Accountability Act (HIPAA) created
several new federal crimes, including healthcare fraud and false statements relating to healthcare matters. The healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including
private third-party payors. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or
payment for healthcare benefits, items or services. In addition, HIPAA and its implementing regulations established uniform standards for certain covered entities, which are healthcare providers, health plans and healthcare clearinghouses, as well
as their business associates, governing the conduct of specified electronic healthcare transactions and protecting the security and privacy of protected health information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The American Recovery and Reinvestment Act of 2009, commonly referred to as the economic stimulus package, included an expansion of HIPAA&#146;s privacy
and security standards called the Health Information Technology for Economic and Clinical Health Act (HITECH). Among other things, HITECH created four new tiers of civil monetary penalties and gave state attorneys general new authority to file civil
actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of June 30, 2015, we had approximately 1,000
employees worldwide. None of our employees are represented by a collective bargaining agreement and we have never experienced a work stoppage. We believe our employee relations are good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We maintain a 180,000 square foot research and
development and manufacturing facility in three buildings at our campus in Alameda, California. We leased the initial 75,000 square feet of the Alameda campus in 2008 and we added the additional space over several lease amendments and additional
leases. The leases for all three buildings expire in 2029, subject to our option to renew any or all three leases for an additional ten years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We
also lease office space in Berlin, Germany; Sydney, Australia; and Sao Paulo, Brazil. The offices in Berlin and Sydney support our direct sales operations in Europe and Australia, respectively, and the office in Sao Paulo supports our Latin America
marketing efforts through our distribution partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are not currently party to any material legal proceedings. We currently are and in the future may at times be involved in litigation and other legal
claims in the ordinary course of business. When appropriate in our estimation, we may record reserves in our financial statements for pending litigation and other claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets
forth information regarding our executive officers and directors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:19.25pt; font-size:8pt; font-family:arial"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00px solid #000000; width:27.35pt; font-size:8pt; font-family:arial"><B>Position</B></P></TD></TR>


<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adam Elsesser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman, Chief Executive Officer and President</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Arani Bose, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Innovator and Director</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sri Kosaraju</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer and Head of Strategy</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Daniel Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, North America</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James Pray</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, International</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lynn Rothman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President and Chief Business Officer</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Robert Evans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, General Counsel and Secretary</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Don Kassing<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Walter Wang<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Harpreet Grewal<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the nominating and corporate governance committee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Adam Elsesser</I> co-founded Penumbra and has served as Chief Executive Officer and a member of our board of directors since our inception in 2004 and
as President and Chairman of our board of directors since January 2015. Prior to Penumbra, Mr.&nbsp;Elsesser led SMART Therapeutics, Inc., a medical device company focused on devices for neuro-intervention, as its Chief Executive Officer from 2000
to 2002 and, after its acquisition by Boston Scientific Corporation, President of SMART Therapeutics within Boston Scientific Corporation from 2002 to 2005. Before his work in the medical device industry, Mr.&nbsp;Elsesser was a partner in the law
firm of Shartsis Friese, LLP. Mr.&nbsp;Elsesser received a B.A. from Stanford University and a J.D. from Hastings College of the Law. Mr.&nbsp;Elsesser is qualified to serve on our board of directors based on his extensive knowledge of our company,
the medical device industry and the competitive landscape, as well as his expertise in building and leading successful medical device companies and commercializing devices. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Arani Bose</I>, M.D. co-founded Penumbra in 2004 and has served as a member of our board of directors since our inception. Dr.&nbsp;Bose was Chairman
of our board of directors and Chief Medical Officer from 2005 until 2015 and currently serves as Chief Innovator. Prior to founding Penumbra, Dr.&nbsp;Bose was an Assistant Professor of Radiology and Neurology at New York University (NYU) School of
Medicine from 1997 to 2004, where he also had a clinical practice. While at NYU, Dr.&nbsp;Bose co-founded SMART Therapeutics. Dr.&nbsp;Bose received a B.A. from Stanford University and a M.D. from the University of Colorado School of Medicine with
residency and fellowships at Yale University School of Medicine and NYU Medical Center. Dr.&nbsp;Bose is qualified to serve on our board of directors based on his extensive knowledge of our company and the medical device industry, as well as his
training and expertise in interventional radiology and neurology and his skills and experience in clinical research and device development and commercialization. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Sri Kosaraju</I> joined Penumbra as Chief Financial Officer and Head of Strategy in 2015. Prior to joining Penumbra, Mr.&nbsp;Kosaraju worked in
investment banking for J.P. Morgan Securities LLC (J.P. Morgan) from 1999 until 2015, where he held a variety of positions with successively greater responsibility, most recently Managing Director of Equity Capital Markets, Head of Healthcare Equity
Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Prior to entering J.P. Morgan&#146;s equity capital markets group in 2006, Mr.&nbsp;Kosaraju served in various practice groups at J.P. Morgan, including Equity
Derivatives from 2003 to 2006 and Technology, Media, Telecom Investment Banking Coverage from 1999 to 2003. Mr.&nbsp;Kosaraju received a B.S. from Massachusetts Institute of Technology in 1999. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Daniel Davis</I> joined Penumbra in 2007. He has served as President, North America, since 2015.
Mr.&nbsp;Davis previously served as Vice President of Strategy from 2013 to 2014 and as Director of Marketing from 2011 to 2012. Mr.&nbsp;Davis joined our sales team in 2007, serving as a Sales Trainer from 2008 to 2011. Before joining Penumbra,
Mr.&nbsp;Davis held various sales and marketing positions at Boston Scientific Corporation. Mr.&nbsp;Davis received a B.A. from Duke University. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>James Pray</I> joined Penumbra in 2005. He has served as President, International, since 2015 and as President from 2005 to 2015. Mr.&nbsp;Pray joined
Penumbra with over 15 years of experience in the medical device industry, much of that in the neurovascular arena. Prior to joining Penumbra, Mr.&nbsp;Pray worked for Boston Scientific Corporation, including as the Director of Marketing for the
neurovascular division from 2000 to 2005. Mr.&nbsp;Pray also worked as a Research and Development Engineer and Engineering Manager for SCIMED Life Systems, a medical device company, from 1990 to 1996. Mr.&nbsp;Pray received a B.S. and M.S. from the
University of Minnesota. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Lynn Rothman</I> joined Penumbra in 2007. She has served as Executive Vice President and Chief Business Officer since
January 2015; as Chief Financial Officer from March 2009 to January 2015; as Vice President, Administration from January 2009 to March 2009, and as Human Resources Manager from 2007 to January 2009. Ms.&nbsp;Rothman joined Penumbra with over 20
years of experience in finance and marketing of medical and emerging growth companies. Ms.&nbsp;Rothman served as Director of Corporate Marketing at Confer Software, Inc., a disease management company, from 1997 to 2000. Prior to that time,
Ms.&nbsp;Rothman worked at Robertson Stephens&nbsp;&amp; Company, a financial services firm, where she worked in both health care research and venture capital focused on potential medical device, service and software investment opportunities. She
received an M.B.A. from The Wharton School, University of Pennsylvania and a B.A. from Stanford University. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Robert Evans</I> joined Penumbra as
Executive Vice President, General Counsel and Secretary in 2008. Prior to joining Penumbra, Mr.&nbsp;Evans was Executive Vice President, General Counsel and Secretary of Waste Connections, Inc., a publicly traded waste services company, from 2002 to
2008, and a partner in the law firm Shartsis Friese LLP from 1978 to 2002. Mr.&nbsp;Evans received a B.A. and J.D. from the University of California, Berkeley. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I></I><B><I>Nonemployee Directors</I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Don
Kassing</I> has served on our board of directors since 2008. Mr.&nbsp;Kassing is President Emeritus of San Jose State University. Mr.&nbsp;Kassing served as President of San Jose State University from 2004 to 2008, Interim President from 2010 to
2011, and Vice President, Administration and Finance and Chief Financial Officer from 1993 to 2004. Prior to his tenure at San Jose State University, Mr.&nbsp;Kassing spent 18 years in higher education and 11 years in private industry, including
eight years in corporate finance and operations management at Brown Group, Inc., a retail real estate developer, and General Motors Corporation. Mr.&nbsp;Kassing received a B.A. and M.B.A. from Saint Louis University. Mr.&nbsp;Kassing is qualified
to serve on our board of directors based on his extensive business and leadership experience, including valuable skills related to strategic planning, based on his long tenure leading a major educational institution, including overseeing the
development and construction of two high-profile campus facilities and having primary responsibility for university business and financial affairs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Walter Wang</I> has served on our board of directors since January 2015. Mr.&nbsp;Wang has served as the Chief Executive Officer of Orlucent, Inc., an
early stage diagnostics company, since 2012. From 1999 to the present, Mr.&nbsp;Wang has researched, advised and invested in medical device, financial and technology start-up companies through Wang Ventures, a family investment partnership and other
related entities. In addition, Mr.&nbsp;Wang invests, develops and manages real estate through W5 Investments, a real estate company. Mr.&nbsp;Wang began his career in 1989 with U-Jin Enterprises, Inc., a food processing and import/export company.
Mr.&nbsp;Wang received a B.S. from the University of Southern California. Mr.&nbsp;Wang is qualified to serve on our board of directors based on his extensive experience in analyzing, investing in and advising medical device and emerging growth
companies and his strong financial background. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Harpreet Grewal</I> has served on our board of directors since April 2015. Since 2010, Mr.&nbsp;Grewal
has served as Executive Vice President and Chief Financial Officer of Constant Contact, Inc., a publicly-traded technology company primarily focused on marketing tools. From 2008 to 2009, Mr.&nbsp;Grewal worked as an independent consultant to small
businesses and early-stage entrepreneurs. From 2006 through 2008, Mr.&nbsp;Grewal was Executive Vice President and Chief Financial Officer of VistaPrint, Ltd., a publicly-traded online printing and marketing services company. Prior to VistaPrint,
Mr.&nbsp;Grewal was Senior Vice President and Chief Financial Officer of GoldenSource Corporation, a data management company, from 2002 to 2006, Chief Financial Officer of eGain Communications Corporation, a customer engagement services company,
from 1999 to 2002, and held various financial and strategic planning positions with PepsiCo, Inc., a publicly-traded food and beverage company, from 1996 to 1999. Mr.&nbsp;Grewal received a B.A. from the University of California, Berkeley and a M.A.
from Johns Hopkins University. Mr.&nbsp;Grewal is qualified to serve on our board of directors because of his extensive business and leadership experience, including financial expertise and strategic planning skills, based on his tenure as Chief
Financial Officer at numerous companies, including several publicly-traded corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Board Structure and Compensation of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Upon completion of the offering, our board of directors will consist of five members. In accordance with our amended and restated certificate of
incorporation and our amended and restated bylaws, immediately after the completion of this offering, our directors will be divided into three classes serving staggered three-year terms. At each annual meeting of stockholders, directors will be
elected to succeed the class of directors whose terms have expired. Our current directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class I directors will consist of Mr.&nbsp;Kassing, and his term will expire at the annual meeting of stockholders to be held in 2016; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class II directors will consist of Dr. Bose and Mr. Wang, and their terms will expire at the annual meeting of stockholders to be held in 2017; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class III directors will consist of Messrs. Elsesser and Grewal, and their terms will expire at the annual meeting of stockholders to be held in 2018. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">This classification of our board of directors could have the effect of increasing the length of time necessary to change the composition of a majority of
the board of directors. In general, at least two annual meetings of stockholders will be necessary for stockholders to effect a change in a majority of the members of the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Director Independence </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our board of directors has
undertaken a review of the independence of each director. Based on information provided by each director concerning his background, employment and affiliations, our board of directors has determined that each of Don Kassing, Walter Wang and Harpreet
Grewal do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and is independent under applicable NYSE rules. In making these determinations, our board of
directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial
ownership of our capital stock by each non-employee director, and the transactions involving them described in the section titled &#147;Certain Relationships and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Director Compensation Policy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Directors who are also
full-time officers or employees of our company will receive no additional compensation for serving as directors. All other directors will receive an annual retainer of $25,000. The chairman of the audit committee will receive an additional annual
fee of $25,000. Each non-employee director also will receive an annual grant of 2,000 shares of restricted stock under our 2014 Equity Incentive Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Audit
Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The members of our audit committee are Don Kassing, Walter Wang and Harpreet Grewal. Harpreet Grewal is the chair of our audit
committee. The composition of our audit committee meets the requirements for independence under the current NYSE listing standards and SEC rules and regulations. Each member of our audit committee is financially literate. In addition, our board of
directors has determined that each of Mr.&nbsp;Grewal and Mr.&nbsp;Kassing is an &#147;audit committee financial expert&#148; as defined in Item&nbsp;407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act. This designation does not
impose on either any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and our board of directors. Our audit committee is directly responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selecting a firm to serve as the independent registered public accounting firm to audit our financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ensuring the independence of the independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussing the scope and results of the audit with the independent registered public accounting firm and reviewing, with management and that firm, our interim and year-end operating results; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">considering the adequacy of our internal controls and internal audit function; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing material related party transactions or those that require disclosure; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving or, as permitted, pre-approving all audit and non-audit services to be performed by the independent registered public accounting firm. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our audit committee will operate under a written charter, to be effective prior to the completion of this offering, that satisfies the applicable rules
of the SEC and the listing standards of the NYSE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The members of our compensation committee are Don Kassing, Walter Wang and Harpreet Grewal. Walter Wang is the chair of our compensation committee. Each
member of this committee is a non-employee director, as defined by Rule 16b-3 promulgated under the Securities Exchange Act of 1934, as amended (Exchange Act), and an outside director, as defined pursuant to Section&nbsp;162(m) of the Code, and
meets the requirements for independence under the current NYSE listing standards and SEC rules and regulations. Our compensation committee is responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or recommending that our board of directors approve, the compensation of our executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending to our board of directors the compensation of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering our stock and equity incentive plans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or making recommendations to our board of directors with respect to, incentive compensation and equity plans; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing our overall compensation philosophy. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our compensation committee will operate under a written
charter, to be effective prior to the completion of this offering, that satisfies the applicable rules of the SEC and the listing standards of the NYSE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Nominating and Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The members of
our nominating and governance committee are Don Kassing, Walter Wang and Harpreet Grewal. Don Kassing is the chair of our nominating and governance committee. Messrs. Kassing, Wang and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Grewal all meet the requirements for independence under the current NYSE listing standards. Our nominating and governance committee is responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying and recommending candidates for membership on our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending our corporate governance guidelines and policies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing proposed waivers of the code of conduct for directors and executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing the process of evaluating the performance of our board of directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assisting our board of directors on corporate governance matters. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our nominating and governance
committee will operate under a written charter, to be effective prior to the completion of this offering, that satisfies the applicable rules of the SEC and the listing standards of the NYSE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Code of Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In connection with this offering, our board
of directors will adopt a code of ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer and other executive and senior financial officers. Upon completion of this
offering, the full text of our code of business conduct and ethics will be posted on the investor relations section of our website. We intend to disclose future amendments to our code of business conduct and ethics, or any waivers of such code, on
our website or in public filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Limitation of Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our amended and restated certificate of incorporation, which will be in effect immediately upon the completion of this offering, contains provisions that
limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as
directors, except liability for: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the director&#146;s duty of loyalty to us or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General Corporation Law; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our amended and
restated certificate of incorporation to be in effect immediately upon the completion of this offering will provide that we may indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Our amended and
restated bylaws to be in effect immediately upon the completion of this offering will also provide that we are obligated to indemnify our directors and officers to the fullest extent permitted by Delaware law and advance expenses incurred by a
director or officer in advance of the final disposition of any action or proceeding and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity
regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. We have entered into agreements to indemnify our directors, executive officers and other employees as determined by our board of
directors. With specified exceptions, these agreements will provide for indemnification for related expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any
action or proceeding. We believe these limitations of liability provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors&#146; and officers&#146; liability
insurance. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation, amended and
restated bylaws and indemnification agreements may discourage stockholders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. Our amended and restated certificate of incorporation will provide that any such lawsuit must be
brought in the Court of Chancery of the State of Delaware. The foregoing provisions may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other
stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. Insofar as
indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such
indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. At present, there is no pending litigation or proceeding involving any of our directors, officers or employees for which indemnification
is sought, and we are not aware of any threatened litigation that may result in claims for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Compensation Committee Interlocks and Insider
Participation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our compensation committee has historically consisted solely of Adam Elsesser, our Chairman, Chief Executive Officer and
President. As a result, Mr.&nbsp;Elsesser determined the compensation of our executive officers. Prior to the completion of this offering, we will appoint a compensation committee consisting solely of independent directors. None of our executive
officers has served as a member of a compensation committee (or if no committee performs that function, the board of directors) of any other entity that has an executive officer serving as a member of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets forth
information concerning the compensation paid to our principal executive officer, and our two most highly compensated executive officers other than the principal executive officer during our fiscal year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>2014 SUMMARY COMPENSATION TABLE </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:94.40pt; font-size:8pt; font-family:arial"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Salary ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock&nbsp;Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option&nbsp;Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total <BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adam Elsesser,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,673,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:arial">Chairman, Chief Executive Officer and President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Daniel Davis,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:arial">President, North America</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lynn Rothman,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:arial">Executive Vice President and Chief Business Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reflect the aggregate grant date fair value for awards granted during 2014. The grant date fair value was computed in accordance with FASB ASC Topic 718, Compensation&#151;Stock Compensation. Unlike the
calculations contained in our financial statements, this calculation does not give effect to any estimate of forfeitures related to service-based vesting, but assumes that the executive will perform the requisite service for the award to vest in
full. The assumptions we used in valuing options and stock awards are described in Note 12 to our Consolidated Financial Statements included in this prospectus. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Executive Officer Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our executive officers are
employed on an at-will basis. Mr.&nbsp;Elsesser, Mr.&nbsp;Davis and Ms.&nbsp;Rothman have entered into at will employment agreements with us that set forth the general terms of their employment. We do not have agreements or policies that would
require us to provide severance benefits or change-in-control benefits to our executive officers, other than the provisions under our equity plans described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Outstanding Equity Awards at Fiscal Year End </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following
table sets forth information concerning unexercised options, stock that has not vested and equity incentive plan awards for the named executive officers named in the Summary Compensation Table as of the end of our fiscal year ended December&nbsp;31,
2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>OUTSTANDING EQUITY AWARDS AT 2014 FISCAL YEAR END </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:19.25pt; font-size:8pt; font-family:arial"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Numbers<BR>of&nbsp;
Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)<BR>Exercisable<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Numbers<BR>of&nbsp;Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option<BR>Exercise<BR>Price <BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option<BR>Expiration Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number<BR>of&nbsp;Shares&nbsp;or<BR>Units of<BR>Stock That<BR>Have Not<BR>Vested <BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Market&nbsp;Value<BR>of&nbsp;Shares&nbsp;or</B><br><B>Units&nbsp;of<BR>Stock That<BR>Have Not<BR>Vested <BR>($)<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adam&nbsp;Elsesser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/01/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">05/01/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/01/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/21/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/20/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Daniel&nbsp;Davis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/30/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/07/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lynn&nbsp;Rothman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">06/13/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Options may be exercised prior to vesting, subject to repurchase rights that expire over the vesting periods indicated in the footnotes below. Accordingly, all options outstanding as of December&nbsp;31, 2014, were
exercisable in full. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>There was no public market for our common stock as of December&nbsp;31, 2014. The fair value of our common stock as of December&nbsp;31, 2014, was $12.36 per share.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>The shares subject to this option were granted under the 2005 Stock Plan and are fully vested as of December&nbsp;31, 2014. Mr. Elsesser exercised options to purchase
300,000 shares of common stock on June 22, 2015. We withheld 52,337 of such shares for the payment of tax withholdings. Mr. Elsesser also tendered 11,825 of his existing shares of our common stock in payment of the exercise price. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Options were granted under the 2005 Stock Plan and vest with respect to 1/4th of the shares subject to the option on March&nbsp;21, 2015, and as to 1/48th of the
total shares subject to the option on each month thereafter, subject to the executive continuing to provide services to us through each applicable vesting date. In the event of a Change in Control, as defined under the 2005 Stock Plan, the issued
options will fully vest, subject to the executive continuing to provide services to us through the occurrence of the Change in Control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Options were granted under the 2011 Equity Incentive Plan and vest with respect to 1/4th of the shares subject to the option on March&nbsp;21, 2015, and as to 1/48th
of the total shares subject to the option on each month thereafter, subject to the executive continuing to provide services to us through each applicable vesting date. In the event of a Change in Control, as defined under the 2011 Equity Incentive
Plan, the issued options will fully vest, subject to the executive continuing to provide services to us through the occurrence of the Change in Control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>The shares were issued upon the early exercise of options to purchase 1,500 shares of common stock. The original grant of options to purchase 1,500 shares of common
stock was made under the 2005 Stock Plan to vest as to 1/4th of the shares subject to the option on January&nbsp;14, 2012, and as to 1/48th of the total shares subject to the option on each month thereafter, subject to the executive continuing to
provide services to us through each applicable vesting date. Our repurchase rights with respect to issued restricted shares lapse over the vesting period. In the event of a Change in Control, as defined under the 2005 Stock Plan, the issued
restricted shares will fully vest, subject to the executive continuing to provide services to us through the occurrence of the Change in Control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Options were granted under the 2005 Stock Plan and vest with respect to 1/4th of the shares subject to the option on September&nbsp;30, 2012, and as to 1/48th of the
total shares subject to the option on each month thereafter, subject to the executive continuing to provide services to us through each applicable vesting date. In the event of a Change in Control, as defined under the 2005 Stock Plan, the issued
options will fully vest, subject to the executive continuing to provide services to us through the occurrence of the Change in Control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:arial; font-size:9pt"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Options were granted under the 2005 Stock Plan and vest with respect to 1/4th of the shares subject to the
option on January&nbsp;1, 2013, and as to 1/4th of the total shares subject to the option on each January&nbsp;2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> thereafter, </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
subject to the executive continuing to provide services to us through each applicable vesting date. In the event of a Change in Control, as defined under the 2005 Stock Plan, the issued options
will fully vest, subject to the executive continuing to provide services to us through the occurrence of the Change in Control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Mr.&nbsp;Davis and Ms.&nbsp;Rothman were each granted 50,000 restricted shares under the 2011 Equity Incentive Plan on February&nbsp;3, 2014. Our repurchase rights
with respect to the issued restricted shares lapses as to 1/4th of the shares subject to the stock award on January&nbsp;2, 2015, and as to 1/48th of the total shares subject to the award on each month thereafter, subject to the executive continuing
to provide services to us through each applicable vesting date. In the event of a Change in Control, as defined under the 2011 Equity Incentive Plan, the issued restricted shares will fully vest, subject to the executive continuing to provide
services to us through the occurrence of the Change in Control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Options were granted under the 2005 Stock Plan and vest with respect to 1/4th of the shares subject to the option on February&nbsp;1, 2012, and as to 1/48th of the total shares subject to the option on each month
thereafter, subject to the executive continuing to provide services to us through each applicable vesting date. In the event of a Change in Control, as defined under the 2005 Stock Plan, the issued options will fully vest, subject to the executive
continuing to provide services to us through the occurrence of the Change in Control. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Employee Benefit Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our officers are entitled to participate in our equity incentive plans. All officers are eligible to participate in our 401(k) plan on the same terms as
all other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2014 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our board of directors and our stockholders approved our 2014 Equity Incentive Plan (the 2014 plan) and it became effective in May, 2014. Our 2014 plan
replaced our 2011 Equity Incentive Plan (the 2011 plan) and our 2005 Stock Plan (the 2005 plan). No further equity awards may be granted under our 2011 and 2005 plans. Our board of directors approved an amendment to the 2014 plan in August, 2015,
which will become effective as of the business day immediately prior to the date of the effectiveness of the registration statement of which this prospectus is a part and will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increase the number of shares of our common stock initially reserved for issuance under the 2014&nbsp;Plan to 3,000,000 shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">include an &#147;evergreen&#148; provision which will automatically increase the shares of our common stock reserved for issuance under our 2014 Plan in an amount equal to the lesser of: (i)&nbsp;2,500,000 shares of our
common stock (after any adjustments for dividends or other distributions, stock splits, recapitalizations and certain other transactions in accordance with the plan); (ii)&nbsp;5% of the number of outstanding shares of our common stock on the last
day of the immediately preceding fiscal year; and (iii) an amount determined by the board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize the grant of performance awards which may be earned upon achievement or satisfaction of one or more performance conditions; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize the grant of other awards that may be based on or related to shares of our common stock or other factors that may influence the value of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of June 30, 2015, there were 1,713,634 shares remaining available for the grant of equity awards under our 2014 plan. As of June 30, 2015, we had
granted options to purchase 536,650 shares of our common stock under our 2014 plan, of which 535,650 were outstanding and 1,000 options had been forfeited. We had also granted 662,361 shares of restricted stock under our 2014 plan, of which 503,646
shares were unvested and were subject to forfeiture. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Stock awards</I>. The 2014 plan provides for the grant of incentive stock options (ISOs),
nonstatutory stock options (NSOs), stock appreciation rights, restricted stock awards and restricted stock unit awards (collectively, &#147;stock awards&#148;). ISOs may be granted only to employees. All other awards may be granted to employees,
directors and consultants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Share reserve</I>. The aggregate number of shares of our common stock initially reserved for issuance pursuant to
stock awards under the 2014 plan was 2,700,000, plus (i)&nbsp;the shares reserved for issuance under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the 2005 plan and 2011 plan which were not issued or subject to awards granted under those plans and (ii)&nbsp;any shares subject to stock options or other stock awards granted under our 2011 and
2005 plans that expire or terminate for any reason, are forfeited or repurchased by us or are reacquired, withheld or not issued to satisfy a tax withholding obligation, up to a maximum of 3,007,276 shares added through clauses (i)&nbsp;or (ii). The
maximum number of shares that may be issued upon the exercise of incentive stock options will equal this aggregate maximum number of shares plus other shares that become available upon lapsed awards or certain other conditions, to the extent allowed
by section 422 of the Internal Revenue Code of 1986, as amended to the date hereof, and the regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If a stock award
granted under the 2014 plan is forfeited back to us because of the failure to meet a contingency or condition required to vest, such shares will become available for subsequent issuance under the 2014 plan. In addition, shares withheld to satisfy
income or employment withholding taxes and shares used to pay the exercise price of a stock option will become available for the grant of new stock awards under the 2014 plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Administration</I>. Our board of directors, or one or more duly authorized committees thereof, have the authority to administer the 2014 plan. Subject
to the terms of the 2014 plan, our board of directors or the authorized committee, referred to herein as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted and the terms and conditions
of the stock awards, including the period of their exercisability and vesting schedule applicable to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike price or purchase
price of awards granted and the types of consideration to be paid for the award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The plan administrator has the authority to modify outstanding
awards under our 2014 plan. Subject to the terms of our 2014 plan, the plan administrator has the authority to extend the post-termination exercisability period of awards and to extend the maximum term of an option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Stock Options</I>. Incentive and nonstatutory stock options are granted pursuant to stock option agreements adopted by the plan administrator. The
plan administrator determines the exercise price for a stock option, within the terms and conditions of the 2014 plan, provided that the exercise price of a stock option cannot be less than 100% of the fair market value of our common stock on the
date of grant. In the case of an incentive stock option granted to an employee who owns stock representing more than 10% of the voting power of all classes of our stock or any parent or subsidiary of us, the exercise price will be no less 110% of
the fair market value on the date of the grant. Options vest at the rate specified by the plan administrator. At the time an option is granted, the plan administrator will fix the period within which the option may be exercised and will determine
any conditions that must be satisfied before the option may be exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The plan administrator determines the term of stock options granted under
the 2014 plan, up to a maximum of 10 years. In the case of an incentive stock option granted to an employee who owns stock representing more than 10% of the voting power of all classes of our stock or the stock of any of our parents or subsidiaries,
the maximum term will be 5 years. Unless the terms of an option holder&#146;s stock option agreement provide otherwise, if an option holder&#146;s service relationship with us ceases for any reason other than disability or death, the option holder
may generally exercise any vested options for a period of thirty days following the cessation of service. If an optionholder&#146;s service relationship with us ceases due to disability or death, the optionholder or a beneficiary may generally
exercise any vested options for a period of 6 months, or within such longer period of time as is specified in the award agreement. In no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may
include (1)&nbsp;cash, (2)&nbsp;check, (3)&nbsp;promissory note, (4)&nbsp;other shares, (5)&nbsp;a broker-assisted cashless exercise, (6)&nbsp;by net exercise, or (5)&nbsp;combination of the foregoing methods of payment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Unless the plan administrator provides otherwise, options generally are not transferable except by will or by the laws of descent and distribution. An
optionholder may designate a beneficiary, however, who may exercise the option following the optionholder&#146;s death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Stock Appreciation Rights</I>. The 2014 plan permits the grant of stock appreciation rights. Stock
appreciation rights give recipients the right to acquire a specified number of shares of stock at a predetermined price. The terms of the stock appreciation rights granted under the 2014 plan are determined by the plan administrator in the award
agreement evidencing the award, including the number of shares, exercise price, expiration date and other terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Restricted Stock and Restricted
Stock Units. The 2014 plan permits the grant of restricted stock and/or restricted stock units. Restricted stock awards are grants of shares of our common stock. Restricted stock units represent the right to receive shares of our common stock (or a
cash amount equal to the value of our common stock) on future specified dates. The terms of the restricted stock and/or restricted stock units granted under the 2014 plan are determined by the plan administrator in the award agreement evidencing the
award, including the number of shares, period of restriction or vesting schedule, and other terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Tax Limitations on Incentive Stock
Options</I>. The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans may not exceed
$100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting
power or that of any of our affiliates unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2)&nbsp;the option is not exercisable after the expiration of
five years from the date of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Adjustments; Corporate Transactions</I>. In the event of certain changes in our corporate structure, including
any dividend or other distribution, recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of shares of the company the administrator will make appropriate
adjustments to outstanding awards to prevent diminution or enlargement of the benefits or potential benefits available under the plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Merger or
Change of Control</I>. In the event of certain corporate transactions specified in the plan, including a merger or change of control, as defined in the plan, each outstanding award will be treated as the administrator determines, without a
participant&#146;s consent, including that (i)&nbsp;awards will be assumed or substituted by the succeeding corporation; (ii)&nbsp;the awards will terminate; (iii)&nbsp;outstanding awards will vest and become exercisable, (iv)&nbsp;the awards will
terminate in exchange for an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of the award or realization of the rights under the award as of the date of the transaction, (v)&nbsp;the
replacement of any award with rights or property selected by the plan administrator or (vi)&nbsp;any combination of the above. In the event that the successor corporation does not assume or substitute the award, the participant will fully vest in
and have the right to exercise all of his or her outstanding options and stock appreciation rights and all restrictions on restricted stock and restricted stock units will lapse and performance goals will be deemed achieved at 100% of the target
levels. Our plan administrator is not obligated to treat all stock awards, even those that are of the same type, in the same manner. Under the 2014 plan, a change of control is generally (i)&nbsp;the acquisition by a person or entity of more than
50% of our combined voting power other than by private financing that is approved by the board, (ii)&nbsp;if we are public, the date on which a majority of the board has been replaced during any twelve month period by directors whose appointment or
election is not endorsed by a majority of the members of the board prior to the date of appointment or election; or (iii)&nbsp;change in ownership of a substantial portion of our assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Amendment and Termination</I>. The 2014 plan will terminate in 2024. However, our Board of Directors has the authority to amend, alter, or terminate
our 2014 plan, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Employee Stock Purchase Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In August 2015, our
board of directors adopted and we expect our stockholders to approve, our Employee Stock Purchase Plan, or the ESPP. The ESPP will become effective upon the effectiveness of the registration statement of which this prospectus forms a part. Unless
otherwise determined by the Board, the ESPP will be administered by our compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Share Reserve.</I> The ESPP authorizes the initial issuance of up to a total of 600,000&nbsp;shares of
our common stock to participating employees. The ESPP provides that the number of shares reserved and available for purchase under the plan will automatically increase on the first day of each fiscal year beginning with the 2016 fiscal year and
ending with the 2025 fiscal year, in an amount equal to the least of (i) 500,000&nbsp;shares of our common stock, (ii) 1% of the outstanding shares of our common stock on the last day of immediately preceding fiscal year and (iii) such number of
shares of our common stock determined by our board of directors. This number is subject to antidilution adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Eligible Employees. </I>All employees who have been employed by us or our designated subsidiaries are eligible to participate in the ESPP, provided
that the plan administrator may determine from time to time in its discretion to not include in the ESPP or any particular offering period employees who work less than 20 hours per week or less than five months in any calendar year. Any employee who
owns, or would own upon such purchase under the ESPP, 5% or more of the voting power or value of our stock is not eligible to purchase shares under our the ESPP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Offering Periods. </I>Unless otherwise determined by the administrator of the ESPP, each offering to our employees to purchase stock under the ESPP
will begin on each May&nbsp;20 and November&nbsp;20 and will end on the following November&nbsp;19 and May&nbsp;19, respectively, each referred to as offering periods, provided that the first offering period will begin on the date that the
registration statement of which this prospectus forms a part becomes effective and will end on May&nbsp;19, 2016. The administrator may designate different offering periods prior to the beginning of an offering period in its discretion, but no
offering shall exceed 27 months in duration. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Purchase Limits. </I>Each employee who is a participant in the ESPP may purchase shares by
authorizing payroll deductions at a minimum of 1% and up to 15% of his or her eligible compensation for each pay period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be
used to purchase our common stock on the last business day of the offering period at a price equal to 85% of the fair market value of the common stock on either the first or the last day of the offering period, whichever is lower, provided that no
more than 2,000&nbsp;shares of our common stock or such other lesser maximum number established by the plan administrator may be purchased by any one employee during each offering period. Under applicable tax rules, an employee may purchase no more
than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The accumulated payroll
deductions of any employee who is not a participant on the last day of an offering period will be refunded or retained for use in the next offering period. An employee&#146;s rights under the ESPP terminate upon voluntary withdrawal from the plan or
when the employee ceases employment for any reason. Eligible employees who have withdrawn from participation may reenroll effective the next offering period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Corporate Reorganization.</I> Prior to the effective time of any Corporate Reorganization, as defined in the ESPP, the ESPP will terminate and shares
will be purchased prior to the effective time as determined by the plan administrator, unless the ESPP is continued by the company or assumed by the surviving corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Non-Transferability.</I> An employee may not transfer rights granted under the ESPP other than by beneficiary designation or the laws of descent and
distribution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Amendment and Termination. </I>The ESPP may be terminated or amended by our board of directors at any time. Amendments that
increase the number of shares of our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders. The plan administrator may adopt and amend stock purchase subplans for employees of our non-U.S.
subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2011 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our
board of directors approved our 2011 plan and it became effective in October 2011. As of June 30, 2015, we had granted options to purchase 145,000 shares of our common stock under our 2011 plan, all of which were outstanding. We had also granted
505,000 shares of restricted stock under our 2011 plan, of which 252,125 shares were unvested and were subject to forfeiture and 1,667 shares had been forfeited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Stock awards</I>. The 2011 plan provides for the grant of ISOs, NSOs, stock appreciation rights,
restricted stock awards and restricted stock unit awards (collectively, stock awards). ISOs may be granted only to employees. All other awards may be granted to employees, directors and consultants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Stock Options</I>. No ISOs were issued under the 2011 plan. Nonstatutory stock options have been granted pursuant to stock option agreements adopted
by the plan administrator. The terms of stock options granted under the 2011 plan are determined by the plan administrator in the award agreement evidencing the award, including the term of the option, exercise price of the option, vesting rate of
the option, period within which the option may be exercised and any conditions that must be satisfied before the option may be exercised, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value
of our common stock on the date of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The plan administrator determines the term of stock options granted under the 2011 plan, up to a maximum
of 10 years. Unless the terms of an option holder&#146;s stock option agreement provide otherwise, if an option holder&#146;s service relationship with us ceases for any reason other than termination for cause, disability or death, the option holder
may generally exercise any vested options for a period of three months following the cessation of service. If an optionholder&#146;s service relationship with us ceases due to termination for cause, the option terminates and ceases to be exercisable
on termination of service. If an optionholder&#146;s service relationship with us ceases due to disability or death, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months, or within such longer period
of time as is specified in the award agreement. In no event may an option be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Unless the plan
administrator provides otherwise, options generally are not transferable except by will or by the laws of descent and distribution. An optionholder may designate a beneficiary, however, who may exercise the option following the optionholder&#146;s
death. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Stock Appreciation Rights</I>. The 2011 plan permits the grant of stock appreciation rights. The terms of the stock appreciation rights
granted under the 2011 plan are determined by the plan administrator in the award agreement evidencing the award, including the number of shares, exercise price, expiration date and other terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Restricted Stock and Restricted Stock Units</I>. The 2011 plan permits the grant of restricted stock and/or restricted stock units. The terms of the
restricted stock and/or restricted stock units granted under the 2011 plan are determined by the plan administrator in the award agreement evidencing the award, including the number of shares, period of restriction or vesting schedule and other
terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Adjustments;</I> <I>Corporate Transactions</I>. In the event of certain changes in our corporate structure, including any dividend or
other distribution, recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of shares, the administrator will make appropriate adjustments to outstanding
awards to prevent diminution or enlargement of the benefits or potential benefits available under the plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Merger or Change of Control</I>. In
the event of certain corporate transactions specified in the plan, including a merger or change of control, as defined in the plan, each outstanding award will be treated as the plan administrator determines, without a participant&#146;s consent,
including that (i)&nbsp;awards will be assumed or substituted by the succeeding corporation; (ii)&nbsp;the awards will terminate; (iii)&nbsp;outstanding awards will vest and become exercisable, (iv)&nbsp;the awards will terminate in exchange for an
amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of the award or realization of the rights under the award as of the date of the transaction, (v)&nbsp;the replacement of any award with
rights or property selected by the plan administrator or (vi)&nbsp;any combination of the above. In the event that the successor corporation does not assume or substitute the award, the participant will fully vest in and have the right to exercise
all of his or her outstanding options and stock appreciation rights and all restrictions on restricted stock and restricted stock units will lapse and performance goals will be deemed achieved at 100% of the target levels. Our plan administrator is
not obligated to treat all stock awards, even those that are of the same type, in the same manner. Under the 2011 plan, a change of control is generally (i)&nbsp;the acquisition by a person or entity
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
of more than 50% of our combined voting power other than by private financing that is approved by the board, (ii)&nbsp;if we are public, the date on which a majority of the board has been
replaced during any twelve month period by directors whose appointment or election is not endorsed by a majority of the members of the board prior to the date of appointment or election; or (iii)&nbsp;change in ownership of a substantial portion of
our assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Amendment and Termination</I>. The 2011 plan will terminate in October 2021. However, our board of directors has the authority to
amend, alter, or terminate our 2011 plan, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Termination of the 2011 plan will not affect the plan
administrator&#146;s ability to exercise its powers under the plan with respect to awards granted prior to termination of the plan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2005 Stock Plan
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our board of directors and our stockholders approved our 2005 plan and it became effective in January 2005 and was subsequently amended
and restated in 2006, 2007, 2008 and 2010. As of June 30, 2015, we had granted options to purchase 5,431,017 shares of our common stock under our 2005 plan, of which options to purchase 1,779,924 shares of our common stock were outstanding, and
options to purchase 24,818 shares of our common stock had been early exercised and were unvested and subject to repurchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Stock awards</I>. The
2005 plan provides for the grant of ISOs, NSOs, and stock purchase rights (collectively, stock awards). ISOs may be granted only to employees. All other awards may be granted to employees, directors and consultants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Stock Options.</I> Incentive and/or nonstatutory stock options have been granted pursuant to stock option agreements adopted by the plan
administrator. The terms of stock options granted under the 2005 plan are determined by the board in the award agreement evidencing the award, including the term of the option, exercise price of the option, vesting schedule of the option, period
within which the option may be exercised and any conditions that must be satisfied before the option may be exercised, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock
on the date of grant. In the case of an incentive stock option granted to an employee who owns stock representing more than 10% of the voting power of all classes of our stock or any parent or subsidiary of us, the exercise price will be no less
110% of the fair market value on the date of the grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The board determines the term of stock options granted under the 2005 plan, up to a maximum
of 10 years. In the case of an incentive stock option granted to an employee who owns stock representing more than 10% of the voting power of all classes of our stock or the stock of any of our parents or subsidiaries, the maximum term will be 5
years. Unless the terms of an option holder&#146;s stock option agreement provide otherwise, if an option holder&#146;s service relationship with us ceases for any reason other than termination for cause, disability or death, the option holder may
generally exercise any vested options for a period of three months following the cessation of service. If an optionholder&#146;s service relationship with us ceases due to termination for cause, the option terminates and ceases to be exercisable on
termination of service. If an optionholder&#146;s service relationship with us ceases due to disability or death, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months, or within such longer period of
time as is specified in the award agreement. In no event may an option be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Options generally are not
transferable except by will or by the laws of descent and distribution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Stock Purchase Rights</I>. The 2005 plan permits the grant of stock
purchase rights. The terms of the stock purchase rights granted under the 2005 plan are determined by the board in the award agreement evidencing the award, including the number of shares, purchase price, purchase period and other terms, provided
that the purchase period is no longer than 30 days from the date of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Adjustments; Corporate Transactions</I>. In the event of certain
changes in our corporate structure, including any dividend or other distribution, recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of shares of the
Company, the administrator will make appropriate adjustments to outstanding awards to prevent diminution or enlargement of the benefits or potential benefits available under the plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Merger or Change of Control</I>. In the event of certain corporate transactions specified in the plan,
including a merger or change of control, as defined in the plan, the surviving or purchasing corporation may, without the consent of the participants, either (i)&nbsp;assume our rights and obligations under the options or (ii)&nbsp;substitute for
outstanding options substantially equivalent options of that company&#146;s stock. Any unexercised options which are neither assumed by the surviving corporation nor substituted shall terminate as of the date of the change of control. In the event
of a change of control, the board of directors may also cancel each or any option outstanding prior to the change of control in exchange for cash, equity or other property of the same value. In the event of a change in control, our board of
directors may provide for the acceleration and vesting of any or all outstanding options and shares acquired upon the exercise of those options. Under the 2005 plan, a change of control is generally (i)&nbsp;the sale by our stockholders of more than
50% of the combined voting power of our outstanding shares, (ii)&nbsp;a merger or consolidation in which we are a party, (iii)&nbsp;the sale, exchange or transfer of substantially all of our assets, or (iv)&nbsp;our liquidation and dissolution, in
each case where our stockholders after the transaction no longer beneficially own at least 50% of the combined voting power of our outstanding shares, or, in the case of an asset sale, beneficially own at least 50% of the combined voting power of
the corporation to which our assets were transferred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Amendment and Termination</I>. The 2005 plan will continue in effect until the earlier of
its termination by the board or all shares of stock available for issuance under the plan have been issued. All awards under the plan must be granted, if at all, within 10 years of its adoption. Termination or amendment of the 2005 plan will not
affect any then outstanding award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Pension Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We
do not maintain any defined benefit pension plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We do not maintain any nonqualified deferred compensation plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>2014 DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">None of our non-employee directors received any cash or equity compensation during fiscal 2014, or held any outstanding options or stock awards at the
end of fiscal 2014. Mr.&nbsp;Elsesser, our Chairman, Chief Executive Officer and President, Dr.&nbsp;Bose, our Chief Innovator, and Mr.&nbsp;Krebs, our Treasurer and a director in 2014, did not receive additional compensation for their services as
directors. For more information on Mr.&nbsp;Elsesser&#146;s compensation as an officer, see the section titled &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Benefit Plans
for Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our directors are entitled to participate in our equity incentive plans, described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We describe below transactions and series of similar transactions, during our last three fiscal years or currently proposed, to which we were a party or
will be a party, in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amounts involved exceeds or will exceed $120,000; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our directors, executive officers or beneficial holders of more than 5% of any class of our capital stock or any member of the immediate family of or entities affiliated with any of the forgoing persons had or
will have a direct or indirect material interest. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Other than as described below, there have not been, nor are there any currently
proposed, transactions or series of similar transactions meeting this criteria to which we have been or will be a party other than compensation arrangements, which are described where required under the sections titled &#147;Management&#151;Board
Structure and Compensation of Directors&#148; and &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Preferred Stock Financing and Tender Offer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">On May&nbsp;16, 2014, we sold a total of 4,545,455 shares of Series F preferred stock at a purchase price of $13.20 per share. Entities affiliated with
Fidelity Investments, who currently beneficially own more than 5% of our outstanding capital stock, purchased 3,030,303 shares of Series F preferred stock in this offering. Prior to this investment, entities affiliated with Fidelity Investments were
not affiliated with us. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In connection with our sale of Series F preferred stock in May 2014, we conducted a tender offer for up to 1,359,541 shares
of our then-outstanding preferred stock at a price of $13.20 per share. Pursuant to the tender offer, a total of 584,052 shares of preferred stock were tendered by our stockholders. One of our executive officers, James Pray, and his immediate family
or affiliated entities participated in the tender offer, tendering a total of 11,710 shares of preferred stock for aggregate consideration of $154,572. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Promissory Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In 2005, we made a loan to one of our
executive officers, James Pray, in the form of a full-recourse secured promissory note in the amount of $85,000, to permit him to exercise stock options granted to him. This note was secured by a stock pledge agreement covering 500,000 shares of our
common stock held by Mr.&nbsp;Pray. This note accrued interest at the rate of 2.92%&nbsp;per annum, with principal and interest due and payable on January&nbsp;31, 2015, provided that upon the occurrence of a change of control of Penumbra,
Mr.&nbsp;Pray would be required to pre pay principal in an amount equal to the product of the number of shares of our common stock that vested as a result of such change of control and $0.01. On April&nbsp;14, 2015, our board of directors forgave
this loan to Mr.&nbsp;Pray in its entirety, including accrued and unpaid interest thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Investor Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have entered into an agreement with our two founders, Adam Elsesser and Arani Bose, and the holders of our preferred stock including certain related
persons, namely Daniel Davis, James Pray, Lynn Rothman, Robert Evans, Walter Wang, Harpreet Grewal and entities affiliated with FMR LLC, and certain members of the immediate family of the listed individuals, that provides for certain rights relating
to the registration of their shares. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Director and Officer Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have entered into an
indemnification agreement with each of our directors and executive officers. These indemnification agreements and our amended and restated certificate of incorporation and amended and restated bylaws indemnify each of our directors and officers to
the fullest extent permitted by the Delaware General Corporation Law. For information regarding these indemnification arrangements, please refer to the section titled &#147;Management&#151;Limitations on Liability and Indemnification of Directors
and Officers.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our board of directors plans to adopt a written related party transaction policy setting forth the policies and procedures for the review and approval or
ratification of related party transactions. This policy covers any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant and a related party had or
will have a direct or indirect material interest, as determined by the audit committee of our board of directors, including, without limitation, purchases of goods or services by or from the related party or entities in which the related party has a
material interest, and indebtedness, guarantees of indebtedness or employment by us of a related party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">All related party transactions described in
this section occurred prior to adoption of this policy and as such, these transactions were not subject to the approval and review procedures set forth in the policy. However, these transactions were reviewed and approved by our board of directors.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets forth information regarding beneficial ownership of our common stock as of June&nbsp;30, 2015, by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person whom we know to own beneficially more than 5% of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors and named executive officers individually; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our directors and executive officers as a group. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In accordance with the rules of the SEC,
beneficial ownership includes voting or investment power with respect to securities and includes the shares issuable pursuant to stock options that are exercisable within 60 days of June 30, 2015. Shares issuable pursuant to stock options are deemed
outstanding for computing the percentage of the person holding such options but are not outstanding for computing the percentage of any other person. The number of shares of common stock outstanding after this offering includes
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock being offered for sale by us in this offering. The percentage of beneficial ownership for the following table is based on 26,038,637 shares of common
stock outstanding as of June 30, 2015, assuming the automatic conversion of all outstanding shares of our preferred stock as of June 30, 2015 into common stock, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock outstanding after the completion of this offering assuming no exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Unless otherwise indicated, the address for each listed stockholder is: c/o Penumbra, Inc., One Penumbra Place, 1351 Harbor Bay Parkway, Alameda,
California 94502. To our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common
stock. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Beneficially<BR>Owned Before the<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned After the<BR>Offering</B></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:129.30pt; font-size:8pt; font-family:arial"><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Greater than 5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with FMR LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,030,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Adam Elsesser<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,700,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Daniel Davis<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lynn Rothman<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Arani Bose, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,545,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Don Kassing<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Walter Wang<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Harpreet Grewal<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Directors and Officers as a Group<BR>(10 persons)<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,671,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent (1%)&nbsp;of the outstanding common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:arial; font-size:9pt">Consists of (i)&nbsp;1,250,000 shares held by Fidelity Select Portfolios: Health Care Portfolio (&#147;Fidelity Health&#148;), (ii)&nbsp;265,152 shares held by
Fidelity Select Portfolios: Medical Equipment and Systems Portfolio (&#147;Fidelity Medical Equipment&#148;), (iii)&nbsp;1,128,787 shares held by Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund (&#147;Fidelity Growth&#148;),
(iv)&nbsp;257,576 shares held by Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund (&#147;Fidelity Series Growth&#148;) and (v)&nbsp;128,788 shares held by Fidelity Group Trust for Employee Benefit Plans: Fidelity Growth Company
Commingled Pool (&#147;Fidelity Group Trust&#148;). Fidelity Health, Fidelity Medical Equipment, Fidelity Growth, Fidelity Series Growth and Fidelity Group Trust are managed by direct or indirect subsidiaries of FMR LLC. Edward C. Johnson 3d is a
Director and the Chairman of FMR LLC and Abigail P. Johnson is a Director, the Vice Chairman and the President of FMR LLC. Members of the family of Edward C. Johnson 3d, including Abigail P. Johnson, are the predominant owners, directly or through
trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#146; voting agreement under which all Series B
voting common shares will be voted in accordance with the majority vote of Series B voting </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting agreement, members of the Johnson family may be deemed, under the
Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Edward C. Johnson 3d nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various
investment companies registered under the Investment Company Act (Fidelity Funds) advised by Fidelity Management&nbsp;&amp; Research Company (FMR Co), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds&#146; Boards of
Trustees. Fidelity Management&nbsp;&amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds&#146; Boards of Trustees. The address for FMR LLC is 200 Seaport Blvd. V12G, Boston,
Massachusetts 02210. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;1,236,838 shares held by Mr.&nbsp;Elsesser, (ii)&nbsp;14,144 shares held by the Siegel/Elsesser Revocable Trust and (iii)&nbsp;450,000 shares issuable pursuant to options that are exercisable within
60 days of June 30, 2015 (of which 353,125 would be vested). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;83,444 shares held by Mr.&nbsp;Davis, of which 37,500 shares are subject to our right of repurchase as of June&nbsp;30, 2015, and (ii)&nbsp;67,000 shares issuable pursuant to options that are
exercisable within 60 days of June 30, 2015 (of which 64,083 would be vested). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;200,000 shares held by Ms.&nbsp;Rothman, of which 37,500 shares are subject to our right of repurchase as of June 30, 2015, (ii)&nbsp;23,458 shares held by Richard Koch&nbsp;&amp; Lynn Rothman and
(iii)&nbsp;50,000 shares issuable pursuant to options that are exercisable within 60 days of June 30, 2015 (all of which would be vested). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;731,518 shares held by Dr.&nbsp;Bose, (ii)&nbsp;14,144 shares held by Arani&nbsp;&amp; Shumita Bose, (iii)&nbsp;250,000 shares held by the Arani Bose 2009 Family Trust, (iv)&nbsp;250,000 shares held
by the Shumita Bose 2009 Family Trust and (v)&nbsp;300,000 shares issuable pursuant to options that are exercisable within 60 days of June 30, 2015 (all of which would be vested). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 16,000 shares held by The Kassing Family Trust. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;517,071 shares held by Mr.&nbsp;Wang and (ii)&nbsp;963,860 shares held by Wang Ventures LLC. Mr.&nbsp;Wang is the owner of a 25% interest in Wang Ventures LLC as a Member. Mr.&nbsp;Wang disclaims
beneficial ownership of all shares held by Wang Ventures LLC. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 14,139 shares held by Mr.&nbsp;Grewal. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;5,804,256 shares held by all current executive officers and directors as a group, of which 530,209 shares are subject to our right of repurchase as of June 30, 2015 and (ii)&nbsp;867,000 shares
issuable pursuant to options that are exercisable within 60 days of June 30, 2015 (of which 767,208 would be vested). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following descriptions are summaries of the material terms of our amended and restated certificate of incorporation and amended and restated bylaws
that will be in effect upon the completion of this offering. Reference is made to the more detailed provisions of, and the descriptions are qualified in their entirety by reference to, these documents, copies of which will be filed with the SEC as
exhibits to the registration statement of which this prospectus is a part. We refer in this section to our amended and restated certificate of incorporation as our certificate of incorporation, and we refer to our amended and restated bylaws as our
bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Following this offering, our authorized
capital stock will consist of 300,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Common Stock </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><B><I>Common stock outstanding.</I></B> As
of June 30, 2015, there were 26,038,637 shares of common stock outstanding (including preferred stock on an as-converted basis) which were held of record by 346&nbsp;stockholders. There will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock outstanding, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding
options, after giving effect to the sale of the shares of common stock offered hereby. All outstanding shares of common stock are fully paid and non-assessable, and the shares of common stock to be issued upon completion of this offering will be
fully paid and non-assessable. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><B><I></I></B><I></I><B><I>Voting rights.</I></B><I></I><B><I></I></B> The holders of common stock are entitled
to one vote per share on all matters to be voted upon by the stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I></I><B><I>Dividend rights.</I></B><I></I> Subject to preferences that
may be applicable to any outstanding preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by the board of directors out of funds legally available therefor. See the
section titled &#147;Dividend Policy.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I></I><B><I>Rights upon liquidation.</I></B><I></I> In the event of liquidation, dissolution or
winding-up of Penumbra, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I></I><B><I>Other rights.</I></B><I></I> The holders of our common stock have no preemptive or conversion rights or other subscription rights. There are
no redemption or sinking fund provisions applicable to the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Effective immediately upon the completion of this offering, there will be no shares of preferred stock outstanding because all of our outstanding shares
of preferred stock will have been automatically converted into an aggregate of 19,510,410 shares of common stock. Our board of directors has the authority to issue the preferred stock in one or more series and to fix the rights, preferences,
privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series or the designation of
such series, without further vote or action by the stockholders. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The issuance of preferred stock may have the effect of delaying, deferring or
preventing a change in control of Penumbra without further action by the stockholders and may adversely affect the voting and other rights of the holders of common stock. At present, we have no plans to issue any of the preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">After the closing of this offering,
certain holders of our common stock will be entitled to rights with respect to the registration of their shares under the Securities Act. These registration rights are contained in our Fourth Amended and Restated Investors&#146; Rights Agreement,
dated as of May&nbsp;16, 2014, and are described in additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
detail below. With respect to any particular stockholder, when such stockholder is able to sell all of its shares pursuant to Rule 144 of the Securities Act without restriction (including any
volume limitations), these registration rights will expire. We will pay the registration expenses (other than underwriting discounts and selling commissions) of the holders of the shares registered pursuant to the registrations describe below. In an
underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions, to limit the number of shares such holders may include. In connection with this offering, each stockholder that has registration rights agreed
not to sell or otherwise dispose of any securities without the prior written consent of the underwriters for a period of 180 days after the date of this prospectus, subject to certain terms and conditions. For more information regarding such
restrictions, see the section titled &#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Beginning 180 days following this offering through the date that is three years following this offering, the holders of approximately 19,641,495 shares
of our common stock will be entitled to certain demand registration rights. The holders of at least 66 2/3% of these securities have the right to require us, on not more than two occasions, to file a registration statement under the Securities Act
in order to register the resale of their shares of common stock. We may, in certain circumstances, defer such registrations and the underwriters have the right, subject to certain limitations, to limit the number of shares included in such
registrations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">After the closing of this offering, if we propose to register the offer and sale of any of our securities under the Securities Act, in connection with
the public offering of such securities the holders of approximately 21,617,845 shares of our common stock will be entitled to certain &#147;piggyback&#148; registration rights allowing the holders to include their shares in such registration,
subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, other than with respect to a registration related to a company stock plan or on any form which does not
include substantially the same information as would be required to be included in a registration statement covering the sale of the registrable securities or a registration that would not customarily provide for the sale of secondary equity shares
for cash, the holders of these shares are entitled to notice of the registration and have the right, subject to limitations that the underwriters may impose on the number of shares included in the registration, to include their shares in the
registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>S-3 Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">After the
closing of this offering, the holders of approximately 19,641,495 shares of our common stock may make a written request that we register the offer and sale of their shares on Form S-3 if we are eligible to file a registration statement on Form S-3
so long as the request covers at least that number of shares with an anticipated aggregate offering price of at least $1.0 million. These stockholders may make an unlimited number of requests for registration on Form S-3; however, we will not be
required to effect a registration on Form S-3 if we have effected two such registrations in a given 12-month period. Additionally, if we determine that it would be seriously detrimental to us and our stockholders to effect such a registration, we
have the right to defer such registration, not more than once in any 12-month period, for a period of up to 180 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Election and Removal of Directors </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Immediately upon the completion of this offering, our bylaws will provide that our board of directors will consist of between five and nine
directors. The exact number of directors will be fixed from time to time by resolution of the board. No director may be removed except for cause, and directors may be removed for cause by an affirmative vote of shares representing a majority of the
shares then entitled to vote at an election of directors. Any vacancy occurring on the board of directors and any newly created directorship may be filled only by a majority of the remaining directors in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Staggered Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Upon the closing of this offering, our board of directors will be will be divided into three classes serving staggered three-year terms. Class I, Class
II and Class III directors will serve until our annual meetings of stockholders in 2016, 2017 and 2018, respectively. At each annual meeting of stockholders, directors will be elected to succeed the class of directors whose terms have expired. This
classification of our board of directors could have the effect of increasing the length of time necessary to change the composition of a majority of the board of directors. In general, at least two annual meetings of stockholders will be necessary
for stockholders to effect a change in a majority of the members of the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Limits on Written Consents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our certificate of incorporation and our bylaws will provide that holders of our common stock will not be able to act by written consent without a
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Stockholder Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our certificate of
incorporation and our bylaws will provide that special meetings of our stockholders may be called only by our board of directors acting pursuant to a resolution adopted by a majority of the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Amendment of Certificate of Incorporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The provisions of
our certificate of incorporation described under the sections titled &#147;Common Stock&#151;Voting rights,&#148; &#147;Amendment of Bylaws,&#148; &#147;Election and Removal of Directors,&#148; &#147;Stockholder Meetings&#148; and &#147;Limits on
Written Consents&#148; may be amended only by the affirmative vote of holders of at least 66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the voting power of our outstanding
shares of voting stock, voting together as a single class. The affirmative vote of holders of at least a majority of the voting power of our outstanding shares of stock will generally be required to amend other provisions of our certificate of
incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Amendment of Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our bylaws may
generally be altered, amended or repealed, and new bylaws may be adopted, with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the affirmative vote of a majority of directors present at any regular or special meeting of the board of directors called for that purpose, or without a meeting if all members of the board of directors consent to the
taking of the action; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the affirmative vote of holders of 66<SUP STYLE="vertical-align:top">&nbsp;2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the voting power of our outstanding shares of voting stock, voting together as a
single class. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Other Limitations on Stockholder Actions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our bylaws will also impose some procedural requirements on stockholders who wish to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make nominations in the election of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">propose any amendment to our bylaws; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">propose any other business to be brought before an annual or special meeting of stockholders. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Under
these procedural requirements, in order to bring a proposal before a meeting of stockholders, a stockholder must deliver timely notice of a proposal pertaining to a proper subject for presentation at the meeting to our corporate secretary along with
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a brief description of any business to be brought before the meeting and the reasons for conducting such business at the meeting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the text of any proposed amendments to our bylaws; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the stockholder&#146;s name and address; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and type of shares beneficially owned by the stockholder and evidence of such ownership; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of any arrangement between the stockholder and other beneficial owners of our stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any hedging arrangements with respect to our securities entered into by the stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">representations as to whether the stockholder intends to appear at the meeting, distribute a proxy statement or otherwise solicit proxies; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other information required to be disclosed under the Exchange Act or that we may reasonably require to determine that the proposed business is proper. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In order to submit a nomination for our board of directors, a stockholder must also timely submit any information with respect to the nominee that we
would be required to include in a proxy statement, as well as some other information. If a stockholder fails to follow the required procedures, the stockholder&#146;s proposal or nominee will be ineligible and will not be voted on by our
stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">To be timely, a stockholder must generally deliver notice: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in connection with an annual meeting of stockholders, not less than 120 nor more than 150 days prior to the date on which the annual meeting of stockholders was held in the immediately preceding year, but in the event
that the date of the annual meeting is more than 30 days before or more than 70 days after the anniversary date of the preceding annual meeting of stockholders, a stockholder notice will be timely if received by us not later than the close of
business on the later of (1)&nbsp;the 70th day prior to the annual meeting and (2)&nbsp;the 10th day following the day on which we first publicly announce the date of the annual meeting; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in connection with the election of a director at a special meeting of stockholders, not earlier than 150 nor later than the later of (1) 120 days prior to the date of the special meeting and (2)&nbsp;the close of
business on the 10th day following the day on which a notice of the date of the special meeting was mailed to the stockholders or the public disclosure of that date was made. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Limitation of Liability of Directors and Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our
certificate of incorporation will provide that no director will be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except as required by applicable law, as in effect from time to time.
Currently, Delaware law requires that liability be imposed for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the director&#146;s duty of loyalty to our company or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any act or omission not in good faith or which involved intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General Corporation Law; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As a result, neither we
nor our stockholders have the right, through stockholders&#146; derivative suits on our behalf, to recover monetary damages against a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior,
except in the situations described above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our bylaws provide that, to the fullest extent permitted by law, we will indemnify any officer or director
of our company against all damages, claims and liabilities arising out of the fact that the person is or was our director or officer, or served any other enterprise at our request as a director, officer, employee, agent or fiduciary. We will
reimburse the expenses, including attorneys&#146; fees, incurred by a person indemnified by this provision when we receive an undertaking to repay such amounts if it is ultimately determined that the person is not entitled to be indemnified by us.
Amending this provision will not reduce our indemnification obligations relating to actions taken before an amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Forum Selection </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of
Penumbra, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Penumbra to Penumbra or Penumbra&#146;s stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any
provision of the Delaware General Corporation Law, or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of Penumbra shall
be deemed to have notice of and consented to the foregoing forum selection provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Delaware Business Combination Statute </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We elect to be subject to Section&nbsp;203 of the Delaware General Corporation Law, which regulates corporate acquisitions. Section&nbsp;203 prevents an
&#147;interested stockholder,&#148; which is defined generally as a person owning 15% or more of a corporation&#146;s voting stock, or any affiliate or associate of that person, from engaging in a broad range of &#147;business combinations&#148;
with the corporation for three years after becoming an interested stockholder unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the board of directors of the corporation had previously approved either the business combination or the transaction that resulted in the stockholder&#146;s becoming an interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon completion of the transaction that resulted in the stockholder&#146;s becoming an interested stockholder, that person owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, other than statutorily excluded shares; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">following the transaction in which that person became an interested stockholder, the business combination is approved by the board of directors of the corporation and holders of at least two-thirds of the outstanding
voting stock not owned by the interested stockholder. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Under Section&nbsp;203, the restrictions described above also do not apply to
specific business combinations proposed by an interested stockholder following the announcement or notification of designated extraordinary transactions involving the corporation and a person who had not been an interested stockholder during the
previous three years or who became an interested stockholder with the approval of a majority of the corporation&#146;s directors, if such extraordinary transaction is approved or not opposed by a majority of the directors who were directors prior to
any person becoming an interested stockholder during the previous three years or were recommended for election or elected to succeed such directors by a majority of such directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Section&nbsp;203 may make it more difficult for a person who would be an interested stockholder to effect various business combinations with a
corporation for a three-year period. Section&nbsp;203 also may have the effect of preventing changes in our management and could make it more difficult to accomplish transactions that our stockholders may otherwise deem to be in their best
interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Anti-Takeover Effects of Some Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Some provisions of our certificate of incorporation and bylaws could make an acquisition of control of us by means of a proxy contest or otherwise more
difficult, including our classified board and ability to issue preferred stock. These provisions are designed to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to
acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection give us the potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or
restructure us, and that the benefits of this increased protection outweigh the disadvantages of discouraging those proposals, because negotiation of those proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Listing </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have applied to list our common stock on the
NYSE under the symbol &#147;PEN.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_16"></A>MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSEQUENCES FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>NON-U.S. HOLDERS OF COMMON STOCK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following
are the material U.S. federal income and estate tax consequences of the ownership and disposition of our common stock acquired in this offering by a &#147;Non-U.S. Holder&#148; that does not own, and has not owned, actually or constructively, more
than 5% of our common stock. You are a Non-U.S. Holder if for U.S. federal income tax purposes you are a beneficial owner of our common stock that is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a nonresident alien individual; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign corporation; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign estate or trust. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">You are not a Non-U.S. Holder if you are a nonresident alien individual
present in the United States for 183&nbsp;days or more in the taxable year of disposition, or if you are a former citizen or former resident of the United States for U.S. federal income tax purposes. If you are such a person, you should consult your
tax adviser regarding the U.S. federal income tax consequences of the ownership and disposition of our common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If you are a partnership for
U.S. federal income tax purposes, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and your activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">This discussion is based on the Internal Revenue Code of 1986, as amended to the date hereof (the Code), administrative pronouncements, judicial
decisions and final, temporary and proposed Treasury regulations, changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein, possibly with retroactive effect. This discussion does not describe
all of the tax consequences that may be relevant to you in light of your particular circumstances, including alternative minimum tax and Medicare contribution tax consequences, and does not address any aspect of state, local or non-U.S. taxation, or
any taxes other than income and estate taxes. You should consult your tax adviser with regard to the application of the U.S. federal tax laws to your particular situation, as well as any tax consequences arising under the laws of any state, local or
non-U.S. taxing jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As discussed
under &#147;Dividend Policy&#148; above, we do not currently expect to make distributions on our common stock. In the event that we do make distributions of cash or other property, those distributions will constitute dividends for U.S. federal
income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed our current and accumulated earnings and profits, they will
constitute a return of capital, which will first reduce your basis in our common stock, but not below zero, and then will be treated as gain from the sale of our common stock, as described below under the section titled &#147;&#151;Gain on
Disposition of Our Common Stock.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Dividends paid to you generally will be subject to U.S. federal withholding tax at a 30% rate or a reduced
rate specified by an applicable income tax treaty. In order to obtain a reduced rate of withholding, you will be required to provide a properly executed applicable Internal Revenue Service (IRS) Form W-8 certifying your entitlement to benefits under
a treaty. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If dividends paid to you are effectively connected with your conduct of a trade or business in the United States (and, if required by an
applicable income tax treaty, are attributable to a permanent establishment or fixed base maintained by you in the United States), you will generally be taxed on the dividends in the same manner as a U.S. person. In this case, you will be exempt
from the withholding tax discussed in the preceding paragraph, although you will be required to provide a properly executed IRS Form W-8ECI in order to claim an exemption from withholding. You should consult your tax adviser with respect to other
U.S. tax consequences of the ownership and disposition of our common stock, including the possible imposition of a branch profits tax at a rate of 30% (or a lower treaty rate) if you are a corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Subject to the discussions below under the sections titled &#147;&#151;Information Reporting and Backup Withholding&#148; and &#147;&#151;FATCA,&#148;
you generally will not be subject to U.S. federal income or withholding tax on gain realized on a sale or other taxable disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain is effectively connected with your conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained
by you in the United States), or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we are or have been a &#147;United States real property holding corporation,&#148; as defined in the Code, at any time within the five-year period preceding the disposition or your holding period, whichever period is
shorter, and our common stock is not regularly traded on an established securities market during the calendar year in which the sale or disposition occurs. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We believe that we are not, and do not anticipate becoming, a United States real property holding corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If you recognize gain on a sale or other disposition of our common stock that is effectively connected with your conduct of a trade or business in the
United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by you in the United States), you will generally be taxed on such gain in the same manner as a U.S. person. You
should consult your tax adviser with respect to other U.S. tax consequences of the ownership and disposition of our common stock, including the possible imposition of a branch profits tax at a rate of 30% (or a lower treaty rate) if you are a
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Information returns are required to be filed with the IRS in connection with payments of dividends on our common stock. Unless you comply with
certification procedures to establish that you are not a U.S. person, information returns may also be filed with the IRS in connection with the payment of proceeds from a sale or other disposition of our common stock. You may be subject to backup
withholding on payments on our common stock or on the proceeds from a sale or other disposition of our common stock unless you comply with certification procedures to establish that you are not a U.S. person or otherwise establish an exemption. Your
provision of a properly executed applicable IRS Form W-8 (usually IRS Form W-8BEN or W-8BEN-E) certifying your non-U.S. status will permit you to avoid backup withholding. Amounts withheld under the backup withholding rules are not additional taxes
and may be refunded or credited against your U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Provisions of the Code commonly referred to as &#147;FATCA&#148; currently require withholding of 30% on payments of dividends on our common stock, and
will require 30% withholding on payments of gross proceeds of dispositions of our common stock occurring after December&nbsp;31, 2016, to &#147;foreign financial institutions&#148; (which is broadly defined for this purpose and in general includes
investment vehicles) and certain other non-U.S. entities unless various U.S. information reporting and due diligence requirements (generally relating to ownership by U.S. persons of interests in or accounts with those entities) have been satisfied,
or an exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. If FATCA withholding is imposed, a beneficial owner that is not a foreign financial institution
generally may obtain a refund of any amounts withheld by filing a U.S. federal income tax return (which may entail significant administrative burden). You should consult your tax adviser regarding the effects of FATCA on your investment in our
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Federal Estate Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Individual Non-U.S.
Holders and entities the property of which is potentially includible in such an individual&#146;s gross estate for U.S. federal estate tax purposes (for example, a trust funded by such an individual and with respect to which the individual has
retained certain interests or powers), should note that, absent an applicable treaty exemption, our common stock will be treated as U.S. situs property subject to U.S. federal estate tax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Prior to this offering, there has been no market for our common stock. Future sales of substantial amounts of our common stock in the public market could
adversely affect market prices prevailing from time to time. Furthermore, because only a limited number of shares will be available for sale shortly after this offering due to existing contractual and legal restrictions on resale as described below,
there may be sales of substantial amounts of our common stock in the public market after the restrictions lapse. This may adversely affect the prevailing market price and our ability to raise equity capital in the future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Upon the completion of this offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
outstanding assuming the exercise of the underwriters&#146; option to purchase additional shares, the automatic conversion of all outstanding shares of preferred stock and no exercise of any options outstanding as of June 30, 2015. Of these shares,
the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise their option to purchase additional shares in full,
sold in this offering will be freely transferable without restriction or registration under the Securities Act, except for any shares purchased by one of our existing &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities
Act. The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock existing are &#147;restricted shares&#148; as defined in Rule 144. Restricted shares may be sold in the public market only if
registered or if they qualify for an exemption from registration under Rules 144 or 701 of the Securities Act. As a result of the contractual 180-day lock-up period described below and the provisions of Rules 144 and 701, these shares will be
available for sale in the public market as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:59.85pt; font-size:8pt; font-family:arial"><B>Number of Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">On the date of this prospectus.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">After 180 days from the date of this prospectus (subject, in some cases, to volume limitations).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">At various times after 180 days from the date of this prospectus (subject, in some cases, to volume limitations).</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In general, a
person who has beneficially owned restricted shares of our common stock for at least six months would be entitled to sell such securities, provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any
time during the 90 days preceding, a sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted shares of our common stock for at least
six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three month period only a number of
securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of shares of our common stock then outstanding, which will equal approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares immediately after this offering, assuming
no exercise of the underwriters&#146; option to purchase additional shares; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our common stock on the NYSE during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale; </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided, in each case, that we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and
by non-affiliates must also comply with the manner of sale, current public information and notice provisions of Rule 144 to the extent applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Rule 701
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In general, under Rule 701, any of our employees, directors, officers, consultants or advisors who purchases shares from us in connection with a
compensatory stock or option plan or other written agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
before the effective date of this offering is entitled to resell such shares 90 days after the effective date of this offering in reliance on Rule 144, without having to comply with the holding
period requirements or other restrictions contained in Rule 701. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The SEC has indicated that Rule 701 will apply to typical stock options granted by
an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after the date of this prospectus. Securities issued in reliance on Rule 701 are
restricted securities and, subject to the contractual restrictions described above, beginning 90 days after the date of this prospectus, may be sold by persons other than &#147;affiliates,&#148; as defined in Rule 144, subject only to the manner of
sale provisions of Rule 144 and by &#147;affiliates&#148; under Rule 144 without compliance with its one-year minimum holding period requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Registration
Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Upon the completion of this offering, the holders of 21,617,845 shares of common stock will be entitled to various rights with respect to
the registration of these shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of
the registration, except for shares purchased by affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of June 30, 2015, options to purchase a total of 2,460,574 shares of common stock were outstanding. An additional 1,713,634 shares of common stock
were available for future grants under our stock plans. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Upon the completion of this offering, we intend to file a registration statement under the
Securities Act covering all shares of common stock subject to outstanding options or issuable pursuant to our 2014 Equity Incentive Plan. Subject to Rule 144 volume limitations applicable to affiliates, shares registered under any registration
statements will be available for sale in the open market, beginning 90 days after the date of the prospectus, except to the extent that the shares are subject to vesting restrictions with us or the contractual restrictions described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Lock-up Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We expect that all of our directors,
executive officers and substantially all of the other holders of our equity securities will agree, subject to certain exceptions, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock for a period of 180 days after the date of this prospectus, without the prior written consent of the representatives
of the underwriters. See the section titled &#147;Underwriting.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC and Merrill Lynch,
Pierce, Fenner&nbsp;&amp; Smith Incorporated are acting as joint <FONT STYLE="white-space:nowrap">book-running</FONT> managers of the offering and as representatives of the underwriters. We will enter into an underwriting agreement with the
underwriters. Subject to the terms and conditions of the underwriting agreement, we will agree to sell to the underwriters, and each underwriter will severally agree to purchase, at the public offering price less the underwriting discounts and
commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:19.25pt; font-size:8pt; font-family:arial"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Canaccord Genuity Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The underwriters will be committed to purchase all the common shares offered by us if they purchase any shares. The
underwriting agreement will also provide that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The underwriters propose to offer the common shares directly to the public at the initial public offering price set forth on the cover page of this
prospectus and to certain dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial public offering price. After the initial offering of the shares to the public, the offering price and other selling terms may be changed by the underwriters. Sales of shares
made outside of the United States may be made by affiliates of the underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The underwriters will have an option to buy up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock from us. The underwriters will have 30 days from the date of this prospectus to exercise this option to purchase additional shares. If any
shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters
will offer the additional shares on the same terms as those on which the shares are being offered. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The underwriters do not expect to sell more than
5% of the common shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The underwriting fee is equal to the public
offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The following table shows the per share and total
underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Without<BR>exercise&nbsp;of&nbsp;option<BR>to purchase<BR>additional&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With&nbsp;full<BR>exercise&nbsp;of&nbsp;option<BR>to purchase<BR>additional shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Perella Weinberg Partners LP (Perella Weinberg), a Financial Industry Regulatory Association, Inc. (FINRA) member, is
acting as our financial advisor in connection with the offering. We expect to pay Perella Weinberg, upon the successful completion of this offering, a fee of $1,250,000 for its services. The services provided to us by Perella Weinberg include, among
other things, an independent financial valuation analysis; assisting in drafting our positioning and investment thesis; assisting us in our interactions with the underwriters; and assisting us in crafting an appropriate aftermarket trading and
investor relations strategy. Funds affiliated with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
employees of Perella Weinberg own 243,561 shares of our Series F Preferred Stock that they acquired in May 2014 on the same terms as other investors for an aggregate purchase price of $3.2
million. In addition, Perella Weinberg acted as our financial advisor in connection with the Series F Preferred Stock financing and received a fee of $2.5 million for those services. Apart from such investment and Perella Weinberg&#146;s role as
financial advisor in connection with the Series F financing and this offering, Perella Weinberg has or had no other relationships with the Company. Perella Weinberg will not sell or offer to sell any securities in this offering and will not
identify, solicit or engage directly with potential investors in this offering. In addition, Perella Weinberg will not purchase any of the offered securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We estimate that the total expenses of this offering, including the fees of Perella Weinberg, registration, filing and listing fees, printing fees and
legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for certain
FINRA-related and other expenses incurred by them in connection with this offering in an amount up to $35,000. The underwriters have agreed to reimburse us for certain expenses we incur in connection with this offering up to $1,325,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any,
participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We will agree that, subject to
limited exceptions, we will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or
indirectly, or file with the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common
stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any
shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written
consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated for a period of 180 days after the date of this prospectus, other than the shares of our common stock to be sold hereunder and any shares of our
common stock issued upon the exercise of options granted under our existing equity incentive plans. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Our directors and executive officers, and
holders of substantially all of our outstanding shares have entered into or will enter into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each of these
persons or entities, with limited exceptions, for a period of 180&nbsp;days after the date of this prospectus, may not, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated,
(1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares
of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such directors,
executive officers, or other stockholders in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or (2)&nbsp;enter into any swap or other agreement that transfers, in
whole or in part, any of the economic consequences of ownership of the common stock or such other securities, whether any such transaction described in clause&nbsp;(1) or&nbsp;(2) above is to be settled by delivery of common stock or such other
securities, in cash or otherwise, or (3)&nbsp;make any demand for or exercise any right with respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable for our common stock. The
restrictions described above are subject to exceptions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">open market transactions after the completion of this offering, provided that no filing under Section&nbsp;16(a) of the Exchange Act, or other public announcement, shall be required or shall be made voluntarily in
connection with any such transaction (other than a filing on a Form 5 made after the expiration of the restricted period); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers that occur by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement, provided that any filing required to be made under Section&nbsp;16(a) of the Exchange Act shall
clearly indicate the purpose of the transfer in the footnotes thereto, no other public announcement shall be required or shall be made voluntarily in connection with such transfer and each transferee, donee or distributee shall execute and deliver
to the underwriters a lock-up agreement substantially in the form of the lock-up agreement entered into by the party subject to the lockup restrictions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers to us pursuant to agreements under which we have the option to repurchase such shares or securities upon termination of service of the party subject to the lockup restrictions, provided that any public report
or filing required to be made under Section&nbsp;16(a) of the Exchange Act shall clearly indicate in the footnotes thereto the circumstances of such transfer and no other public announcement shall be required or shall be made voluntarily in
connection with such transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise of stock options granted under a stock incentive plan or stock purchase plan described in this prospectus, provided that the shares received upon exercise shall continue to be subject to the restrictions on
transfer set forth in the lock-up agreement and that any public report or filing required to be made under Section&nbsp;16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to the exercise of a stock
option, that no shares were sold by the reporting person and that the shares received upon exercise of the stock option are subject to a lock-up agreement with the underwriters; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers to us upon the exercise of options to purchase our securities outstanding as of the date the party subject to the lockup restrictions entered into the lock-up agreement or pursuant to a stock incentive plan or
stock purchase plan described in this prospectus, on a &#147;cashless&#148; or &#147;net exercise&#148; basis, provided that the shares received upon exercise shall continue to be subject to the restrictions on transfer set forth in the lock-up
agreement and that any public report or filing required to be made under Section&nbsp;16(a) of the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to the &#147;cashless&#148; or &#147;net&#148; exercise of a
stock option, that no shares were sold by the reporting person and that the shares received upon exercise of the stock option are subject to a lock-up letter agreement with the underwriters; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of common stock, provided that (i)&nbsp;such plan does not provide for the transfer of common stock during
the restricted period and (ii)&nbsp;no public announcement or filing shall be required or shall be made voluntarily in connection with the establishment of such plan during the restricted period. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We will agree to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have applied to have our common stock approved for listing on the NYSE under the symbol &#147;PEN.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares
of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the common stock,
which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short
sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess
of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the
underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short
position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that
the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also
engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in
stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market
price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The
underwriters may carry out these transactions on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Prior to
this offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we
and the representatives of the underwriters expect to consider a number of factors including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the information set forth in this prospectus and otherwise available to the representatives; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our prospects and the history and prospects for the industry in which we compete; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an assessment of our management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our prospects for future earnings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the general condition of the securities markets at the time of this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other factors deemed relevant by the underwriters and us. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Neither we nor the underwriters can assure
investors that an active trading market will develop for our common shares, or that the shares will trade in the public market at or above the initial public offering price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">An affiliate of Wells Fargo Securities, LLC, one of the underwriters for this offering, has provided us with commercial banking services in the past, for
which it has received customary compensation. Certain of the underwriters or their affiliates may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us or our affiliates
in the ordinary course of their business, for which they may receive customary fees and commissions. In addition, from time to time in the future, certain of the underwriters or their affiliates may effect transactions for their own account or the
account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Selling
Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Other than in the United
States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may
not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under
circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the
offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is
unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In relation to each Member State of the European Economic Area (each, a Relevant Member State), no offer of shares may be made to the public in that
Relevant Member State other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:arial">provided that no
such offer of shares shall require the Company or the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Each person in a Relevant Member State who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged
and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive.&nbsp;In the case of any shares being offered to a financial intermediary as
that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary
basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares&nbsp;to the public other than their offer or resale in a Relevant Member State to
qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company, the representatives and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and
agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">This prospectus has been prepared on the basis that any offer of shares in any Relevant Member State will be made pursuant to an
exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Relevant Member State of shares which are the subject of the offering
contemplated in this prospectus may only do so in circumstances in which no obligation arises for the Company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such
offer.&nbsp;Neither the Company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the Company or the underwriters to publish a prospectus for such offer.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">For the purpose of the above provisions, the expression &#147;an offer to the public&#148; in relation to any shares in any Relevant Member State
means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in the
Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (including the 2010 PD Amending Directive, to the extent
implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In addition, in the United Kingdom,
this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive) (i)&nbsp;who have professional
experience in matters relating to investments falling within Article 19 (5)&nbsp;of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies
(or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;).</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Any person in the United Kingdom that is not a relevant person should not act or rely on the information
included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. Any person in the United Kingdom
that is not a relevant person should not act or rely on this document or any of its contents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The validity of the issuance of the shares of common stock offered hereby will be passed upon for us by Davis Polk&nbsp;&amp; Wardwell LLP, Menlo Park,
California. Goodwin Procter LLP, Menlo Park, California, is representing the underwriters. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The consolidated financial statements of Penumbra, Inc. and its subsidiaries as of December&nbsp;31, 2013 and 2014, and for each of the two years ended
December&nbsp;31, 2014, included in this prospectus have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements have been so included in
reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="toc923792_21"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the common stock offered hereby. This prospectus
does not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. For further information with respect to the Company and its common stock, reference is made to the registration statement and the
exhibits and any schedules filed therewith. Statements contained in this prospectus as to the contents of any contract or other document referred to are not necessarily complete and in each instance, if such contract or document is filed as an
exhibit, reference is made to the copy of such contract or other document filed as an exhibit to the registration statement, each statement being qualified in all respects by such reference. A copy of the registration statement, including the
exhibits and schedules thereto, may be read and copied at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at
1-800-SEC-0330. In addition, the SEC maintains an Internet site at www.sec.gov, from which interested persons can electronically access the registration statement, including the exhibits and any schedules thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As a result of the offering, we will be required to file periodic reports and other information with the SEC. We also maintain an Internet site at
www.penumbrainc.com. Our website and the information contained therein or accessible therefrom shall not be deemed to be incorporated into this prospectus or the registration statement of which it forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">134 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="index"></A><A NAME="toc923792_22"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin923792_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin923792_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin923792_3">Consolidated Statements of Operations and Comprehensive Income</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin923792_4">Consolidated Statements of Preferred Stock and Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin923792_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#fin923792_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="fin923792_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the Board of Directors and Stockholders of </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Penumbra, Inc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Alameda, California </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We have audited the accompanying consolidated
balance sheets of Penumbra, Inc. and subsidiaries (the &#147;Company&#148;) as of December&nbsp;31, 2013 and 2014, and the related consolidated statements of operations and comprehensive income, preferred stock and stockholders&#146; deficit, and
cash flows for each of the two years in the period ended December&nbsp;31, 2014. These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the financial statements
based on our audits. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its
internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the
consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for
our opinion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In our opinion, such consolidated financial statements present fairly, in all material respects, the consolidated financial position of
the Company as of December&nbsp;31, 2013 and 2014, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December&nbsp;31, 2014, in conformity with accounting principles generally accepted in
the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">/s/ DELOITTE&nbsp;&amp; TOUCHE LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">San
Francisco, California </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">June 9, 2015 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="fin923792_2"></A>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>(in thousands,
except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma<BR>Stockholders&#146;<BR>Equity at<BR>June 30,</B><br><B>2015</B><br><B>(See&nbsp;Note&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Marketable investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Accounts receivable, net of doubtful accounts of $471, $602 and $501 at December 31, 2013 and 2014 and June 30, 2015 (unaudited),
respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Deferred taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Restricted investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Deferred taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>Liabilities, Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Credit facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Other non-current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Preferred stock, $0.001 par value&#151;25,000,000, 25,000,000 and 25,000,000 shares authorized at December 31, 2013 and 2014 and June&nbsp;30,
2015 (unaudited) respectively; 15,594,618, 19,510,410 and 19,510,410 shares issued and outstanding at December 31, 2013 and 2014 and June 30, 2015 (unaudited), respectively; aggregate liquidation value $85,218, $149,361, and $153,738 at
December&nbsp;31, 2013 and 2014 and June 30, 2015 (unaudited), respectively; 5,000,000&nbsp;shares authorized, no shares issued or outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Common stock, $0.001 par value&#151;40,000,000, 40,000,000 and 40,000,000 shares authorized at December 31, 2013, 2014 and June 30, 2015
(unaudited), respectively; 4,391,591, 4,736,689 and 5,747,638 shares issued and outstanding at December 31, 2013, 2014 and June 30, 2015 (unaudited), respectively; 300,000,000&nbsp;shares authorized, 25,258,048 shares issued and outstanding pro
forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Notes receivable from stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Accumulated other comprehensive income/(loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Total liabilities, preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="fin923792_3"></A>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sales, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(474</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income (loss) before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Foreign currency translation adjustments, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(589</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unrealized gains (losses) on available-for-sale securities, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net income (loss) attributable to common stockholders (Note&nbsp;16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net income (loss) per share attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average shares used to compute net income (loss) per share attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,304,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,609,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,520,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,500,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,609,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,743,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net income (loss) per share (unaudited) (Note 16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average shares used to compute pro forma net income (loss) per share (unaudited) (Note 16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,680,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,510,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,037,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,510,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="fin923792_4"></A>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>(in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional</B><br><B>Paid-in</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Notes<BR>Receivable</B><br><B>from</B><br><B>Stockholders</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated<BR>Other</B><br><B>Comprehensive</B><br><B>Income/ (Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Balance at December&nbsp;31, 2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,594,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,192,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Foreign currency translation adjustment, net of tax of $213</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Unrealized loss on investments, net of tax of $10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Balance at December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,594,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,391,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Issuance of Series F preferred stock, net of issuance cost of $2,788</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,545,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Repurchase of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(629,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Repurchase of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Forgiven notes receivable from stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Foreign currency translation adjustment, net of tax of $245</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Unrealized loss on investments, net of tax of $168</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Balance at December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,510,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,736,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Issuance of common stock (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,034,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Shares held for tax withholdings (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Repurchase of common stock (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Stock-based compensation (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Forgiven notes receivable from stockholders (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Foreign currency translation adjustment, net of tax of $92 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(589</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(589</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Unrealized gain on investments, net of tax of $ 159 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net loss (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Balance at June 30, 2015 (unaudited) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,510,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,747,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="fin923792_5"></A>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>(in
thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months</B><br><B>Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Provision for doubtful accounts</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Inventory write downs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Write off of note receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Provision for sales returns</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Loss on minority investment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Realized loss on marketable investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Provision for product warranty</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Release of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Deferred taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Issuance of common stock to third parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Prepaid expenses and other current and non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accrued expenses and other non-current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Purchase of marketable investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from sales of marketable investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(818</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,001</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from issuance of preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Payments of deferred issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from exercises of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Repurchase of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from credit facility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Repayment of credit facility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Repurchase of common stock and stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Payment of employee taxes related to vested common and restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Effect of foreign exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Net Increase (Decrease) In Cash And Cash Equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">CASH AND CASH EQUIVALENTS&#151;Beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">CASH AND CASH EQUIVALENTS&#151;End of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>NONCASH INVESTING AND FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Purchase of property and equipment funded through accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Deferred issuance costs not yet paid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B><A NAME="fin923792_6"></A>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>1. Organization
and Description of Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Penumbra, Inc. (the &#147;Company&#148;) is a global interventional therapies company that designs, develops,
manufactures and markets innovative medical devices. The Company has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. The conditions
that the Company&#146;s products address include, among others, ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2. Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Basis of Presentation and
Consolidation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted
in the United States (U.S. GAAP). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Subsequent events were
evaluated from the balance sheet dates of December&nbsp;31, 2014 and June 30, 2015 (unaudited) through June 9, 2015 and August&nbsp;14, 2015 (unaudited). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Use of
Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets, liabilities and equity accounts; disclosure of contingent assets and liabilities at the date of the financial statements; and the reported amounts of revenues and expenses during the reporting period. On an ongoing
basis, the Company evaluates its estimates, including those related to provisions for doubtful accounts, sales return reserve, warranty reserves, valuation of inventories, useful lives of property and equipment, income taxes, the valuation of equity
instruments and contingencies, among others. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other data. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Unaudited Interim Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The accompanying
interim consolidated financial statements as of June 30, 2015 and for the six months ended June 30, 2014 and 2015 and the related interim information contained within the notes to the financial statements are unaudited. The unaudited interim
consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited interim
consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#146;s financial position as of June 30, 2015, and the results of its operations and cash flows for the six months ended June&nbsp;30, 2014
and 2015. Such adjustments are of a normal and recurring nature. The results for the six months ended June 30, 2015 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2015 or for any future period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Unaudited Pro Forma Stockholders&#146; Equity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The
unaudited pro forma stockholders&#146; equity information in the accompanying consolidated balance sheet reflects that there are 25,258,048 shares of common stock outstanding and assumes the automatic
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2. Summary of Significant Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
conversion of all outstanding shares of preferred stock into shares of common stock in connection with the Company&#146;s proposed initial public offering (IPO). The unaudited pro forma
stockholders&#146; equity does not assume any proceeds from the proposed IPO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Segments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company determined its operating segment on the same basis that it uses to evaluate its performance internally. The Company has one business
activity: the design, development, manufacturing and marketing of innovative medical devices, and operates as one operating segment. The Company&#146;s chief operating decision-maker, its Chief Executive Officer, reviews its operating results for
the purpose of allocating resources and evaluating financial performance. The Company determines revenue by geographic area, based on the destination to which it ships its products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Foreign Currency Translation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s consolidated
financial statements are prepared in United States Dollars (USD). Its foreign subsidiaries use their local currency as their functional currency and maintain their records in the local currency. Accordingly, the assets and liabilities of these
subsidiaries are translated into USD using the current exchange rates in effect at the balance sheet date and equity accounts are translated into USD using historical rates. Revenues and expenses are translated using the average exchange rates in
effect. The resulting foreign currency translation adjustments are recorded in other comprehensive income in the consolidated balance sheets. Transactions denominated in foreign currency are translated at exchange rates at the date of transaction
with foreign currency gains (losses) recorded in other income (expense), net in the consolidated statements of operations and other comprehensive income. The Company recognized net foreign currency transaction gains (losses) of $(0.3) million,
$(0.3) million, $(49,000) (unaudited) and $0.1 million (unaudited) during the year ended December&nbsp;31, 2013 and 2014 and the six months ended June 30, 2014 (unaudited) and 2015 (unaudited), respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As the Company&#146;s international operations grow, its risks associated with fluctuation in currency rates will become greater, and the Company will
continue to reassess its approach to managing this risk. In addition, currency fluctuations or a weakening USD can increase the costs of the Company&#146;s international expansion. To date, the Company has not entered into any foreign currency
hedging contracts, since exchange rate fluctuations have not had a material impact on its operating results and cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Concentration of Credit Risk
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable
investments and accounts receivable. The majority of the Company&#146;s cash is held by one financial institution in the United States in excess of federally insured limits. The Company maintained investments in money market funds that were not
federally insured during the year ended December&nbsp;31, 2014 and held cash in foreign banks of approximately $0.6 million, $0.8 million and $3.0 million (unaudited) at December&nbsp;31, 2013 and 2014 and June 30, 2015 (unaudited), respectively,
that was not federally insured. The Company has not experienced any losses on its deposits of cash and cash equivalents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">All of the Company&#146;s
revenue has been derived from sales of its products in the United States and international markets. The Company uses both its own salesforce and independent distributors to sell its products. Concentrations of credit risk with respect to accounts
receivable are limited due to the large number of entities comprising the Company&#146;s customer base. The Company performs ongoing credit evaluations of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2. Summary of Significant Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
customers, including its distributors, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">During the years ended December&nbsp;31, 2013 and 2014 and the six months ended June 30, 2014 (unaudited) and 2015 (unaudited), one customer (a
distributor) accounted for 14%, 12%, 13% and 11%, respectively, of the Company&#146;s revenue. No customer accounted for greater than 10% of the Company&#146;s accounts receivable balance as of December&nbsp;31, 2013, 2014 or June 30, 2015
(unaudited). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Significant Risks and Uncertainties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The
Company is subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product
liability, uncertainty of market acceptance of products and the potential need to obtain additional financing. The Company is dependent on third party suppliers, in some cases single-source suppliers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">There can be no assurance that the Company&#146;s products will continue to be accepted in the marketplace, nor can there be any assurance that any
future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s products require approval or clearance from the U.S. Food and Drug Administration prior to commencing commercial sales in the United
States. There can be no assurance that the Company&#146;s products will receive all of the required approvals or clearances. Approvals or clearances are also required in foreign jurisdictions in which the Company sells its products. If the Company
is denied such approvals or clearances or such approvals or clearances are delayed, it may have a material adverse impact on the Company&#146;s results of operations, financial position and liquidity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Fair Value of Financial Instruments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Carrying amounts of
certain of the Company&#146;s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Cash, Cash Equivalents and Marketable Investments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The
Company invests its cash primarily in money market funds and in highly liquid debt instruments of U.S. federal and municipal governments and their agencies and corporate debt securities. All highly liquid investments with stated maturities of three
months or less from the date of purchase are classified as cash equivalents; all highly liquid investments with stated maturities of greater than three months are classified as marketable investments. The majority of the Company&#146;s cash and
investments are held in U.S. banks and its foreign subsidiaries maintain a limited amount of cash in their local banks to cover their short term operating expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company determines the appropriate classification of its investments in marketable investments at the time of purchase and re-evaluates such
designation at each balance sheet date. The Company&#146;s marketable investments have been classified and accounted for as available-for-sale. Investments with remaining maturities of more than one year are viewed by the Company as available to
support current operations and are classified as current assets under the caption marketable investments in the accompanying consolidated balance sheets. Investments in marketable investments are carried at fair value, with the unrealized gains and
losses reported as a component of accumulated other comprehensive income. Any realized gains or losses on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2. Summary of Significant Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the sale of marketable investments are determined on a specific identification method, and such gains and losses are reflected as a component of other income (expense), net. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Impairment of Marketable Investments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">After determining the
fair value of available-for-sales debt instruments, gains or losses on these securities are recorded to accumulated other comprehensive income until either the security is sold or the Company determines that the decline in value is
other-than-temporary. The primary differentiating factors that the Company considers in classifying impairments as either temporary or other-than-temporary impairments is the intent and ability to retain the investment in the issuer for a period of
time sufficient to allow for any anticipated recovery in market value, the length of the time and the extent to which the market value of the investment has been less than cost, the financial condition and near-term prospects of the issuer. There
were no other-than-temporary impairments for the years ended December 31, 2013 and 2014 and for the six months ended June 30, 2014 (unaudited) and 2015 (unaudited). The Company did not have any marketable investments as of June 30, 2015 (unaudited).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Accounts Receivable </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Accounts receivable are stated at
invoice value less estimated allowances for doubtful accounts. The Company continually monitors customer payments and maintains a reserve for estimated losses resulting from its customers&#146; inability to make required payments. The Company
considers factors such as historical experience, credit quality, age of the accounts receivable balances, geographic related risks and economic conditions that may affect a customer&#146;s ability to pay. In cases where there are circumstances that
may impair a specific customer&#146;s ability to meet its financial obligations, a specific allowance is recorded against amounts due, and thereby reduces the net recognized receivable to the amount reasonably believed to be collectible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Restricted Investments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Restricted investments of $6.0
million as of December&nbsp;31, 2013, classified as available-for-sale investments in money market funds, are held with a major financial institution as security for the Company&#146;s credit facility. Refer to Note 5. There are no restricted
investments as of December&nbsp;31, 2014 or June 30, 2015 (unaudited). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Inventories </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Inventories are stated at the lower of cost (determined under the first-in first-out method) or market. Write downs are provided for raw materials,
components or finished goods that are determined to be excessive or obsolete. Market value is determined as the lower of replacement cost or net realizable value. The Company regularly reviews inventory quantities in consideration of actual loss
experience, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The estimate
of excess quantities is subjective and primarily dependent on the Company&#146;s estimates of future demand for a particular product or components or raw materials used in the manufacturing of such product. If the estimate of future demand is
inaccurate based on actual sales, the Company may increase the write down for excess inventory and record a charge to inventory impairment in the accompanying consolidated statements of operations and comprehensive income. The Company periodically
evaluates the carrying value of inventory on hand for potential excess amounts over demand using the same lower of cost or market approach as that has been used to value the inventory. The Company also periodically evaluates inventory quantities in
consideration of actual loss experience. As a result of these evaluations, the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2. Summary of Significant Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
recognized total write downs of $0.9 million and $1.9 million for the years ended December&nbsp;31, 2013 and 2014, respectively, and $0.5 million and $0.3 million for the six months ended June
30, 2014 (unaudited) and 2015 (unaudited). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over five years, which
is the estimated useful lives of the assets. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life. Upon retirement or sale, the cost and the related accumulated depreciation
are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Impairment of Long-Lived Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company reviews
long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When such an event occurs, management determines whether there has been impairment by comparing the
anticipated undiscounted future net cash flows to the related asset group&#146;s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised
value, depending on the nature of the asset. There was no impairment of long-lived assets during the year ended December&nbsp;31, 2013 and 2014 and for the six months ended June 30, 2014 (unaudited) and 2015 (unaudited). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company has classified the preferred
stock as temporary equity in the consolidated balance sheets due to the existence of certain change in control events that are not solely within the Company&#146;s control, including liquidation, sale or transfer of the Company, that trigger the
ability of the holders of the preferred stock to call for redemption of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Revenue Recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Revenue is comprised of product revenue net of returns, discounts, administration fees and sales rebates. The Company recognizes revenue when persuasive
evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable and collectability is reasonably assured. Evidence of an arrangement consists of customer orders and the Company typically considers delivery to have
occurred once title and risk of loss has been transferred and the product has been delivered to the customer. The Company typically recognizes revenue when products are delivered to hospital customers or distributors. However, with respect to
products that the Company consigns to hospitals, which primarily consist of coils, the Company recognizes revenue at the time hospitals utilize products in a procedure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Deferred revenue represents amounts that the Company has already invoiced its customers and are ultimately expected to be recognized as revenue, but for
which not all revenue recognition criteria have been met. The Company had a deferred revenue balance of $1.1 million, $1.6 million and $0.8 million, as of December 31, 2013, 2014 and June 30, 2015 (unaudited), respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s terms and conditions permit product returns and exchanges, and it records returns reserves in the period when revenue is recognized.
Estimates are based on actual historical returns over the prior three years and are recorded as reductions in revenue at the time of sale. Upon recognition, the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2. Summary of Significant Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
reduces revenue and cost of revenue for the estimated return. Return rates can fluctuate over time, but are sufficiently predictable to allow the Company to estimate expected future product
returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Cost of Revenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Cost of revenue includes
direct and indirect costs associated with the manufacture of the Company&#146;s products. Direct costs include material and labor, while indirect costs include inbound freight charges, receiving costs, inspection and testing costs, warehousing
costs, royalty expense and other labor and overhead costs incurred in the manufacturing of products. Cost of revenue also includes stock-based compensation, warranty replacement costs, cost of revenue related to product return reserves and excess
and obsolete inventory write-downs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Shipping Costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Shipping and handling costs charged to customers are recorded as revenue. Shipping and handling costs are included in cost of revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Research and Development (R&amp;D) Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">R&amp;D costs
primarily consist of product development, clinical and regulatory expenses, materials, depreciation and other costs associated with the development of the Company&#146;s products. R&amp;D costs also include related personnel and consultants&#146;
salaries, benefits and related costs, including stock-based compensation. The Company expenses R&amp;D costs as they are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The
Company&#146;s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites. The Company estimates preclinical and clinical trial expenses based on the services performed pursuant to contracts
with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and
the level of patient enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third
parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Advertising
Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Advertising costs are included in selling, general and administrative expenses and are expensed as incurred. Advertising costs consist
primarily of trade show and booth costs, product demonstration, and marketing materials. Advertising costs for the years ended December&nbsp;31, 2013 and 2014 and the six months ended June 30, 2014 (unaudited) and 2015 (unaudited) were $0.1 million,
$0.3 million, $73,000, and $0.3 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company accounts for stock-based compensation arrangements with employees in accordance with ASC 718, Compensation&#151;Stock Compensation. ASC 718
requires the recognition of compensation expense, using a fair value-based method, for costs related to all share-based payments including stock options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s determination of the fair value of stock options on the date of grant utilizes the Black-Scholes option-pricing model and is impacted
by its common stock price as well as changes in assumptions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2. Summary of Significant Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
regarding a number of highly complex and subjective variables. These variables include, but are not limited to, expected term that options will remain outstanding, expected common stock price
volatility over the term of the option awards, risk-free interest rates and expected dividends. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The fair value is recognized over the period during
which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period) on a straight-line basis. Stock-based compensation expense recognized at fair value includes the
impact of estimated forfeitures. The Company estimates future forfeitures at the date of grant and revises the estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates. To the extent actual forfeiture results
differ from the estimates, the difference is recorded as a cumulative adjustment in the period forfeiture estimates are revised. No compensation cost is recorded for options that do not vest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the
underlying equity instruments vest. The fair value of options granted to consultants is expensed over the service period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Estimating the fair value
of equity-settled awards as of the grant date using valuation models, such as the Black-Scholes option pricing model, is affected by assumptions regarding a number of complex variables. Changes in the assumptions can materially affect the fair value
and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop. For all stock options granted to date, the Company estimated the volatility data
based on a study of publicly traded industry peer companies. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies. The risk-free
interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Income
Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company accounts for income taxes using the asset and liability method, whereby deferred tax asset and liability account balances are
determined based on differences between the financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides
a valuation allowance to reduce the net deferred tax assets to their estimated realizable value. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The calculation of the Company&#146;s current
provision for income taxes involves the use of estimates, assumptions and judgments while taking into account current tax laws, interpretation of current tax laws and possible outcomes of future tax audits. The Company has established reserves to
address potential exposures related to tax positions that could be challenged by tax authorities. Although the Company believes its estimates, assumptions and judgments to be reasonable, any changes in tax law or its interpretation of tax laws and
the resolutions of potential tax audits could significantly impact the amounts provided for income taxes in the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The calculation of the Company&#146;s deferred tax asset balance involves the use of estimates, assumptions and judgments while taking into account
estimates of the amounts and type of future taxable income. Actual future operating results and the underlying amount and type of income could differ materially from the Company&#146;s estimates, assumptions and judgments thereby impacting the
Company&#146;s financial position and results of operations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company follows ASC 740-10 &#147;Accounting for Uncertainty in Income Taxes,&#148;
which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2. Summary of Significant Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
uncertain tax positions taken or expected to be taken in the Company&#146;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in
interim periods, disclosure and transition. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company includes interest and penalties related to unrecognized tax benefits within income tax
expense in the accompanying consolidated statements of operations. The Company has not incurred any interest or penalties related to unrecognized tax benefits in any of the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Comprehensive Income </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company is required to display
comprehensive income and its components as part of the Company&#146;s consolidated financial statements. Comprehensive income consists of net income, unrealized gains on available-for-sale investments and the effects of foreign currency translation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Deferred Offering Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Deferred offering costs, which
primarily consist of direct incremental legal and accounting fees relating to the proposed IPO, are capitalized. The deferred offering costs will be offset against IPO proceeds upon the consummation of the offering. In the event the offering is
terminated, deferred offering costs will be expensed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Net Income (Loss) Per Share and Unaudited Pro Forma Net Income (Loss) Per Share of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company calculates its basic and diluted net income (loss) per share attributable to common stockholders in conformity with the two-class method
required for companies with participating securities. Under the two-class method, the Company determines whether it has net income (loss) attributable to common stockholders, which includes the results of operations less current period preferred
stock non-cumulative dividends. If it is determined that the Company does have net income (loss) attributable to common stockholders during a period, the related undistributed earnings are then allocated between common stock and the preferred stock
based on the weighted average number of shares outstanding during the period to determine the numerator for the basic net income (loss) per share attributable to common stockholders. In computing diluted net income attributable to common
stockholders, undistributed earnings are re-allocated to reflect the potential impact of dilutive securities to determine the numerator for the diluted net income per share attributable to common stockholders. The Company&#146;s basic net income
(loss) per share attributable to common stockholders is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. The diluted net income per share attributable to common
stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock
equivalents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The unaudited pro forma basic and diluted net income (loss) per share reflects the automatic conversion of all outstanding shares of
preferred stock as if the conversion had occurred at the earlier of the beginning of the period or the date of issuance, if later. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The unaudited pro
forma basic and diluted net income (loss) per share amounts do not give effect to the issuance of shares from the planned initial public offering nor do they give effect to potential dilutive securities where the impact would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Recently Issued Accounting Standards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In May 2014, the FASB
issued ASU No.&nbsp;2014-09, <I>Revenue from Contracts with Customers</I>, which outlines a comprehensive new revenue recognition model designed to depict the transfer of promised goods or services to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2. Summary of Significant Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The accounting standard is effective for annual
reporting periods (including interim reporting periods within those periods) beginning after December&nbsp;15, 2016. Early adoption is not permitted. The Company is currently evaluating the impact of this accounting standard. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In July 2015, the FASB voted to defer the effective date by one year to December&nbsp;15, 2017 for annual reporting periods beginning after that date.
The FASB also voted to permit early adoption of the standard, but not before the original effective date of December&nbsp;15, 2016. The final accounting standard formally amending the effective date is expected to be issued by the FASB by the end of
the third quarter of 2015 (unaudited). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In November 2014, the FASB issued ASU No.&nbsp;2014-17, <I>Pushdown Accounting</I>, which provides an
acquired entity to elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs and allows the acquired entity to determine whether to elect to apply pushdown accounting for each individual
change-in-control event in which the acquirer obtains control of the acquired entity. This accounting standard is effective as of November&nbsp;18, 2014 and the Company will apply the guidance to future change-in control events. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In July 2015, the FASB issued ASU No. 2015-11, <I>Simplifying the Measurement of Inventory</I>, which requires an entity to measure most inventory at the
lower of cost and net realizable value, thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. The accounting standard is effective prospectively for annual periods beginning after
December 15, 2016, and interim periods therein. Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact of this accounting standard (unaudited). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>3. Fair Value of Financial Instruments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which
prioritizes the inputs used in the valuation methodologies in measuring fair value: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Level 1&#151;Quoted prices in active markets for identical
assets or liabilities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Level 2&#151;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets
that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Level 3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or
liabilities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant
to the fair value measurement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company classifies its cash equivalents and marketable investments within Level 1 and Level 2, as it uses quoted
market prices or alternative pricing sources and models utilizing market observable inputs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company determined the fair value of its Level 1
financial instruments, which are traded in active markets, using quoted market prices for identical instruments. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Marketable investments classified
within Level 2 of the fair value hierarchy are valued based on other observable inputs, including broker or dealer quotations or alternative pricing sources. When quoted prices in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>3. Fair Value of Financial Instruments&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
active markets for identical assets or liabilities are not available, the Company relies on non-binding quotes from its investment managers, which are based on proprietary valuation models of
independent pricing services. These models generally use inputs such as observable market data, quoted market prices for similar instruments, historical pricing trends of a security as relative to its peers and&nbsp;internal assumptions of the
independent pricing services. To validate the fair value determination provided by its investment managers, the Company reviews the pricing movement in the context of overall market trends and trading information from its investment managers. In
addition, the Company assesses the inputs and methods used in determining the fair value in order to determine the classification of securities in the fair value hierarchy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company did not own any Level 3 financial assets or liabilities as of December 31, 2013 or 2014 or June&nbsp;30, 2015 (unaudited). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">During the years ended December&nbsp;31, 2013 and 2014, and the six months ended June 30, 2014 (unaudited) and 2015 (unaudited), the Company did not
record impairment charges related to its marketable investments, and the Company did not have any transfers between Level 1, Level 2 and Level 3 of the fair value hierarchy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following tables set forth the fair value of the Company&#146;s financial assets and liabilities by level within the fair value hierarchy (in
thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December 31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Marketable investments:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s marketable investments as of December&nbsp;31, 2013 of $15.5 million included $6.0 million of
restricted investments, which were held with a major financial institution as a security for the Company&#146;s credit facility. Refer to Note 5. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December 31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash equivalents:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Marketable investments:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>3. Fair Value of Financial Instruments&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June 30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Financial Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Cash equivalents:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Marketable investments:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">During the years ended December&nbsp;31, 2013 and 2014 and the six months ended June&nbsp;30, 2014 (unaudited) and 2015
(unaudited), the Company did not have any transfers of financial assets measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3. The Company did not hold any Level 3 assets or liabilities as of December&nbsp;31, 2013 and
2014 and June 30, 2015 (unaudited). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other current assets,
accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>4. Balance Sheet Components </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Accounts Receivable, Net </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s allowance for
doubtful accounts comprised of the following (in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Balance&nbsp;At<BR>Beginning<BR>Of Year </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Charged&nbsp;To<BR>Costs And<BR>Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Deductions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Balance&nbsp;At<BR>End Of<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Allowance for Doubtful Accounts</B> <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">For year ended:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B></B>December 31, 2013<B></B> <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B></B>December 31, 2014<B></B> <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B></B>June 30, 2015 (unaudited)<B></B> <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Prepaid Expenses and Other Current Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s prepaid expenses and other current assets comprised of the following (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B><br><B>2015</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>4. Balance Sheet Components&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Marketable Investments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s marketable investments as of December&nbsp;31, 2013 were as follows (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:81.20pt; font-size:8pt; font-family:arial"><B>Marketable Investments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Gross<BR>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Gross<BR>Unrealized<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s marketable investments as of December&nbsp;31, 2013 of $15.5 million included $6.0 million of
restricted investments, which were held with a major financial institution as a security for the Company&#146;s credit facility. Refer to Note 5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s marketable investments as of December&nbsp;31, 2014 were as follows (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:81.20pt; font-size:8pt; font-family:arial"><B>Marketable Investments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Gross<BR>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Gross<BR>Unrealized<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">U.S. Treasury</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Mutual funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company did not have any marketable investments as of June&nbsp;30, 2015 (unaudited). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">For the years ended December&nbsp;31, 2013 and 2014 and the six months ended June&nbsp;30, 2014 (unaudited), gains or losses realized on the sale of
investments were insignificant. During the six months ended June 30, 2015, the Company sold all of its marketable investments and recorded a realized loss of $0.5 million. As of December&nbsp;31, 2014, there are no securities that have been in a
loss position for more than twelve months. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The contractual maturities of the Company&#146;s marketable investments as of December 31, 2014 were as
follows (in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Due in one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Due in one to five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>4. Balance Sheet Components&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Inventories </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The components of inventories consisted of the following (in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B><br><B>2015</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Raw materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Work in process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Finished goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Property and Equipment, Net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Property and equipment, net comprised of the following (in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June 30</B><br><B>2015</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Machinery and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Computers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Depreciation and amortization expense for the years ended December&nbsp;31, 2013 and 2014 and the six months ended June
30, 2014 (unaudited) and 2015 (unaudited) was $0.7 million, $0.8 million, $0.3 million and $0.8 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Accrued Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table shows the components of accrued liabilities (in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June 30,</B><br><B>2015</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Payroll and employee-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sales return reserve</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preclinical and clinical trial cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Product warranty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sales tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>4. Balance Sheet Components&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The estimated product warranty accrual was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June 30,</B><br><B>2015</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accruals of warranties issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Settlements of warranty claims</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance at the end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>5. Credit Facility </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In May
2012, the Company entered into a revolving credit facility of $15.0 million with Wells Fargo Bank, National Association. The credit facility was collateralized by the Company&#146;s investment balances. The interest on the credit facility was based
on the daily one-month London Inter-Bank Offered Rate, plus 1.75% and was payable monthly. Any outstanding balance on the credit facility was due in full on June&nbsp;1, 2015. The credit facility contained customary covenants for credit facilities
of this type, including limitations on disposition of assets and changes in control. In May 2014, in conjunction with its Series F financing, the Company paid the then outstanding balance on the credit facility and terminated the credit facility.
The Company was in compliance with the covenants as of December&nbsp;31, 2013. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>6. Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Notes Receivable from Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In March 2005, options to
purchase 875,000 shares of common stock, subject to repurchase by the Company, were exercised in exchange for full recourse promissory notes totaling $0.1 million. The notes bear interest at 2.92%&nbsp;per year, compounded annually with interest and
principal due on the earlier to occur of January&nbsp;31, 2015, or the date the employee ceases to be an employee, director or consultant of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In July 2011, options to purchase 5,000 shares of common stock were exercised in exchange for a full recourse promissory note totaling $10,250. The note
is noninterest bearing and is due in full on December&nbsp;31, 2016. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of December&nbsp;31, 2013 and 2014 and June 30, 2015 (unaudited),
outstanding promissory notes were $0.1 million, $0.1 million and $31,500, respectively. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>7. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Lease Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company leases its offices and other
equipment under non-cancelable operating leases that expire at various dates in 2029. Rent expense for the years ended December&nbsp;31, 2013 and 2014 and the six months ended June 30, 2014 (unaudited) and 2015 (unaudited) was $1.7 million, $1.8
million, $0.9 million and $1.4 million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>7. Commitments and Contingencies&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Future minimum lease payments under the non-cancelable operating leases as of December 31, 2014 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">are as follows (in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:86.80pt; font-size:8pt; font-family:arial"><B>Year Ending December 31:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Lease&nbsp;Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Future minimum lease payments under the non-cancelable operating leases as of June 30, 2015 (unaudited) are as follows
(in thousands): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:80.80pt; font-size:8pt; font-family:arial"><B>Quarter Ending June 30:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Lease&nbsp;Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Future minimum lease payments under the non-cancelable operating leases as of June 30, 2015 in the table above includes
lease for additional space at the Company&#146;s campus in Alameda, California. This lease commenced in June 2015 upon landlord&#146;s substantial completion of tenant improvements and expires in November 2029. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Purchase Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company had non-cancellable
purchase obligations to suppliers for the year ended December&nbsp;31, 2014 and the six months ended June 30, 2015 (unaudited) of $9.9&nbsp;million and $6.3 million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Royalty Obligations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In March 2005, the Company entered into
a license agreement that requires the Company to make minimum royalty payments to the licensor, on a quarterly basis.&nbsp;As of December 31, 2014 and June 30, 2015, the license agreement requires minimum annual royalty payments of $0.1 million and
$0.1 million in equal quarterly installments, respectively. On each January 1, the quarterly calendar year minimum royalty shall be adjusted to equal the prior year&#146;s minimum royalty adjusted by a percentage equal to the percentage change in
the &#147;consumer price index for all urban consumers&#148; for the prior calendar year as reported by the U.S. Department of Labor. Unless terminated earlier, the term of the license agreement shall continue until the expiration of the last to
expire patent that covers that licensed product or for the period of 15 years following the first commercial sale of such licensed product, whichever is longer. The first commercial sale occurred in June 2007. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>7. Commitments and Contingencies&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In April 2012, the Company entered into an agreement that requires the Company to pay a 5% royalty on
sales of products covered under applicable patents, on a quarterly basis.&nbsp;The first commercial sale occurred in April 2014.&nbsp;Unless terminated earlier, the royalty term for each applicable product shall continue for fifteen years following
the first commercial sale of such patented product, or when the applicable patent covering such product has expired, whichever is sooner.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In April
2015, the Company entered into a royalty agreement that requires the Company to pay a 2% royalty on sales of certain products covered by the agreement, on a quarterly basis. The Company anticipates that the first commercial sale of the covered
Indigo products will occur in June 2015. Unless terminated earlier, the royalty term for each covered product shall continue for twenty years following the first commercial sale of the covered products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Royalty expense included in cost of sales for the years ended December 31, 2013 and 2014 and the six months ended June 30, 2014 (unaudited) and 2015
(unaudited), was $0.7 million, $1.1 million, $0.5 million and $0.8 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for
such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There have been no contingent liabilities requiring accrual or disclosure at December&nbsp;31, 2013 and 2014 or June 30, 2015
(unaudited). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company enters into
standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified
party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company&#146;s technology. The term of these indemnification agreements is generally perpetual.
The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and
officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. No liability associated with such
indemnifications has been recorded to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Litigation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">From time to time, the Company is subject to claims and assessments in the ordinary course of business. The Company is not currently a party to any
litigation matter that, individually or in the aggregate, is expected to have a material adverse effect on the Company&#146;s business, financial condition, results of operations or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>8. Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The preferred stock at December&nbsp;31, 2014 consisted of the following (in thousands, except shares): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:20.40pt; font-size:8pt; font-family:arial"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Proceeds,<BR>Net&nbsp;of&nbsp;Issuance<BR>Costs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Liquidation<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,287,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,005,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,388,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,168,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series D Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,944,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,881,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series E Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,973,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,909,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series F Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,303,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,545,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Undesignated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,102,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,510,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The preferred stock at June 30, 2015 (unaudited) consisted of the following (in thousands, except shares): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:20.40pt; font-size:8pt; font-family:arial"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Proceeds,<BR>Net&nbsp;of&nbsp;Issuance<BR>Costs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Liquidation<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,287,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,005,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,388,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,168,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series D Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,944,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,881,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series E Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,973,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,909,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series F Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,303,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,545,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Undesignated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,102,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,510,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The rights, preferences and privileges of the Series&nbsp;A Preferred Stock (Series A), Series&nbsp;B Preferred Stock
(Series B), Series&nbsp;C Preferred Stock (Series C), Series&nbsp;D Preferred Stock (Series D), Series&nbsp;E Preferred Stock (Series E) and Series&nbsp;F Preferred Stock (Series F) are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The holders of each share of Series A, Series B,
Series C, Series D, Series E and Series F preferred stock are entitled to the number of votes equal to the number of shares of common stock into which each share of preferred stock could be converted, and have voting rights and powers equal to the
voting rights and powers of the holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The holders of Series A, Series B, Series C, Series D, Series E and Series F preferred stock are entitled to receive dividends out of any assets legally
available, prior, and in preference to, any declaration or payment of any dividend on the common stock of the Company, at the rate of 6% of the original purchase price (adjusted for any stock dividends, stock splits, or recapitalization) per share
per annum. For any future dividends per annum, the preferred stock would participate with common stock on an as-converted basis. Such dividends are payable when, as, and if declared by the Board of Directors and are not cumulative. No dividends have
been declared or paid since the issuance of preferred stock through December&nbsp;31, 2014 or June 30, 2015 (unaudited). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>8. Preferred Stock&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Conversion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Each share of Series A, Series B, Series C, Series D, Series E and Series F preferred stock, at the option of the holder, is convertible into the number
of fully paid and nonassessable shares of common stock, which results from dividing the original purchase price of the Series A, Series B, Series C, Series D, Series E and Series F preferred stock by the conversion price applicable to such shares.
The initial per-share conversion price of the Series A, Series B, Series C, Series D, Series E and Series F preferred stock is $0.30, $1.63, $3.19, $5.07, $7.60 and $13.20 per share, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Conversion is automatic at the then-effective conversion rate either (a)&nbsp;immediately upon the closing of a firm commitment underwritten public
offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of common stock in which the aggregate proceeds raised, equal, or exceed $15,000,000 or (b)&nbsp;at the election of
the holders of two-thirds of the outstanding Series A, Series B, Series C, Series D, Series E and Series F preferred stock voting together as a single class on an as-converted basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Liquidation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In the event of any liquidation, dissolution, or
winding-up of the Company, either voluntary or involuntary, the holders of Series A, Series B, Series C, Series D, Series E and Series F preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets
of the Company to the holders of common stock by reason of their ownership, an amount per share equal to the original purchase price, plus 6%&nbsp;per annum compounded annually from original issuance date for each outstanding share of Series A,
Series B, Series C, Series D, Series E and Series F preferred stock (as adjusted for any stock dividends, stock splits, or recapitalization), plus any declared, but unpaid, dividends on such share, respectively. As of December&nbsp;31, 2014, the
holders of Series A, Series B, Series C, Series D, Series E and Series F preferred stock are entitled to receive an amount per share equal to $0.55, $2.93, $5.34, $7.98, $11.31 and $13.70, respectively. As of June 30, 2015, the holders of
Series&nbsp;A, Series&nbsp;B, Series&nbsp;C, Series&nbsp;D, Series&nbsp;E and Series&nbsp;F preferred stock are entitled to receive an amount per share equal to $0.57, $3.01, $5.49, $8.21, $11.65 and $14.10, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">If upon the occurrence of such event, the assets and funds distributed among the holders of Series A, Series B, Series C, Series D, Series E and Series F
preferred stock are insufficient to permit the payment to such holders of the full aforesaid preferential amounts, then, subject to the rights of series of preferred stock that may from time to time come into existence, the entire assets and funds
of the Company legally available for distribution will be distributed ratably among the holders of Series A, Series B, Series C, Series D, Series E and Series F preferred stock, and holders of such series of preferred stock in proportion to the
preferential amount each such holder is entitled to receive. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">After payment has been made to the holders of Series A, Series B, Series C, Series D,
Series E and Series F preferred stock, any remaining assets and funds are to be distributed among the holders of common stock ratably, based on the number of shares of common stock held by each stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Mergers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">A merger, reorganization or sale of all or
substantially all of the assets of the Company in which more than 50% of the voting power of the Company is disposed of shall be deemed to be a liquidation, dissolution or winding-up. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>9. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally
available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>10. Common Stock Liability
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of December&nbsp;31, 2013 and 2014 and June 30, 2015 (unaudited), the Company had outstanding options to purchase 3,092,176, 2,900,676 and
2,460,574 shares, respectively, of common stock. Proceeds from the exercise of unvested stock options are accounted for as a liability. The liability as of December&nbsp;31, 2013 and 2014 and June 30, 2015 (unaudited), were $0.1&nbsp;million,
$0.2&nbsp;million and $0.1&nbsp;million, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The options are not considered exercised and the underlying shares are not considered issued
until the Company&#146;s right to repurchase lapses, when the employee vests in the award. Employees who have exercised shares prior to vesting are current employees of the Company. There were 16,305, 33,081 and 24,818 shares subject to repurchase
as of December&nbsp;31, 2013, 2014 and June 30, 2015 (unaudited), respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>11. Warrants</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In connection with the sale of Series B preferred stock in 2004, the Company issued warrants to purchase 211,138 shares of common stock at a purchase
price of $0.01 per share. The warrants were exercisable upon grant and had a term of 10 years from the date of grant, which expired on December 31, 2014. The value of the warrants was calculated using Black-Scholes option pricing model and was
deemed to be immaterial. As of December 31, 2013, warrants to purchase 79,645 shares of common stock were outstanding. No warrants were outstanding as of December 31, 2014. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>12. Stock Option Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2005 Stock Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s board of directors and stockholders approved the Company&#146;s 2005 Stock Plan (the 2005&nbsp;Plan) and it became effective in
January 2005. The 2005 Plan was subsequently amended and restated in 2006, 2007, 2008 and 2010. As of December 31, 2014 and June 30, 2015 (unaudited), the Company had granted options to purchase 5,431,017 and 5,431,017&nbsp;shares of common stock,
respectively, under the 2005&nbsp;Plan, of which options to purchase 2,707,176 and 1,779,924 shares of common stock were outstanding, and options to purchase 33,081 and 24,818 shares of common stock had been early exercised and were unvested and
subject to repurchase, as of December&nbsp;31, 2014 and June 30, 2015 (unaudited), respectively. Under the 2005 Plan, the board of directors could grant incentive stock options (ISO), nonqualified stock options (NSO), or stock awards to eligible
persons, including employees, nonemployees, directors, consultants and other independent advisors who provide services to the Company. Stock purchase rights could also be granted under the Plan. The board of directors had the authority to determine
to whom options would be granted, the number of options, the term and the exercise price. ISOs could only be granted to Company employees, which include officers and directors of the Company. NSOs and stock purchase rights could be granted to
employees and consultants. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price for an ISO could not be less than 110% of fair market value. Options are exercisable immediately upon the optionee
entering into a restricted stock purchase agreement with respect to any unvested options. Options generally vest annually at a rate of 1/4 after the first year and 1/48&nbsp;per month thereafter. The term of the options is no longer
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>12. Stock Option Plans&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
than five years for ISOs, for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than 10 years for all other options. Stock options granted under
the 2005 Plan generally have a contractual life of ten years, and generally vest over a period of four years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2011 Equity Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s board of directors approved the Company&#146;s 2011 Equity Incentive Plan (the 2011 Plan) and it became effective in October 2011. As
of December&nbsp;31, 2014 and June 30, 2015 (unaudited), the Company had granted options to purchase 145,000 and 145,000&nbsp;shares of common stock, respectively, under the 2011 Plan, of which options to purchase 145,000 and 145,000&nbsp;shares of
common stock were outstanding at December&nbsp;31, 2014 and June 30, 2015 (unaudited), respectively. The Company had also granted 505,000 and 505,000&nbsp;shares of restricted stock under the 2011 Plan, of which 367,126 and 252,125 shares were
unvested and subject to forfeiture and 1,667 and 1,667&nbsp;shares had been forfeited as of December&nbsp;31, 2014 and June 30, 2015 (unaudited), respectively. Under the 2011 Plan, the board of directors could grant ISOs, NSOs, restricted stock, or
restricted stock units (RSU) to eligible persons, including employees, directors and consultants who provide services to the Company. Stock Appreciation Rights (SAR) could also be granted under the 2011 Plan. The board of directors had the authority
to determine to whom options would be granted, the number of options, the term and the exercise price. ISOs could only be granted to Company employees, which include officers and directors of the Company. NSOs, SARs, restricted stock and RSUs could
be granted to employees and consultants. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price for an ISO could not be less than 110% of fair market value. Stock options granted under the 2011 Plan
generally have a contractual life of ten years, and generally vest over a period of four years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>2014 Equity Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s board of directors and stockholders approved the Company&#146;s 2014 Equity Incentive Plan (the 2014 Plan) and it became effective in
May, 2014. The 2014 Plan replaced the 2011 Plan and the 2005 Plan. No further equity awards may be granted under the 2011 Plan or the 2005 Plan. As of December&nbsp;31, 2014 and June 30, 2015 (unaudited), respectively there were 2,688,513 and
1,713,634&nbsp;shares remaining available for the grant of equity awards under our 2014 Plan. As of December 31, 2014 and June 30, 2015 (unaudited), the Company had granted options to purchase 48,500 and 536,650&nbsp;shares of common stock under the
2014 Plan, 48,500 and 535,650 of which were outstanding and 0 and 1,000 options had been forfeited as of December 31, 2014 and June 30, 2015 (unaudited), respectively. The Company had also granted 0 and 662,361&nbsp;shares of restricted stock under
the 2014 Plan, as of December&nbsp;31, 2014 and June 30, 2015 (unaudited), respectively, of which 0 and 503,646&nbsp;shares were unvested and subject to forfeiture as of such dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Early Exercises </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Stock options granted under the 2005 Plan,
2011 Plan and 2014 Plan allow the board of directors to grant awards to provide employee option holders the right to elect to exercise unvested options in exchange for restricted common stock. Unvested shares, which amounted to 16,305, 33,081 and
24,818 as of December&nbsp;31, 2013 and 2014 and June 30, 2015 (unaudited), respectively, were subject to a repurchase right held by the Company at the original issue price in the event the optionees&#146; employment was terminated either
voluntarily or involuntarily. For exercises of employee options, this right lapses according to the vesting schedule designated on the associated option grant. The repurchase terms are considered to be a forfeiture provision. The shares purchased by
the employees pursuant to the early exercise of stock options are not deemed to be issued or outstanding for accounting purposes until those shares vest, though they are legally issued and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>12. Stock Option Plans&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
outstanding. In addition, cash received from employees for exercise of unvested options is treated as a refundable deposit shown as a liability on the consolidated balance sheets. As of
December&nbsp;31, 2013 and 2014 and June 30, 2015 (unaudited), cash received related to unvested shares totaled $0.1 million, $0.2 million and $0.1&nbsp;million, respectively. Amounts recorded are transferred into common stock and additional
paid-in-capital as the shares vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Activity of stock options under 2005 Plan, 2011 Plan and 2014 Plan is set forth below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>Available for<BR>Grant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Life<BR>(in&nbsp;Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance, December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,092,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional shares authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(286,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(268,050</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(421,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance, December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,688,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,900,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock granted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(662,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock withheld for taxes (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options granted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(488,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options exercised (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(927,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options withheld for taxes (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options cancelled (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance, June 30, 2015 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,713,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,460,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested and expected to vest&#151;December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,890,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercisable&#151;December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,852,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested and expected to vest&#151;June 30, 2015 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,408,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercisable&#151;June 30, 2015 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,939,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>12. Stock Option Plans&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table summarizes information about stock options outstanding at December&nbsp;31, 2014:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Options Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:arial"><B>Exercise Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock<BR>Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Life (Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Options<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$0.17&#151;$1.54</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,562,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,562,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$2.05&#151;$3.98</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$4.49&#151;$5.99</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$7.75&#151;$9.06</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$12.36&#151;$12.36</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$0.17&#151;$12.36</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,900,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,852,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table summarizes information about stock options outstanding at June 30, 2015 (unaudited): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Options Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:arial"><B>Exercise Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock&nbsp;Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>Average<BR>Remaining<BR>Contractual<BR>Life&nbsp;(in&nbsp;Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Options<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$0.57&#151;$1.54</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">731,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">731,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$2.05&#151;$3.98</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">834,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">834,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$4.49&#151;$5.99</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$7.75&#151;$9.06</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">$12.36&#151;$14.46</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,460,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,939,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The valuation model
for stock compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term (weighted average period of time that the options granted are expected to be outstanding);
volatility of the Company&#146;s common stock and an assumed-risk-free interest rate. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended </B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.63%&#150;0.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.76%&#150;2.02</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.76%&#150;2.02</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.56%&#150;1.78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected dividend rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Fair Value of Common Stock.</I> The fair value of the shares of common stock underlying our stock options has
historically been determined by the Company&#146;s board of directors. Because there has been no public market for their common stock and in the absence of recent arm&#146;s-length cash sales transactions of their common stock with independent third
parties, the Company&#146;s board of directors has determined the fair value of their common stock by considering at the time of grant a number of objective and subjective factors. The Company&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>12. Stock Option Plans&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
board of directors intends all options granted to be exercisable at a price per share not less than the per share fair value of their common stock underlying those options on the date of grant.
The estimated fair value of their common stock was determined at each valuation date in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity
Securities Issued as Compensation. Their board of directors, with the assistance of management, developed these valuations using significant judgement and taking into account numerous factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">independent third party valuations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">progress of research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">their operating and financial performance, including levels of available capital resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rights and preferences of their common stock compared to the rights and preferences of their other outstanding equity securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equity market conditions affecting comparable public companies, as reflected in comparable companies; market multiples, IPO valuations and other metrics; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the achievement of enterprise milestones, including progress in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of achieving a liquidity event for the shares of common stock, such as an IPO given prevailing market and medical device sector conditions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of their preferred stock in arms-length transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the illiquidity of their securities by virtue of being a private company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business risks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">management and board experience. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company considered the following approaches in the preparation of their
valuations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Market Approach.</I> The market approach values a business by reference to guideline companies, for which enterprise values are known. This approach has two principal methodologies. The guideline public company
methodology derives valuation multiples from the operating data and share prices of similar publicly traded companies. The guideline acquisition methodology focuses on comparisons between the subject company and guideline acquired public or private
companies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Option-Pricing Method Backsolve, or OPM backsolve.</I> The OPM backsolve method derives the implied equity value for a company from a recent transaction involving the company&#146;s own securities issued on an
arm&#146;s-length basis. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Probability Weighted Expected Return Method.</I> Using the probability weighted expected return, or PWERM, method, the value of a company&#146;s common stock is estimated based upon the analysis of future values for
the company assuming various possible future liquidity events like an initial public offering, or IPO, sale or merger. Share value is based upon the probability-weighted present value of expected future net cash flows, considering each of the
possible future events, as well as the rights and preferences of each share class. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>12. Stock Option Plans&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the Company also considered an enterprise value allocation method: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Option-Pricing Method, or OPM. </I>Under this method, each class of stock is modeled as a call option with a distinct claim on the enterprise value of the company. The option&#146;s exercise prices would be based on
a comparison with the enterprise value. The method assumes that a formula, such as the Black-Scholes model, would calculate the fair value when provided with certain values, including share price, expiration date, volatility and risk free interest
rate. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The per share common stock value was estimated by allocating the Company&#146;s enterprise value using the OPM method in
October 1, 2013, May 16, 2014, and September 30, 2014, which determined the common value to be $7.75, $9.06 and $10.92, respectively. The per share common stock value was estimated in December 31, 2014, March 31, 2015 and June 30, 2015, which
utilized the PWERM method, which determined the common stock value to be $12.36, $14.46 and $20.51, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">In determining the estimated fair
value of their common stock, the Company&#146;s board of directors also considered the fact that their stockholders could not freely trade their common stock in the public markets. Accordingly, the Company applied discounts to reflect the lack of
marketability of their common stock based on the expected time to liquidity. The estimated fair value of their common stock at each grant date reflected a non-marketability discount partially based on the anticipated likelihood and timing of a
future liquidity event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The key subjective factors and assumptions used in their valuations primarily consisted of: (i) the selection of the
appropriate market comparable transactions, (ii) the selection of the appropriate comparable publicly traded companies, (iii) the financial forecasts utilized to determine future cash balances and necessary capital requirements, (iv) the probability
and timing of the various possible liquidity events, (v) the estimated weighted-average cost of capital and (vi) the discount for lack of marketability of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">At each grant date the board of directors reviewed any recent events and their potential impact on the estimated fair value per share of the common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Weighted Average Expected Term.</I> The Company derived the expected term using the &#147;simplified&#148; method (the expected term is
determined as the average of the time-to-vesting and the contractual life of the options), as the Company had limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Volatility.</I> Since there has been no public market for the Company&#146;s common stock and lack of company-specific historical volatility, it
has determined the share price volatility for options granted based on an analysis of the volatility used by a peer group of publicly traded medical device companies. In evaluating similarity, the Company considers factors such as industry, stage of
life cycle and size. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Risk-Free Interest Rate. The risk-free interest rate is based upon U.S. Treasury zero-coupon issues with remaining terms
similar to the expected term of the options. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Dividend Yield.</I> The Company has never paid any dividends and does not plan to pay dividends
in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial"><I>Forfeitures.</I> The Company is
required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>12. Stock Option Plans&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
data to estimate pre-vesting option forfeitures and record stock based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the
estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The total intrinsic value of
stock options exercised during the year ended December&nbsp;31, 2014 and the six months ended June 30, 2015 (unaudited) was $3.8 million and $17.7 million, respectively. The intrinsic value is calculated as the difference between the estimated fair
value of the Company&#146;s common stock at the exercise date and the exercise price of the stock option. As of December&nbsp;31, 2014 and June 30, 2015 (unaudited), the Company&#146;s common stock valuation was at $12.36 and $20.51 per share,
respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The weighted average grant date fair value of the employee stock options granted during the years ended December&nbsp;31, 2013 and
2014 and the six months ended June 30, 2014 (unaudited) and 2015 (unaudited) was $2.63, $3.69, $3.58 and $5.72 per share, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The
following table summarizes the activity of unvested restricted stock: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Weighted&nbsp;Average</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled/Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(273,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled/Forfeited (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested and expected to vest at June 30, 2015 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">755,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of December&nbsp;31, 2014 and June 30, 2015 (unaudited), total unrecognized compensation cost was $2.9&nbsp;million
and $11.4 million related to unvested share-based compensation arrangements which is expected to be recognized over a weighted average period of 2.8 years and 3.5 years, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets forth the stock-based compensation expense included in the consolidated statements of operations (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;2013&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;2014&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;2014&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;2015&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sales, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>13. Common and Preferred Stock Repurchase </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s board of directors approved the repurchase of 70,612 shares of common stock, 45,000 stock options and 45,611 of preferred stock from
shareholders in May 2014 for $13.20 per share for a total purchase price of $2.0 million. For the repurchased shares of common stock and stock options, the Company charged the difference between the purchase and market prices of $0.5 million to
expense. For the repurchased preferred shares, the excess between the purchase and the issuance price of $0.5 million was treated as a deemed dividend. In addition, the Company closed a tender offer in July 2014 to repurchase shares of preferred
stock from existing shareholders at a purchase price of $13.20 per share. The Company repurchased 584,052 shares of preferred stock for a total purchase price of $7.7 million. The excess between the purchase and the issuance price of $5.8 million
was treated as a deemed dividend. The repurchased shares of common and preferred stock were retired and remained as authorized but unissued. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>14.&nbsp;Employee
Benefit Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company offers a retirement savings plan under Section&nbsp;401(k) of the Internal Revenue Code (the IRC) to its eligible U.S.
employees whereby they may contribute up to the maximum amount permitted by IRC. The retirement savings plan provides for employer contributions to be made at the discretion of the Company&#146;s board of directors. The Company has not provided any
such matching contributions through June 30, 2015. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>15. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company is incorporated in the United States and operates in various countries with differing tax laws and rates. A portion of the Company&#146;s
income or (loss) before taxes and the provision for income taxes are generated from international operations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Income or (loss) before income taxes
for the fiscal years ended December&nbsp;31, 2013 and 2014 is summarized as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="center"><B>Year Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;2013&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;2014&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total income (loss) before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Income tax provision in 2013 and 2014 is comprised of federal, state, and foreign taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>15. Income Taxes&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The components of the provision for (benefit from) income taxes are summarized as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;2013&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;2014&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,087</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,286</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s actual provision for tax differed from the amounts computed by applying the U.S. federal income tax
rate of 34% to pretax income as a result of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Income tax at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State income taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Foreign taxes differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">APB 51 prepaid tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Foreign exchange gains and losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">IRC 199 deduction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Meals and entertainment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>15. Income Taxes&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Deferred income tax assets and liabilities consist of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">UNICAP adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred income taxes, net - Balance Sheet Classification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current deferred income tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Long-term deferred income tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company assesses the realizability of its net deferred tax assets by evaluating all available evidence, both positive
and negative, including (1)&nbsp;cumulative results of operations in recent years, (2)&nbsp;sources of recent losses, (3)&nbsp;estimates of future taxable income and (4)&nbsp;the length of net operating loss carryforward periods. From inception
through 2012, the Company had determined that it was more likely than not that all of the net deferred tax assets would not be realized. As a result, the Company had recorded a full valuation allowance against those net deferred tax assets to reduce
them to their estimated net realizable value as of December&nbsp;31, 2012. As of December&nbsp;31, 2013, the Company determined that it is more likely than not that a portion of the net deferred tax assets will be realized for federal and U.S.
states except California and released the valuation allowance of $5.0&nbsp;million. The Company continued establishing a full valuation allowance against the net deferred tax assets of California, Germany, Australia and Canada. As of
December&nbsp;31, 2014, the Company determined that it is more likely than not that German net deferred tax assets will be realized and released the German valuation allowance of $0.3&nbsp;million. As a result, the Company has continued establishing
a full valuation allowance against the net deferred tax assets of California, Australia and Canada. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>15. Income Taxes&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The valuation allowance against net deferred tax assets changed as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance at December 31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Release of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other reserves and deferrals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance at December 31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Release of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other reserves and deferrals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance at December 31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">At December&nbsp;31, 2014, the Company had approximately $17.8 million and $2.0 million of state and foreign net
operating loss carryforwards, respectively, available to offset future taxable income. The state net operating loss carryforwards will begin to expire in 2017. At December&nbsp;31, 2014, the Company had research credits available to offset federal
and state tax liabilities in the amount of $0.7 million and $2.8 million, respectively. Federal credits will begin to expire in 2027 and California state tax credits have no expiration. As of December 31, 2014, the Company had fully used $22.6
million of federal net operating losses, which the Company had accumulated in its first six years of operations, from 2004 through 2009. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Internal
Revenue Code sections 382 and 383 limit the use of net operating losses and business credits if there is a change in ownership. In 2009, the Company determined there were changes in ownership in 2004 and 2008. As of December&nbsp;31, 2014, the
section 382 limitation has no impact on the Company&#146;s deferred tax assets prior to the valuation allowance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">As of December&nbsp;31, 2014, the
Company has $1.7 million in unrecognized tax benefits, of which $0.7&nbsp;million would affect the Company&#146;s effective tax rate if recognized. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">A reconciliation of the change in the gross unrecognized tax benefits from January&nbsp;1, 2013 to December&nbsp;31, 2014, is as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Beginning Balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross increase for tax positions of current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gross increase for tax positions of prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Settlements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lapse of statute of limitations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ending Balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of
December&nbsp;31, 2014, the Company had $69,000 accrued interest and penalties related to uncertain tax positions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company files U.S., state and
foreign income tax returns in jurisdictions with varying statutes of limitations. Due to net operating loss and credit carryovers, the tax years ending December&nbsp;31, 2004 through December 31, 2014 remain subject to examination by federal and
state tax authorities. In Australia and Canada, tax years ending December&nbsp;31, 2008 through December 31, 2014 generally remain subject to examination by tax authorities. In Germany, tax years ending December&nbsp;31, 2013 through December 31,
2014 remain subject to examination by tax authorities. As of December&nbsp;31, 2014, the Company is under examination by the German tax authority for tax years ending December 31, 2010 through December 31, 2012. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>15. Income Taxes&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company classifies its unrecognized tax benefits as non-current income taxes payable, as no amounts
are expected to be payable within the next 12 months. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>16. Net Income (Loss) per Share of Common Stock attributable to Common Stockholders and Unaudited Pro
Forma Net Income (Loss) per Share of Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">A reconciliation of the numerator and denominator used in the calculation of the basic and
diluted net income (loss) per share attributable to common stockholders is as follows (in thousands except share and per share amounts): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Net income (loss) per share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Numerator</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: Deemed dividend paid to preferred stockholders upon repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Less: Undistributed income (loss) attributable to preferred stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Add: Undistributed loss attributable to preferred stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net income (loss) attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Denominator</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average shares used to compute net income (loss) attributable to common stockholders<BR>&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,304,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,609,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,520,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Potential dilutive options, as calculated using treasury stock method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,101,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Potential dilutive common stock warrants, as calculated using treasury stock method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Potential dilutive restricted stock, as calculated using treasury stock method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average shares used to compute net income (loss) attributable to common stockholders &#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,500,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,609,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,743,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net income (loss) per share attributable to common stockholders<BR>&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>16. Net Income (Loss) per Share of Common Stock attributable to Common Stockholders and Unaudited Pro Forma Net Income (Loss) per Share of Common
Stock&nbsp;(Continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following outstanding shares of potentially dilutive securities were excluded from the computation
of diluted net income (loss) per share of common stock for the periods presented, because the effect of including them would have been anti-dilutive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months&nbsp;Ended&nbsp;June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,933,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,485,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">755,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,300,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">503,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,241,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">Unaudited pro forma basic and diluted income (loss) per share is computed as follows (in thousands, except share and per
share data): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma<BR>Six&nbsp;Months&nbsp;Ended<BR>June 30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Unaudited pro forma net income (loss) per share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Numerator</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net income (loss) used in computing pro forma net income (loss) per share attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Denominator</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted average shares used to compute net income (loss) attributable to common stockholders&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,609,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma adjustments to reflect weighted average effect of assumed automatic conversion of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,071,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,510,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Denominator for pro forma basic net income (loss) per share of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,680,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,510,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Potential dilutive options, as calculated using treasury stock method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,161,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Potential dilutive common stock warrants, as calculated using treasury stock method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Potential dilutive restricted stock, as calculated using treasury stock method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Denominator for pro forma diluted net income (loss) per share of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,037,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,510,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net income (loss) per share&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Pro forma net income (loss) per share&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Penumbra, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Notes to Consolidated Financial Statements&nbsp;(Continued) </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>17. Geographic Areas and Product Sales </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company&#146;s revenue by geographic area, based on the destination to which the Company ships its products, was as follows (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months&nbsp;Ended&nbsp;June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Japan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The following table sets forth revenue by product category (in thousands): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Neuro</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Peripheral Vascular</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company does not have significant long-lived assets outside the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>18. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:arial">The Company has evaluated subsequent
events that occurred after December&nbsp;31, 2014 through June 9, 2015, the date that the audited annual consolidated financial statements were issued, and determined that no additional subsequent events had occurred that would require recognition
in these consolidated financial statements and all material subsequent events that require disclosure have been disclosed. The Company has evaluated subsequent events and transactions for potential recognition or disclosure through August&nbsp;14,
2015, the date the unaudited interim financial statements were available to be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:arial" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </B></P>
<P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:14pt; font-family:arial" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g923792g60a08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:12pt; font-family:arial" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:70pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:arial; font-size:16pt">
<TD VALIGN="top"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>BofA Merrill Lynch</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:arial; font-size:12pt">
<TD VALIGN="top"><B>Wells Fargo Securities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Canaccord Genuity</B></TD></TR>
</TABLE> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2015 </P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;to&nbsp;Be&nbsp;Paid&#134;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NYSE listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advisory fees payable to Perella Weinberg Partners LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent&#146;s fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be completed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">The underwriters have agreed to reimburse us for certain expenses we incur in connection with this offering up to $1,325,000. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the amounts set forth above, other than the SEC registration fee and the FINRA filing fee, is an estimate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other
employees and individuals against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or
proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to the registrant. The Delaware General Corporation Law provides that Section&nbsp;145 is not exclusive of other
rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Article VIII of the registrant&#146;s certificate of incorporation provides for indemnification
by the registrant of its directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law. The registrant has entered into indemnification agreements with each of its current directors and executive officers
to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the registrant&#146;s amended and restated certificate of incorporation and amended and restated bylaws and
to provide additional procedural protections. There is no pending litigation or proceeding involving a director or executive officer of the registrant for which indemnification is sought. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a
director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the director&#146;s duty of loyalty to
the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;for unlawful payments of dividends or unlawful stock repurchases, redemptions or
other distributions, or (iv)&nbsp;for any transaction from which the director derived an improper personal benefit. The registrant&#146;s certificate of incorporation provides for such limitation of liability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registrant maintains standard policies of insurance under which coverage is provided (a)&nbsp;to its directors and officers against loss
rising from claims made by reason of breach of duty or other wrongful act, and (b)&nbsp;to the registrant with respect to payments which may be made by the registrant to such officers and directors pursuant to the above indemnification provision or
otherwise as a matter of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposed form of underwriting agreement filed as Exhibit 1 to this registration statement
provides for indemnification of directors and officers of the registrant by the underwriters against certain liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales
of Unregistered Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2012, the registrant has sold the following securities without registration under the
Securities Act of 1933: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Issuances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2014, we issued and sold an aggregate of 4,545,455 shares of our Series F preferred stock at a price of $13.20 per share to a
total of 38 accredited investors for aggregate consideration of $60,000,006. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Grants and Common Stock and Restricted Stock Issuances
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2012, we granted to our directors, officers, employees and consultants options to purchase an aggregate
of 1,866,550 shares of common stock under our equity compensation plans, at exercise prices ranging from $4.49 to $22.04 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
January&nbsp;1, 2012, we issued and sold to our directors, officers, employees and consultants an aggregate of 1,447,896 shares of common stock upon the exercise of options under our equity compensation plans at exercise prices ranging from $0.17 to
$7.75 per share, for an aggregate amount of approximately $2,287,008. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2012, we granted to our directors, officers
and employees an aggregate of 1,170,861&nbsp;shares of restricted stock under our equity compensation plans at a fair market value ranging from $4.49 to $22.04 per share, for an aggregate amount of approximately $12,936,290. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2012, we issued to our consultants an aggregate of 55,000 shares of common stock at a fair market value ranging from
$4.49 to $5.99 per share, for an aggregate amount of approximately $288,950. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2012, we issued and sold an aggregate
of 25,568 shares of common stock upon the exercise of warrants at an exercise price of $0.01 per share, for an aggregate amount of approximately $256. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2015, we issued 7,500 shares of restricted stock in connection with the acquisition of a privately held company at a fair market
value of $14.46 per share, for an aggregate amount of approximately $108,450. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will grant an option to purchase 450,000 shares of
common stock under our 2014 Equity Incentive Plan to our Chief Executive Officer at an exercise price equal to our initial public offering price, which options will vest over a period of four years from the date of the prospectus relating to this
offering. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public
offering. Unless otherwise stated, the sales of the above securities were deemed to be exempt from registration under the Securities Act in reliance upon Section&nbsp;4(a)(2) of the Securities Act (or Regulation D or Regulation S promulgated
thereunder) or Rule 701 promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. The
recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed
upon the stock certificates issued in these transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The following exhibits are filed as part of this registration statement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation of Penumbra, Inc., as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation of Penumbra, Inc., to be in effect upon completion of this offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Bylaws of Penumbra, Inc., as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of Penumbra, Inc., to be in effect upon completion of this offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Investors&#146; Rights Agreement, by and among Penumbra, Inc., Adam Elsesser and Arani Bose and the investors listed on Exhibit A thereto, dated May&nbsp;16, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Davis Polk &amp; Wardwell LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease for facilities at 1351 Harbor Bay Parkway, Alameda, California, dated November&nbsp;28, 2007 and amended on May&nbsp;7, 2008 and June&nbsp;23, 2011</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease for facilities at 1411 Harbor Bay Parkway, Alameda, California, dated September&nbsp;11, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease for facilities at 1321 Harbor Bay Parkway, Alameda, California, dated September&nbsp;11, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Distribution Agreement between Penumbra, Inc. and Medico&#146;s Hirata, dated August&nbsp;2, 2009, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2014 Equity Incentive Plan, and forms of Restricted Stock Agreement, Stock Option Agreement and Early Exercise Stock Option Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2011 Equity Incentive Plan, and forms of Restricted Stock Agreement, Stock Grant Agreement, Stock Option Agreement and Early Exercise Stock Option Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2005 Stock Plan, and forms of Notice of Grant and Early Exercise Stock Option Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement by and between Penumbra, Inc. and each of its directors and executive officers, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement by and between Penumbra, Inc. and each of its directors and executive officers, to be in effect immediately prior to the consummation of the offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Adam Elsesser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Arani Bose</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Sri Kosaraju</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Daniel Davis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with James Pray</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Lynn Rothman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Robert Evans</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Employee Nondisclosure and Assignment Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2015 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated 2014 Equity Incentive Plan, and forms of Restricted Stock Agreement, Stock Option Agreement and Early Exercise Stock Option Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Engagement Letter between the Penumbra, Inc. and Perella Weinberg Partners LP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Independent Registered Public Accounting Firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Davis Polk &amp; Wardwell LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Financial Statement Schedules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All financial statement schedules are omitted because the information called for is not required or is shown either in the consolidated
financial statements or in the notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreement
certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the provisions referenced in Item&nbsp;14 of this registration statement, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is
against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or
controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Act and will be
governed by the final adjudication of such issue. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The undersigned registrant hereby undertakes that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a
form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Alameda, State of California, on the 31st day of August, 2015. </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>PENUMBRA, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam Elsesser</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Adam Elsesser</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman, Chief Executive Officer and President</TD></TR>
</TABLE></DIV>   <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been
signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam Elsesser</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Adam Elsesser</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman, Chief Executive Officer and President (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;31,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sri Kosaraju</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sri Kosaraju</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer and Head of Strategy (Principal Financial and Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;31, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Arani Bose,
M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Innovator and Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;31, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Don
Kassing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;31, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Walter
Wang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;31,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Harpreet
Grewal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August&nbsp;31, 2015</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Adam Elsesser</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam Elsesser</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attorney-in-fact</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation of Penumbra, Inc., as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation of Penumbra, Inc., to be in effect upon completion of this offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Bylaws of Penumbra, Inc., as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of Penumbra, Inc., to be in effect upon completion of this offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Investors&#146; Rights Agreement, by and among Penumbra, Inc., Adam Elsesser and Arani Bose and the investors listed on Exhibit A thereto, dated May&nbsp;16, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Davis Polk &amp; Wardwell LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease for facilities at 1351 Harbor Bay Parkway, Alameda, California, dated November&nbsp;28, 2007 and amended on May&nbsp;7, 2008 and June&nbsp;23, 2011</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease for facilities at 1411 Harbor Bay Parkway, Alameda, California, dated September&nbsp;11, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease for facilities at 1321 Harbor Bay Parkway, Alameda, California, dated September&nbsp;11, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Distribution Agreement between Penumbra, Inc. and Medico&#146;s Hirata, dated August&nbsp;2, 2009, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2014 Equity Incentive Plan, and forms of Restricted Stock Agreement, Stock Option Agreement and Early Exercise Stock Option Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2011 Equity Incentive Plan, and forms of Restricted Stock Agreement, Stock Grant Agreement, Stock Option Agreement and Early Exercise Stock Option Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2005 Stock Plan, and forms of Notice of Grant and Early Exercise Stock Option Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement by and between Penumbra, Inc. and each of its directors and executive officers, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement by and between Penumbra, Inc. and each of its directors and executive officers, to be in effect immediately prior to the consummation of the offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Adam Elsesser</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Arani Bose</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Sri Kosaraju</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Daniel Davis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with James Pray</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Lynn Rothman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter with Robert Evans</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Employee Nondisclosure and Assignment Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2015 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated 2014 Equity Incentive Plan, and forms of Restricted Stock Agreement, Stock Option Agreement and Early Exercise Stock Option Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Engagement Letter between the Penumbra, Inc. and Perella Weinberg Partners LP</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Independent Registered Public Accounting Firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Davis Polk &amp; Wardwell LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>2
<FILENAME>d923792dex1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.18</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.18 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PENUMBRA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 1<I>. Purpose of the Plan.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of this Penumbra, Inc. Employee Stock Purchase Plan (the &#147;<B>Plan</B>&#148;) is to provide Eligible Employees (as defined
below) with an opportunity to acquire an equity interest in Penumbra, Inc. (the &#147;<B>Company</B>&#148;) by purchasing shares of the Company&#146;s common stock (the &#147;<B>Stock</B>&#148;) in a convenient manner. This Plan is intended to
qualify under Section 423 of the Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;). This Plan is effective on the the effective date of the registration statement on Form S-1 (the &#147;<B>Registration Statement</B>&#148;)
filed by the Company with the Securities and Exchange Commission for its initial offering of Stock to the public (the &#147;<B>Effective Date</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 2<I>. Administration of the Plan.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Committee Composition</U>. The Plan shall be administered by the Board of Directors (the &#147;<B>Board</B>&#148;) or by a committee of
the Board designated to administer this Plan (the &#147;<B>Committee</B>&#148;). Unless otherwise determined by the Board, the Compensation Committee of the Board shall be the &#147;Committee&#148; hereunder. To the extent permitted by law, the
Committee may delegate responsibilities for day-to-day administration of the Plan to one or more officers of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Committee Responsibilities</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Committee shall interpret the Plan and make all other policy decisions relating
to the operation of the Plan. The Committee may adopt such rules, guidelines and forms as it deems appropriate to implement the Plan. The Committee&#146;s determinations under the Plan shall be final and binding on all persons. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Committee may determine the Participating Companies hereunder from time to time. A &#147;<B>Participating
Company</B>&#148; means (i) the Company and (ii) each present or future Subsidiary designated by the Committee as a Participating Company. A &#147;<B>Subsidiary</B>&#148; means a &#147;subsidiary corporation&#148; of the Company as defined in
Section 424(f) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 3. <I>Enrollment and Participation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Offering Periods</U>. An &#147;<B>Offering Period</B>&#148; means a period with respect to which the right to purchase Stock may be
granted under the Plan, as determined pursuant to this Section 3(a). Unless and until otherwise determined by the Committee, two Offering Periods shall commence in each calendar year on each May 20 and November 20, and each Offering Period shall
consist of one Purchase Period; provided, however, that the first Offering Period under the Plan will commence on the Effective Date and will end on May 19, 2016, and the second Offering Period under the Plan will commence
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on May 20, 2016, and end on November 19, 2016. The duration and timing of Offering Periods may be changed pursuant to Sections 4 and 20.. The Committee may change the duration of Offering Periods
if such change is announced prior to the scheduled beginning of the first Offering Period to be affected; <I>provided</I> that no Offering Period may be longer than 27 months. An &#147;<B>Offering Date</B>&#148; means the first day of each Offering
Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Purchase Periods</U>. A &#147;<B>Purchase Period</B>&#148; means a period during which contributions may be made toward
the purchase of Stock under the Plan, as determined pursuant to this Section 3(b). Unless and until otherwise determined by the Committee, the Purchase Periods shall consist of the six-month periods commencing on each May 20 and November 20 and
ending on November 19 and May 19, respectively; provided, however, that the first Purchase Period under the Plan will commence on the Effective Date and will end on May 19, 2016, and the second Purchase Period under the Plan will commence on May 20,
2016, and end of November 19, 2016. The Committee may change the duration and timing of Purchase Periods at any time if such change is announced prior to the scheduled beginning of the first Purchase Period to be affected; <I>provided</I> that no
Purchase Period may be longer than 27 months. A &#147;<B>Purchase Date</B>&#148; means the last day of each Purchase Period (or, if such day is not a trading day, the trading day immediately preceding such day). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Eligibility and Enrollment</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) An &#147;<B>Eligible Employee</B>&#148; means any employee of a Participating Company; <I>provided</I> that the Committee,
in its discretion, from time to time (i) may determine that Eligible Employees who customarily work twenty (20) hours or less per week or not more than five (5) months in any calendar year (or, in each case, such lesser period of time as may be
determined by the Committee in its discretion) shall not be included in the Plan or an Offering Period and (ii) may exclude employees that fall into an excludable category as described in Section 423 of the Code and the regulations thereunder. The
foregoing notwithstanding, an individual shall not be considered an Eligible Employee if his or her participation in the Plan is prohibited by the law of any country that has jurisdiction over him or her or if complying with the laws of the
applicable jurisdiction would cause the Plan or an Offering Period to violate Section 423 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Any individual
who, on the day preceding the first day of an Offering Period, qualifies as an Eligible Employee may elect to become a participant in the Plan for such Offering Period by, prior to the commencement of such Offering Period, following the procedures
specified by the Company in the manner and by the deadline specified by the Company from time to time. An Eligible Employee who so elects to participate in the Plan is referred to herein as a &#147;<B>Participant</B>&#148;. The Company shall
establish an account on its books for each such Participant (a &#147;<B>Plan Account</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Notwithstanding the
foregoing, any individual who is an Eligible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Employee immediately prior to the first Offering Period will be automatically enrolled in the first Offering Period. Any such Eligible Employee will be entitled to continue to participate in the
first Offering Period only if such individual submits a subscription form in the form prescribed by the Company (i) no earlier than the effective date of the Form S-8 registration statement with respect to the issuance of Stock under this Plan and
(ii) no later than ten (10) business days following the effective date of such S-8 registration statement or such other period of time as the Administrator may determine (the &#147;<B>Initial Enrollment Period</B>&#148;). An Eligible Employee&#146;s
failure to submit the subscription form during the Initial Enrollment Period will result in the automatic termination of such individual&#146;s participation in the first Offering Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Duration of Participation</U>. Once enrolled in the Plan, a Participant shall continue to participate in the Plan until he or she
ceases to be an Eligible Employee or withdraws from the Plan under Section 5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 4<I>. Participant Contributions.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Frequency of Payroll Deductions</U>. A Participant may purchase shares of Stock under the Plan solely by means of payroll deductions.
Payroll deductions, as designated by the Participant pursuant to Subsection (b) below, shall occur on each payday during participation in the Plan; <I>provided</I> that for the first Offering Period, payroll deductions will commence on the first
payday on or following the end of the Initial Enrollment Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Amount of Payroll Deductions</U>. As part of the enrollment
procedures described in Section 3(c) above, an Eligible Employee shall designate the portion of his or her Compensation (as defined below) that he or she elects to have withheld on each payday during the applicable Purchase Period for the purchase
of Stock. Such portion shall be a whole percentage of the Eligible Employee&#146;s Compensation, but not less than 1% nor more than 15%. For purposes of this Plan, &#147;<B>Compensation</B>&#148; means all base straight-time gross earnings,
exclusive of commissions, payments for incentive compensation, bonuses, overtime, shift premium and other similar compensation, unless otherwise determined by the Committee on a uniform and nondiscriminatory basis; <I>provided</I> that the Committee
shall have the discretion to determine the application of this definition to Participants outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Changing
Withholding Rate</U>. Unless otherwise specified by the Company prior to any Purchase Period: (i) if a Participant wishes to increase or decrease the rate of payroll withholding to be effective for the next Purchase Period, he or she may do so,
subject to the limits set forth in clause (b) above, by following the procedures specified by the Company in the manner and by the deadline specified by the Company from time to time; and (ii) if a Participant wishes to decrease the rate of payroll
withholding to be effective during an ongoing Purchase Period, he or she may do so one (1) time during a Purchase Period by following the procedures specified by the Company in the manner and by the deadline specified by the Company from time to
time; <I>provided</I> that such decreased withholding rate shall be subject to the limits set forth in clause (b) above unless otherwise determined by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 5<I>. Withdrawal from the Plan.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Withdrawal</U>. A Participant may elect to withdraw from the Plan by following the procedures specified by the Company in the manner
and by the deadline specified by the Company from time to time. As soon as reasonably practicable thereafter, payroll deductions shall cease and the entire amount credited to the Participant&#146;s Plan Account shall be refunded to him or her in
cash, without interest. No partial withdrawals shall be permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Re-enrollment After Withdrawal</U>. A former Participant who
has withdrawn from the Plan shall not be a Participant until he or she re-enrolls in the Plan under Section 3(c). Re-enrollment may be effective only at the commencement of the next Offering Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 6<I>. Change in Employment Status.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination of Employment</U>. Termination of employment as an Eligible Employee for any reason, including death, shall be treated as
an automatic withdrawal from the Plan under Section 5(a). A transfer of employment from one Participating Company to another Participating Company shall not be treated as a termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Leave of Absence</U>. For purposes of the Plan, and to the extent consistent with Section 423 of the Code, employment shall not be
deemed to terminate when the Participant goes on a military leave, a sick leave or another bona fide leave of absence approved by the Participating Company so long as the leave does not exceed three months or, if longer than three months, the
individual&#146;s right to reemployment is provided by statute or has been agreed to by contract or in a written policy of the Company which provides for a right of reemployment following the leave of absence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Death</U>. In the event of the Participant&#146;s death, the amount credited to his or her Plan Account shall be paid to a beneficiary
designated by him or her for this purpose on the prescribed form or, if none, to the Participant&#146;s estate. Such form shall be valid only if, before the Participant&#146;s death, it was filed with the Company in accordance with the
Company&#146;s procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 7<I>. Plan Accounts and Purchase of Shares.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Plan Accounts</U>. The Company shall maintain a Plan Account on its books in the name of each Participant. Whenever an amount is
deducted from the Participant&#146;s Compensation under the Plan, such amount shall be credited to the Participant&#146;s Plan Account. Amounts credited to Plan Accounts shall not be trust funds and may be commingled with the Company&#146;s general
assets and applied to general corporate purposes. No interest shall be credited to Plan Accounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Purchase Price</U>. The &#147;<B>Purchase Price</B>&#148; means the price at which
Participants may purchase a share of Stock under the Plan, which unless otherwise determined by the Committee, shall be the lower of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) 85% of the Fair Market Value of a share of Stock on the Purchase Date; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) 85% of the Fair Market Value of a share of Stock on the Offering Date (of, if the Offering Date, other than for the first
Offering Period, is not a trading day, on the first trading day following the Offering Date); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that the &#147;Fair Market Value&#148;
shall be equal to the closing price of the Stock on the stock exchange on the date in question or, if the foregoing provision is not applicable, then as determined by the Committee in good faith on such basis as it deems appropriate; <I>provided
further</I> that for purposes of the first Offering Period, the &#147;Fair Market Value&#148; will be the initial price to the public as set forth in the final prospectus included within the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Number of Shares Purchased</U>. As of each Purchase Date, each Participant shall be deemed to have elected to purchase the number of
shares of Stock calculated in accordance with this Plan, unless the Participant has previously elected to withdraw from the Plan in accordance with Section 5(a). Subject to the limits set forth in Section 8 below, the amount then in the
Participant&#146;s Plan Account shall be divided by the Purchase Price, and the number of shares that results shall be purchased with the funds in the Participant&#146;s Plan Account. The Committee may determine with respect to all Participants that
any fractional share, as calculated under this subsection (c), shall be (i) rounded down to the next lower whole share or (ii) credited as a fractional share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Available Shares Insufficient</U>. In the event that the aggregate number of shares that all Participants elect to purchase during an
Purchase Period exceeds the maximum number of shares remaining available for issuance under Section 13(a), then the number of shares to which each Participant is entitled shall be determined by multiplying the number of shares available for issuance
by a fraction, the numerator of which is the number of shares that such Participant has elected to purchase and the denominator of which is the number of shares that all Participants have elected to purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Delivery of Shares</U>. By enrolling in the Plan, each Participant shall be deemed to have authorized the establishment of a brokerage
account on his or her behalf at a securities brokerage firm selected by the Committee. Alternatively, the Committee may provide for a Plan share account for each Participant to be established by the Company or by an outside entity selected by the
Company which is not a brokerage firm. As soon as reasonably practicable after each Purchase Date, the Company shall arrange for the delivery to each Participant of the shares purchased hereunder to the Participant&#146;s brokerage or Plan share
account in a form determined by the Company. Notwithstanding any other provision of the Plan, unless otherwise determined by the Committee or required by any applicable law, rule or regulation, the Company shall not deliver to any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant certificates evidencing shares issued in connection with any purchase under the Plan, and instead such shares shall be recorded in the books of the brokerage firm selected by the
Company or, as applicable, the Company, its transfer agent, stock plan administrator or such other outside entity which is not a brokerage firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Unused Cash Balances</U>. Following the end of any Purchase Period, any amount remaining in the Participant&#146;s Plan Account shall,
at the discretion of the Committee, either be refunded to the Participant in cash, without interest, or be retained in the Participant&#146;s Plan Account for the next Purchase Period but only to the extent representing the unused Purchase Price for
fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Stockholder Approval</U>. Any other provision of the Plan notwithstanding, no shares of Stock shall be
purchased under the Plan unless and until the Company&#146;s stockholders have approved the adoption of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 8<I>.
Limitations on Stock Purchases Under the Plan.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Share Limit</U>. With respect to any Purchase Period, no Participant shall
purchase more than 2,000 shares of Stock (or such other number of shares of Stock as may be determined by the Committee prior to the start of any Purchase Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Dollar Limit</U>. No Participant shall be granted a purchase right under the Plan which permits his or her rights to purchase stock
under all employee stock purchase plans under Section 423 of the Code of the Company and its Subsidiaries to accrue at a rate which exceeds $25,000 of fair market value of such stock (determined at the time the purchase right is granted) for each
calendar year in which such purchase right is outstanding at any time, as determined under Section 423 of the Code and the applicable rules and regulations thereunder. If a Participant is precluded by this subsection (b) from purchasing additional
Stock under the Plan, then his or her employee contributions shall automatically be discontinued and shall resume at the beginning of the earliest Purchase Period ending in the next calendar year (if he or she then is an Eligible Employee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Limit on Five Percent Holders</U>. Any other provision of the Plan notwithstanding, no Participant shall be granted a right to purchase
Stock under the Plan if such Participant, immediately after his or her election to purchase such Stock, would own stock and/or hold outstanding purchase rights to purchase stock possessing 5% or more of the total combined voting power or value of
all classes of stock of the Company or any parent or Subsidiary of the Company, determined pursuant to Section 423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section
9<I>. Rights Not Transferable.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of any Participant under the Plan, or any Participant&#146;s interest in any Stock or
moneys to which he or she may be entitled under the Plan, shall not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transferable by voluntary or involuntary assignment or by operation of law, or in any other manner other than by beneficiary designation or the laws of descent and distribution. If a Participant
in any manner attempts to transfer, assign or otherwise encumber his or her rights or interest under the Plan, other than by beneficiary designation or the laws of descent and distribution, then such act shall be treated as an election by the
Participant to withdraw from the Plan under Section 5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 10<I>. No Rights as an Employee.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing in the Plan or in any right granted under the Plan shall confer upon the Participant any right to continue in the employ of a
Participating Company for any period of specific duration or interfere with or otherwise restrict in any way any rights of the Participating Companies or of the Participant to terminate his or her employment at any time and for any reason, with or
without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 11<I>. No Rights as a Stockholder.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Participant shall have no rights as a stockholder with respect to any shares of Stock that he or she may have a right to purchase under the
Plan until such shares have been purchased on the applicable Purchase Date and issued to the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 12<I>. Securities Law
Requirements.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Stock shall not be issued under the Plan unless the issuance and delivery of such shares comply with (or are
exempt from) all applicable requirements of law, including (without limitation) the Securities Act of 1933, as amended, the rules and regulations promulgated thereunder, state securities laws and regulations, and the regulations of any stock
exchange or other securities market on which the Company&#146;s securities may then be traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 13<I>. Stock Offered under the
Plan.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Authorized Shares</U>. The aggregate number of shares of Stock available for purchase under the Plan as of the Effective
Date shall be 600,000 subject to adjustment pursuant to Section 13(b). The number of Shares available for issuance under the Plan will be increased on the first day of each fiscal year of the Company beginning with the 2016 fiscal year and ending
with the 2025 fiscal year, in an amount equal to the least of (i) 500,000 Shares, (ii) 1% of the outstanding Shares on the last day of the immediately preceding fiscal year or (iii) such number of Shares determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Antidilution Adjustments</U>. The aggregate number of shares of Stock offered under the Plan, the share limitation described in Section
8(a) and the price of shares that any Participant has elected to purchase shall be adjusted proportionately by the Committee for any increase or decrease in the number of outstanding shares of Stock resulting from a subdivision or consolidation of
shares or the payment of a stock dividend, any other increase or decrease in such shares effected without receipt or payment of consideration by the Company, the distribution of the shares of a Subsidiary to the Company&#146;s stockholders or a
similar event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Reorganizations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Corporate Reorganization</B>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) The consummation of a merger or consolidation of the Company with or into another entity, or any other corporate
reorganization; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) The sale, transfer or other disposition of all or substantially all of the Company&#146;s assets or
the complete liquidation or dissolution of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Any other provision of the Plan notwithstanding, prior to the
effective time of a Corporate Reorganization, any Offering Period and Purchase Period then in progress shall terminate and shares shall be purchased pursuant to Section 7 on a date prior to such effective time as determined by the Committee in its
sole discretion, unless the Plan is continued by the Company or assumed by the surviving corporation or its parent corporation pursuant to the plan of merger or consolidation. The Plan shall in no event be construed to restrict in any way the
Company&#146;s right to undertake a dissolution, liquidation, merger, consolidation or other reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section 14<I>. Amendment or
Discontinuance.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board or the Committee shall have the right to amend, suspend or terminate the Plan at any time and without
notice. Except as provided in Section 13, any increase in the aggregate number of shares of Stock to be issued under the Plan shall be subject to approval by a vote of the stockholders of the Company, and no amendment shall be made which shall allow
a Purchase Price for offerings under the Plan to be less than the lower of (i) 85% of the Fair Market Value on the Offering Date or (ii) 85% of the Fair Market Value on the Purchase Date. The Committee may adopt and amend stock purchase sub-plans
with respect to employees of non-U.S. Subsidiaries with such provisions as the Committee may deem appropriate to conform with local laws, practices and procedures. All such sub-plans shall be subject to the limitations on the amount of Stock that
may be issued under the Plan and, except to the extent otherwise provided in such sub-plans, shall be subject to all of the provisions set forth herein but shall be considered separate offerings under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>d923792dex1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.20</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.20 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Perella Weinberg Partners Letterhead] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">June&nbsp;5, 2015 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PERSONAL AND CONFIDENTIAL
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Penumbra, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Penumbra Way </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alameda, CA 94502 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Adam Elsesser, Chief Executive
Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Adam: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Perella Weinberg
Partners LP (&#147;we&#148; or &#147;Perella Weinberg Partners&#148;) is pleased to confirm the arrangements under which it is engaged to act as exclusive capital markets advisor to Penumbra, Inc. (&#147;you&#148; or the &#147;Company&#148;), in
connection with a potential initial public offering of the Company&#146;s equity securities (an &#147;IPO&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Services to be
Rendered</U>. During the term of our Engagement we will provide you with a range of advisory services including but not limited to the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">review the business and operations of the Company and its historical and projected financial condition; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">perform an independent financial valuation analysis; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">assist the Company in its review of potential financing alternatives; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">assist the Company in presenting financing alternatives, execution considerations and valuation analyses to the Company&#146;s board of directors; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">assist in drafting the positioning and investment thesis for the Company; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">assist the Company in identifying appropriate underwriters for an IPO syndicate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">assist the Company in negotiating the economic terms with such underwriters and/or pre-IPO investors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">assist the Company in coordinating diligence sessions for underwriters; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">assist the Company in crafting an appropriate aftermarket trading, investor relations and monetization strategy. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Compensation</U>. As compensation for our services, the Company agrees to pay us in cash, by wire transfer of immediately available
funds when due, an &#147;IPO Advisory Fee&#148; in the amount of $1,250,000 payable promptly upon completion of an IPO. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Penumbra,Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Expenses</U>. In addition to our fees for professional services, the Company agrees that it will promptly reimburse us for all of our
reasonable, documented, out-of-pocket expenses (including, but not limited to, professional and external legal fees (not to exceed $25,000), charges and disbursements of our legal counsel, any sales, use or similar taxes (including additions to such
taxes, if any) arising in connection with any matter referred to in this letter, travel and hotel expenses, printing costs, data processing and communication charges, research expenses and courier and postage services); provided that the Company
shall not be obligated to reimburse us for any expenses allocated to us as our pro rata share of syndicate expenses. The Company&#146;s obligation to reimburse expenses incurred by us in connection with the Engagement will survive the completion or
termination of the Engagement. Nothing in this Section&nbsp;3 shall modify or otherwise affect the Company&#146;s obligations set forth in Annex A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Confidentiality</U>. The Company may not disclose, summarize, excerpt from or otherwise refer to any advice rendered by us, whether
formal or informal, without our prior written consent. In addition, the Company may not refer to our name or the terms of our Engagement without our prior written consent. The Company&#146;s obligations under this paragraph will survive the
completion or termination of the Engagement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not be providing the Company with, and the Company will not look to us for, tax,
legal or accounting advice and we agree that nothing in this letter is intended to impose any conditions of confidentiality within the meaning of Section&nbsp;6111 of the Internal Revenue Code of 1986, as amended, or US Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.6011-4</FONT> and the Company may disclose to any and all persons, without limitation of any kind, the United States tax treatment (federal, state and local) and tax structure of any transaction and all
materials of any kind relating to such tax treatment and tax structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Information</U>. In connection with our Engagement, the
Company will provide us with reasonable access to the Company&#146;s officers, directors, employees, accountants, legal advisors, and other representatives (collectively, &#147;Representatives&#148;), and will furnish us and cause its
Representatives to furnish us, with such information as we reasonably believe appropriate to our assignment (all such information so furnished being the &#147;Information&#148;). The Company recognizes and confirms that we (i)&nbsp;will use and rely
primarily on the Information and on information available from generally recognized public sources in performing our services without having independently verified the same, (ii)&nbsp;do not assume responsibility for the accuracy or completeness of
the Information and such other information, (iii)&nbsp;will not make an independent evaluation or appraisal of any assets or liabilities of the Company or any other party and (iv)&nbsp;with respect to any financial forecasts that may be provided to
or discussed with us, we will assume that they have been reasonably prepared and reflect the best then currently available estimates and judgment of your management. To the best of the Company&#146;s knowledge, the information to be furnished by the
Company and its Representatives, when delivered, will be true and correct in all material respects and will not contain any material misstatement of fact or omit to state any material fact necessary to make the statements contained therein not
misleading. The Company will promptly notify us if it learns of any material inaccuracy or misstatement in, or material omission from, any Information theretofore delivered to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Penumbra,Inc. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Indemnification</U>. The Company acknowledges that we have been retained hereunder
solely as an independent contractor and that nothing in this letter or the nature of our services shall be deemed to create a fiduciary or agency relationship between us and the Company or its equity holders, employees or creditors. In order to
induce us to accept the Engagement, the Company agrees to the indemnity and exculpation provisions and other matters set forth in Annex A, which forms a part of and is incorporated by reference into this letter. Prior to entering into any agreement
or arrangement with respect to, or effecting, any proposed sale, exchange, dividend or other distribution or liquidation of all or a significant portion of its assets in one or a series of transactions or any significant recapitalization or
reclassification of its outstanding securities that does not directly or indirectly provide for the assumption of the obligations of the Company set forth in Annex A, the Company will notify Perella Weinberg Partners in writing thereof (if not
previously so notified) and, if requested by Perella Weinberg Partners, shall arrange in connection therewith alternative means of providing for the obligations of the Company set forth in Annex A, including the assumption of such obligations by
another party, insurance, surety bonds or the creation of an escrow, in each case, in an amount and upon terms and conditions reasonably satisfactory to Perella Weinberg Partners and the Company; provided, however that none of the foregoing shall
apply where such obligations would be assumed by operation of law. The terms and provisions of this Section&nbsp;7 and of Annex A shall survive the completion or termination of the Engagement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Termination</U>. Our services hereunder may be terminated with or without cause by you or by us at any time and without liability or
continuing obligation to you or to us; provided, however, that no termination of our Engagement shall modify or affect (i)&nbsp;the Company&#146;s obligation to pay our fees and to pay or reimburse expenses through the effective date of termination
and (ii)&nbsp;the Company&#146;s other obligations hereunder, all of which shall survive the termination of our Engagement; and provided, further, that we shall be entitled to be paid the full amount of our IPO Advisory Fee if, within two years of
such termination (the &#147;Tail Period&#148;), an IPO has been completed; provided, however that the Tail Period will not survive if Perella Weinberg Partners terminates the agreement without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Other Perella Weinberg Partners Activities</U>. Perella Weinberg Partners is a financial services firm engaged directly and through its
affiliates in investment banking, financial advisory services, investment management, asset management and other advisory services and sponsors special purpose acquisition vehicles. The Company understands and acknowledges that in performing the
Engagement we will not be under any duty to disclose to the Company, or use for the benefit of the Company, any confidential or non-public information obtained by us or our affiliates in the course of providing services to any other person or
engaging in any other transaction (including as principal) or business activities. In the ordinary course of business activities, Perella Weinberg Partners LP or its affiliates or their respective personnel may at any time hold long or short
positions, and may trade or otherwise effect transactions, for its or their own accounts or the accounts of customers, in debt or equity or other securities (or related derivative securities) or financial instruments (including bank loans or other
obligations) of the Company or any other party to a Transaction or any of their respective affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Penumbra,Inc. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Regulation Relating to Client Identification</U>. Federal law and regulations require
financial institutions to obtain, verify and record information that identifies each person with whom they do business prior to doing such business and to provide reasonable notice to such persons that the financial institution is verifying such
person&#146;s identity. Accordingly, the Company will provide Perella Weinberg Partners, as necessary and upon request, certain identifying information, including, but not limited to, a government-issued identification number (e.g., a U.S. taxpayer
identification number) and certain other information or documents necessary to verify the Company&#146;s identity, such as certified corporate documentation, partnership agreement or trust instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Other Advisors</U>. It is understood that no Indemnified Person, as defined herein in Annex A, shall have any responsibility or
liability to the Company or its affiliates or any other party in connection with the advice, opinions or actions of any other advisor, or any other party that is or may be engaged by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Public Announcements</U>. The Company acknowledges that we may, at our option and expense and after the completion of an IPO, place
announcements and advertisements or otherwise publicize such transaction and our role in it (which may include the reproduction of the Company&#146;s logo and a hyperlink to the Company&#146;s website) on our internet website and in such financial
and other newspapers and journals as we may choose, stating that we acted as financial advisor to the Company in connection with the Transaction. The Company agrees that we shall be named as a financial advisor in any public SEC filing or press
release issued in connection with the Transaction (other than a &#147;Rule 134 or 135 release&#148;); provided that, without our consent, the Company will not publicly disclose the amount of fees received by us in connection with an IPO, except, as
may be required by the SEC, FINRA or other regulatory authority or a court of competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Authorization</U>. The
Company acknowledges its agreement with the terms set forth herein, and acknowledges that the Company has reviewed and agreed to be bound by the terms hereof, and that the Company has all requisite power and authority to enter into this letter
agreement on behalf of itself, and has been duly and validly authorized to do so, as evidenced by the signatures affixed hereto. Facsimile signatures shall be deemed original, binding signatures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Governing Law</U>. All aspects of the relationship created by this letter (including Annex A) shall be governed by and construed in
accordance with the laws of the State of New York, applicable to agreements made and to be performed entirely in such state. All actions and proceedings arising out of or relating to the letter shall be heard and determined exclusively in the U.S.
District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court located in the City of New York, to whose jurisdiction each party hereby irrevocably submits. Each party hereby
irrevocably waives any defense or objection to the New York forum designated above. Each of Perella Weinberg Partners and the Company (on its own behalf and, to the extent permitted by law, on behalf of its shareholders) waives all right to trial by
jury in any action, suit, proceeding or counterclaim (whether based upon contract, tort or otherwise) related to or arising out of the Engagement or the performance by Perella Weinberg Partners of the services contemplated by this letter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Penumbra,Inc. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are delighted to accept the Engagement and look forward to working with you on this
assignment. Please confirm your agreement to the foregoing by signing and returning to us the enclosed duplicate of this letter which then will be a binding agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PERELLA WEINBERG PARTNERS LP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Philippe McAuliffe</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Philippe McAuliffe</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Partner</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreed and accepted as of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the date first set forth above: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Penumbra, Inc. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam Elsesser</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Adam Elsesser</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Penumbra,Inc. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annex A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Company agrees to indemnify and hold harmless Perella Weinberg Partners and its affiliates and its and their respective officers,
directors, partners, members, employees, consultants and agents and each other person, if any, controlling Perella Weinberg Partners or any of its affiliates (Perella Weinberg Partners and each such other person being an &#147;<U>Indemnified
Person</U>&#148;) from and against any losses, claims, damages or liabilities related to, or arising out of or in connection with our engagement or any matter referred to in this letter (the &#147;<U>Engagement</U>&#148;), and will reimburse each
Indemnified Person for all expenses (including reasonable fees, charges and disbursements of counsel) as they are incurred in connection with investigating, preparing, pursuing or defending any action, claim, suit, investigation or proceeding
related to, arising out of or in connection with the Engagement, whether or not pending or threatened and whether or not any Indemnified Person is a party; provided, however, that the Company will not be responsible for any losses, claims, damages
or liabilities (or expenses relating thereto) that are finally judicially determined to have resulted primarily from the bad faith, gross negligence or willful misconduct of any Indemnified Person. The Company also agrees that no Indemnified Person
shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with the Engagement, except for any such liability for losses, claims, damages or liabilities incurred by the Company that
are finally judicially determined to have resulted primarily from the bad faith, gross negligence or willful misconduct of such Indemnified Person. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Company, or any of its affiliates, will not, without Perella Weinberg Partners&#146; prior written consent, settle, compromise, consent
to the entry of any judgment in or otherwise seek to terminate any action, claim, suit, investigation or proceeding in respect of which indemnification, reimbursement or contribution may be sought hereunder (whether or not any Indemnified Person is
a party thereto), nor will the Company or any of its affiliates participate in or facilitate any such settlement, compromise, consent or termination on behalf of the Company&#146;s board of directors (or similar governing body) unless such
settlement, compromise, consent or termination includes a full release of each Indemnified Person from any and all liabilities arising out of such action, claim, suit, investigation or proceeding. No Indemnified Person seeking indemnification,
reimbursement or contribution under this <U>Annex A</U> will, without the Company&#146;s prior written consent, settle, compromise, consent to the entry of any judgment in or otherwise seek to terminate any action, claim, suit, investigation or
proceeding referred to in the preceding paragraph. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If the indemnification provided for in the first paragraph of this <U>Annex
A</U> is, for any reason not available to an Indemnified Person or is insufficient to hold an Indemnified Person harmless in respect of any losses, claims, damages or liabilities referred to herein, then, in lieu of indemnifying such Indemnified
Person hereunder, the Company shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (and expenses relating thereto) (a)&nbsp;in such proportion as is appropriate to
reflect the relative benefits to Perella Weinberg Partners, </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Penumbra,Inc. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
on the one hand, and the Company, on the other hand, of the Engagement or (b)&nbsp;if the allocation provided by clause (a)&nbsp;above is not available, in such proportion as is appropriate to
reflect not only the relative benefits referred to in such clause (a)&nbsp;but also the relative fault of each of Perella Weinberg Partners and the Company, as well as any other relevant equitable considerations; provided, however, to the extent
permitted by applicable law, in no event shall Perella Weinberg Partners&#146; aggregate contribution to the amount paid or payable exceed the aggregate amount of fees actually received by Perella Weinberg Partners under this letter. For the
purposes of this <U>Annex A</U>, the relative benefits to Perella Weinberg Partners and the Company of the Engagement shall be deemed to be in the same proportion as (i)&nbsp;the fees paid or to be paid to Perella Weinberg Partners under this
letter, bears to (ii)&nbsp;the total value paid or contemplated to be paid to or received or contemplated to be received by the Company or its stockholders, as the case may be, in the transaction or transactions that are the subject of the
Engagement, whether or not any such transaction is consummated. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d923792dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
consent to the use in this Amendment No. 1 to Registration Statement on Form S-1 (No. 333-206412) of our report dated June&nbsp;9, 2015 relating to the consolidated financial statements of Penumbra, Inc. appearing in the Prospectus, which is part of
this Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to us under the heading &#147;Experts&#148; in such Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>/s/ DELOITTE&nbsp;&amp; TOUCHE LLP </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco,
California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;28, 2015 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g923792g07k32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g07k32.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2A^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $@< 5H  QLE1QP"   "JW8< E  "')R,C$R,C@V' (% "=-:6-R;W-O
M9G0@5V]R9" M(%!E;G5M8G)A($9O<FT@4RTQ+D1/0U@X0DE-!"4      ! >
MC6C!XC>[)500XE>]BD;^.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/T       2 #4    ! "T    &       !.$))
M30/W       <  #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             "$    <8          0
M       !              '&   "$                      !
M                 !     !        ;G5L;     (    &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   "$     !29VAT;&]N9P   <8    &<VQI
M8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$
M;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,
M15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *
M15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   A      4F=H=&QO;F<   '&     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    #.$))300,     !Z1     0   (H
M  "@   !H  !!    !YU !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" "@ (H# 2(  A$! Q$!_]T !  )_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MDK/0G@]>PM2276#Q_P %8^#^D?\ ]_4.K8EWJ4D>HSVN;%C7"?:YK>/6J?\
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M$_XOT]_ :&XE4&06@C6>?=R/S?=[4V7:YF.ZPM!#1+I=M @QR[9[6_2=[O\
MBTE/'O\ J]7CO+QDDQ.T"N( ^F9?D'_OB@^[#JK;2<5MUE9#F76;=P(.YX8[
M;>[:Y:75+G N ;9#=Q<2V0-/=[?3VM:Z?_4:Y'J&9:RX@ QH6C60/[?_ 'YJ
M2G?Q[A9:-M0I:)EK22WW>WZ#V"O>YOZ/?77OV+0Z1Z?[2QS6!!<_;$ ?0LW.
M:(J<N4P,M[K(<0.(DCQ&[3U6[O:NB^JU&9E9U/4*V$X58L'VEY'O^E7Z=,%S
MW[7O][O97^C>DI[)<QZ;/Y/_ "WN[<_?]-=.O//VAF?Z(_\ BO\ L_T7?S7^
ME_G/_!/YG_@DE/\ _]?U&RFJVEU%K0^I[=KFNU!!TATK(R/J\:P]_3WACH<1
M4]UE8<[5S&')P[*;F,W>U[[&97_7%MI)*>.PLGZT[O2MZ3U#'EK&^I]JP\B#
M^>[?<^K=Z?\ ;];_  BL957UA:\N;CWY+F.?M>&8C9^BS>S=F-<SU6MW_0W^
MS^:WKJ4DE/"/K^L9>7'I>4XG1S@S#!/]:<MV[<H>C]9R_<.E90YB?LK3K](!
MS,[V?F+ODDE/"_9/K*3ITW)8Z1#B<4C4;==N?^;[D.SIWUH;:T,P+_=^>#C$
M $>G[S]L;]%K?S&_^"+ODDE/!.P_K"T[3TK(='.W[(9$>WW?:V?R-OL]B,W#
M^L@8VTX-P+M16/L^\1]#U-N1Z?T6_OKMTDE.+TB_K%991G4[*@(#RP"-!^=1
M;DM_>_G&U?\ &J_E6N].'56#3=(&]O&K7-K=[VJVJN11BL:U[K3C"LDL+;"Q
MH).YTUD^B_\ ZY6DIY3/=0V02 &F/<R(,G;NW5_SO]=UO_'+GLIE!>8+8/@1
M$_2_D^*ZSJ->+DYC:*NJ''I+-V1F.M8YQWES648;G_HJ[ZXW>YCZZZ[/YBSU
M/T5#+^K7U(RV#;UNRE[SK=5FUES@.&_IO6K;MC_!,8DIS>EX;\G*KQ:'!MF0
M=C7/W@-#0ZQ]GL<QSMM3+/9_A?\ 2?X5>D4U,IJ936(96T,:  (#1M;HV&KF
MNG?5GZJ8S*W8&4\75M-9RJ\MQM>7#:[U+&6?O-W>G_->S^;6E53US#;^CR6=
M4KK :6W!M=QV[MWZ:D>B^YWL;[JZ6)*=1[VL8Y[SM:T$N)[ <KS+8_PM_F?^
M<_&+_._O_2_G/^[2[+J/4ZNI=-NP,0.^UY+QA74:>I3Z@B^RUF]NWTL5[K]V
M[_1J_P#L3IG^A_[2_8?IO_H_^A^G_P""_P ]_P (DI__T/54DDDE*23&8,<]
MESF1C_61MMA9O?6[TJZBVV""PGU+W5R[:V]S_=_._H?\%18DIZ1)4&#K50#3
MZ&4 238YSJG&?HC8RJYC=O\ 64+,_J[-!TMUD"99=7$R1M_2&IWT?=]%)3I)
M+.'5<R/=TK+&I:8..>)]W]*W;';?9[4QZO>#'[,S#\!3X;O^Y*2G2266.M7D
M2WI6<1('T:6Z$[0Z+,ECOI?V_P#"/_1>]"R>L]794ZRCHM[@V1#[*0[33=Z5
M5M]CV?\ %_I'_P"#24WNIB\X;Q22/](6.+7AD'>:7-:]WJ_N+&Q.GX'4@XY-
MU9-GN;36UK7>X[VV^I9OM=OV^K6W_/\ 561]8/K-]?,/IM5V#TH66.<[U[!5
M80QK&C_ ^KZK6O\ TC_6_F_\'_PJXCZP=5^MUEU/V"[,>TU2^S':?=!<[UGO
MQ/T+7[?S:/T7ILKN_P +ZB2GUW)^KV&^C;2(M&H<]SB'']U^NW:_^2SV?X/]
M(J%W2ND4,+\_ R&M9&ZZNRZQOTG,8[95>^[WQZGT/T?^$7)=(=_C6N?58ZM[
M<-^(TL:356=P;7N>_P!?==]KO>Q[[?7_ --;Z?H_F:G3^F_XQZ[F"RZ+0'@9
M%U[;*0TN:YK;,=F]S[7-VLJM]'V>G]-GJI*=LX?U7EK6!U#VN+?H/WN+O\&_
M[378ZUO[M:855NR"WIU60&@; 16:*V$>YWJVV>G;L=N_1LQZ_P!'_-IF8GU[
M+1OSL-KA ,5DS&F_Z ^DA/\ JY]9<X']H]58!I%3&.=7,GZ3&.PVO]O[^])3
M"W-LQLO[3ZAR+ZG; X PYH.TU,]NWWM_._\ !/T:ZQ<]TOZG8V'91?E9#\NV
M@&*]K:Z"9W5V>A^DM<ZK\SU<FWW^_P#T7I]"DI__V0 X0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
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M     0   A          !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0%(34T
M*@    @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
ML(=I  0    !    O    .@   /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP-3HR,R P-SHT,SHR, !R<C(Q,C(X
M-@       Z !  ,    !__\  * "  0    !   !QJ #  0    !   "$
M       & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@
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MTM/7V.3Q_\0 % $!                     /_$ !01 0
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M\U!-&*RW3N@J9\=99)"')M7$ZMGSGH'FR$L93JL>)07-KQ2*M#9Q."4C7"\
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M;Z""]\K%:,XL-")?$5X'6N>TO70VE8K0379[G@)+*(NA &4G'GITG,#;LF)
M5;S>U--T^02-<2"":5ZKKO\ C35I\M6U8<V6B*D.#H"U3RRJ12S5K5S%*Q7-
M^+0[."TY#/\ F0^<U^;+8@:\;3>R[=!BBO? KS^:E'"Y5$X:GAC9:<L#X'LJ
M>_@2=(I]=7J%E7-"N1,LFN:,9<$,S(LF+I; L7T&*&ZTJ"^J@-JU$H2SA4N7
M@Z$J'-?YUTIZ/F'ULNO'0[*]:5P6UN(GP"P&JS_$N5V82SSS (Y.>KZ:XD\#
MXN<E]' *VUB9A[1Q1HVVUQ2T+J>5[EB86*.$/==FM"9E-26>\%/SP*H<.=P1
MS+E?9=:26F3WB@FC @+B-1G+!A4ZA-;P7[I]8YAJ8/@^0U:1SD &-"Y6H*2U
M("1IM:^0Y2#0 KPQJJ@0977T&##RT>;0JEAIS"83*XLE/\<YL$R#@NDV5,A:
M:U,6M3WG+$1)N5Q!(_,ASJV;K%L:6)UHMEF@B)0UV1A_-7)@*2XJZ@1NP'H5
M'%7T7<O$JU1G>%KJEKP<LF5*XD\$YQ!6P#T=%G)Z<2L8'><T$,V"^P:!7/7N
MCA"LL4AGP">#.F -1 !(4UQ4;2XL!R@["5=@8MN8:FPIB1"&4# *0T&$!WM^
ME(V 4@%$R-FK;+Q>&/'VFFE=*E>0N)$'N+3$"Q#IX K#)<4N=1T:X30#!+84
M-.:C9(V.4".INM$@PLI"-3I69"[B(I8$@+?;NI6SXYMYC9^?-U(6-]+5LU>A
MDB:&RXBJV?!Z86EGC+3(CLU@P0=@.7UW[*OE;2&>2FJ7K&:YO=>V.<:H:]FM
M9Y[0!@C<%G5V+NH!37EJB3^#AN7!V6'N:A-::!!R#@1'/ZL>Y;$80S/7V\2"
M XA+]:% R!HD@V)?HDVW3Z([?JOH$JE1W'.H>0=JZZKX%&*RP8(_YAB5$_<6
MH3FOF)AK&B,N913S"3\!KA0;GZBM0\/&^IV50MLHR7=WCAK)%-"8 T*;$G>N
M O%<4G\_:X,Y>7(>X"T2=9-I?LBQGQ61;QR#U>@UDO'H5@8X:%)@SU"[4[1K
MF6[AZ3FRE@1Y3E?2+2..3!LQB7#5,E$5BN(MEQL9AEBVH?;JTR +3\[R/)4.
M;43$M$S5KZM&(WW@:A.L"8!?R&UI*)X!V<@7V=;RKT+8DZ(JK0%$-+)7[:^1
M6EF&8UO](\O;UHWAFDLOK<<+S0[,F[7D/Z#JJ/?@O2S7LS))K6*]DTK#1-QI
M#CCNJ%BW.-X4/PCK8WUJ6O-[6MV)JY$Z>A/RF+:J'18XW(K!]:Q>S=IWH["@
M=6?38,OUSD)RMO4U%V0H) $+"MYJ&A$-HO/8*$56LII(-8G[1D)>?.H2M3DV
M)83)[?>S51.3W3S%@_MCFF#\AU @26W++0B\]";<14I6K*^2#9%<<:9=I,6I
MHO&N(NOI4UNCA/F6%IFO$+[R&:T-L+<"4$4L(+X52/#QV2:T*7XMAK0VO%,2
MY#7O1C]";7HRCI$#G+4:MN<<2$U)Y4$KERRZ"Q9*Z_1W+Z+@1(!B.A6C5.J7
MC&HFH=8WX-"<A,5TP_DB477$!NBDJ;@9,S$C6N4L(.66:-$3%JK&G%A+$E(L
M##A<[\N0]]*%@Z9^^?Q7Q08N)9%4#E$0J8ECQ&" B!99,A0X%;M8WD,0:10S
MKA5Y(M >(6D9"VTQJ1- ?N4OA<47-0OA,FHCW!*V!PX9TH"J*K^&!"^BF<*E
M)Y%LV2JB-S&(*!Y#-1,\5D%989I8 XS6]:=9HE+&DT:="^<B BUJL]3$HLDF
M\K@5:7;:.)?= FLF=EK0D%55[)(=R5Q!4P^_Z782,A%K1S9R!_&-0EO&IMBC
MIJA6P$?_ )R(Y(C&F=%%4^;OBU?L P%]N<\8#5 -,P9#V$1A4>7LP9&64R<&
ME61X@3C@+;N(7$D4PC$HN5L>8E0OMKYKMY":<CHD9K15POY+5EQ*5\U'%M4I
M_(17S?N1?!?!83:91*=%?(]?P;#)#WSY*]B[B$X@_?56)M:;.\Z(AZ6.;O'9
MVR/>K EC+@/.<JUO"56:H1'&L*3&@%L@K11K6)U%@P[#YD+.+ BHUPJ->:XP
M< 3D:AI8CC0H<JF0LHB1A;?;592GHIY'D4^H&XX=V+^/E"MJO8O(HOB.&PS]
M#\VH_I;O6^@2X<>7= 4ARK>93@T'NZTQ)%+"B_BF@<J%D;O;F2)'@>RRJ7$8
M52C*N(.Q]2%:2R\&O).09!(A:/KZW9"WB764$0(P;A3MJ>*[JX6_A[EB"-<^
M;*K1_;G+@JJT;FVN0<O^U$]_\7X3_I#_ /N>@KEZ54T<!L"V? #\QA44BO"#
MUT'S.]8W':+& 5SIEIK: !"Q#)?LB0L\WTM*+^3W5MC6+P5F.#GYZ3M$OI4J
MGUB!$".Q@ # 8KWY<D\Q,,IM:V"9V(K2R"^"]@YTRW?#-#:.>& R:]C)2K"0
M29_++ 'U-I3RG)R3_NF3>=R0%J4@/B12>-"XC.9F[-9^M>Q+/5FRUXP!CM<V
M+$;T"9IFP".-0*#<NJ7&79EA>J%L9%RMC(4'GY8?">V=2 []\!FQZD=S)$V7
MJNO^!-&=K;-DB#'OS]TQ06!P(..^:D@N"TPS,VL_1JT'8CQ,AM.X<P5VD!J\
M[ND]%91%JJ'-YU&832*6\<UD2<:BR3L0,&: \V D4B<? D;7P.6/6<=?8=<7
M :ZP8PLR+\A:N^?924T3!+V=!G-:U3S"XX(UA8'19*>;A#*Q*OR4<BW,32[Y
MKE)#ME9<39$EF"5ENOU-U-17/#2XB_FNFEC:0U+2'OJ/Y&"&#-DUPC(DSBV
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g923792g09m51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g09m51.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1ZP4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #U    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M04-L<@    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    ) $( :0!Z $@ =0!B #  ,@      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \
M   !  $#P     $  3A"24T$)@      #@             _@   .$))300-
M       $    >#A"24T$&0      !    !XX0DE- _,       D
M  $ .$))300*       !   X0DE-)Q        H  0         !.$))30/T
M       2 #4    ! "T    &       !.$))30/W       <  #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M[@  !*,          0                         !              2C
M   "[@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "[@    !29VAT;&]N9P  !*,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   NX     4F=H=&QO
M;F<   2C     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0   !5.$))300,     !3N     0   *    !E   !X   O6   !32 !@
M ?_8_^T #$%D;V)E7T--  /_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !E * # 2(
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MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U1K6L:&, :UH :T"
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M!C@;MS 6%Q>'6;6O])L/K;<]KMG]M)3U57UVL+R;,&ST1])S(.T^&_<YMO\
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M!;L?9[WL=N_G/SUN)*?_T_54DDDE*7*]2PL+"ZK:,G%&7TK+8<B_'<UCV57
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MVQ'&GT?^BOEA))3]4Z)U\JI)*?_9.$))300A      !5     0$    / $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J
M    "  ' 1(  P    $  0   1H !0    $   !B 1L !0    $   !J 2@
M P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D
M    T  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$U.C U.C(Y(#$U.C,P.C(Q   #H $  P    '__P  H ( !
M  $   2CH , !     $   +N          8! P #     0 &   !&@ %
M 0   1X!&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $
M     0              2     $   !(     3A"24T#_0      "
M    _^$!,$U- "H    (  <!$@ #     0     !&@ %     0   &(!&P %
M     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"'
M:0 $     0   *0   #0   #P     $   /      4%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,34Z,#4Z,CD@,34Z,S Z,C$   .@ 0 #
M ?__  "@ @ $     0  !*.@ P $     0   NX         !@$#  ,    !
M  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (   (!  0
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ \ %\ P$1  (1 0,1 ?_$ !\
M 0 " P # 0$!           ("08'"@,$!0(!"__$ #\0  $% 0 !! (" 0,"
M P4%"0,! @0%!@<( !$2$PD4%2$B%B,Q,D$7)%$E,V%Q@0H80E*1H28T0U-B
M<Z+1_\0 %0$! 0                    '_Q  8$0$  P$
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MJH$=NC>3]=C:J;<2Y$*GJH@E>25(_P!TB?X^Z,8B*Y7G>OL@F,&JN7^D1?\
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MH_*;6[_N%:=\:'U75KPOQYCR&D"2BYQ3S)"V]]%<8B,#.O6QI]];?4![S&?
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M))08\5ZN2(_YA YC3.$X49PE#0_EG74GD[Q#+=NKYD6MVF<&3-ZR01/\!S8
M7!$EPX7L9D.1*%$KC3"*_P"@97S5560VB&$'/QZ=CT/)NYUN;!,&L?H,AK,Y
M/EJ]'T^YJIACT91EA/ ,<L4RM_A;)2N5IX3 %&U630%]!_IE>./6H?<>)<ZZ
M?%^+#:;.Q"VT9%]W0;^%\JZ^@D3V16$BVT66-6.1'-1&^Z(OH-V^@>@>@>@>
M@>@>@>@>@>@]>9*!!B2ILE[11H<<TJ01R^S1ACC<4KW+_P!D:QCG*O\ Z)Z#
MC\_(MWZ5T'HMW5T\PCG7%@<THHWJK(E4 ZB&%/DXJM8-'+_2#<UK2.^'R5K!
M^@T=^(/H7-JCRSM>K]!TE17\_P",YW?5-9+O&-]F:")E+2TL[BO<8:*MH,#"
M5U7#BJ6:=]HL8#"R"^SP_GG%YHZ#RF[<QL]D^#DI$N934M.22C@9+(E@/F"S
M;2"3]<5]J(\0=MJ9S!D.H#BK6&;$"!0A4YXR$U5WW,A&3)%;0.L;.H^IL(]Q
M^W$/%LS2U=61%+.FP7*>*,K(S6&;\&$0B-B_/T$R/#VECZ;HCL!':&&*1LGT
M8IA[8=6<5GMI.?Y_6$_A(P"6ES7L9>V3I-9$^D$)#).LY3XL4D"8%^WY3^]M
M"/GW@/Q@C@18</+!WJ5!3O,*%'B_I9W$$43G/*\P5@W%BAA%<8I*[Y$?(20/
MT%H'ASX?XW@O!H6'TF>I;O1:^I^SH:6,&-819C; (%7-O') K35=>$01.C%:
M\;IR29+?[(BH',AH^B)XO>9.BJ<$*751>4=5MX6'F/GED/S</^5>,&7.R60[
M[''W8I#XLM\\A+2"7Z8S)SH5A]  E?Y6^5F-\W^Z>/= 23_X=<^Q@"0=Q)V1
M U0<UI+RZC1=U(L3'>H@1*.%0###)+<WYH$Y9 PM,K4#1/G_ #.-[#S!L.C\
M=C4LSEMMS>LY3K+E:HB@G[^HY_=V*2Z+)7,_+S"4]5C:;&!/I*ET9D.SJS.4
M\U)\9LH(E4.[V.AYSRVAD9]VD;%WG.MG8VDBWOZ(X5Z9@=!F5JUFP-!:WP/Y
MY*^1!_9K%%7!<Z)3Q1C,>/7S0Z2O ':>)W#>"X347?:<(?H?1:2#_J6[L[^/
M(F0S5B)4)G&$4?[53 K2UCAG':?K%+.#(?)1I J((6HY'HN!WT;]O$;/,:R,
MG]N+G[NNM4;[?\_-(<@KF>W_ '^2)[+_ $O]^@H8_,YX*5FCS-EY2<\JF OJ
MI(PNF5L$:"_DJQHE '1(,36M0T=1 !/*W_?(I1'=\T0CAA3K^/#\AVR\1>@1
M<R1C[GG5_-_6N<Y(DO!!.XB. "6,Y&JVOF1".:4<U!D_VF?4='QW.9Z"Y/.>
M:_.YWGA2:KGH[&FS'3\U3#V%59I7@^.NB&2KERXJ5[S!(&?5)6J<YG.+(FI(
MD_)B*U/0=!8#BDA%( ]I G&PPGM5%:\9&H]CD5%5%16JB_TOH/+Z!Z#D<_/5
MU"5=^8'BYS1DPJ4>,^^R/'9[O$.[M,_K[25(1G^34,L6#3 4C6M(U *SY_!S
MT]!E.?B_/JW3J-TDXF67AQCI-0SZOG'DA931#/D"1[&BFD228I_DX9D9]2.'
M[JX:O#CUZ&6]F=!!ARG_ -BFOK.# "B-8]9=Y;N0\DS&)[-F/ Z.'Y?%'HP4
M=$;[-9Z"R[J4=^0\0I]0.RDC//TX0QJW_;D1GU@ZN98#>QQJ\:B1\FM;),!)
MIQ-<)7^PU<X3 K M-/>;"7 A"E!9%IZRM!^P:2)*3,5\00XP'_:]61?Y1T=H
MV.DC8KEE._CZ\8T 0Y0D+XT<JM.S;T.#S%8RRCBE/_DKBS&]J*$;G*>XURM7
M[)+!N>QM/4DDBA#03/V@D*5?W0N-U=_D/#7%T]3743)71;%A$9&DL#)ES2#5
MX!7TEPD&$5<V:P[($>$P:JP+HJN8<<WZ0J"Z):ZWH>W=>7FTL$LI]D^;,KZ-
M\I^I,1_R.Q8[T"T;0L8B%CNB-D@8(*.7XB:(?H-K<99=\;=G^M9I]Z>KA:(O
MU0[9YOY"95$>-)(YLL;!@5]B1LUL16N5&3QJ\8B?K'1H6=^5?*>?>54[DVUX
M[8UTC<:VL W1QJSZT.S-6L']@]].C@^1:XHICA/8Z:Q[FRI9H@U>Z*X<<)KX
M6=QOPLX/+RN=+#E;-:-37-B9PS?8^' 1'-ED<0<ME=!%&40@1W?9+40X49/;
M[I( JNT$"Q\S,9NHF/UEK/TC[$LY*4TI!"LAP%ES ELT>S[I=@Y\&..(!I?T
MXE04*@#\FO(P*5^S.B\[PIL[/AM2_LI$>DB*>&S]J).KU(&<=".:AQ,<:QE+
M_MN4<A(R)[O^'^(6,_CF\F)W.)>?XAV- P.4]GI1?Q<FYB1RQ#294I*&+<.)
M,*\ :NP^G^/M7S&O:T;ZVP425!B$&&RL#:6_@_YJV/()C?\ ]Q[&X*.BD2WJ
M>+<X+7_.56J"4=S&&)6EEV6:([^VQ'U)@JB_47T&'T]FSA?EKV#Q@VPGKSWL
M\>P7)'D/:RI'<2$$:O+%))>".R-)KI 8@W_\/-#LR*B$+\QA6OIL?*X?W>KC
M#ER( JCH%;+HAG;((]@EMXB&.BA8R.UU<RO'7R&QD3W$:$U7)]36##_0N_$3
MU/\ DZ[O'%9!S/\ ]#:?,]!H&&;];%H.I4([62^$Q2/_ /)NO(DV6-6H-$2P
M:CQ"(YS$"YCT#T#T#T#T#T#T#T#T#T&A_)G6+C.([ZW&7ZI#Z617Q50OU/4L
MUJB<C%145Z_1]JN&BI\AH]'?X^_H.#+R=W$W/TF^U\@IF7FGM@8_,/4B*4<B
M0PDF<4'LTCQL!$-&^\HB#>5QC!1CT(5S P/@/)+72\TR^?H8MM;Z'2],Y)>T
M-, !R0=);:.??X:%"23# I&$BVLAHYCO9!E0)HS1G,0/P"2?F9A\;P;RK@<6
MSDT%D7ECLAG=+<A*^>;4;2SQP[C;7DQCV_%IB::\F5H(3&-2#$@Q("HUX7^X
M?-XAXP6\+E4[R(N(/\=EX/=I',:H5E%LCQYLT.:VFMLY(HD*=42C1*^#106G
MDMO(+(KYC#',\(S(@?"XS7[O*YK0OR G55OI4Y_;ALH<[,5Z0X9]1.F1)P8\
MX1]-;,);1J+]$>.E+7#E1HI;ED@@(:C"\/\ $OPB^[7T^U\ENHR9NB/EIW[Q
MK:[(^987'0)#0NCH6693$.VB8!TL[BD:5LW]9OP5CW(P.EKT'!CY8V@=WY;=
MTNZV9'C9LF]T<B\LIH4_7'2K;##]K6D/'^N7]8W+#0AXYBSQ@%$,SYE-'#R<
M>T'-IG4*@W3K+1Y;C,J]MHNFL*1O['3+6!11(,F;89]MG%/$C J#LJK5^='2
M,ED9"6T@USGUV;I*\-&ME9VX[A;VN>#II_.,_8=$TF?CZ(H-!,!D[BUT<ZME
MV,G41+3YVGZ)J:')D$;I+27:2IT1H+&Z*-X0CCQR<3J.SSF;I*>UHB1=%&,X
M=):6<-]IBJK-N;J; =I<CGQZV$_69VWM(H94DJU$JWAU=+"GS(T!R!TO] _$
M7TG.<EQ76N*[2\ZOJO\ 3=)LM-S7H (M=J7RK2CBV]]$R-_&;63+0Y)S11I&
M1UYOV+1&D.&\AZ=H9A@Q/Q2Y*3MM'./PWH=]B?)#G@YA[C&:D2X5+ML*<0$M
MF9T=,&'H<[>TI#1JV[I--6D-%L&ADR?U*FQCEB!87QWS)+)!<>-GF71SZR=.
M$3%6EYIH8H4X:VXE&&-N(BF8GZ4J-*CK4;2L82NL&)&EO(KSI-4.43\@?CS:
M^-7>^AX& KRUT"<:TRUO"8B1Y-18-257&$1/9BB+&,)R,5Y&,0HU^S_GW"-7
MCUY#:2'VGF1=!:R)$Q=/7U+I!U:TB.=\0 ]U<@QI\?I;\R?6I'E1JD4OS5OH
M/]&+QGVZ;_C..O'$^V0R V#)?\ODJEBHB(KG?\>ZC<SV1$1$;[(B(B>@WUZ!
MZ#A+_,UJ_P";[IG>R(5_\=4=2TU<>8CT:D>IH>E[;F<LZ$7W5&Q*Z5#DJC%1
M6@#[+[,5R($J,]V <71>%_<63OJHMMS1>);@,@?V!%+HY]E15TZQ$5[#":Z9
M80FN<]'H00W$()C6%>(*0O,/QRE\V\KZ2U.(D?&7&Y@6H[\_ZX84VA+/?.AV
M0CH0#'1I,",Y@CB&,,HOS6.]S0(BAOSJ3*/7^-EM"C090#Y_1P'?S3V ETYH
M$FUU51%'"F,!%ERF*V6P8@R@QX<@,:04,V4(<=9 5(9?-[/J73H?">(XP]I/
MJK0@)!7!"1@K2.U8]QL=A9M^<4=71+^S)JRR3)%BL8SZ!*\GU*%]G)L5ROPD
MX1-L9]S$NIK#6!;2[*-BWN^W/W^T0-<(JLF,HHLDZ/%\WM1L<+Y[D>1L(!PI
MNZSY'VG0];?7,J;:7VJF6<@GRC2B0ZJJCJ3_  B)+^;92ABM;\$!%/'0:,8U
MSR?%["![W*^7:KI42PO;2\934--(!7H"G+'KA_MV I,Z6DE_Q626%!IHEE9W
M%@5HQ18\<03R6DD1&/"SN9S&AZIE\=A.6$GQ<E42(EGJ=G:17UU='- C%C5E
M%5C7Y&LB@C2;"SFL&!P/Y706"(]0-5S0D;3;+EGC-DVYC#FC3MB8;(L5T:,
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M/HJ0!U6K+[M?[Q[ZL-/I9#5:Y%9-1WQ56-5 Y!(@L_L 2L#:U[KD&7KK-:<
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MGDQAR(P(^HF H:>(!&F2(^-23'28\N,61""@FKG;*KN<G&S4FZ5O.='>G9:
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MA/M_&\%1K2]2Y7'2JOJ:1^]J,?&<1AXX8T@4A]I2".C3E%$DQ1RE"YJ%8@B
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MQ#&NG8.$W2XJSCN^ULDMIE4E0;>$Y[$13) J/U1M<YIVR%0ZH&H-]JO!O9*
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MK2QH& J+F,(,> .6TTR1H*^"]H[&4VH"LH<1S/U([HR.:V6CWG*'4^$0HXA
M -@@A&P01#:C1C$-J,&-C4]D:QC$1K6HB(B(B)_7H/)Z!Z!Z!Z!Z!Z!Z!Z!Z
M!Z!Z!Z!Z!Z!Z!Z!Z#\N:U[7,>UKV/:K7M<B.:YKD]G-<B_TK515147^E1?9?
M0:0LX%93V$JH P$435:84<:-#_LG3YM5K4_Y:B^[/DGNGR:K?^I'>X?0CR0,
M&U/M9\43V]U<GR]E3W3^T_O_ (_X_I/?_P"?H/.DZ*G]+(%[_P!^W^XW^U_[
M^R>Z^Z)[>_\ Z_VB_P#IZ#\.L83??W.-/;_G_+^O_7W_ +7_ -/08S8;W,UQ
MECR+6*AOJ,?ZV$^UZ CJGW%<@T<C!C]VHY[U:UKG(WW^3D3T&BNM>1T'FI*Z
M#'RVBU-Y>QGGJ:RAB+)*UC%:C23R*Y?TV$>5B-^;/E[*Y7,:UJKZ"/\ H=WY
M#ZBK%)OXP>6U%H_ZH<9LI9N@.%ZN<QK61AE*TWU*GS1 B:-556E5B(OH-!;;
M:\YY+4SZVDMY.G[)HH[QV-K,*LVSIA2F*CHL)R*=H)4@#E8XKWN?&:]_NYCG
M(B!,S\<O1DM^?6V2T;(E3JXUL>:.N^U/NE02>_UF57.<I)*C^!3,^;G-^S^O
M?XO1@64^@>@>@>@>@>@>@>@>@>@]>7$BSXLB#-CAEPY@"QI460-I02(YV.&8
M)A/16$&4;G,>QR*US55%3V7T'.3Y>\9U?A'W.CZMR(Q:K#;VU(N<,,;SQZG0
MH*7+N.;W@W?)DO,W-: DNH',(K$498 V_,3'(&]:WPG\,?.[#0.PS.=OP.\G
MD?%U<WGMQ8Y.TJ-9%8ULYY UIA09;9"$_:@3I$)YS0I3/F1IVO085V>1_ASB
M_%#H.!H<GY9>08[_ %DFYF5&7E=%L*MJ@HJYTA@_YP,IJQG2GBA4D 3(\3]R
M1*FHDD/UO$H9KC.1><76,Q0CEOZO6AB33)(8?:JZ@N8C7&6#*,7HCH%I:5SP
MO&V9&*S1UTWX-)%D?6I0('PT_&GVF5(FS;;)!,5TT*$B#UC;.P)6#(1WRBS3
M/6*AT&P:!&UKF?<=SW(H1K[AG5AXL_\ AU3/I"T,KG3K67_Y76Z7I(+6SC2@
M,1@FTE+#N*IRL^TK&'A!C%%[N1Y(J^[44-L<\'N\)JZ+3:OLL[20JQ8 8]A8
M1Y5*]M=#CA;%S,.M98_8VK#'(BGEV\.LN)I%0IQS$>LHX2)[77<1\B6R*_IO
M;- ;'%@"B6^)SY%H<M>C,8!2!N;4,)MTZ QK_P!4D(-U5P#I]O[@98B(HP^W
MPSQ>\-N&:K(]$Y/R"&'1Y<Y)=/H(TN4<ZK(B&@R2QYTF?*$4KXL@K6.D$5BH
MK&*]K6(1H6Y9Z^B:2K!;0@6$>.=7(T=E"/!D>[?;W5K#-^)A*J_[<F,0\4WL
MJA,]$54#[?H'H'H'H'H'H'H'H'H'H'H'H'H'H'H'H'H'H(@>5.3O+4&7L\V=
M8]C*DGH7N266$CR+'E6%>Q) B,>,CGBEL9\4]G?)4=[K\$]!7169ORKJ+!12
MZGHQ@(4B!/%M8MA#0?S1S/B5LM7/"B?XL4J*Y6*GLJKZ#.V8OR\MG125*R*P
M3E]Y9;N1&1/I_KW:,*%>12*[^U7^D1%5JK_2-<&YJ_ =&;"C)NM3F*UPO\I,
MFVM7G_R5%8[X0&&APW,:]%^'W(O^7]^W^"HH9MD<%RS*U\N(76SKF-(AOC63
ME+,DP7Q727S"C5849[! +**XCVC*UCG.1/\ H1B>@V51ZOCJE(RHOLZ(\=K6
M$+*,D0K&HB?%I#V'TJGO\?9J(3V<J>R(OM_8:K[+MJ$T D&JB.OI1AJT<RIG
MB1$ 5'_8-3QRNE(%ZL9]J1FHPS/9KB-3^_05^GYU87=P]]%CZZF+.,OV2/E&
MCO57?]3E-)+]RH[V<KGN=_?NG]HKOCZ#;='XL]3KID.]SIB4=DB#>Z56R6->
M[ZW_ #8]2(]6N=_2^Q$5?9'(GO\ TJH$Y^9F\CHLL%9H)S+"M&(;729HX,F;
M[M;\/F^0\3W*U?;_ ''O+_U?Y+\G.]!+JO%/&!O\C);)DJB*_P"L;!B8O_Y6
M?%C'._\ BYR)_P#!$]![_H'H'H'H'H'H'H'H'H(J>;'.8/3?&CI],>%73+*F
MI7:_-/LU,V-"T>8>EI72G%C/&<2/:*1#*\;T58\LS%16N5%"FSQ0[EV'A\_I
M-WT3G.1J.&9SE-Q; G8BYN-)N-7K<X!MM&;_  1(OUO=-$.RIZH#9I9\F9-B
M"07V25^ ?4@[7)=.\KN1=1ON:;PQ9N1;35FJW^5D0,]A!"F7%S)MFQBN.6/?
MWEE.CP(3Y[*^+7B=+*:8*4V+&*%MV:)"U4I\0$.VO(@V_&1)4U@&J56/<Q6B
M>DNMJ#+]C6^R5T$S48J/5I&^[E#TC)5Y)+F1HK*FOH$=DE[,[4T8K/\ BFQW
ME]DDV)$9$CD&!?JD/M2 ;\A.>IAM]QM"CWR#\A+;HW>9ZX3/:*^EY>&ZERT:
M712"YNJC2% 2P4#:Z.64ZV(L<SHTC]6O@-(@@&/8!$L@8?&R7CIY@='LCNM\
M$/0YS0/2;+B]$"V'3 >\#8JS(RC@1-/22'QF*H65%_'?'0GSDAF$4["!81R;
M\=,AC:L^WNRUPXJ#<?(XJVTKZHC4$]OTSK:\MI9GB^1E^U(T6(XWU"]R_'YM
M>%C&-\9^3Y:AIZ(^3J;F-2F/+B,N ):JV9*F/GGD%)-0BF<Z0]5:%&CAL&C0
MMC?6UJ>@D&B(U$:U$:UJ(C6HB(B(B>R(B)_2(B?TB)_2)Z#^^@>@>@>@>@>@
M>@>@>@>@>@>@>@>@>@>@>@>@U-VBMM;#$G+25K[6UJI8[6%$&$IR.+%C2VJH
MQ 1QGD<,KQ,0;7/^9&JB?_B0*H:GRUZ3E!RN9,HBR=C'N"T\2RFU-Y>K'(=&
MDB1IK  !'C*(;GM=(E2WC1Z(-4<OLJAF3I_D1L1_"=H-3#84+Q_JT49M:[[W
M-=\4>H (1C/G\4]U,5J":Y/97.]VA\,?CUV.U;7R;"+-LY<<SGN2PG%B1B#*
MW_-) V%9)E*BHBM4Q'*QRJJ>_P#V"0]3S#J+()8A,_B8A21!Q%DOBK+,03&(
MC$+^U,DM>@GI\V+\&JJJWYM<U/;T&@]%X6]*L23#Q=!'$:1)64\IY[Y:E^3G
M^X/H>)@QC]G?$:-7V$B?%J?%$3T&(5OA7VR.9SBW]<1HE<D%RE>TT4;E5/K1
MX7M8YJ>R*SV%[^W^*K_SZ#8V<\%-S.G1Y=UH/^',<8H9DO\ P]U;]S&N7ZF.
M^0_M&QJO5K5?]B_VWV4)L<V\?=/B;P\B;U&[LL:\+/U<0:-'F+"EM07^X#2R
M?_: 83OK>Y]:P#T^PSGAF :WX."4$>,"*)H8XVB&W_AK?=55?_5SG*KGN7_N
MY[G.7_NJ^@\_H'H'H'H'H'H'H'H'H'H,,Z)FS;##:O+QW(TU]1SZL3E-]#6D
ME <-BN*C"_!GR5/FOUO_ ,?=%8Y%]E"L'R@\4_*B]Y-S?F'CB_E4/[NP96VZ
MO=;"8V')_P#">D ,]K64#4S5LV5H+:Z8">)YF1VP4BJ@I/R,OH-\\FX!U?';
M6K30ASDK#LRDZ/./'O/MMQZ-TJO6$(8F4D4A:AL,4]CVI+&KCR!N,(S1M1H3
M0K\^.!';& ( 0M;\?@)$:B__ !<B,:U57_O_ $G_ /P/RW)4J!:#^,C-$B*G
MUL]T$B+\E5$&GLQ&JKE541B)[*J>WLOH/U&R5%#55C5%<%_]+\VQ0H[Y)_P[
MW0:_W_W]T]O[3W_^'H/K)50OC\5"SXJONK6-0;?^E&__ (/9?^W_ "BHOOZ#
MWQC&)B#$QHV-_P"&L:C6I_\ 1/9/_K_W]!^_0/0/0/0/0/0/0/0/0/0/0/0/
M0/0/0/0/0/0/0/0/0>I(@09BHZ5#BR7-3V:XX!%<U/\ ^USVJYO_ #_7Q5/;
MT'INHZQ4]F1T%_\ XGO;_P"J_P#'NK?^Z_\ ;T'C_@8?_8AT3^_Z^0U_Y7W_
M *]Q?UZ#^-H8J?\ )9#O^?\ ES$_Y7W7W]F)[_W_ .OH/*VC@)_RPC__ (.?
M[)__ *(Q?_V^@]T4&&'V^N.)%3_A5;\G)_\ )S_DJ?\ T7T'M>@>@>@>@>@>
M@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>
M@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>
M@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>
M@>@>@>@>@>@>@>@>@JQ_-KU[IO!/Q4^:O8.-;:^YQT_!\H#<8[;Y>8L"_P [
M:.V&8A+.K)B->H)"Q)<F.KT:O^V8C?;^_04ZP_.KS&\/R=FON?S_ "_[9XQ=
M5Z7X->/GBST?\@7C_P!GG=&H/(GNNJU%5W2WS'*HG.N.>2W:>68S$UM794^4
MKLX*=J.E/@Y+": @+&Q*@2DJ/R/_ )$MEJ?&7@4#G'+>/]>[EKO/O'LZ=Y >
M,OD9S?.:G,^*N=Y[T+E';<?X\;CHN%ZGGLUU+'ZFPHKG)ZC8RSU>J#+GUVED
M0L^2EN0U_2?FO\CM+XXZ;M4/G7'*RXJ/P7L_)=$J#U6QG5O_ (^QMWM\;.S)
MGMV<247E!TR8IL2C:4.KC_M/$;92?BC_ $'[\A_RT^<N%U_D?8<RHO%UG//&
M'J/XR,7?T&WPW4;37]"@_D!S?,(MFRLT]'U:FJ,<7GVNV=G;0K"1E]1_*T*0
M:8U:"; /<6H:=ZUY9^;/?^C^(_.#[CBF/\CO'[\XW8_#XO0<Q@^FUO"NA46.
M\*=UT:GU.NXVG93ZZ?&9!W#1R<8_K:P).ASE99CN(8RN;&"1?#/R@>=_DMO?
M%/Q\P=1XK87K_3*3S[J.T[S58GJVGYY VG@EY.X/B]E><PRE7TRAO39SI.9M
MKF5$H]'J#2\Y=VL&:306L7,R*33!N[Q*_)+V_KOY!*?QQT6OX5V7@'7^-^2'
M4>3=.XYP#R&Y#$I++Q\ZWSSG<[/5W2^P:Z^Q'D;22HVUFQ;K><GJ*G.UVJHW
MQ8I3090/L#U,K![#YP_DX_(!S[3^5ODYP+F?@/H/$W(<AY7X[;RBYO1[$W4N
M.Q>S['>=<%/R.EE]$#H+BS7(5558&%FX.>H)(8T'^8/,G,#66._*5Y+[?4\E
MW.MRG$#>*'E[Y&^</B1ROGE+GNAU'?.<V7C!G^\/H>@]%Z O13YC2Q.@R^!:
ML6BQ^;PV+LL1#TV=DUNONI-?.60&IOQ/]1N=_P"8G@#+BQ5Q6.UW_P!GBP?0
MF<LS^GW]U@\]?67E+C0,+5#Z%K]MIK"17UT@E1"N]5I=%IUJ_:),O);%<K@U
M]YJ?F HE_*!X]\PPOF;B.-\:\>?.;G/BUW+E;.B9J@T/6K>_P>^U'<=MT6AE
MR?YJ-QOE6DK^4<:RUE-%75UIU*VZ<![IHH&<DO#P=%\J/*B/3^5_G_!\A>W5
MNJ\;OS2Y[P6P_BK!OJP/C]K/'2I[MQC@5IB;GE[*.4^XZ%OZ;H6@Z0G1WV<C
M6U]T6F3.2XF?@BKY(?BJ\I_*B7!YWY\E\A.X"U&Z_-^O@):^*IM!6_\ @%5^
M-4SR"T'C@S"1N7,HO>/TRHHZJ/THO2_Y >O-J!RW29:YLC*P8;XZ+Q7\M7/+
M;+MX!M?(G5PK3KWG_BM4_I?8@[(%/RO?;C.<<\/NAQ5U%[)(A>5Y/3.[S 2.
MPMK,K\!I5MH$N_M8]78!>?X=1>NP?$KQBA>0#KM_=8?C_P ?B]F?I9L6RT3N
MI@Y_GQ;YU]803R8<ZX74MM%LID20>-)F?<8!BC>UZA(_T#T#T#T#T#T#T#T#
MT#T#T#T#T#T&-[+..V&0U>1;H-)DW:G-WF<;JL;8CI]?F77=7*K$T&4MS19P
M:K24RROY&CL2PI@X-I&BR7Q9#1*%X<GG+N_^2?A]PG\O'EP_R9\B/)W2^$GG
MU9>'?(.6>374BZSDUAS";I_#\#;K4UF=S^=N2]*B ZQL(U;LZ^RCPH 98/NR
MUB,)XTP)>_D#_(EYN>!?/XDZUZGX?=1[-R;E NZ=UXWB/%+RMO"ZGGEYVZ]Q
MV?M8&ZSW6[S(^->3?D8P,W4[3L4[3IM.DYK5R*:FC5#5JJL-%^5/EYY4^0_=
MN8SJ._YGSKQ:X%^>KP\\-H^+J*#?![SNK_,KA]/L==J.C1.BQ<2S W]CN9M&
M#G"\RDEL*2%!M)VF<1SH<D,8XSY)^4EOU#\<6!X!J.7<(P/:_P H_P"67)=1
MRA,]V3HD3<MX#:^4TMY=%8:?O3KB34ZZL@3-*3*1;"'F,]UZ/DMG1U,;*Y4'
M/98;-\;?-CR%L8?)?&+Q1R_ .1=/[]Y0?E\V=MN.LT_;NN<XI<CXA>2UIFYX
MX>7G]PJMG8;WK&DW6;LK8D3HU;B\5"#J)N=Q$> 2CSL4-::K\XGF9NN+W?:^
M'83QNQ-;SO\ %!SW\DNZSG4,ITK=3;[00NQ]LY7U+DF3L\UTO!AJ:*^_\-H%
MEAME:P;:;0"&=MM1:/\ G1$SH3,ZW^4#MN'\V."\]Q&HX7T?@?3/*'@GBST?
MGE%P+R&?T3CVI[AQD71 EU/E@[6,\<2="H[&757"<:K\C*U9>>7M596):R<0
MAVA@'B7Y(=1X?^(7\FWDE03)^UZ3PCR!_+=N,$S4R;#2"'8<Q[1V.QQM=(%+
MD&D%SM&^J@L;4!*..&HB.@Q6@"C4:'UZC3]J\&_"7A7DQ1>4?>_+'R&\X+'P
MJX[0-\J][&VWCEANM^5NJQ5=)ZG4X+#T6)M<IBLV/46\P&,R&JK8-O!@TF<%
M*KY4PF@$&)4OFMU;J7EAXC<-\@\1R/5]AX%^5?N'BOI.G\[%U[ 8NU92^ &R
M[SF.G8'!,ZW:CJ+ZPS6VAXG4X_IMOUW-0##NK6E$"PF4MA3!,W\">BT&L_$S
MXF:#4WMSI;ZPC=I6?=Z"SFW-O.6-Y%==AQEF65B>3,DK'AQX\4'W&?\ 5& $
M _B(3&M"W_T#T#T#T#T#T&G^_<#Y)Y1<=WO .[Y 6]Y%T^F;G]UCSV^@H!7U
M.V=$LFPWW&5MJ+0P$2; B'^ZKMH,A5"C%-]3R,>'J]V\=^.>2W*[/BW:\8'9
M\[M).=L75/\ +W^>LZNZR%S7Z+):3-:O+VM)KLGJ<O?U-;<Y[49F\J;^HLH8
M94&Q 5%<H:MQO@KXSXFWXWI(.1V&BUO DZ\G+=IT;L_;.J;.C?WFOB5762V>
MKZ3T/4WNN+K*Z#$B*_8SKY:((&-S7\-_?N&D]%^(;\>VHRO/L-9\'F@QW,^"
MVGB[G<[1]B[KF:ZR\?+>5*L9')MW_ISIE7)Z=D(UQ-D7]3!Z-(U)*71.9?U)
MX=N $P8;5T?X[_#?6LZ@/0\8B6+.SZ#QSU/3$=L^CQ_]3WWB4M"OCU8$6'L(
MZU;N=+F*+Z(](M;$T7Z#?]7@T'WROO#TM+^.3P[U4J]LYW++2KO]!Y":?RND
MZO)=5[%B=A6>16PY[&Y5?]7R^KR&_I=!C]'*P,0.>CARUC44]<!"RZVKB6$F
M5+,&1\D\#?$[A=OQ70<MY)$R][X]8?J7.N37#=5NK:?G\QV[55.XZVRT->:>
MR_UE>]!V5)7Z?2:[;-T6MF7:3)Z78SV=DZ6&%<=_&CX<<"Z/A^K<GYWKLKK^
M9)U"-SEO_CAW:ZRF$H>S6++OI.+R6 T'2K7!T'/=+HQ@U)N?UN;CXZ%JXE?I
MJZEB7=;7SHP?4[5^.CQ$[_V*-WWHO.=$/K;:+/9:ZU_/NO\ 9^/R-SF,G;OO
M<QG>FU_).@XFHZ=2T%J1\FJK][ T((;%_3$U(/M%]!X\[^.#PTRO;+[R"I.0
MOC=(T%OTS2N^_H/3K#"9_7]IK5INO[K"<FL=G*Y9SK?=/JW&@[K<X3'9W5Z4
M$NQ2SMSNM+-TL,UXWX0^+GC]J.;[/D/*XV.TO(O'&L\2.=V8M5NKAV<\>*;4
M0=G6\Y'%T.GMX5C'C:6MA6::.XC6&P*X"13: D)Y8SPROJ'-?'CN.MY2+I0L
MOKMGX_\ ::GIO,*Y=E-KKC%=KI,#>FJIZT]#?UI;*ZB\XV=U;MS6BB6=>7.V
M[-">F* <&P"&G[?\;_AI?=_3R9M.0DD=27HU!V64)G0NGQN8V?:,I21LWF.S
MW/#8NS#Q6ZZYGZ6'#A5'2;7 2]C!="A30W#;"%$EA!'_ !O^&L;R!=Y-!Y"5
M.I+TJ7VMH7]"Z>7EX>WSJ%<O-[=&X67:/XG%['*H7/@'Z='Y^/:$<0L]US_)
ME)->$XO0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/00[O/ /Q&TG.?(;DUUQ^+
M.Y[Y6]E7R"[_ )U=AT$ ^A=?67@)W^L3V,;6!M\\7]KEN#+_  V2L*'.^] Q
MG\1]<^U;.#X?DC^.;Q#\M-=>;CNG.+_2Z'5\E3A>S+GNN=DYO6;OE(+RWU%1
MCM[G^:[[(T&XK\SJ+ZWTV2+JJRWF970S77-#)@3PQCA#YLC\9WAA,Z?'Z_,Y
M;?2]J#I'*NT/=)['VXN6G]LXK#SE9SGM=S@7=&_T+>]@J*C)T5)9=,NLY/V>
MKHXTJGUMS>5UO<QK /I3OQR^($JDYW10>:Z#*BY/W7I?DGSNYP78.U<_V63[
M'V6SUUKUC356]Q?0Z+;!K^AGWFNBZK(+H'8RRJ+R31/S[:8<6!'#Y&M_&-X4
M;'#T//YO)KBBILKT[L/8<Q;8/KO:N<[W/;WR#M=#<]OGTO3L)T//=&K*;J<S
M5WP]ECHFI%C;:OFCJB4#:VOK(L(/K6GXV_"*VH--E9' L]$S.O\ %2D\(KZ@
MI-!M\Y3R/%K.6=W<4O)H5=GM161*:O@V6CNY3-%2BK]D5T][)&C*(0!B#'[W
M\7OA5H>DR>KS.::Z%KI/4.:]O>//=U[YE<D+L_)*3/Y?#=:B<^S?3JK!PNE5
MV2R]-C[#;1,V'1Z#*!F9Z_L;*KN+B-/"1O+?&GAG%\!M>6<YYY54W/.C;+J.
M_P!SDK"9<ZJHTVJ[5H+?4]1G6@M=97KS0]A=WMO*L*-I&4( SBU]?60ZU!Q&
M!"JB_%S^-CG63W7#H^&/%Q^ZS>&SLWF&L\E>Z:"MQV:9T>/>\MC\FS>NZ]9K
MQ1L+JU'%F\XM.31L98P=E4 CY>>*? ''"&^.>?CV\1>7MY67)\KD);\;[%M_
M(3%ZO1=#ZALMP?M_2<==\^W/4=SM]=M+O5]2V&CQ>AL\Y-L^FV^N45:M>*&.
M*M-3.KPWAP/@7)/%_DN2X7PK("P7*L*V[9E,F"XT%\*I;HM';ZVY1MMJK:\O
MI?[NAOK:Q59]K*4+I:QXRAAACQQ!N'T#T#T#T#T#T#T#T#T#T%7_ (RBO,SY
M-_E9DP.==C%!O.N\WVV!?H\/U'&YWHY8/BYS+-:5.5=!Z!0UN-T #=)SNDI&
MGQMY8T]9-8.>$8:>1 DR KA_'_RCS!YES'LV0\?,J',]0D<;\)WY'I_1N&;O
MQ^YM/Z#G+_H,;J62\D\+TO'TFH[5VFGS\UQ?([R-Y8'/Z?M-7,P=94UO+-=G
M!'(&\^[<]Z/;]I\#KZIYO;7'F/E)&=C]FZ+!\;K>!T,,NPX#UC.R]1K_ #:Q
M.,I>"S^%X[5:2!)T_%JVNA1M?>+0Q*^72W;!Y:R#*/Q@\YM\ATS-S\?R+H7'
M\?'\$>&9;RB#N^7[;E\O?>;];IK8^NTMY(VE%2/ZWU"OJW:O_P 1^QT\C7 U
MH=!D'2]QH #J'10^#S>7Y,=#YGXP9RZV7FK4=AVW<KZJ\['R,IU/$P<#(C^-
M/E9HG5/-M+982OQV7Y2/L]#S&HSFBY);R,Y9@3F0'W\B=NH9M.&T?%^#YM3>
M!=QI]+HNUR.O[?P(\;^@X*Y[/7S:<^;\P.E<>Z]%ZI24IK*AH8>8)F][1<YF
M:+G<0,:%SRRGL^5/2I=_2<(VTP<1S7A?#ZKQMXWY/^-.<E8R]9Y56G%/$7NV
M"[GI/)2IX:8?)!])L6<9/M.K29&^37%V7083-I3W_08>#I=]L)^?V@JS4!M#
MC.>\L-5Y-<(U_>N<Z^+=9SRPI]%K+>%@YL/&40;K\,&.S^ZMX>CKJ@=3-QK?
M)"\W&#A:219SJP>U4V&A6?[\"/41PO2] ] ] ] ] ] ] ] ] ] ] ] ] ] ]
M ] ] ] ] ]!6S05LV%^6;I%]&QO5@YZ_\'>;YV=NY7/>L?\ A%.W&?[#MK@N
M>J^CSZ!>4-TD/(75)+DTM)H1V!OO.DB*:SC6;0!7+S[FWD/5>;?>MYSOG.YJ
M]WO6^?E?77S>/6V"Z#SJRL--D!\3O.C^4'2,1/X?Y'\KW"\[SUQX^8,0)TCB
M&;V1LT\'1:W"6TS+AL;S;Y[VC5^%V7K/)/G%%V#SKJ;G?V^-L.1>,>ZZK*DR
M![V':0<=XH=RQ.5,GAY=ZV%68-F'ZGV*5>Z+&0Z>1=;N+K6YBWU=<'UN+\TW
M<+S)Y9?,Y9M*/R,KO-7SBU7EEVJPY3LJ>FW7A/JLUY" \8\6_N<[.1\1T7-0
M27'AW$PW/Z#:7<S)6?-M,C*6OEXW;?6&QM%?=^M)OD55@TWES7=Y/Y:<ORE;
M246%Z8'D>=\2+CR^X+FA:?DMZ/ R^/RY9O'6QO;S::FKT-QN:<LWKL^_= AX
M:Q;D@R?PNJ?*;+=YS-?TW3>2&IY[?X+SN@:(G8P7EC055CQWS8R6#\5) +.S
MS]<&HOM9XZVN@MZN:Z6VQZ]FX2[Z631NKG7C BOR#.S>8^.6FE0^+=<Q?GN;
MKF>A^;W=LIXR]47M&TXO>>:=!_XS:#&]\C<SG1.N0C<7GRM'S>GYUL-II\MS
M:(DCF>=KK3%!KJ</#1U?EGTF5 )N<9V[5Y*N[3X'6_-+_:<NTT'967*,!^8[
MN%QG])N),W(U&C#I:#Q1SW'-WTJ-IPP[K-9<M?M]W6TL^ZMITD.B7T#T#T#T
M#T#T#T#T#T&B/(GO^?\ '#"56XO\EN-V30]#YURS,X_G47,R]9HMKU/75>)R
M%77ILM5BLQ&'*O;>&.7.N=-5PH<922"G]F?%0UGS_P [_&G>Q^>QS[A<!KND
M:[7<ZI^>=&@DSNRK.E8/HVEY#K.>Z 0'V>?K]17=.Q^CQ%<(.AF5FMNZYK,5
M9Z2+.K94P/CWOY _&F!<X.'G^@9_89[4=8V/*-3O*BXB1L1S>9A>*=Q[;HM+
MHM-9)%II^8KJ;@FQIIMM13["#"M6JLF4,$">X(?:MO./QZQW_B%/Z9T3'<]S
MN,V-1D*FWM]+%F3]6>SXQ@.WF</+0(Y-+1VM;C]Y'MYN:LZ[^;!EZ\FT/'!G
MI'[,<,XA>6OC=:=+J^/T_8,A>='NC5T6LS5#*DWI),VUQ]?T.!7)95$6;3"L
MSX"WI]U_&'L13Q8VYIM0>..CMJZ=)#4+?/\ Y&+N^OX?;8OKM#$Q?;\[XUVO
M:K3,YYW$W=WUO*\)V+-<V2_K-A8Z^KL;O'](R0JR^TF&HL9-T]G'R<;2DT$N
MO@30S%GGCX>%QB=!#Y"\Y/D":6-D(5M'M2R/Y?1V&/G]!J*V@KP1B6FB=?X.
MKLMGFI-%"L8>FRT"7?4$BQJP$E-#U=;YQ>.]5D>EZ#$]*PW1[?FW&9O<)U12
MZVNA41<>W"U71J:3:=#E#+B,N*_QNAS&IAFN[8)A9/2TNL)#6@L(DXP?7P7F
MGXX=%U_0,+1]%KH>EYOTW8<BNX5^(]$*PVW/\6S>;>#G95BP(+D&8H!71[0P
M7#()F7T4X8"4\$5G*#<#>I9RXYY8]&YZ.7UFOBYT&AJZ/G<BBGZ+2ML,_ U%
M)3TX;VZSU1%NK^EMJB=51M)<T$58MM73)TV#!DME($'[_P#)EB,]S:ZZD?QM
M\HYV?P_0-#R?K,.NI>&EN^2=.H-?2XL6#U$*3WJ*#4:+2VNES3\='Y),Z5&T
MZ:&HK:R4712OX1@;3Z1YQX/F&R[7G[[F'9IV/\=L;8;+L?8Z6GP,GFF.# Y@
MWK24+QS.C5_1KO13<Q+I8\2+G.>V\#^9T=+"EV<4)I4N&&Q.->46#[=:1\]F
MZ+;4VIC5_096SS6DK*5L_FEES?JM]QBWSFXGY[0Z+.@NKG>8_=0<@N=N]'3Z
MFNPFLN*JW-6UHY$D))>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@>@KIY_\ D\\=
M=G93(VCI^I<AI#577;[$;+IV9HA9;J5'PKLM'P+J-C@SX36;NV<;-]/U.5HA
MT&MI\GJKL&DK;3/T-I7,L)$$-V3O-?QC9$R3Z+K^.UUKT/G4OJ?/*/+V2W,_
M78L,:Y)"O([J\,H%/67$W/7=-56&@)5Q9UW3W%1&(:RJ+*)%#':'SAXUH,UR
MO61[[.P*?;PPS=ZZWV-#72>/_9XT6'E(>MT@2D5ES?57-PU5O>4=(4MC39ZY
MCZ^<$5"%QB!])_GMX<LRMAMD\A>=FS-7LIN GV,6RD2W@U==C ]'GP/X^+$-
M9DBQ.=28_0#W089*(>&.+7K9?Z=(VQ4/WV#S#Q7+(O#RT/.^N]PG^0W\Y(YK
M0\;S^8G7=A3YW'/WEM?3(?0=ESL<:OCYEG[@H@9$J]FE>.'"II$I[1*'GRWG
M+XG["+RZ14=NQPR]CPU)T7 UMJ>72VUCE]'!T=A1GLZVTB196:M+4>-V<:MH
M-(RJO;&QQNMK(%=)L,U=1X0>O$\\_#NQRUAM*OR#YY;YNNU=/B'SJ>QDVYI^
MHT69G;6@K*&LK8DJVTW\YC:JXUU1-SL&TKK++TE[H(<LU326LR&&,3_R ^/&
M8WY^<[_65^2NS6/85I)0IK=+52\KP_+XC5[G4W\VC!(;D%KZ_<5[B4-TQMM'
M$+]J4,0)D-Q0D]G>K\TUUU99S,;K+WM[4.IV6%76W$.3,CDT&7@;:F$@AE53
M&GX^UJ]0$(/M*E#9UUJ1C(4Z*8H8AEO(#![?M'1.'9%MSH-%R2NJB=+T4&+!
M3&9#2WD&HNZGGLVVE64>=9;LV7O:?6V-1GZBXB9G/V]#(UME0S-/F(-R$8+_
M /);PW-WUS5V>-["RD_U7TGFW-=VS.Y'_1W=.N<DWD7EVZY+RPY=V*^'LZWH
M9IN6A2.DT'.L?>FHM#<T6KL<S33+Q@2"X5Y0<Y\AV#=SZ'J?G&RL?1Z<5U6U
M\-<3:'UFJQ),'I3P[BQANW,&_P /K13Z[/R;ZJBU]1'N772U&DR$W0!(WT#T
M#T#T#T#T#T$7_++QO#Y1X#%<_EZNUQ\#,]UX9UZQL:&ST]#>SJ[D'2\_OIE!
M2:;&:/)ZG)VU\"D?5P=11WD6PH3R&6$=IGA03PBGUK\>NHN-9RZ#Q+I=5S7A
M?---PGH=;R"U-UFTK6=-Y)Y2'\EMON)S:;J-'2]"T_=["4R!NM7UVFWVDK;^
MI'M*J<:_O[V4\-7:7\6&TZ1XZ\ \5NB]OSP.9^*^U-:<:U'/L5H,WTDV<IN#
M]PY%SF=M9<[<6V7M=OCKSI6%VT]64#\+LY7/[>KU&1L*+<RJ:G#;K? /;W/0
M]1U+8]>S<W4[CH6HZ5I@T6#L:RG_ )[8> //?#"XCU,>9KK&3%KF:+%S>DPA
MR),HPJFTCY,I2RH1-#*"+?CSX@>1W$?,S+%-RJ'KN29?H.6LF=+ORP8.*IJ;
M.^!F#\=+#K_/J^D\G/LA]ET^EQ:X.56:CQ.M+^+@=-KHA>SGI%J"E"0&T_'%
MM^E=-[Y'V7:,L+QP[KY:83R_N<+G><V\3KC-MSG@W#^19;(KTN=OIN6C9*'J
M.&YKI$D\3FRWDXR?Z86=&KR29A@_G"_QP:;FA?'>SU?1,G=ZK@71,[<R-;5Q
MNSW5STO"8?Q;[[XYXRBNB=<[3TU<A,K9G=[?9QZG'$A8VF&*QH:RE?\ R8;.
M &H(7XEM]6\@MN(T'<<QBLOH/! 'B1N[7(9_ID9O9=I!\;\-X^4'5^J\VL.K
MS>4S+3'1<:&QS^AS^7J>GGS$7,\[L=\3,T$@=R&:>27X\>C=&YCVO 4FJK[3
M_P 6/,K*]KPE_G(K\GM>38GL=16<,\L'W-U:Z8E=H3-\>==V.OQBYV!56JR+
MZ!'? L+( 9; F19>/G3JCG/EIFN-ZWC/#]YW'2V5URWHW.>)CH[/%$E\MY]S
MV#J>I1F:HP>M=1I"9.:VKVS_ /3@!9B'A,Z2B*#)*^Q#5V:\)M6'G_C5SB^T
M_+,]D> ]CNNX6^1YIAMS$S?4-O60-%:\NL]M)W?3]IL-!9478=*O>-YH-!J;
MC2]"Z?F<S?SKB%/;;3+$,(T7@!K^R=CX[TOR$D>*EXF-$V]['?<N\<[/#])\
MA]%<^-6L\=MM@.A:C0='VC9W"[R-M[:\%C[5EY/2FSV!QLJ89F:+H+(,;B_B
MQIJ3LG-.M9G8YVLF9WI$_H&H=+S%Q;WU88/<L=U^K;RG16NHFV.4M=5GL8SE
M/9+JS-;S>H5>PZ!MKHG^JMIJ4O0MT] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ]
M!4YC?QF.Y3Q:53<PZ=/K_(DN^VMXG9[31=@8$?,>A>5)O(S=<2R42MZ@.^XM
MC=_6#I\AN)'$KS#GT-O1UFPM8EA)BCKO0>#QX_'WVCQU#,I\[V;F>@S^]XX_
MBO5_Y_G>WE7Q*7,]9\GND\_T&#N9'4)<V)<DA>2]I1;(&VE;!DN7FH-[6SAR
M;&TCR@PO,?B@T&1X?E?'VJ[R&5@,(_K5CB_YO'VEQ?4UMW7PUZ/X[=.%+OIV
MQ-:7]79]?Z5IN\U:W4J7;UD>^M.=,LGT\'/3ZH-<>4G@7VNGTAMKRZ#HNK-V
M^TA66B@X"'#H]/FZ:F\.,)XQDSDIYO*KQ0N[3,] /D)MK=S:3L]>"D;*IH5I
M@M82+#UN4";.S\=/(':4OA%OL/>\1X?U_P <LK9LTV*ML)JNF<G@66ZXT#G>
MCR^0B9[HG.KEM-C)Y3_Z8/(OC#G5L"-&D_'[5E-"-6(_$? YA<9*KS'1XFNY
MQ&YIR?.;"NZ&3JX+8_3N.OW=I0]8H,WSWK&,Y-/L;;4[*+I?XC>X#6AR-E2O
M?GYAH]FD.M#*-1^-'4R>?2\_F^C8XNVC\^\5\AB-U:UW5L??<NU/CEQ[I/)2
M=4Y]JN0]6P>ZSVQN(O1)I(0H&GC0'YB1IL-H?YFHU4R1'#97//!'<<]ZYC^H
MFZY0=!+&U_?I/1HVTPTE)>UQOD#C^ 4>E01:?11*^#L@W7 J^R)-/6RLY,A:
MRWA_P4=\&&0H8IX*^#^SX+@N!S-M7<W/N<9N>PZ7<6?0<77=!['!S\_$0."\
M*K.?=5JM0E;@-)G?'KG/'</U&QKH>J@[BLS\^FCNK1G2<@>H7\<VUI/(BQ[A
MSOHW)LM*INU]U\EN?:*7QZQG]4E=.[9PK=<C+SCKNSK-Y1+T'QZSFGWA^GCQ
M4(&;N;.PR7.Z'^9K5QXM!8AL&D_'1@[CM%GUCKI,_J:0F3U4:LY#E(VZH.6#
MZSUT5)/[QWAV2ON@ZNGS?0=I?UM@3.R.=0,6>CCZ/57^IM-YOK\6LI0UKS?\
M7-5S#N_'NR9O79&O?BY6?TVT6NPLB%II6LH ]_ASH7.] 302SY;';VA[;EL)
MNX5RNCN;SGWC_P JH[>UO+41-#5A;=Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!
MZ!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!Z!
-Z!Z!Z!Z!Z!Z!Z#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g923792g22q56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g22q56.jpg
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M20LM5MB,(),D<I=$N%T/2U$,<$S)64[GL,S:EM)&&R5($KYOGM$D4<6Q,_\
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M5*^:JST\(GA$\(GA$\(GA$\(GA$\(GA$\(I8A?\ Y\I?_P V+G^\0_.M6?\
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M )C>7[KTO^!BG\%QC\"J]S:C_&P_^*X;^+3U#.?_ *BIC_[A:'_F-X[KTO\
M@8I_!<8_ IW-J/\ &P_^*X;^+3U#.?\ ZBIC_P"X6A_YC>.Z]+_@8I_!<8_
MIW-J/\;#_P"*X;^+3U#.?_J*F/\ [A:'_F-X[KTO^!BG\%QC\"G<VH_QL/\
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M^4K?PR?DICW[#_,TOMT_H<?2:?X0+2_R OYOX_+7X,^$OY2M_#)^2F/?L/\
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M/Z''TFG^$"TO\@+^;^/RU^#/A+^4K?PR?DICW[#_ #-+[=/Z''TFG^$"TO\
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MP'[<=<V'2I2 -H"#.E]-R0*1F+&L,[YV[H>M>VRC"YQ&#[,C"9HU-JIMVO\
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MJVW,E<]"ZIL,#6UB&UKBPNP>W5T/.V[*<5N(5=8UUOS=(O80%09L=05"J]J
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MS)6]U<-W/!?&=IU;&EART:M?)B?\8DX9A[G.<:2':=$V$NV+$1,$8:QI%BP
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M:];/%D*D)_;SY*=FPZ^7Z-_'<>G+K4NT^D\7N1&\H2J$HK:BHJHSR45<;"4
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MQN_VV=YEXUWKK/W;?ZC%H85WPI?WG^ERYU=]:KBMI%E/U;J<IQ'Q[63:9UA
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MVF3!A.DK:'W\DR@N9E\G%)L:%('P\I64.Q.G94STQ;,?BK.DJIQ$334P,)J
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M>$77CZ2W]1*G];0+\'/GEV;_ ">L*C]WE]17G<E0"LU]_IRN\M_-?)3)V^W
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MD1J4C85%V5HZMRU4IUD[,0+XIE5KVT%1(K[!?W616%BM26Z*HZC=T*27-S$
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MP?M&J;3B2':;#'LAI@<62 $@/:"TEFT^:+OI/EM,1#U*+W7P@0I$Y6U5TG*
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ME]V:L@0Y;JS3L16,_8,!+4?:6+E>(<&/QQS(YRX\M.)VG9GYQX]:]#, +6W
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M=2JOL&)##;C"Y-$!6]2K&1L(\G8LL<*!TBF\M!7]9P@NJBYU/G38%KV%O%U
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M1+<LE1,$,Y6Z:V@6\I!:]YG#F-S'*+G/KW[N-CZ@IF'ZI4J"L^';X\*S?/6
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M8GZGX-'<(TC0P[91'>L/?W\OCS2Y]_?KMXLE\8W46JQ3I6CBM8$UG94*Y?\
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MO ;/S;QW)PKP9A_V*F]FG='$/VZL^TS?^]/7A=7M?M'[P&S\V\=R<*\&8?\
M8J;V:=T<0_;JS[3-_P"]/7A=7M?M'[P&S\V\=R<*\&8?]BIO9IW1Q#]NK/M,
MW_O3UX75[7[1^\!L_-O'<G"O!F'_ &*F]FG='$/VZL^TS?\ O7IG=LY:+UZZ
MN,UOJ]64GRP@,JM'19CI6L XMP.'BQ4A%(&S0D'O73)>.&@,\LQ\GP3PJ1.W
MPM<?X]IQVY9^>:G$[3LS\X\>M?>HVAP;<#-H]%]]BM057N57 <DK(UE=7:_8
MVTLW,NC%K2ZLY0@SS4L*W%ZIU:WJWK1R%-+E.U,$\Z4-;524QRH>M506MF#N
MYS022QK)6YU/,J^P-X Y#(VN0?%Z<E8Z=VVHAE/ Q!3J4MKT5S.4\/1I^0^N
MRN9<3:MZMG7S<8,0HH35\@;5QT4)A3$9A)+9F%8@,G<2AA?(@"'+G4\RFP-!
MQX:"ZPO'<*HS)!4@(_3!58^&.'2?QN22W5NN:0Y?L1;=\4G5P_+'8LD]\^'D
M[407DNA+3JU9KBP<@E!(]J*1MP':N=3S*GHQQ#>/#39)\SE&ZX[9(S;9(TH1
MZMH.BCG%8Z>P]<O$'7V+76-C]EW*V:ZB#"$#4&S^?0.0^JRP EE8$P/R"'R.
M#\8>6TRI\,8N=3S*C8 OD+Y\!G8 ^3)3<;VRIG8D]7K$8.J55KB_VDF4;+5E
M_8P5F5LX*D]C6ZL4.KG2:AC5+;S*@<-%HB-+KQP;AC%F!#D\P3C$>W15S8N=
M3S*%@!(L,KC<+7%[Y^3+B= K>+S8)?LI:%<JE>=;TZJNN"!4]@V\2<*1VN;H
M]QK,V622FB$*4":TP4A:%98KW"5@R&0-F<L)LW)%ZUH/J7<YAI=VIY_W4;+;
M7MF;Z<+=78M7F/MI79H4C:!/712JUR; D.Q@8,FFUB\CSE8V9TS[B=A:>*L9
M&*/B<+I7DUUB88C>N!OE60(/ H(N(?8%=@W&O&T=3S*L(QH--W'::#;_ *E(
M>V_:*J^L'3ZNK2T5CUP)WU8M)R;36UE[7U-<5)T-&K<78%E&Y475F*+2X.&T
M@&2U\. E[BDMZ?T>!EKQ$;2Q" VCJ>:!C2ZULKV)L-;?W/5=8^QNT*K7Y]ZL
MG72'7QGZY)5ZM77S $#K>))M5A)K'54CV.XM(0[Z2V].WKA8P/\ F./1]2%O
MD;5R1ILK78FWWV*5DVCJ>:@,:> O:^X6WVMZ[^2RV%ZMF-%@O;C5MRU'USE-
M0>B.MW8P6<K"JL%Y=CJ_8V== .*A$(3.8<YA4^C&Z//<[G*.1"0' 0?#S="6
MK2(<V)M7.IYE"UN1 XD6(%\K=7&_IWK=SU-U#[*JW_T,L?E?BYU/,JMAH.03
MU-U#[*JW_P!#+'Y7XN=3S*6&@Y!/4W4/LJK?_0RQ^5^+G4\REAH.03U-U#[*
MJW_T,L?E?BYU/,I8:#D%55LU15L* CY0ZU0(F4BU:YA2,HJ<NZ,M\.4QQ=4J
M)NYU#L.=L:3JYYU[]&?OM6[7SSALPRQYYX\D$ZG<>/455P&60^<."UK[>6I7
M75Q_ZX:-]!U(9JRPV5LBW2Q[48-R:KI)%XJ@2(_#<8\37#^0E9F=PIVQ9)&+
M+UBJ[&,IO3\!L%\YY1M'4\RN0,!!R&5K9#/WX==EJLC^D*H>?72@QM/51*)L
M&CK0DV_:NM-55W3I77]AZ9;.YA!?%KQ($1E1*ZQ4M<%3T/9MDXWP'IN4UG:'
M*:-A@^-C:-KW-K7WE28QH+$D#+AM;-_'?@MI8]\4T:N212JIU63RY^#84U-)
MEB$! "!!P<#1/6'L&TMN[9F G3]^D6F=EQXT<&A094\PR*DJ)EF.&%M98=-S
MJ>95=D6O8<O'V*HA/>3K'J#KK78'5M?0$QIK:M+T@,\@+7AN&)HN[*L[#V94
MKFUZX8B/\A,+!OZW-:.<3=.TIBO-C0B1HC"?BFID@6VCJ?.IV!GD+BXM;B"
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MO;82]Q)1P;7E[:,[>65V*H+;V8<75F8&UE,KJH/%+0'YQFBL0.!" 1 Z+&@
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M04C_ %6!_P"?XL=#R*7&HYA/696_M!2/]5@?^?XL=#R*7&HYA/696_M!2/\
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M,9)G@B4TMQ9>Z-J'SS8"))RF;I?,X=\WXP]E* +^.X \MUL7U_=(=JSK@4K
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M-;]$>A8ISINKK#94YR=$< PM=?R-LA.8IT3W# 'XQ/$E9,2+/T9Z9&P7**@
M)64'DY[Q4HH##$=\/9,%P-\>JM<\_?MYG514KUCZ^&PV:^3I]#DB,QX87C#^
M08NCXO!77>390#5"WQL=,F!F$L"9*<A,B%NT21['OV%HF[5,R^%\)?W\>]9
M1UVHD!C P!U(@!]8K%%P&:ABR,@Z1^%8-#6ZUWKA:8T?7JBZDIM>7%A6M6G#
M#6(*LAB7#QU;)NWG(IN=3S]]!R6,@=7NO H^K- RG$& >2=0_2KD(8")'S$X
M!L3.(+G5IU8XQM^Q=Y9&+:M[I>F1M7)# <DA,X$@N0VR"7.I7'+]5.N1W17\
M4I3:+(C56NJBE7<? -JBZ%%:0B0@TB!1&J'E'PTP$<T!$&4S3GCLX53$#24
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MU:ITM,3R^+"HK.8B+K'+AG5@5T["8+3JXUYC)6^&PG1L_;"SU<SA# ;#SOC
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M0=K7-6K9CSIWKK(-%BHQP#,UR!!3@4*V38>[<,@[(Y1=?:LZEK6F@$A7JU+
MI *83VFI\ %#XC\$2^V"/%<DR4C/+9+)3M8@0'"QI,Z1(VQ @<.%BY:18H?$
MC$WJQ/"+KQ]);^HE3^MH%^#GSR[-_D]85'[O+ZBO-?[)?VB+X^N2S?QH:\](
M8%WDPCZLH?NL2^%8MWUQ/ZPK?O,BI7S56>GA%=777]==??MC=_ML[S+QKO76
M?NV_U&+0PKOA2_O/]+E(>IEP@Z"[!UW;K''/R@Z;O8I$G2KZX>T]\,44& #
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M-ZU8),D&8XQ%;*=H6.I)/C!M8;^&>O4H'47H_+N -E<.5A4W0\C!5[#4/?+
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MT[*:+')ITL* DT^0Z\P+FCXED K8Y434$=0DR=EF;T@9I.3U\CD47%[W]/\
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MMLU-0-GH[6FD%NBC=%%:SLNBB>^..WS(WN8VS7$'.<=G.R'!%X+XW[<V!2S
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M:#D$^(PO_@XO_P!/J_<\)8:#D$^(PO\ X.+_ /3ZOW/"6&@Y!/B,+_X.+_\
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MY2PD]MDB"CG/8F%@:>&\K"FLL1M.FFR"4C,96>4D$N??E;Q6RMNMDON/ZD4
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MK/Y2I>.CB3KV%FY;!.$S;%VZ-NQO%Q6KW_#!AR1Y*;G4Y;EQ=75^H(#.CLX
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MWO)A<8RUL=H^R3AUU31IWX- 81X9&CL8P3*:&&/+)D5D#HEF82^SR9F0@:4
M7 USY  \^I5OK])$Q_*)D7(H\)A(J1@@ NQ&>FU".S4O8F.UC9U2%3J9YSJ[
M5S;/PIU(8G:?"8?5=*'!L0R[SQ)8R^S4-)L]>_=EU YYY;^M8V;?_9-BZP]/
MV-3;!V%@73VI'UD^-LC-669W"-'=+8RD0PVC?4]D*T>9-%HP@#)W9I>,GD9L
MG;HA"":D:S$8EAG]$'RFW6-;^HC)?19])&].$2O=(2@E/$_>B[U^?Z0BE+H,
MQ0\RO>R$^UAR7-M,G#I@B00G$)G6>B6T*@$&^0->MCSAB&@G+72/PY-GKW7O
MY+;L\\SU*1=V>T'8.HI]L+-;#$4)$4>B-O\ 8#!SD'9!!E#V>N'Q0%=CB5LM
M7Q9;,@!4C;A\)N,RXW)/6:ES)07#E>B#3Y  ?^H"W"QOQNHX7]))801VQJKG
MK$2;K17FFW!K\NU:=M.S1NE>JIEID1MG(914Z^S9QDX=$70,+:(UB!*H3QA!
M=(@RCS'X+A2FXFSUZ6O;C??GU<+J\NQ7<IBHINO ="JD4WJ'7WK:D]@W<UL>
MS8EJ+[;,.WXH)"2GIHFM&S22SV-5)Z-;*P3V0=L#@F?,B)762>&X$%" 7MGO
M-O1VY*AVCTCENK8Z'QNZKZ1Y^!".'FB"_/EHU3&E*@BZZKIZ$Q($%[ZW#7@_
M%/>MH(P1/G8DH>K1N#,037((X18)DB0-N=_BM8\"=;<-5D(7I(FS/,CH(46N
MZ-]8,DP)?W,*VRDK4OPOIEV!TV$$JA^'J>'NM"1,/UHS/I$4QZJOW# W(1?T
M2"A<WKD1"%MN/"X_Z0[//+(C7BN*1])B;VUJWN"]3:O\ZJ_PA*34E,=DV#E(
MW7RK";P.7U1BCQ6_7ZS65C.4\)J0,;DLTE2!@)ZL[;V@_DFQ%39$/$V<\S;K
MMPRL<R-]U/E#N8=C5MWCO V/F-:S4-E5EJJ-%VY!UZ3"7[!Z8]/[6$)Q1C'"
M)6>J/,LZYF.>::RT9DF@H!F7S'U30P02%T$MF!QX\SZE&DOM!?\ :_<RGJ9R
M$K=;K26![B\=@%Y9>8C4-:FZDRO4:"F[UM@9J,T'#2I@ [,AR>X6.WU49S92
M)J*4/[8=<11=D$L-DGK;;R[77_R]:CQ+NG?8XR?F[ZLR;)H"^.X]>UW6E4ND
M>9)M(9U[JEI8%T(WPSM*%F?0:/&E_3L&Z*Z,\$]14ECEEH;HL'0GFR6&76 ;
MGA<VZO.OHS^DU+*2UO<B53JTA2BT%<=GPF?%LNT$"=[6IH7V )MO7A2)-W6
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M_JRYXX_K\9:'F.Q,]1R/:L4OXV:U@P+,MW?7IH T!H#"NEA]6;Y$(R#*0XY
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M%]4R!=W.+]<FIT ,MPFM]Z1]=^OTEVQB2$0H+&'(]R(#P\G#,&#R?D"9&33
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MA8]X^KG-I<J.-=\7"J<N'+]@$V)G +B7SS-Y9-;)[@'8*XP_KDX%N>(66/\
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M8*3A!L53E91;2KPA)QT%XV?.B%"8HN^7*V>YE_TZ8^G'+9MSY_JPQXYYY\D
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M[+KAKGS=#PH[&4TC(>KWA,]=W6JOIS/IU<)0I;=85L)D[6G)?N/?9A:E'!*
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M57Q!KUBLE3G= )=M^%M]K?\ ,#;R#+?Z5:)"NNP1"_*1*5V6[0U1UR# ZCG
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M6M<;!SMAU@2=EUK'?7NE;3_='4+(82J*^:X6T195++C';1[ELUP:W00W=@K
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MC,Y)D1<*:RT/,=B6=J.7]U-N0-Q\;?@.;?2.-WP/,CX'FJ=W&WXOCEQAEO\
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M(KF4XWR8D(AOPV9B5^=KAXX1-F.V;E'T[,M.K9GOU^67_/=])WI*]#Q_-;]
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M4O*9VKMK"&;$HX3 *.G<4[0Z\B+>2V_,<!IOT7-,^CGM=D=BK+L!+*K#(41
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M9^,?%WUARNYU22> &9C4D#JIL=,UK(HX]LM;LD"6J>^KD9M-O?H.G;2[R (
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FK5!U2IL.-LE[-6.C#?+C:<MG&S?JQSNP$','=V*CR",B-_:O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g923792g36f76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g36f76.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1A44&AO=&]S:&]P(#,N,  X0DE-! 0
M     $@< 5H  QLE1QP"   "JW8< E  "')R,C$R,C@V' (% "=-:6-R;W-O
M9G0@5V]R9" M(%!E;G5M8G)A($9O<FT@4RTQ+D1/0U@X0DE-!"4      ! >
MC6C!XC>[)500XE>]BD;^.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M          !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT
M:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C
M=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O
M<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/      0 "
M.$))300F       .             #^    X0DE-! T       0   !X.$))
M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/T       2 #4    ! "T    &       !.$))
M30/W       <  #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             #R@   X0          0
M       !              .$   #R@                     !
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M;&]N9P   \H     4F=H=&QO;F<   .$     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    #.$))300,      YG     0   )0
M  "@   !O  !%8    Y+ !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" "@ )0# 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MQF1CU]3I+@#?265V-;R[8Y[L9K7[?H,=5LLL_P *MK]IMK#/7KLK:X?3<P@
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MV)TW%9B8C/3J9\W.)^E98\^ZRQ_YSW(.7U(LR/L.&T7YI:'N83[:V.,-MO\
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MK%Z?B8@_0LAQ^D\ZN/Q<5924I))))2DDDDE*22224__9 #A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@ +<;    G$  MQL   "<0
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP-3HR,R P-SHS
M-#HU,P!R<C(Q,C(X-@       Z !  ,    !__\  * "  0    !   #A* #
M  0    !   #R@         & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 4A-
M30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$U.C U.C(S(# W.C,T.C4S ')R,C$R
M,C@V       #H $  P    '__P  H ( !     $   .$H , !     $   /*
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0             #P
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!-@$@ P$1  (1 0,1 ?_$ !X
M 0 " @,! 0$            ("08'! 4* P(!_\0 ,Q   00#  $$ @(! P,#
M!0  ! (#!08  0<("1$3%!(5%B$B%R,Q&"1!,C-""B4F47'_Q  4 0$
M                _\0 %!$!                     /_:  P# 0 "$0,1
M #\ ]C4MX6!5IR3FO'?KO1N%6/50<K-<BQ)%-TYE'$MJT^#*S%+L&_VT\Z.4
MVPM2'+>+_M-;&:VT&3(BG!TTO=O.[C+4\7.<QYYY356,9JX%<?Y5*O<VZU89
M&0>;8G925IEO=-I$3$QKJW-_ +>SRF@TB%+)+_.14 ':5;U .'2$K8:WT0.]
M\1LE3EVZU.A]/JQ($,NU(^JD^"@+7".3=?GW@E&"NZ=',9^T"0@YAK;31J1
MF?%3<+.LO$0DO%S+ [^Q2'XJ0$D&6"=,LD;&><$=>0T_H<AA_;*U)<^%]EW\
M?P=0I0=I@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#&
M+12:9=V !;I4:Q;AHJ0'EXL>T0$5/L1LL(K\A9,!F5$+;#D!E?Y#FCI;)95_
M;;J=X$*K%Z=_*46.!N/'>@=K\>K/!S<I87B.:=&F#8:S2,DT]KXK7 7M5N$.
MC&7GW=;CXER#2_'$EQ+CNA%!Z!#@B >HIR%@-3EDXOY4P0RYN:G6Y2OR/'^@
M.L:V2X'5JY(P<A.5O_%'U'(PZ1JLL:I:38PY;VG@)$4,=@_4NHM;D(FL>3_(
M^I^+]N,AWY4Y=LBOY10V=C:UMQF*M$*P+9I)ES6G=CFG\^@V7-,.?(EG;@VB
M GG0>F<^ZE!!V7G5RKURA#Q!3ASH&3&.TD8UOY1E%,-K^T"ZXCW]QCF!R6U)
M6VZTAQ"TI#.<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@==+1$3/1Q</.Q<=-1![7P'1<L$-(QQK/Y)7\)8)C3PQ+7Y)2KXWFEH_)*=
M^WOK6\""-^]-'Q:M,T3<*)!6[QXOSS/Q-W/QPOEJXV6W[OH)4MZOT^3 IT@I
MQUMM3O["ND[=^)K3FU):1K0:Z?XQZC?"&)*0Y!Y,0GE%7HN"'U%\Z\E*C7&[
MG+R(NEZ?%B^A41/+D#%GHVCZ\E<I>;'9=;0@Q*TK>,V'<'>H-*\;8D=>7/C[
MT;BX4#J!#F.D0$;*W/D3LW/K2V(!'W)R)A8\A2W5I8_"--G%(*]Q5N:=_'6P
MF)R7R,X5W<-\WC_5J1T)H0<,HYFN3@A9\<T?I7UOV<7M;<E&NK4A;2V#A!WV
M"&W!WVVWT*;T&Z,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@?E:$.H6TZA+C;B5(<;6G2T+0O6TK0M"M;2I*D[VE25:WI6M[UO6];P(
M==D]/_Q![O(24[?^'4M=JF[)&VF?NM;CFJE=K!(QR1F5,3ELKJ8^=E(V2$%:
M$E0"C7&3$:T5[-R30YS(::=\1_*GE#[A7C?YBW8R//L8IY](\A2R>HUP. #1
MK3$'!SMHC[K;HEC:4Z!>8@Y*OM.!*T]I:9%ALI0<X'RJ\K>8%QH/D9X?VZ4C
MIFVE1C5]\<M?ZDP,'6D*0V/+V&HQLM9+F,XG:DO.+^%ELMA_388WW12!=AMK
ME'G]X=]FD!H&F]]H(MP*.7&,<]NTIKG/2%GH:T1]5'/[XBO6YQQP922FM-1#
MFG1E)>1O;>_RP)B8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M# 8# 8# 8# 8# 8&.6"H5:U#EBV.OQ,RV=%'P9*C@F'B%P\HW\<A'(+VC1;
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M^P:6EIX-H<IQO9CC3ZO@^0%10SKNMZ'?>3[*V&4X# 8# 8# 8# 8# 8# 8#
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MO>M[]E(5K:5)W_:5:WK>M;U@?K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M0\R%*PT] 3<+&2T*8,D-]X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MJ]^N,GSBZ>)78#4_ZE<#DY)=8%-(CG)E7.]R;(,E!D*ARS8221SJV&_I&I:
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M='(J/U^;R![[;&T[U(NR>K-'"H*>6 \;-U2+%:(&>?4[J.4,<0%IN P& P&
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M-C6:4093&HP- + \<,S'(@-!:!BFUQ$?MC8,007&CBE/!,W 8# 8# 8# 8#
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)& P& P& P/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g923792g47d02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g47d02.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1%B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $@< 5H  QLE1QP"   "JW8< E  "')R,C$R,C@V' (% "=-:6-R;W-O
M9G0@5V]R9" M(%!E;G5M8G)A($9O<FT@4RTQ+D1/0U@X0DE-!"4      ! >
MC6C!XC>[)500XE>]BD;^.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+'C4
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/T       2 #4    ! "T    &       !.$))
M30/W       <  #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@              V   !UP          0
M       !              =<    V                      !
M                 !     !        ;G5L;     (    &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG    V     !29VAT;&]N9P  !UP    &<VQI
M8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$
M;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,
M15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *
M15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   -@     4F=H=&QO;F<   =<     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    #.$))300,      =U     0   *
M   2   !X   (<    =9 !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  2 * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MR27SLKEH]S*JPYOJ-]OTK['[$"FK[:&7P]M4?HJFN=7IK[[W?H]FZ?YJNO\
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M5)+Y5224_P#_V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #
M     0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !
M,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0
M +P   #H "W9,   )Q  +=DP   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,34Z,#4Z,C,@,#<Z,C,Z,S4 <G(R,3(R.#8       .@ 0 #
M     ?__  "@ @ $     0  !UR@ P $     0   -@         !@$#  ,
M   !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!
M  0    !   !1@("  0    !              !(     0   $@    !.$))
M30/]       (          #_X0%(34T *@    @ " $2  ,    !      $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M?@$R  (    4    G $[  (    )    L(=I  0    !    O    .@   /
M     0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M-3HP-3HR,R P-SHR,SHS-0!R<C(Q,C(X-@       Z !  ,    !__\  * "
M  0    !   '7* #  0    !    V          & 0,  P    $ !@   1H
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( $4"6@,!$0 "$0$#$0'_Q  ?   " @,  P$!            " <)! 4&
M @,* 0O_Q  S$  !! ,  00" 00"  4%   $ @,%!@$'"  )$A,4$146"A<A
M(B,Q&!DE,D$D*#1"4?_$ !0! 0                    #_Q  4$0$
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MW;CV53HQYYPAXQ%YW)M/MTW5%3,4V,7EL6Y6IU]AQT8.,BORY&"^!8MK2O\
MK)VZ-$5>]A<B:,R$'@%>9.EVG?UAL)?TQEN6 Z$K-@TW 5-+I;A3#%="OMU^
MAAEMY^P3#?\ QOAWYVIO5<9",<C.S^0I*02AUP$,[BN^P@SSRAT--#DRH_5$
M^X&.AU*BLOMP<@]\BUM9:6Q\:&PK&G=&>O)5[@S8ML[=N70E CE9?*@./^A^
M>M*74P52Q7C1P:YM7C2D5R3*3E+[<2$;?XQQ3.,B$6(-PK$@('%F=.]#:)D)
M&;I_8O4NL-HC1H$S&<@>L'IC7<#K3;Q#?M'*I])ZZU=7*M5*K8IM\D8&MS$5
M?+%!"3GQA62$6*24=$!>;P_VIKWM[3S&PZO$3%"O%?,Q6=P::MJF,774E^'8
M0X?7)KX/P/*192%8D:M:H[&8NRPCS!C20Y!N3B8T'*\ \ \!9.M8;J^<U&0+
MQI;=64_<C<T&0@W;H4B_69"MICY5J2B@I&.@+=_'Y]V1>AS(Z;/IUMC&F@3
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M4O2W/V^&<+T]N77.PR<-$NDP];M42998U(;_ -8Q$U5<DMV2"?$?_#9(TQ%
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MFS[O4=<T>OC*,G;A>;'$5.L0PJ,9RHB3GITP"+!:QC&?]R2FTYS_ (QG.?\
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M69-X0)HU9HCU$.:J=!UVN=*:HZVAH(0IAVO[QHUUUO;/UD>PE$%"U?:$;?\
M:DR](D)_*).:V4W<OE=:82+^J%=7]4-0SZI5:U&4U ]Y\^;LX?EDN(9)V%<:
M^_M7EUY3R6_J/"].:K#G=?PS9JU+PD78**-(@?AIN4$#>>2WX%AFLMQ:DW5
M)M6G=HZ\VO65I84FPZWNE<N\+^"4+6/[I.M24F&A3R&W%-I4\E2\-N?C'^BO
MP$C^ > > > > > > > > > > > > > > > > > > > > JETTY:*+=9'='/W
MU0IN54R7M+3N<@1-5W.U'HL!"#8PYYO]?1]J/GSGVG;HX*\+<FXV/KEN>CV%
MBVVO!P\SVEJF5UJ2R14)^R;2GW2*,KER7@U ;-E[4?&BKD*G/5:RB#I#KC<?
M*M/3UF/%+K+\.XY^D>LY1\+&305JTCTC=L1=NKV]*[8=+:<7&[0.W)&<%%U&
M4VOR55YP^O"@)#CY$V6C"*Q>U28_WC-@4:G(A(-;SH%2IK<0, R@)\M'K$:P
MY<VQ_8OU**C&<8[ EZ._L?7=CB+K(;[U'M&J"V,RMEHK%IJ%$A+G&6<$H5+Q
M%:MFN8$AT1S#X1).5CM/AO'O7E](P9A!)';>N6&EJ6G\O5O9S:V_8VEQ2GV5
MT7#PS?M7C&'2&VFE+PMI*\N-N(2''E?U"WH_(<^ ;L:IROO;0K*@Z;LAL?.'
MEO-(;61)T^/&2O*F7<.M..I6.CV.%)9:>96X"<7#U;?0Y=F9.S:U[+N'/5QE
M2B)*8G-$1>QZC%6*41&!Q0DG;J.JH2FN[8N,9CP_IYF*P^2XG!*&GELF2'R
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M;5VU]U[KML5(P[[P,I'Z_P"7JA=]7T.1$FG8MHF)V/M3+A\=B<';8C) %!"
MSSKEOFV7J$Z)TSP[O#G&,JTQ'3^P.SN]]X5/1QMB@1 86JV**N/-4?)7?:4[
M&+KXGS4\,UG6J6IYB,&PU,04E9J%/!*.MQ.YNU[]L2J7_P!1)7.M8:A8>STW
M5W+V@8;5&Q9.F3<C))@;>N];P>VE;IBO2#460M$_KHX:&E!<Q!.)*.:DBHI\
M)U%]%GFHFQ*O=WW+V)M#9[XK8)NT;YT1.FW@Z/'?(*#B2I.'BH5AZ# ),,>!
M@WA'8ME99*EC/./O..!T9'I2U"O.MGZ@Z9Z*UZ<Q@9:8ZUN:EWO4#B!4&)0N
M6A-SZOMLVMDA1;:SF(.V5_)60 48=:;20@D-_':VWKS_ $8J3W#K#DSJR+@G
MBC)N]4S7].Y;ML15F7U/O3<U5;Q)W?6<QF'B_E)F3!=A4!I+065@PICI&6F0
MZ;46TM"]+I;=YYT1J><B6X&$G)VQ7V$I-0(K;5G"8.@DNZX8AY791BRQ7"2P
M2)N!IE9L(P2GZY;I$$AD_ 1ST%Z0G+W9J-;/]?5N#O[VK;@;:ZS7=5UQC2-"
M6U((CT'P$[$0!TM9K-&27ZL#]@[-7$DMML1(T(Y!C'V!J<!^*]SKS_4X&&J]
M8T?J.!KE=C 86"A(K751"C(F)C1FPP(X 1B(0R,((*TTPPRVE*&VT)3C'^/
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MA'0IN.P&L\DD<5LM4?\ 9<RZ^&_^<IR$.T:$ZDU1*$0]IMD#TKK5PQQ</9)
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MG]S] 7$9M-QO\\<ZT0^%'"X?,&H] C7666JOKFMOL5J &8:4VP0>H@]\&Z\
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MB1$<$/K%LQ%Q\A(P4M%OK,B\G1\BR]&6FNX*6YB4J5@9+AI0,DQG#8A3[9[
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MZ')(267&TNLPU9#--2TAC[QS$.&&@X]3+:&W#B\/%NI3CY'E9\#NO / / /
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MB<EH4.S)/.)4G -[X!X!X'YG.,8SG.<8QC&<YSG/XQC&/\YSG.?\8QC'_>?
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MU2$ZO[$@?==8;^VSIL&"VJK!"5,[6I!,M-X>3(QLX5.F$//Q0>'8_8G/,1_
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M2A"$)PE"$)QA*4I2G&$I2E.,82G&,8QC&,8Q^/ \O / / / / / / / / /
M/ / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
3/ / / / / / / / / / / __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g923792g52i76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g52i76.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1?T4&AO=&]S:&]P(#,N,  X0DE-! 0
M     % < 5H  QLE1QP!6@ #&R5'' (   *K=AP"4  (<G(R,3(R.#8< @4
M)TUI8W)O<V]F="!7;W)D("T@4&5N=6UB<F$@1F]R;2!3+3$N1$]#6#A"24T$
M)0      $ %2RCII*@TH";(._BHX/[0X0DE-!#H      .4    0     0
M    "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M    26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R
M:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M# !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M  !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M<L>-0         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 !
M \     !  $X0DE-!"8       X             /X   #A"24T#\@
M"@  ________   X0DE-! T       0   !X.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-! H       $  #A"24TG$
M"@ !          (X0DE- _0      !( -0    $ +0    8       $X0DE-
M _<      !P  /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              )X   %CP         !
M      $             !8\   )X                      $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   )X     %)G:'1L;VYG   %CP    9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   ">     !29VAT;&]N9P  !8\    #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     #=L    !    H
M $<   '@  "%(   #;\ &  !_]C_[0 ,061O8F5?0TT  __N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $< H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M+G_]MH63_C@^KU8<VG$R[;0V6M>VNH$^&ZV[U/\ ,JL79Y'3\#*(.5C57D:
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M  %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (
M   )    L(=I  0    !    O    .@ +=DP   G$  MV3   "<0061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP-3HR.2 Q.3HR,CHT. !R
M<C(Q,C(X-@       Z !  ,    !__\  * "  0    !   %CZ #  0    !
M   ">          & 0,  P    $ !@   1H !0    $   $V 1L !0    $
M  $^ 2@  P    $  @   @$ !     $   %& @( !     $
M $@    !    2     $X0DE- _T       @          /_A 4A-30 J
M"  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD
M!     $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$U.C U.C(Y(#$Y.C(R.C0X ')R,C$R,C@V
M   #H $  P    '__P  H ( !     $   6/H , !     $   )X
M  8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M 0 "   " 0 $     0   48" @ $     0             #P     $   /
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M  0" P4& 0< " D1$A,4%18*%R$B(R4Q&"0G,R89-C=Q@?_$ !0! 0
M              #_Q  4$0$                     _]H # ,!  (1 Q$
M/P#?XX#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.!QVV6^IT*O2
MENO5HKM+J<&/]N:L]LFXVN5Z'%]Z6_LRDU,$AQL>/\BT-_,62RW[UI3[O<K&
M,A2]V7_D8>)#K,Z;&2':"(W5: <NX76.N$45N'*_@?4.1_\ G$*L;4XRAW&B
MU.M2&P@WDL1LP5AK(T-+/!A1)O+^:/1\.G1G6?I].$+1E2 K'OFX.1J_5S&4
MMK,HVNHN=4VH=U;."ATW_P"3WM2HZE#NQB<FA5')?R/O+QVALLH+5=QU#3T
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MK%HO<M-AK*XX*Q8-.]?WX") #6X2EIN1W3>=BGL0A:,O#M/2</.54E[,0>^
MPTV6RTD(ZU+^.%Y-^TI(5[[=]@JG2;++J-'G2]I7W;&^]LQD8XV+]?(TS%[A
MGJN46^LJ26L%%B% C208@L9;KHHC806UZ!_BW])=?HBI#?.U.P'8R<!^)PJ+
M>V!9-8ZW*)P7D]YUNI5J>D;(.E9.&&T,IORAD!1\<UD=1 ZRG@O(T5TIZC]9
M664:#ZXZ=U82QC*4S55HL$)9W$^GIA)5L>$?LQB4X_PA)<L_A&/7",)QG..!
M)_@. X#@. X&L5_)T[@5W5/5FF]7Q+?78>U[RMU?N-QCI*;KH1B=5:TFD6D?
M"@C=SZ5L:1YJ]5^*DE/P=@?:F:[0;Q52F<OS(;) 4'?QR('9':?RZ&;MN$E+
MVR T=J"T6ETF<NTOL<2MCOAHU?18AN;E^P6VWA[ *3(DBQ_W695TQN O,L*7
M&D&.ONA]&;@. X#@. X#@. X#@. X#@. X#@. X#@. X#@:^GF[[/Y%&H/2N
MK_DI63V6/7=A;:KM?M@-/F;'KUV\AU"@:Q9LP>X-2VRI.[LVMF&UJ/:(25QB
MM%SD=:95Y-6A;(VL*2YFW7)RDD/BW^YVA<T$@QK\7?=SU9RVILK>#&38TIWO
M.#BJM7UO>T-,0PSQ8V:'_P":VG8=[X<](WFZT%?+]OLN+2-+F7BQA#KR],YG
MRM@['D8YY#K@5C3;,PC7>ALA,22*4WL#]55A3S-8E,Z\4RMX)T-8>^BJ!V#W
MM8XW6VE<;#LUNG)P""B(<#;ES.-;-48<&X,2'-=_FAY5Z <H4R](N/$C!V<C
MKKLH%!*L=D8K$D%I=1_C2=G;W3J=9K3V5C-:3TH+%2<[K*WKW[89FE*.@T2#
MT,1<*OV\N$19IJMR =$JYQ#3V(F9*HEALS1#@NP)>*(#RK=_%)W2Z6212^_,
M T&[(Y2%%2M [!@8!@EE%CJ9+E?_ "MLY<O)-UXOZ*2&F(7#LHUF7RXT\XV@
M4,667^.]Y&M(5S\[K3<]<W?866"U&52B; W=1I*52_%G*-  EK]VDU[!1SI[
MQ=DBXZ409'O0Q=YC;&(V,5J^L)(".FQ= ^4/1D(3=NPFF]IQ%&;EY2$=L1>W
M)F!#DS2K%=H9Q(4+#]^\OUEBV25@LBJ^4,'^*IPV\]?2,.8FO]8ZW("!@('L
M)#;'BVS9:^?G8YOUD")F..V37A4LY&Q:G;']3'=MG!<.L=]Z\-UX=+F&ZXK.
MNV6,_2""8#',C0*JB0'E:S:[=0PHQE3Q.)'9NS[,BO9@E3Y$E-EH8[X,O38U
M&CM=VZ2E@!?G(MK/4_88D?\ 8([ TQ)(<RCG-D17V!7-@VID2OME+-KEHOM\
MN E5?@%EN%#27W>_!0ME_1R--V<.<<%20/<D]4MGMLX?CNRL4+9@F=U_[Z=I
M^LJW(_5>R)J!&;D$L.4FXR\=M6E?99M#<6[ +B=A=MK6^$8824)K_$_"2H.6
MIG(EO=?5%*D&G@OCZY^>O75F,@Z[V5UC)Z]:/"AL9W1KJ2@;MK(T^8.J@@#Y
M]'C+-.[5J0DL+LC4LJ P/%WC(Z-HUZ+D#AY.(MK, %VVF-\Z6[%4J.V+HK:5
M'VQ290<,@:PT:Q1L^&U]\$:2&%D4 ON$P\ED$P4AZ)EF I05#[>"@V5J]O R
MUP' <!P/S./7&<8SE.<XSCW8]/7'KC_O'KC./7'_ 'CUQG'K_P!XSC_' PK)
M:DLTF(8$YO\ W6*T8A]M3D:K4D<6.A]N81C 9PFIFC!5L9E!7&'FGTD)<@8?
M*G5I5,)EPX WU0B5'NGR6]^U4OE_"/E$<[ 76% RMM/M2XT+4GJZD3.?\*6T
M'D<=Q2?5QE>%+PH/ ;Z*]7G9U-HL.O)&_P!D2H5:IS:>Q=G[5.6L-I++.?\
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MUVR+UHK7?8'8M,3E\^,C'#9"OW+2] N<3&CE23+JGH@>YNN1:T32&_Q@D^1
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MNFW::(-]CJC&$V7KR0()D=XIHKU,,VU%NJ0%F*L6#EO BY$=JUF:>0G]?F%
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MMJ<:5.U],Q7EDCEB-RJBA"F& E[P' <!P' <!P' <!P' <!P' <!P' <!P'
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M]K+MQ8V:H1"V$_8^LH&R6AG3D9IR V"J!J<](PDQ#0\-)ST6Z]5H6S":UF
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M?^6IMHKMMBOD<9_)UF;C)Z/^9I:VG6ONQ1)0WR-NMN-N-_)[D+;6A6,*2K&
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M%)84MD@=]I:'67FEK;=;4E:%*2K&<AY/ <!P' <!P' <!P' <!P' <!P/$/
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M*J2#](A%1;RS<Z&M+FO;6_(%!-B1GZ51+%$?*!9J3I-T2SO0^L(J ?#7BO\
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M0P1-*-KE59TZX(*RX[:9WQ@F",-F2E:CH<+B/&OJ;N+?MEP\!N2X:7&U8PS
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M2L>@1H"8B==5G$R T ^Z4"T!+$1[\@"T(2^Z2,T(2RVR0M3[:4NY]_ ECP'
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MNXVP/S-D'E-L[!>D%/:\#9M@L'*ML>6"X(EX^$SU[DQMA*D*],,VYGI9W&9
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M8*3LMFM%NG?SUUN-7I&L]:5F(LMJ(<C[3=#8:K1L<Q:).WLO!AQ=?9E9,,Z
MR@Q[:7&T&#>]3*6VY$ V+?=4_'CR:4M#R# SSJFAB4I)PA"LBE,&!$?&8"6R
MR&-]S[7UMHZAV7;&RY2,B8BBUJ?L'S/X%=G2QPAF5$Q%6!6K$C+SDX5F-AXN
M#B$O'SDR=$1(HY!IH;#@4X>*?3E\WQN?='E%[ U0*$M^V"9S7G72+(B:JZ='
MZC27%?L^Q0K"-JS65X-B[Y(P,-1]?.7P$JU8TMK*AKDSY!,HV4Z%]' <!P'
M<!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P'
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6P' <!P' <!P' <!P' <!P' <!P/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g923792g52x14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g52x14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1;^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %@< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   JMV' )0  AR<C(Q
M,C(X-AP"!0 G36EC<F]S;V9T(%=O<F0@+2!096YU;6)R82!&;W)M(%,M,2Y$
M3T-8.$))300E       0UMXE57@?2!ZIE*=UKU:6 #A"24T$.@      Y0
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M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M \     !  $#P     $  3A"24T$)@      #@             _@   .$))
M300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M      $ .$))300*       !   X0DE-)Q        H  0         ".$))
M30/T       2 #4    ! "T    &       !.$))30/W       <  #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M   "50  !?$          0                         !
M  7Q   "50                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   "50    !29VAT;&]N9P  !?$    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   E4     4F=H
M=&QO;F<   7Q     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M      0    ..$))300,      SS     0   *     _   !X   =B    S7
M !@  ?_8_^T #$%D;V)E7T--  /_[@ .061O8F4 9(     !_]L A  ," @(
M"0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1
M# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  _ * #
M 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<(
M"0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(
M!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/P
MX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U
M 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086
MHK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U-C&5L:QC0QC
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M]3_!9.-CK$NQ_0RIH#LK;);>W=MH#M(R;"+6O8^/S_5MMJ_1Y]?\Y<DIZ/\
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M;/124__9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, -@    $ .$))300B      %&34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    )    L(=I  0    !    O
M .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q-3HP-3HR.2 Q.3HR,3HP,@!R<C(Q,C(X-@       Z !  ,    !
M__\  * "  0    !   %\: #  0    !   "50         & 0,  P    $
M!@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !
M  $   %& @( !     $              $@    !    2     $X0DE- _T
M      @          /_A 4A-30 J    "  ( 1(  P    $      1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @    D   "PAVD !     $   "\    Z    \     !
M   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$U.C U
M.C(Y(#$Y.C(Q.C R ')R,C$R,C@V       #H $  P    '__P  H ( !
M  $   7QH , !     $   )5          8! P #     0 &   !&@ %
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MOP'G P$1  (1 0,1 ?_$ !X  0 " @,! 0$            ("08'! 4* P$"
M_\0 ,Q   @(" P !!0$  @$"! < ! 4#!@('  $("1(3%!46$1<A(A@D"B,Q
M,ADE)C,V05'_Q  4 0$                     _\0 %1$! 0
M         !'_V@ , P$  A$#$0 _ /?QP' <!P' <!P' <!P' <!P' <!P'
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MA,"-$(PQE@*$*'SD@)'GCRQDAFADSCDPRQSPRRQ[Z[X'+X#@. X#@. X#@.
MX#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.
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MR00UGYS7[6 2=8:#VN<8ON,WI<J"K?B2ARQ/J6OIVJT9F$\<:+H:.R,J\@L
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MU9@RLB8L6#-!L7!0%+WV+"U[SE4/H\(8\ [&O(ES' %;JAL@MRX#@. X#@.
MX#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.
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M)-2J^$E&[#6@)QR9H<>Y3V&*M5 ,N!S9L92V,PXD$<.$Y4GT]=_]Y=AL;@.
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M@ [4'9LPL62W$-D&3DP79==]XG@XPS9]EA9===]XE#]20=]==_Y)P.WX#@.
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MDW\BHJ,VW(YLC:OK"MK[Q+ >+5O]Z)77R]@GK"1S>1CT]& :!DR6RS:_VTZ
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M[DSU=K#5]6H:QD/N'7S\N?5:VO8P1Y=@SNMKN/Z:[#5]979:T%4W<!3=7&\
M=VJ$(J3-5%SM]YH5U14JG[)2)73=SKN;"H%'/G%9"<R;Y2$5;+M05=+=_P 8
MG2[D9U4492UA2V'=='-9"I/0'3A2&!EN;E)<\[1HL]/JGU&8G!41;FHUF6N'
MUI>T,)=7R:,RSA#QK6PBMFB.DFNL\;2#(J87%;I/;R#\,_>4M>X$D*K^AV68
M3J3:JG5E9VYMMTA8-_5D5[R*KNYXMM 391/=6=$5A% -LG:*%< DIRA[FQJ%
M3&J]Q?KH["30YJD %GZ:EZ]O.PVIR]XB[TQY6I[M6_'3%P5Q<;=KG4EBYI.3
M-G715Z@5'JA-+KHE;^_+E3T^S@%G,AK0JFF("&5%W17]@HTE>T90:+M;<[_:
MB?T?LVOT@I0'623T8+5WK57V:JEL#,ZMZ((CU74H*WFG(*9&)K+,)-6/P,&D
MX=IK?6NXMHNO.VQBK6CJ-?>[]WO;6]9K9*M[LC7-^.V,XUE:+0=9; *4I?[&
M!ELJ&N3,@459_F*D">$/7LFYK#IH$V?/WAWS@]L>V]C['U]3][6>/=%K0538
MFUT==O5R@34A)6=?V!8S;3HQ@C".]A5B\&EX=PFR0RF= %D1S@]K5P65JU2M
M&N#4)5H"=2N@P%7JU88Z]<"+%U_D0P80D<(PL$?7_6$,$6$>'7_6./77 Y_
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MU 8U0$+!5]KC[RQ"$P![8.YNY>_O3AH?<VS[1I=(N2V6 =Q5[<JJ[VZ@)U&
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M?L.Y3JE:=5:FUU6+/LYW8*7"U:[*I,6OV6NR8=D7VXG+"T*LXN:"IZU-44"
MX&+(] IK9,<1T0+$/$0-1JP-DZTNK9/NBJTL:XL(%ZL$E9>Z('F\'&0H\2E#
MVT/G2*>OD6:ALQ;M6V$";+.CEU/7A@]:8 3-WM=#N7;\U+1Y5EG1Z%;ZQL2<
MZZ#2'V'4:53;>^Y&UOJ;L>OM&#62''8X%Q?5F4X&)8BJJK:4B HC.'S_ )RW
M8.MU(JV;6K]KS:7KF*?:/C:D;0MU?U;HQGLW45ELVMI6N4SRDD;'76&UURM
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M33P_>"Z32.U]:;)Q@]'JRJ#KK66@*?U2ZC7D5DUV.:W?O,FHUI@>(4)LHE'
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M*57+"E_;H,@$EBK)]GKE>0X&Y+T_?0;VJNQ!TE,K.13D-/L(60$Z[D8@O#W
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MVV[U]K)I^=!"IIIP@6<8RZ[5Z,IC:CU2J2;+M3U 0[(&#<Q#AL74VF-7'/\
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M)Q#,[>U',:CN3R <CF10:AW'\:..WK TO["PZY2WQP&R'DQI>OL:16E[ @:
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M0CN%:(UOK$RI;9_' ] 2!7!-<]F7W\[MQ&YM-"+L6N]6U16XB@;]#*Q+B=D
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MB;,MK=6"?[DJ2)O5S'CI$+TLM=-L/028IN9D,+CF,5*AA7YI)C+.'M!X#@.
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MKRDK:=VG5TS)UVZ?_L#*(OS&IC*?ICUA^Q0E88+DF&&*5>$P. X#@. X#@.
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M@. X#@. X#@. X#@. X#@?$B",D><:7_ 'N(B&6"3KKO_.^XY<,H\_\ ._\
MO_._IR[_ ,[_ ,[_ ,[X'C<^,O!@GUVGU_"JE+?[AO\ 8J9D0U;:]2L5E'53
MK:Y@3 B666-T0&_-1V@HHL92LGS1Y/E,3.KKL_\ ]7AZ7:0I4UFM#U:.F%F:
M-KI5B**M],(!-K%U CK\;']Y8J\*\FL]BK,XY>=7S75]=:@7E@5%]EH1:@*K
M.R#O5H59<@8;&JNPQ5FNT[L'%+663&Q/:OTW@9#+0XCD&5H%S#-*8_STE'I
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M($!$*TI2GHJ-2FC&SG8-\2LX1 >Y8RQV60TZDI1E"$'A_G9 7S<!P' <!P'
M<!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P'
M<!P' <!P' <!P' <!P' <#JWG6621QUAU_N?:MAUCU]7>/\ N78DW6/7U8_[
MEC_O?^=?5CU_O7_UZ_[X'D0^"_\ RH539^N*ZQ;N;+N%86._H;1A9V;I*LK@
M1'=PEI#JT/<4W1+I4;#%,PB'"[E,@KD9\<T\0,T8>F>B"T*\F9M]:DW+79-;
M@Q3A"X=,D2MQ .+F%^453F762BS@*(9^AE;$R$R(,J3$@;&/'L>8P.WL#*5
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M!P' <""/HWY&?-?EX[="[9#.V%D: UCKS9NSLJG7.G@R/K<-YEU[I_7V!<C
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M^L/8GFO/3^C=^8;35Y:A])V'4M4TA=>E%G_"O]@WJ:$NU.M7@?H_W*Z2XFL
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MF!3#(OP72'8LV"P,P/G9_26B:;O#6WFNR[0JJO?6W4-EM.N]4R&YD7*QUBH
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M[T%_R=$IU_ZVIFYK50\,ZS;S-!)G@>I1+?K^II*Y>X:A'79P:/\ O(5Q9F'
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M].T[7=P3'UNTTK6VW]O/6FO0[#6F@H+*M.[-5@UVP6]?8B#,DS*XE+VD$+*
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ENO\ .NNNNO\ KKKKK_KKKK_KKK_KK@?O <!P' <!P' <!P/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g923792g57t30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g57t30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C,4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $@< 5H  QLE1QP"   "JW8< E  "')R,C$R,C@V' (% "=-:6-R;W-O
M9G0@5V]R9" M(%!E;G5M8G)A($9O<FT@4RTQ+D1/0U@X0DE-!"4      ! >
MC6C!XC>[)500XE>]BD;^.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/T       2 #4    ! "T    &       !.$))
M30/W       <  #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             #4P   68          0
M       !              %F   #4P                     !
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M;&]N9P   U,     4F=H=&QO;F<   %F     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    #.$))300,      [?     0   $,
M  "@    S   ?X    [# !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" "@ $,# 2(  A$! Q$!_]T !  %_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
M @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1
M Q$ /P#U.NNNJMM530RM@#6,: &AH$-:UH^BUJDDDDIH]8R<O'P_U(-.5:]E
M=6\ @;C^ELVN?4U_HX[;KF5NMK]5]?I;U5Z7@=8.&Q^=U+*%[MQ<QS<0$ N=
MZ6_T<5U?J>CZ?J;+-F]%ZY4^^JFAEWHM<\FTLUM]/8YECL?]Q[/4][_]$H_5
MSJ;^I]-KR7Q+VLL9K[_3M8S(H]8?Z;TK6>IM]B2GG\#!SG?XP.IMNS[R:L.H
MXU@](N%=GI>HTUV4''9OOQW_ ,Q1^9^F6[U# ZLRIMN)U#,L<VP.LJ8,3>ZN
M"'5T_:,>O'W;]COTCV?\8JV-_P"+W._]-F-_Y^RET*2D&%]K^QT?;MGVSTF?
M:?2GT_5VCUO2W>[T_4W;$=)))2DDDDE/_]#U5))))3RGUKP#U3ZQ] Z>YY;C
M.^U7Y+.6V,I^RV#&NK/MLIMM-?JL?^8MW HQJ,K,9CM:P;J][6Q (K:T>UOT
M?T8K69]9<?/;U3I'5<1[&58%EC<K<TN<ZN[TF/J:6N;Z>]M;O>__  [,=:N'
MO=E9=VGHO<P5&2=VU@]1_P#G.]+_ *TDIS,4#_GSU ]QT[$ ^=N8M]8.+_XM
M^H?^F[$_\^YJWDE*22224I))))3_ /_1]522224T>K,-E J@EIEY:-L.+/<V
MM_J2WTW?GJA7FY-?ZO7:VLUL:13%32ROW5UN].?;3^B>UO\ Q2T<XM-M5;@(
M<VR21I$-;MF'?2W+F.O].Q78^3DCI>+U/J.+61C56T>H7S[FU^W<_P"@_?6S
M_MOTTE):LT#J-O4:[V.RK\6H/<+*2PX['668^0QK3]"VRZS]/O\ 25W]LYY!
M+2QT:F"P\B6\.<O/+<OZS/%3G?4G# H$5?JKMK1+K7-:W?MV;[++/^,>NNHP
M<#$:[[+C8V-Z@!>*J R2!IO=5LW[=Z2GK>G76W8C;+B'/W/:2( (:]];?HS^
M:U654Z7'V,1'T[.!'Y[U;24I))))3__2]5223$@"3H DIHYC9S*WN]K65/:'
M<27[2_G]UM.Y4;KM[@22UGT6G>!H-=W\K=])$ZI3=F466&^[%8(V"B&V0T>K
M[WEC[&^LWV65,V>S_";UP^9]8L3 RGT8M5&4RFU[+GY.6!<+?\.VFK+=D7OK
M:[]!ZS[*Z?5_T6+^L)*>B.1E.R7A[@,5S6"EC7S9ZDN]?UH!;Z>WT'5[?_2:
M4V$& XD?\*)DSMT&YZJ=+ZIB=4QQ=B>^HR X8[VM<!$N9ZFQVWW;?_/:AB=$
MHQ>N6];]5WJ6UO8ZKT6@ V'>]S[&_I;:V>G2S'KN_F?\&DIZW"9FNQFBNQC&
M!SQ):;''WG\[?4UO^:]7P"  3) U/BJO3 !AM T <_3;M_.=^;JK:2E))))*
M?__3]50L@D5P#!>YK9[ZD!W,_FHJK9S[6UL]&/4<\-;(D D.VN=_):Y)31SL
MUEC7LI]P)?+O<9ANS]'L;^^W:ZW=^C7D/7OJ-UO)ZQD6XCQ=C66.LI=9N8&"
MQUF3Z,O8VKV/?9[ZOT5O_&7^FO6.H%N.YE=;7%K 0QC6 C1SOW2U9[C:YQ<[
M<23J35_YDDIPNDXS,2K'Z;;ZI./0&F\-M;66@>[].*G4,_XOUO5_ZXJW2?J]
M=C]<LS[K*Z[Z[;2[+HL>QF53<T[:\BHTL8VVBST[;<C&_P )_@?6_65K8>;U
M*_J653=6&XM!<VL>A%FA_1V>HZ[;:VVKW>VKV;_2_G/45_WQ&O'^B'CK^=^<
MDIWNE9..^LT5O#GM)<0TN<()_?<!_F+07-X-UE-D^K]FK<??8^H;0"(:'.WA
MM7Z3_"/_ /1BUL>CJ3++M][7!SP6E]<@C;6/T89:WTV^U_TOS_>DIO)('VAV
MS?M'TO3B?SM_I?YGYZ22G__4]55;-!+:W<"NP/)\ T._K*RA9&E8=^ZYIGR#
MAN_Z*2G!ZP6?:Q.P$-,;G[9][W=OBJ0+ 2 6-)_X0_+A7.I%WVIX;NVM&T$-
M;  <\_\ F"S[,PM,5>H]W/T  #IXQNX24YP;U&G+LMMS&64V-;MQ3:XAA:?I
M!V[Z+_W-BM'.K@;65$\D&TP?WO\ S%"+KG'<[>2?%@3M-FPZ/D$'Z \^-4E.
M]T1E%V0]A:Q]99,;MX(D.9['_NKH5SOU7>]SW!V[V,+=6AHT(V_]%RZ$B01,
M3W"2FG-_I[-K9CUYW'Z7J>KZ7T/H?Z^FDC;WQ,/^A_)^E,;?I?SG_@222G__
MU?4ZW;V-=$;@#'Q2>)8X>(/^O=.UH:T-' $#Y*-MM=-3[K#MKK:7O=X-:-SB
MDIY#J]W2V9;J\K[1=[&.-&&SUK77.-GJ?18[974VG<_UO\)D+$LZ]]6ZWD'I
M/770=H=]FK /?\]S7+L#T9O4ND?9>J;ISXOR'.;6\UV%[;F8[69;+ZO3I:?L
MM6^C_ _Z=9UG^+'ZNV.+R7AQ$#;3B- ^5>$Q)3S='7>BW95@;B9XQ:V ^CLJ
M;E5O;ZEF1=FNOM9BXN"VCT=F]RV[L/I]6)C9)KR*,:RRHVON%5D,MW,9LOQ/
M7I]1SK:7U;/7];^C?SMJC7]3NELS+^C9;;,W!IJHRJ=P8"<FVS+JM;Z5-=5+
MW>C75[K&?H?TEC_8M]_2Q7TVZ;WN'HN.^QY>T0WVNKJ?^K-;5^9ZM%J2F/1:
M.DXV18<"RQ]IAE]5H+'L'^#>_'LKHM9[OSO36XJ6/>^W$IR75D"^MMCH;+FE
MS6O;N8#^9_(]3Z"L^M5$EX/C'_D4E,MAF9[S'RVQ_P!^20/5NG=Z;_W]NGT?
MH>GS_._X3:DDI__6]56?UH"W"&'_ -SK&8Q;XUO/ZT!_Z!MR'+05#(_2]8Q*
M>6T5VY)\G^W%I_SZ[\M)3><UKVEKA(/(4"VP"&/'&A<-Q_ZIJ(A9(#L>T&8+
M'3M,'CLX?124Y>197B]2R+KCN#JL>HD@M/Z>XX[6ML^AMW?0K^FB_60%_1KL
M9N@S'58;B-"UF5;5@VO;_*KKR'/:LYE&*[KN1@N-K_LU568&N>"V7FX5G</T
M^^IV+[/?^C6AUS=7TJJR7$49&'9:YQ$[*\C'??98[V_0J:^VQ)3J    " -
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MJYK_ */LM]B[=)2DDDDE/__9 #A"24T$(0      50    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@
M  @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q-3HP-3HR,R P-SHS-#HQ,0!R<C(Q,C(X-@
M     Z !  ,    !__\  * "  0    !   !9J #  0    !   #4P
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
M  $  @   @$ !     $   %& @( !     $              $@    !
M2     $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P
M  $      1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
M    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$U.C U.C(S(# W.C,T.C$Q ')R,C$R,C@V       #H $  P
M  '__P  H ( !     $   %FH , !     $   -3          8! P #
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M 0$! 0$!_\  $0@!$ !S P$1  (1 0,1 ?_$ !\   $%  ,! 0$
M   &!P@)"@0%"P,! O_$ "T0  (" P " 00" @(" P$   0% P8! @< " D2
M$Q05$18*%R$B(R08&B4Q_\0 % $!                     /_$ !01 0
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M7.-5VM^B'15'?C.Q36)QNH[Y1]*&HY14!;5%L6XDNEPWEVLQ#!;7ASPZHVF
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M#&O4*X)RISR]XX=/YWG,8,2RV;1B7(0P:M##&3$HHXL@B0'"\ \ \ \ \ \
M\ \#/G[J\M!O_;/:L[V4Z:BH?KVLIM[N]8:[L+9JU1\JY_Z9$5SJ=NT>J##D
ML M0ZS<(9MN>0)5K@&/%I=L#[/GI*!(@"4'QF>W]R]DPVK%_F\.J!TY0UZSP
M6UWH%$$Z8<RKVU%II!DL5?05(0:OV9TYPYI 1]52V'5? Y8.,'PLE1LH6V>!
MDL]&RH2?\K/Y1X=1_HE7^I0H\A'U3_S+]_;TC+UUSKOC$/\ UUFQC&T/\_\
M&/IW_P"^,^!K3\ \ \ \ \ \ \ \ \ \ \#'C<OD$O\ [I^S?L'\4%(Y=1+M
M;.J>Q?NYZG]6Z_U6RNE\?'O7 2[7B2XJ:$KJM=+?6%Y8J37*M@/$CE>BK[9#
M4(;$"<ODA<JPM&](>%]I]</9/TXYMT>%"*-'\</M(%9(TH$4QI-WK_MIZ[69
M7BT-Q?\ \L1RMJ'5X8C $6TJ9I:3KN4NFF4JE,FP7D>!DH]#1,__ &KOEC,B
MW^J/3U<0QEPZPZ?R.02'Z6ZCE3$QZ?SC5E ND'&'GD^YKLE,FCBUCE^Y*&M?
MP#P#P#P#P#P#P#P#P#P#P,M_P3^N5.N???D_]D.G4VMV+I(OR/\ L4$D<OD/
M[!S7WP/1SF9[FON]6F$8VNY@2_.HRVK#F*6 D^8+$3J26'$&@5^5!+[9\C&B
ME2S3">O7L?DS3[LV]@#R1T7U1W%TCCCQL,.K,CTFD,_+VB)G('6; ZRPQF[1
M!(OP,LGHO%G7_)S^5>7\#(^)?6*D?^[M ;'ECMH3ZZ1YVTG)&B'(B%UUT@QA
M?.4-%-B?63>,W8N&(-3?@'@'@'@'@'@'@'@'@'@'@97?AK]P^<4_W[^0/TJT
MRU@$Z+[>^SE[Y*Z:88[X9/:OTF^36"H;1L81R4^G]#6@6-%&7I'NXF66S.@(
M<B_]A8@O<NLJY;[Z^NT\>B;]G9?5WVL0&ZPKE6;-.*IZ5ZGOTIA;3(W[K6KJ
M-];('H)J;A;J\LP\FP<I,WY X3&\#+CZ09SG_)J^47.,[YUQZLT^/_G$F--=
M]''K_)MIKG)4T6VVNLVDFWVX!-L8EUQ)'+_TGD#4=X!X!X!X!X!X!X!X!X!X
M!X%"7M+P.L^G_=-_9U);:W1*E9;EU_K;=^'16I=DYR58%$-FZC8'#%:>< _3
M'6AI:[;JS85&T6+=K:TM"55S=<"!8T@6?\\JT?4>O5#VF8UQ:OP%P@WF]#.E
MV$):%)^B6&G=#LUC2- BB-V=(M\%:HVB."QK*A:T1E9<[F5[ ]F_]4)7>!F!
M]*898_\ );^3.7(OV82/5>M;QDXSG.I<L=AX##-G;^0QL8D@TC'BSKK.P^F/
M[6V2],R?@A!I^\ \ \ \ \ \ \ \ \ \ \"L7M]EM:?JI_<E;!-^XH!3#D5/
M3LEZ<M7!O^0>786(&^K&![O8ITEC /?P'/5*<M"DVV%IA+*O*[&S!'1^UGL<
M3G0@9CS\@;.Y>OXPB0:8SZXM(M80_N26",3#"0W$P$0\\HHL\N8R=6&H.PY)
M@=2[]OO912BT::;THS3[,.&18586G[I_L ,YC&4 FW0%BYN'*3"OWVBG>ILP
M@F"X#(9,L6$"JA7IS=,9Q[W4[?[^5):3MWOV2J W..@J2-$9M.B&1F5*<89>
MLU(7.E9T8M#3(ACF[<]7LTA:F2%B GB0:A.7'OUWW$$,&HO.]RHYYM22=ZKI
MG.\&1=(X=M!R>N)QYI<&,ARH-:X7;9F"U25OD%>=L6L'#FS>_P#VT<R8K*BG
MSK8BA==@=:L1B3?6-;B<T88D.^L;5/++.M/^P0MYV]$SN[5[RD@@K29F 2N]
M/^_]8[)8^FHND05/<6EI>>&+&U97X5_G,K>(\;,Q) L6>SXP.I7QHP\3Y,TE
MV:_N!YH(?Q8LS!.SP#P#P#P#P#P#P#P*Z^J)'1HG3"UZVGM&0-S/(1+V9@HK
M'44U\S":&[--JC+ I)*)T&73+&<=D7;IBACS+ ,38@:X$%2GN?9O?WG=?H%D
M]/?6)+U_5+>[,X[?6I+U1E5KFY MK8\T8%)A=OA'EKNMW+,W8KR*Y!.W535-
MBJ9U(YC8ZNN7!#.T][^<R]5^LLJ_\9/%ZK]R9%=[(!9/:'C#\2S@PJ'.A?,W
MR6R%UYE0;,?9=JZMC)+4,M*7D+*5ABIC%->B(PZWICSY:.?=O7,0/4&A/^/6
MZB\K7""I[W2_XKG5+<2&?9F3N]*BNDOYZUR5DYFL-K<V&HA\M*55$61?)E[9
MM*B<")VZ?\V>NTFY/Q\\K._L]:J[1%-I[(\L$W2N#H>9K;73KE#L9;5VP:<B
MQ7X;8T07GD(]>&(/FL=A;@JU5H">'*HO:=MSFJ[]=XRLYKU,V/<.S<ZISQ/T
MA"!%!9+5J%A5:$1*S=D#:*S*LL^D9O3.=Q*3AH438-D4!"U*"W7T1474:\=5
M;6W\TN$SG?%EJUD6O5AXQ(JDZ#L:IQ)$AJSS>8;!HK3<=S75^PPKD'[<QT\I
M7XH67> > > > > > > >!7\F^BR,>QG1;BQ_=Z1T)%J0T=,]82 *W;V":< =
M:\M1RXE(.S$M9Q,Z$.GJE;("QPLDQ>9&[]^$1[A2Q4EN:)FG4F(06C0N4(:R
MM*<1HJWE=ODHP[K!E]U_)^G&!AIX@H@BW=4U^U(X#RP<3* R'?-![._+/Q?W
M"!HOIET;V<:<7L/(Z$U0;\SXX[>:BV"8FUPO5FMTCK5L);7#Z8\;7$^OO1)I
M)=X:XY%WWK,&V J!(][/GV,CE(EL/N)D7!<!,^L'KX0*O_80L(WHADXHG+(
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M@"U:+ " "+#KC2$8,,6.(<8>+3&-8X88](]-<8UUUQC'\>!S? / / / / /
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MVMEJD'Y\@DQ=BTAUF 8A7)[*C=?L$O5BYP4@A32VUS^N5NM@[6]$X2;4Z-3
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MWY6?2;W@%K?.O:7UBD%Y:TXLQ9&6Q>?T:L<^06RN.3:XVU66X&T7?2CV3/\
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MYF$!6MEDB=J=L3KC04M;4-]7Z?=KI&I.&>(EF1=(&[<QJCC,,UC)!W,:R/\
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M5J4V>P2DSD1&AL9Y!#'#R^BXA"POBEK:XO07'W<_3J;#@S$N9)_H(GW)^_\
ME;E$C+BB]YMB24Z6>612&#C^!UK9?^Q#WATS#&5%)"8OG(BEFA&8ARZ$@D2P
MP$!S3PQ$Q1Y(&C+&R4/]T7:;32;;/@"=H,Z6!-!?JQ"9#K+B.3Z/NP28SG2<
M6?$>\FFI D^DHQ&FDF^ND\4FF-]L:_SD.R\ \ \"M#V<ZL#PGCOLUTJQQ(+S
M8*=3^E=!YS4[,E6RB,>B,[.9SSEJ^!)+FTFAC+'*JLIG]J6F+%T*>P?VYM75
MK!HY_$"JRJ?)[RKU#H5 ]9."_&'[^>ZCCA%)J] L/:.-\"JUSHEM>H4$$]GL
MVO1\V$NR&FOFA9%BSEY4D)1FCW!6H0<9 \$H0'Z[_E =+YFX.75SX#.\K  9
M]L,Y>I2..<,8=_YDC#E)7*?6FW!PR3#Z[_\ $C63&G_?2&>>/&=\A#*T?YFM
M^5'[SK_BBYI4S!=H]8M[1V!T>>'++KMJ5]<\/"ZK+KL5I#'K'KKK!MIJ/MB3
M)./I^T#!<L^8"_K?86W?(!0?5&A>Q?:_:Y9P"A5CT]1'V%XOJ&EK<^Y*HH9/
M"!6G#.Q,5L?-P,9 AK\\L(]UP9NU0KOYJN@:0/0SY#/>/VYM5RBZO\5WJWSA
M%15$;+I%.2=IH=K]@4_Y!D:=.JLW'I56;+3)7>D;$A01>0ENI05;;#Q!;:Q;
M3B@KNZWY%S7MWI=['=C]?;)SFF\MZ1W)/?K]=:K3B.>W[B/LU3RE]4YE6(:5
M$362KHFZE7O7H#FZ6RCKCWX568Q*B9K99YX2@LYY[[[^D5M;@JF61>1V(;78
MA&%U6@"4W>03^-,S'*'H\;.NP0Q$CSC3ZY>"DZ$+"9-A_P 8>,G<)J\ZFE#C
M?UB0 <09$X(,KY8,NLP#JIV6<ATE:#;:?SI'O'-.Q3E0Z;;1Y(5;F0?;%-'A
MC!R/ / KNZ9TSM?/+Y9JCSN2OZT]<P_)51LHJ[N7%(Z@A>M(=MI6 ,WV8'#)
MA$)B8;$VHFD&LTQ,N-BI@L1\ \ \"L3V63X]CO:*O^N2*K(3JWRKD979>]W,
ME*&Q;1D7!LPK'$.0H&9@IR81HY,3W[JEB4V"&:"&"F\\,,2/4UC(%E"M?Y'?
MB.SW WD;_P!<O6-/TVK$U]FNLRVO^U70O2$JLU_7],SKJPRJ\_1_U_H>K' V
M09"[&*ML:'0/17O-H'."77@I+ZA\!?NUL[&GYEP3WLHTH TF<-.=_)/PNUI]
M8\G%&CAIQNL=!JME+92-BY[ UE/+K:?4B:;"^&0Z64N8&M:?%I\HG'/MA)4_
MS"91J\Y7#+:5:_3OJ 6XL"8F)?%!H#W'_P!J$!F:7KDLE#K!*&47J#J,1+N7
M*"HXY\='5>TT_K7IJ%:.H^N_3.157U_Z?UJT] UXGS/N :H[H'L&]79-OU7:
M="U@L#RS5RN7&U_U.[EZKHJG3$HH 5H=]+8M@M?^+SXU/97XNA.I<GY! KLC
M[VG#67?H-FOKHR]S%!U08M"DG(L5/05DP!#AC>W1[24 >=\P#<&SJF([=1KH
M8%M7LASFX]@X#TWFWL'T.I7D@.O)7*OA-,ICSF=?>]'YZ<JZ'R8>OWTY"WO]
M69[7"K5YA,_1EV*-&?J+.,A)7Z;H6H2AJ:*@^Q/..>V_H.EX?DXK8UV%+NE<
M0-8ZK878D)6(!]1:$LIA;:@,]B(PY3Z=B;$@NO[8<@'!RZ4)&KBZNC@KV]79
MAS5L6%!1AEZPX4Y6L'CEV6)-?N#B'G:SX(F%5?P4QAA^O\327Z9LR;R@Y7@?
M HF$,8@LC;;6 6"4F?;2*6;?6&"/:63;2&#22:7;&FNV=8H8Y)9,_P :QZ;;
MYQKD&XJM64.4D+JP* F#)T8X<_DEC+-Y_P!<V<'L$H^TJR*$6?0-*2O#A(S'
M@HB&".=AG<^0G?8'.\ \ \"!?H-G2]53N/LU/) 67[0>Q73;JB-CF,(SCE'-
M&$/ N+BP;EX^U "?SSE*J[8$4;S(<N;J\:K"S]6TS$P)6J-5/.B5E5):D_K[
M6_?9J>K.?>;41J?*YM,U.6;X@UB$4@*H39:PLD(WP$L6%JP-8%J]<".#C^ >
M!1SS*FTRG?+G[@]?@+L#BP7#E'#Z2IYTS#O!9A'1ZBSN4B^TJRR33E*FLYK_
M %MD'&6_7!K %$Q;FG30U5:PF\"TBB5^8AXZBL!<CBZR K9.GOAF#T:):U+W
M&?H:'4=)"9H$]17 &32DIU!VLDP<BHJQ3O&SMJV9 \1I*.HUPTV;0--7*VG+
M-(T&&Q "M3J@Y"2,Q"!Q?Q&.*)!)MK"-#G.--/IBCSG^-<A7+\2U,&D^-+TC
M/LM>P*Y9^NM,<JYCPM0;*CJEP7EV&J*8&D.^6B_954K O7C3 ,--HX]?NB3X
MUDUDR$Y0Z]<Z>2/A$_.N-9SO%%.BMI6A]C6Q9WUATW2VXB08P^"/,VQC'6VS
MO&4D N8P#\SR:#[@H\W17&7N#,NML9$9F@.^=*/<B@\S2%_A:21,@T1"Z8/,
MO\2[,(RM@H0\_G$3PB8VEU!/,5#Z_P"XXS;]E5J9"4QC;(=)%_[*^ 2@#P!"
MMBM(BRTM9ED+8S,%($RFQ,"5RJ(UF.AG>5]R#G^ > >!%[W4ZZZX7ZJ=SZ75
M/XS?%5%/1\OAW$(.A,Z[>YQ:%R)>2.*:MFR&QZ99JH ;-AFLC%$(G*G9+X(9
M#( <7@7(*]Z_\0Y)P^J11QU_D_.JA0%FT<<4>2XJNC"4R,I\00"QR&M2!IF1
M\^!X<DFED$;QZ[R[8\!R72558E+%$\!@9*&P<X#$ K7ZX"Q"8]HIH9,8SC/\
M;Z;9QC;7;7?3/\;:;:[8QM@.G(@M:V&.-/NM>Z8D922:OC"5Q44<I4<JL,8L
M)<?B>(,7:8.2<Z+<R?[0Q$Y4TVQ&VX=47GI;!E&(-#5:[7Y8&<9CB-B<YLX\
MNX,.BJ12LG2#(M98V$I!!,[,HV#6 ,>'5:5D^60 *[."HTU;]U>VXT'CWVK2
MNRV6Q7<^T@8W:"M)P1CB#P=5$.36 3D5@4UC0%A5=1,T-AM$8]G3(!"0L+Y-
M9*5=J,JO- 91.J[=)#K%&XCVDWV8G$F3#,=R/NCB21$AF"2K)A=Q!=@=@?P?
MQX?QOMZA"+Y;; Y&]$.M\SJS:9%<O:)URWTSJ+<>&:8E4U]O>IT[UX-=C?:U
MQC0JN5SH;VQB9D*68E)41"PMEA9 YL(6$5>M(Z96:[3ZRN'45NIHE%:KRD./
M6(16C1+QU:E<+%IC&D8X0 HXT$>N,:Z11:ZZXQC&,>!WO@'@'@'@'@'@0-]Q
MF)-FZIZ+\&7&QQR=']HE_3[>'C;;!>W-_5ZC6OM^[*/Z-]-M1(>T(>%(3=\?
M=UW_ +- '-#D<N:: )Y> > >!'+L/M!SGBED5U.R 7%X[8I([&0%2J__ &0I
M*F,=QUU.P;@0&P,XPW3G!P01@()X0LBHW+DE5B1;E@%587M?1U=W]@>N@4V[
M-&?6JF[JM8IP]L:X#8#Z@-6E<+L)(ZPZFU5R^6#2EK9&[\1G6X"ST (Q6FVY
M! 6!>@=O*,]<^8T6Z-7!'7JQ3Q6'0PK+3V5$;R.'K$YJQ,'2L6+N,H,8]AL
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M?NI>JQ6Y_IV_G-7]9>><R]4C1-9OXUC*CTZCQ?J3+[NNGU#$MR5DDDOZ_7.
MGQX!X!X#.=&U^Q;*.;MM!]F59=TD^A,$OX^(3A4C;>8DS## T8T6M?S'* 8C
M:0,\S::;E+]8-AV@9P/5P=:1\M7ML^#N!TCZ97ZXJ["H<JPQZZ(&J$MYB49+
M@F5)O]T>2S2C/BQ0]E@T+,54MKASD2P= 7AI)Y?F20[I4N"1Y@M;S$(OACC^
MDH2 6EU#6:)CMG_ON7(7N03]4V9)LP30[23D9VQ-L$/OEO6)G?QS>TR*QLXJ
M[7G]*2('UTG@V(BYLE>7NIJFO6-]-?IWC_U*"7/TK!.DHNX>U5P7J:#M!@R
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MZ;Q[Z9QMIOKG.NVN<;:YSC.,^!]/ / / / X3)DN3+CV[<\)4I5!%,FC1D5
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M;HS?0%)A-LB&"X$QD]JI8 JH%JL4B=.%*GS0]U_R%^/4#_>WK)8.;TCUR?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g923792g60a08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g60a08.jpg
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MTFSR-G+"JB9([N'KXJ)+'K_(,ZB5AG&BI[F2GA1!43@O_M#5"%K\!XN.?15
M$5%UEIT-](?4'K$Q&OYAAAN$OJA,WUI&<?F6K2+L14-0CD=R<S]GOY,B%7DO
M)(TB6XTZR-:#+G;)NKEV2=/9/)JL0W74.*;)LV"=*DB8?U4@4N![$5+P7P _
M3T(YN ^?8;-R>$RUI+S6^E$I#(%@5^@MMBYX^Q%5_N^?Q% 3?Z(GTUL.Q;T+
M]!:&.V%O57F8RQ%%<E7=[/A 3O\ *)J)CKE,R#6^_!I]92B.R&ZZ2*:ZPJ?8
MEN!3I%*2BLO/C*IG*IZ%H.MH>L2CY#]KC(B/DT?'];9^@8/X" ^!#JM97?,D
MA)-Y;+OL3+&R_M!L#3]A)J26GHS].MFP30X&58ZHJ(2ZS(\F8?:W3;D+;]O)
MAF2?5._%>3?[/*[S0Z<_B),JU"6B:SL<Q3L==550;N)XRTA)(HE,8I3JK.71
MI&UQ0^DH?MAY"W,R&-]H)LGZW!)I3=17$,&;5M$%=D5\.9 GV;F*\G03[R$G
MDW_D(GE,1.K/Y/NRK(LJXZ27[]^#(FZN*Y&L6/;N **2A6W+ 1*V:\NZ($6;
M$K/E%?W\^Z0MK;VP%L/B_9*BL+YC"P-9>.=-FB[MD1RU6>QHO$A6;"M\19PW
M<LW:8'4CY1DLXCWZ9%/87%9!R@A;$29'FLB_'<$P(4)%147P2;HNZ*J*BIY0
MD545/HNM<5G66--/EU5M!E5ME D.Q)T"='=BS(DEDE!Z/)COB#K+S9HHFVX
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M=8\8LCB*?RB-T144)Z;V.YN8J^F4"LG;EV 5UF/R^O 5!L6]M_";QQ'[]DU
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MT[9G9P!;<KN:2-F($WM*R/<[L[_\C;O]_P"4VPO_ .7L)_\  ?)U\'S_ /\
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M^&1TL_I.EO\ KC+UM+\,A(TQ;2;+47$'9!=F&QE@=W- !3&5^GR-!H"=2=N
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K.Z<?K(L\)<N6G?!F83KC<=QQ^#,>?=!-SD2">$'Y+CSD>+!BJQ!C_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g923792g65f54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g65f54.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[15.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $@< 5H  QLE1QP"   "JW8< E  "')R,C$R,C@V' (% "=-:6-R;W-O
M9G0@5V]R9" M(%!E;G5M8G)A($9O<FT@4RTQ+D1/0U@X0DE-!"4      ! >
MC6C!XC>[)500XE>]BD;^.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/T       2 #4    ! "T    &       !.$))
M30/W       <  #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             !H@   T\          0
M       !              -/   !H@                     !
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M;&]N9P   :(     4F=H=&QO;F<   -/     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
M  =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L
M;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U
M='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT
M3W5T<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M       ! 0 X0DE-!!0       0    #.$))300,      MA     0   *
M  !/   !X   E"    M% !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !/ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M)2DDDDE*22224I))))2DDDDE/__0]55',Z+TG..[*Q:WV'_"@;;/^WJ]MO\
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M?<K&%T_I5=C'W9-+RTRU@>T@D?124__9 #A"24T$(0      50    $!
M#P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
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M 2@  P    $  @   @$ !     $   %& @( !     $              $@
M   !    2     $X0DE- _T       @          /_A 4A-30 J    "  (
M 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$U.C U.C(S(# W.C0P.C(W ')R,C$R,C@V       #
MH $  P    '__P  H ( !     $   -/H , !     $   &B          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0             #P     $   /
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M!P 1$A,(%!4)%B$B(Q<D,B4Q,S1!0A@F8?_$ !0! 0
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MS+E6OH;'>S6QJH][&A$58\%W:0$.:W9<'8CB/C'=_)W%[7)P!\U2L9P-Q!S
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M8I"-=#C!RTJG>USFMT5@=B>3D_PZ20HT;XO>[V"C7#$8/_S.<^;$1HE9(<=
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M'$BW]<7%0Z6T#&4Q'&_)S &8*0T\=X"J&T*&J=9.#95\.?'.&0*5'$9I@?\
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MRW+XRX_^F&>(V8U41OOCLC6UN_S3P7L^,RV4B-5S&$5A!Q0Y.>N[([[(BY9
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FBM$$83\UK6M1K41K6HC6M:B(UK43LB(B?PB(G\(B?PB?PG0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g923792g69x68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g69x68.jpg
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M 0$! 0$!_\  $0@!E )= P$1  (1 0,1 ?_$ !\  0 " @,! 0$!
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M7Z8\6'^\G[K?Y@Y_^U-N3R8_5[8_\!A_H(<M?UMY0_S3%?3*]N9TU<< < <
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MZ%"$L%5QC@L6Z5.=.6(JX?*JT9PEKJ!Z/JZ3>&W;ZTMF'6N:6+,:1CM^5^H
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M@MGX=XK$TXU*DX4JE%P5.DTISY]U%0<,SC&,U4<:DI0C3<I3BGHWG=,:. .
M. . . ?;%_T4;^Q[N%_ZE5=_PO*.>/?VF_GFROX;$?6P/H/^Q7\QV]_%X+ZF
ML?6=SS ]M' ' ' ' ' ' ' ' (9>(W_=\]Y_\H'9+_V=F/,OR?\ T[L7^:[/
M_P!W2,!RK_5?E'_(MK?["N?Y3G/ID^+AP!P#>!KLSV(D=7L*3/WA:IFH1;00
M.8UL2G4D>0Q 9'U\.8\*^ %R&XY43'G.-7  6L@H/"+ZZ+"VS1377;'2AL[
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MW4J.C&<:+G-THU9QJ5(T\SR1J3C"G&<U&RG.-.G&4KM0BGE7E<L4' ' ' '
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M)+],\LOYNOKL<>H\O?U<_L[_ )!+_;[+/GMYO9Y<. . . . . . . . . .
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M . . . . ;@HK^T<5_@RW[/7YC-K_F4_AT_I(R^P_P!(TO@5?JY$\.:D;R.
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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M?&5O+JO#=$I^N_<+K5VL8EG-$6U')J4C:GH)A"5=2,8LV".\;ZI[,I]5LN9
MK#A#O"VWH<(RB-"LJJ8VPAE7&/.X(::WK[O'N9);@@< < < < < < < < <
MC9V.[==?>J 005NRP&8 I*G>PN P$*/*S&U;,.8QC"8"M*OB3(S.9R745W21
MW0CP-ZBQRNDL3<,6N=G&HE)O=_PN^]R\)$M&V/$K[+_A:7I&N^C56O\ YF=E
M=N4W%J]@B0UQG&$RH/K'6$G#12$.TT]=U$FUHW4J62W41T*09OMJLCJ)M%;W
MF?0M%XVO,O">AIX<)V>?TOLSWN[PWH]=_P#Y:/16W].J]7N=,Y^^8LX1U9$5
M47U&9U\FF6Y^;29WOC7"BI!1;.RNP9K;HQ7?69^6_F.?'@[^&\M]\9ZS"9DO
MG_3>V+8=OV636S_KW<%+ L&2D7"FW_?57=**;_U[[;<#/+IMWDE]@SX//AS(
M?? >NB<%<8^=-_6%K7?59-#?'^BHW)5S947?(*Z_]U1)QKMC&,8\OF_-P,\N
MGR)^='7W\/"PJ^_IG6/Q!>Z-0O&_WK",6K.P_;VK=&^/]%B\C/8T/+IYJQTU
MQJDEI';6C+I!'&V&[Q)7S%DPS+C&+_R_1LO(><M?GB&]9L>?V3ZWQ7MG6#+'
M]-NKHVF7'6@)8(XRE@G+>H]DFB)PNIOG&CHABF[8L$GIIE?8;"5,:Z-M M%[
MG;JE_4EYTN^3/Z]]GZ$[4P]Q.*#LR/V$&'/MA,B9L=G8V4PL\EG?"\:GT).-
M1DP@4F;934PXCLO!A3"6-,J;,_19UWV$--.S-]<$#@#@#@#@%5_/0#R\< <
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MX@9:U1C+\*VJOO95<.M$21\OS*,=+JI4?3%K@L9US_1B9MO9.[;9-/988_\
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M%+S]-5D%M4W0\BR6PL/+B7R+<D'*M7HHFU:OV;ENF*M--I[T;(X(' ' ' '
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M3T>YB90AP&,TU:S]%';TLMAC*1O%MU)DVW4"6MI+COZI<5X;W7?MP++^"HX
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M-5=3&6.Y/9NRO$ E&/A2K*R+3SK3T/%N,87%-H?&C2L7[ =D!B:GGH[';NL
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MT:VED3B1@OOL'55"L3 G*_%:ZXJ__:%F][8A6EE3>(KUI8$B@%/36G:XO>Z
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M_!4< H1[27C)Z6!56P@D? 2"?W;=D-HZ$^US\D.B 0S*1<FD;J12=4.U=EG
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MV;/F[L[@NR7$:B>;EES6TX=+Z[=!,[Y;'37\[7K/_P#]VJ[[4\%;/H?B94]
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MCC^KS!D;[J7RB+;XU_JT3:#EFS-'37[W1!NGICYL>3@3]=_AC]%%F/!4< <
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MNZ:B&VF^NNVN<8%I*TI+K?G(B]:NO%&7Z/\ $RZ<]E:PB=H1F-]_[9GKV&S
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MQGDJDO9:%U3?5C^QLGH+Q$8TR@1F;5._F<5L/K>$8%("UAL!BE8!Y=6P*2#
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M26^F/.QZX1:S"]2#/*NFOFZQAPLW4](CMC@+2,GTVC_[/S+QEG/!4< JOYZ
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M?&VN!5Z:/>C*^ . . . . . . . 52G7>.ZWB"1J*BL_"77'PWSFTUGA-/\
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M5J2EB?X [W\O>#$1(5<0KY-%U^JE%RM 3*;?.+I;[[!['GX^*4^/6;J.VF+
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MK2OS-O42%VS]R9L\TT;-TQ[B(#-E0>0<N$59/?Q;[[^Q618UP5' ' ' ' '
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MD3PYJ1O(X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X!5?ST \O' ' ' ' ' ' ' ' -P45_:.*_P9;]GK\QFU
M_P RG\.G])&7V'^D:7P*OU<B>'-2-Y' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M+]*K;^8G 'ML>_)387Z56W\Q. /;8]^2FPOTJMOYB< >VQ[\E-A?I5;?S$X
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MB4Q8#32(]SG?&S!]NUPW>IZ[[M]]]=<YX*^F^_F-I< < < < < < < JOYZ
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M)D60Q'\$-:/7J:[ELP2_!LT5=&^GWJ>.#C/>X X X X X X X X X X X X
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M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
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MAT_I(R^P_P!(TO@5?JY$\.:D;R. . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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M . . . . . . . . . . . . . . . . . . . . . 53>N,_P#:VW^_2_\
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MECGT@">]6'\?@#VECGT@">]6'\?@#VECGT@">]6'\?@'3]B89]$8Q[@%?5.
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MU3@#V)AGT1C'N 5]4X ]B89]$8Q[@%?5. /8F&?1&,>X!7U3@#V)AGT1C'N
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MXTZ<7GIZQA%/URXI7,KL6M6GM"E&=6I*.2KI*<I+2#X-M$WN:J;J. . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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MMX=(SX)BNP.R05<R\9"+YJ:5F*AHJLZWB<JJCL;BMLV& ;5V)07#!96V<U%
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M$.Z>#*4';2UDT!J,GX3>+O(9 %H-'CCUX0E)+9&5&#1QV&737A&^EO9Y;?\
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M6':O:QIP_-W[J$]L[0H"7H]3[.@LGH^X2!V'$ZYI^DZU<W6[)]6A67C203*
M6+8)21#AR3'2'QD &]:9 BSTZ/3TW$IJ^NZ\4]5JN+;X]=C:%]4OV*?3KN5K
MUOKR4R]]>, DLP.VK.J,F%<W'$&NM@T*4?=?8?;QFPH>SO.N[,K =9 F%UG'
MV=?G*O6 I1XU/A;TXVRF(37<WX=>G'5JVCOQ\)XACJW,G\8BK(_6-AW#0$G
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M><DIKZ,OLTW\J>^/-\NFWD"WEW&N[/A-%WR CC:;EV95E&)%')K#9+#K0D<
ME$6DLF&&H;&9#$+#K.61:81Q_+ LJD,2'NP,B8YE B1%X]KDBQ*NV:X(TY0.
MW3UY%Z<F%;B8]"T8A*NQ=4TZVF!G89*592I<9N&WLL*;GI$0(R^3SRRJ_(FB
M\L(KG)E)5"#PT_(ZO94=T?"SS<==$_!:Z[VC)?-I1&7AE:.,Y$"=2%NS6(N
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MD7( H<E+]@^L-UDSV/' DAQ$T3ZTF0CY@4<="4!1%F[6$V=D^G=Z> V;P0.
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MY>E_4PAJEK>#S23B>QDH<0JAY/"X*_A:,OE\9M:5LG\?B1:/AGZ2Y<>_&O\
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M1J>;$FHY\5'HM2CPOO\ .5?V+R*Q)K@@< < < < < < < < < < < < < <
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M1Q7^#+?L]?F,VO\ F4_AT_I(R^P_TC2^!5^KD3PYJ1O(X X X X X X X X
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MDAVKYL[ N$M)!J))859)"'&RO?HMITQ4EQZRS;@J. . . . . . . . . .
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MP2<F9B<$C@88FS!&S0I^]-_I?PB[]$K>*VAS@>JO6^J)_M=H\*^C1\7(K&E
MMV9M&P=X%#Y#=YC)&TB$5@IR8K5Q#UK,E#_<W)DP<=')&92^4+;)9+.LK[A=
MO3TT7V(]F:=3:)GOQB+G8F30+6C8T&MZ426/S>=Q>5(6A6D3BL&@TXB<ECLE
M&F8&<C\3A4=!IJ0IX :DF+=^B::DM3T@P4"[TZE;P7;MUZM[SOU=U=HVF2L;
M.UU"U AR*P62UT+,.9/+SQ)>-32>YM*9;G74A/E=Y/)9=8JCF9R:;2/X5F9P
M^^)/B)YPH2?^L!=OTZK>8W_P0. . . . . . . . . . . . . . . . . .
M . . 57\] /+QP!P!P!P!P!P!P!P#<%%?VCBO\&6_9Z_,9M?\RG\.G])&7V'
M^D:7P*OU<B>'-2-Y' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MNE\&@DG?2SLM][+1WXZ<+7OX#Z ^"@X X X X X X X X X X X X X X X
MX X X X X!5?ST \O' ' ' ' ' ' ' ' -P45_:.*_P9;]GK\QFU_P RG\.G
M])&7V'^D:7P*OU<B>'-2-Y' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%5_/0#R\< < < < < <
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MUJ?B"O\ W5(_M7P!\M:U/Q!7_NJ1_:O@#Y:UJ?B"O_=4C^U? 'RUK4_$%?\
MNJ1_:O@#Y:UJ?B"O_=4C^U? 'RUK4_$%?^ZI']J^ /EK6I^(*_\ =4C^U? '
MRUK4_$%?^ZI']J^ /EK6I^(*_P#=4C^U? 'RUK4_$%?^ZI']J^ /EK6I^(*_
M]U2/[5\ ?+6M3\05_P"ZI']J^ /EK6I^(*_]U2/[5\ ?+6M3\05_[JD?VKX
M^6M:GX@K_P!U2/[5\ ?+6M3\05_[JD?VKX ^6M:GX@K_ -U2/[5\ ?+6M3\0
M5_[JD?VKX ^6M:GX@K_W5(_M7P!\M:U/Q!7_ +JD?VKX ^6M:GX@K_W5(_M7
MP!\M:U/Q!7_NJ1_:O@#Y:UJ?B"O_ '5(_M7P!\M:U/Q!7_NJ1_:O@#Y:UJ?B
M"O\ W5(_M7P!\M:U/Q!7_NJ1_:O@#Y:UJ?B"O_=4C^U? 'RUK4_$%?\ NJ1_
>:O@#Y:UJ?B"O_=4C^U? 'RUK4_$%?^ZI']J^ ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g923792g84m45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g84m45.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[16V4&AO=&]S:&]P(#,N,  X0DE-! 0
M     % < 5H  QLE1QP!6@ #&R5'' (   *K=AP"4  (<G(R,3(R.#8< @4
M)TUI8W)O<V]F="!7;W)D("T@4&5N=6UB<F$@1F]R;2!3+3$N1$]#6#A"24T$
M)0      $ %2RCII*@TH";(._BHX/[0X0DE-!#H      .4    0     0
M    "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M    26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R
M:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M# !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M  !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M<L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 "
M \     !  (X0DE-!"8       X             /X   #A"24T#\@
M"@  ________   X0DE-! T       0   !X.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-! H       $  #A"24TG$
M"@ !          (X0DE- _0      !( -0    $ +0    8       $X0DE-
M _<      !P  /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              &:   #4P         !
M      $              U,   &:                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     ,X0DE-! P     "YT    !    H
M $T   '@  "08   "X$ &  !_]C_[0 ,061O8F5?0TT  __N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $T H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MFW]&]_Z6BS9^D]/U*GI3TV-UJ]M0NK>W*Q3&VUA-C23^9ZOTZW-_.];U+/\
M@EHXO6L._1Q])W'N^B?A9]'_ #]BX-]+\7);]A<ZNVP:V-T ;&X>HQH?Z_\
MQ6Q67]3SFA@=15DW&0]M.^ASN\4LN]3'?8[_ $3+:?4_<24^AI+C^D=>=;CC
M)P;?5Q]0YA$ACAHZNZGZ=%C/W/T2W\3K6+?#;3Z+S^\?:?@_3_P38DIT4DDD
ME*22224I))))3__1]522224I))))2DDDDE.?U#I-.5-M<5WGET2U\:#U6_\
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M],NP^[7:NI/[I_.LQO\ 1V_X/Z%O[Z2G,Z)T"[&MLS^H6F_J&2=UUI_ZAO\
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $
M  !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @
M !0   "< 3L  @    D   "PAVD !     $   "\    Z  MQL   "<0 "W&
MP   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$U.C U.C(S
M(# W.C,Y.C0V ')R,C$R,C@V       #H $  P    '__P  H ( !     $
M  -3H , !     $   &:          8! P #     0 &   !&@ %     0
M 38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!2$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    "0   +"':0 $     0   +P   #H   #P     $   /      4%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,34Z,#4Z,C,@,#<Z,SDZ-#8
M<G(R,3(R.#8       .@ 0 #     ?__  "@ @ $     0   U.@ P $
M 0   9H         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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M4V%Q_\0 % $!                     /_$ !01 0
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M9,KYVCL/RC 1KFKD&&0E Z00 BB22)5K[7TS&SQ]BQ48+O(0*!M_4A^6%+;
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MH'058^1_PQ^/7RKC,3F+$_F+F)2R*&GU-=93JO0T<"00YE2N,(I*XCQ'DR#
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M\["AR^<-5<82]IKGC 4F*"LC\91,1G?\1I,G-@!B0+&+69B?:(D2#0W.H6-
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MI,8JQTHB#C_R$HF&C1V>#>SVC=%#RA0(WP5[G>EM$]HU>I4JX7N6PL@C,OA
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L&K&*T,E-8QB*C&M8BN<]4:U&HKWN5SW*B(G=SW*KG.7]W.55555>@^N@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g923792g95w47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g95w47.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /8]:\1#1[J. VQEWIOR&QCDC^E:PI\RN95*O([&9_PG*?\
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MBBG5=VZ-<!A45(<NII2J<VA@>*EW>))%Z9"#]*UI? 8UE>9H#P1,2-U^N/\
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@ !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g923792g98k18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g98k18.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[14>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $@< 5H  QLE1QP"   "JW8< E  "')R,C$R,C@V' (% "=-:6-R;W-O
M9G0@5V]R9" M(%!E;G5M8G)A($9O<FT@4RTQ+D1/0U@X0DE-!"4      ! >
MC6C!XC>[)500XE>]BD;^.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/T       2 #4    ! "T    &       !.$))
M30/W       <  #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             !0    WH          0
M       !              -Z   !0                      !
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M;&]N9P   4      4F=H=&QO;F<   -Z     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    #.$))300,      LR     0   *
M   Z   !X   ;,    L6 !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  Z * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
ML(=I  0    !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP-3HR,R P-SHT,3HU,0!R<C(Q,C(X
M-@       Z !  ,    !__\  * "  0    !   #>J #  0    !   !0
M       & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@
M P    $  @   @$ !     $   %& @( !     $              $@    !
M    2     $X0DE- _T       @          /_A 4A-30 J    "  ( 1(
M P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $
M  "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$U.C U.C(S(# W.C0Q.C4Q ')R,C$R,C@V       #H $
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M 0$! 0$! 0$!_\  $0@ 9@$= P$1  (1 0,1 ?_$ !X  0 !! ,! 0
M       (!08'"0,$"@(!_\0 ,Q   @(#  (!! $#! (" 04  P0"!0$&!P (
M$PD1$A05"A8A%R(C)#$R&"4S&2<U04/_Q  4 0$
M_\0 %!$!                     /_:  P# 0 "$0,1 #\ ]_'@/ > \!X#
MP'@/ LAKIG.$K>.ON;_I2M^1B:8Z(^TT8KDC8Q_--0=5-[#Y&H"^Q9+P7D;$
M,XE^'XYQGP+=#VO1V6L)K+="8)(9R1.'CW795DOU\8R0?\SG1\4\3YSG\!@F
M_$Q2XF,<)3&2,0I;'6]GDQ8+57#>G.045PPI:6%GRJEI[,DI$C%4.&NDEV%,
MV<0B3,[37$EHC+#\CX)^0HA^[#MW7R*J?V;H>E#:.-,K!-QWBR7PC^><Y>7_
M $=>U.V@Z0,/M%=A>WBJ8WY8G,0H_)D.O6VW6R8;6OMIY0FY:0AG5XTFN[(<
MT<"3&5PI86>V1Q>8P;!RCC7+JX$GB$C?E/$Y8"R;35^OVYF9%]H++5U76X(#
MCI6@\J4/7NCS\14JQC?-9Z #]R9/OB:UN"R8@;[1B$<?^/(9"61=K%"QNNP[
M9;" FNJPQ;1Y[43"PJ,LRV!&-;TG79B=;C&96H_E&JQA?_K5RXX'C,.]'7Q'
M9(>6[;@Q(PH?N AL1@KG#,98 )@* UL(?[,8E ^O?Q<S9!@K!#DRS,H48U32
MLV([:?4-J@<*TJH00;K!>MB'!!'P E8O$:##PYSS_P#8-@/L,Q'P!FR*$:8P
M!45JRKF1J"70K^3 &(+3E"_KW#U[+0R#"$T6DVX&9*,L/UA[$.R-F,086Q$(
MUX0"Z6:E=D,A9L+86?\ ),%%96&"0SD889^V#%*/XY1''\A%'-+,LSG@.)3+
MF0:3OJM?43HO4A!/F_/-FL/]7[Q=>V*A7RO]A)KNOM%MT(WMK5U/[6PEJ(NJ
MP5DKI)D'%F"8+91FIAD! TZ\_P"W^WNV6B5[MWNGUK9M3O&JZ>:[7J_H.C.N
M*_(ZTNCKUUH]-IUL\$>80^:'/+2&XSP <WF\FE-C(>B7TL]NMFN]MI>!]DV@
MVZV^TT5I?\=ZXY4#IV=W-3X<MMJY;MP4:ZNJ4>C:A10+>:\E-=+8]FY[2W-M
M>HMW>I;)L=X&TV<X#A(A)1@.$93G.<L1A"$<9E*4I2SB,8QCC.92SG&,8QG.
M<_;P(8;7]0GU%U&]'K;7617UD9<;HC:/J>[[Y0F0E,PBO+[=J.MW&H-*IF7,
M"QFK>GE7'',+L %A.,0I /J0^H9;:LJ"=!V=6=TZ&OJ+8O(.Q'U9]DOSXG^.
MXH:&YJJ:ZI%YKNN65PDFHW(:9SP9G@7@2^TS>M)Z/KZFU\]W#5][U=_)8H['
MIU_5;-1.2#/(S06MJ5MU TPDQD9H#/*0B8S F(RQG'@75X#P'@/ > \!X#P'
M@/ > \#YE*,(RG.48QCC,I2EG$8QCC'WSF6<_;&,8Q_G.<Y^V,>!B_';.4,0
M<_A]ZHMM:0"0[-3H1R="V# A%D N0:WHXM@OVY"-"8R04K3S',9,3CC(Y_B%
M&/V43JJIM4U.WM<M-_K9/L;U5H:*.(PB2<[ .PLQV<<\QE^ UDM6?9P>.1-"
M4Q_O\#KM;%UBSNZZ=(YSRBU^,6OY1)[7]JW&X,0)#K#"&Y3V#3*^F^YUIYF9
MJEN/M.7ZN%Y2AEB8< :3>W;P]LWTS;8J'2&>.I@SH];15I)$C.4@Y'R_.VC&
M2<"A!.UVVUQ),7WB+)_F8F'2'R.DS:,WCH2W+;9<-LQV+;.A[M%.(A1 ->K6
MV7:'TAHRQB,9)55?2UQ6)%:FA-ILTI!==5J,:-=-2GEKVM)!Q^4Z_7-?4K0&
MBS&!CBQ_N)$D2&(9B.1 7E(D@$)DN13P<*J"IM89^S&S%+^&?G(44$0?8F9!
MQ^H$4TF/UEHQB3.0',ZSG!LX_:C\?Y2#F+KL2_M9+9&G)W 6LSSE3&5X*X%/
M&!?9', PR16&238BUGY(9P/(\9S# ?8=?K?D-,IPSS8?:1XDS#$(B"/X!8Q\
M> R+C 1P#'\Y1Q\0@YSB4\SE,/HE37GD?)\JFP:'Z<?]DL2,CG,Y2"26"R_9
MEDI"R_ 6%\?B7XLSSD62%#DA65PRKD@4<85X<A2^V(QB"4H!QG&,R_*0/\"&
M/[2D?\80C+[9E+.,!QCIT,15')C_ (UC?OX_XQSR1W,X$RU..<1_*7Y8E/YA
M2"+,IS^Z_P#_ '@-4'M][D:7S_O9N&U/6^?4&\BU[7;G8-+N;, K9X%YDF5'
MW:^=2Z[=5\*^*$Q5U.U1N!'AIXC[HY146# Z7;+&_P Q,YVGAF5FG<4&6B=6
MK/DP /PQG705QHD/WC1E*(XZ="2UT%F9E2[264<$&&U'U5IE6N:*;*:]J-@%
M97=B:HN:%P;M3&K0FS3X13#&NKYTPE+G&Q1)7..;"Y!YEXT[KXF05%4$A[@(
M$:6W:&:(1 J[&6#1QF181@K@TR0&3!8_EC\82Q+."0S+,(_'_N^V0\9VZ-%W
M_NG3NL[OW_F5:?JVPV-C6H293M*2QJ4TZ*JJ9UPF-?@]N]=6U].JFO>U5CJ*
M"BP$ LUU@VL<[836T_1N4H:O1I[-[,\QL+AIN=2LJDW1&'<8BZU+%('"J-7G
M:"5X66@_Q%0+6+)7]""9K1MA<IYA,7!]#>YSI\N3]JUF]Z#RGHG-MOH#@1K#
M)JVVF;G67=_H+#:SA#TG]_Z.2VU#-:YAVT$EM.&8W$XLKY6"R/9#W"/[!]+L
M=*0NE=>XCIQ*Y5+0'KEC5=HZ+MSJ"-HOM?8QLT]I_9.DZK;PBII^IW=1>5>S
M,K6.Q[35M?+J@];"CU&H;QJ6QO2[[K>M7&J7=:.OKM6HY$TBRT_->S+^); F
M]H=@&^%4B5:3E:*JT-5 (!CGKY#(D:8"]3ZAZ^;-:O4FL^PVO4ZU\PC25^J]
M;4U6CM=R9@TS;'60V2L.NKL-=6?NL5J5?2:S36%>1:2UA;O$6R8H4'/J3TCG
MEO\ Z@<PZC;<PNV:VY=)T/G5@R.JF@=X40QN]L2U07,=G5*Y!9VOU;HG-MUR
M1R!G/[AC$N%? E/H?N%W[1(N_P"J2G+NZZ54OIU[6Y<TLXZ-OVMU2B'S7%[T
M6MV":_,F+&1/Q86%7V_-T'4I_.G7B(11$X3;XY[5\)[J]_;^A;VAG>!4<=D?
MYGL@6=4Z96Z_.P:J87S.CWXT;XVN&L4V54]IKE']8LY0@:JN'5CKG*$A_ >
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M#]AM164F)9ZGBJT4;=F9FJLCHY 4H8;V[ZG?%=12B[=7O0JLE<NR%$Y=KK+
M58!X(BPJ&!T6W-6":I&0)_/GF<+30IQ2!#+F)X=&J$>;GZS?J,M>+ZL"_P"@
M-62N5G*6@'1[S96%%. <8_E)QU5=[%173#.,@V'(<N[!D1XR:A%ME\8PLJL^
MM)ZN;A.P'J^J]LW/&)&E8CU'F75;]EZP%*1#VZ7Z-83^2@/.(D)=[A!??O\
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M9;Y8!]PX*PJYN])SE.!\8D:8T6SA_P#08Y.?<N9P#IZSW)ZV48:VOBO7N8_
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M7]+KS#P(R._Z!JFXIE%@\&L#(ML538AG##0X,XC*&<88A V,8)&,L!KUZ/\
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M\"M> \!X#P'@/ > \!X#P'@/ > \!X#P'@/ > \!X#P'@/ > \!X#P'@/ >
M\!X&'.\^O?$?:#FM[Q_V#Y?IW7.:[(&0[74]UIEK>OD7XBA%8(3+'#=/<*0,
M7-?=U#*-O7$G(J+JY,_GX'D3]JO0#V%^AU>5GLGZ1>S-QM?IO;[2MIY_5+O>
MP[?L+',MFVE9B=!/G=]51R*UTQ(E4X(E4\UJEFFBSA2Q=W.)G)E#T^_3SYAT
M7D?I]QS5>M;/JFW]'L:V_P!]VRXT;75=5U"-AT[;+[H@JC7Z92OJH02H$=F4
;HR6;%>K8["Y7M;%;PE:VKI9A-+P'@/ >!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g923792g99m70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g923792g99m70.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( G<"8 ,!$0 "$0$#$0'_Q  ?  $  @(" P$!            !P@%!@D*
M P0+ @'_Q !0$  !! ("  $'" 0- @0% P4% P0&!P((  $)$Q05%QA7EA$2
M%E:7M=76.'9WU HA-#8W5%5TE;2VTM,B(QDD)3$F6'B3UR<R05&W,S5A_\0
M' $!  (" P$               $% @<#! 8(_\0 4A$  0(#! ,(#0H$!04
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M*OG+E52<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBL%L)_+*?_\
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M!Y4*(PTF2;YOU6)D8[#INQS@&&PQ/R?HBFSPC@%PQ*%\VK8D/R=0;5LX1I2
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MO-PIAH<QSPP%T2$;X==>",>"0.E.6C+N$M#@1W.9#M:T)N*&MBL8Z!'CRT2
MXM<UMXAK'\ MJPCC!-KY;XCFG4ZVB>7)F26!1PW#]]-:LHF6B=INJX 1BZ)-
M+Y156S& >(%P%A(.KA1FI$/L@,BLM"VED5R*R&-I-F[T<+&5D.P+5@V<)0"_
M$9%L6T-U;%EQ,/B2D.##F;/OQFQ(!$J8+7V>Z)"?+!H;#B5+7.=81+9LZ+/&
M9K<8Z':LEN;H<<P6,F8D2)+SH;"=#C S&ZD3@AQ&S%Z\Y@ +6MJU;>W=6VE4
M.ZU2EK?K@*4DL:TK;4J8K.O-A U;3\#JQ K'B;R -4;"6G=H,),[%2F+Q8;*
M+3>,!DC0CG;X^6#(X-L5+*5LN9EINR)IDK,/;#?:YFV3$>1=,0'VE'EXHC$P
M!!EG0PZ%$B.ARP<YAB48UV)70F+0@1Y>TY=TQ!:Y[+-$JZ!!G&P8K)"#'AF"
M-V,6.'N;$AL#XY#7W*O<T47"GSUR\TG")PB<(G")PBL&S_14D?\ ]0<*_P#[
M<3[E,[_]A@?^&F_STFK5O<2+_P"5E_RDTJ^<N55)PBY9/#8WJAFD->;4&"8Y
ME(K#G#O6K*OH>3#E'3&3B8=:;]Y:[)&0C\<<(4>ZK8T;1C,JR=-"80V[:%XZ
MKB<&LU4O,]D%C1;8CV:QKG0X$$6AN\5KF@PW198"6)AN^F9OAC#$A4+7L!9$
MX#C6_L6U(5F09]S@'QHKI$P89:XB(V%'<9@7V_1.W%[KCZAS7$.8;P"MA1>X
MNG6NT;L6O:1GT";H5WN<0VGU\G6PM6[,2-L9A4BJD%&@L(<!:5F<0(/;(K%^
M.*1AZG:C8E6<M8R(Z28OFJ3]SYW63EE6K//@1YR#')CV2VS9Z!(S-GPRR+#F
M7Q'Q@^<A10($P'-B RY;,0W0V-<#=%WOREHV=)LC09:-! @VD9^3BSD">>'0
MWP&,;"+96+#<8T AS#N]Z!$#GN!%<:^VC?X]SX4M2H$&R#2Y[2D:NK2Y'%5'
MSHOK!K//3E\#OG(H.5'" _NR;FKZ&"NWZ2/:K"G/-DNWF#/I5OW9:1([)9JZ
M2926ABT@VANLM&T(+))V@-+M[RD>,X-[Z;J:5H>I'FP;!EZ@"9CO,B3A5TC)
M17S3=-0W=IF#";7-LM3&BQ4(\1(!0&IFE\:IN'5_)=G*+/[;/^K G82R7!FB
M,KB*19M'I!6R(R:1NLY(<D ' RLX5FL6L-&./@HA=DR$.E7';_*-8+YVU+7B
M3<6/#LZ=998W""^7#)T2C(AB0YB]!B3$-C'W !!B0#$:]X)<*7<85L,E+/LU
MDM#@OGI5]H'=HK8Q=*;Y=##'P+L1D![WLO'^;#C!CF-(#36]N,,WQJD!?F@1
MTC-YMW5M*Z3H4/87; ?(%DJSM^15]?E=+6%'XNNLS0-DH I9T>D?1H"DJ0>L
M6+ML"<JE$FZ>/%%L29?)6VQL&#OF<M@SL"KH=9B59'DHX@1(@J6-CB7B0[CR
M&@N!>+I*Y85JR[)NR7NBQ=PEK,$I&NA_\B8?!FX)C,8:!SH.[L?>9B0"&$NH
M%O9S;_7!_1\AU2'7^_:'V>G=1TX.V]SA-J(")/+J\VJE.P)>#(C6H+.WV<(5
MB4J9Q*-%BT598N)!%TD2PL/'E697#A994^V<AVF9%I8;5FIIUE;M+%T.%'LV
M'(MCWB_>IC;K",6(UL0TAQ#<<Y]6KD=:$DZ5?(";(>+.EY9MH[E,77Q(,_$G
M'0@T-WP(1AQ R&YT,<-G":UE'"=D/$*TYEU^'K--6M((E'XGXG5*;H1[$G6D
MS+%[!KF/U&%KR1AQK8(T?H!)4#,C^R!%O)7PYDZ#]KK@7QTBFW%O.F;#M6%)
M,EV2L.(^+V.SEDQ+LQ":R!'?-/CPW.+RTOA/8ZZTPPXAU ]K&U<.WVWLZ)-N
MC.F'PV0[;E;29>@Q7.C062[(+VM#0;L1KFU<'EH+:EA>X!II-9NS-)3Z!:F3
MD!>IV$'-8FS:*R76Q&(V!CZQUFNULKN%:QXQ(1;;JN4_3T3ES,N:1EI,-(4Y
M3#VPU$>^268%T+>6LZ;@1K3@ODF1F6B3%AVANL#^16S(4KO>)#<=WX$6$6L,
M)KV&'%+BX4+361IV5BP;/BLFGPGR($.))"'&_G$3\28,:&]HW'A0X@<[='-?
M?AAM#@X8L9L;1D+\8T?MQZU?IM1#[;4]?CB8"HI/6Y ##I=.S\O2C[J,26/"
M9(L:BX\JV%D&PH<]%*.T%,0;\BRQ3<99/D)V-V*.LO>VXSHLQDD(3HL$M?%A
M060C$$2&]T,,B.:7-+G-=0\-K3@L6SDK"[(FVAN^ZRIM!TV8C8<4%D.)%=$N
M%CV->70PX-<&M+20;A<*%6Z7WXU9B<NH1ZQMG*4R6L:]\0(8_G]244_U^JX+
MGL/3IR.U(!CE21@9'F&-A93EWBM-;3%0B-/B#58'W)#,CPC[%X'JQ8EI1(4\
MTRNYPYB-89; F9UL],/WA-PXDS$B341SW;AN+:0I9T:(&D/W-K+[@ZP-K2,.
M)*EL>^^!!M=IC2\J92 TSDLYD!D.78& 1=U-8D=L-A(++[GA@+(0TNV9U5KB
ME"6-E6LZ&W#9->[CU?:[FQ4=CIJ^05MZH'<,I\W"1\+<%ZFQA:SY?)O:1"51
MB16=V23&* &:@1MBZ8=RU[.M.8G&[WE@Z4EX]E3$L(&\(((E9ML::;&=&#)G
M=@!66;"B0Y>Z77S?-'=:S9V0@2SMVCELS&A6C CF-OR(09B7,.7?"$(NE]R+
MB=\&(Q\>]=+!=%1N;?Q#*!&Q0D.?'I)+F [3'PNZO%P1R"/>BC-D:KV]2LWN
M*,))$4, S!%()#94BR.NNVXDVHKVBR>..WW72G";"GG16O:R'"+K6[(YET8/
M9?9+VE*S<&4B$M-]QOQ89<QM7,S(%%F+7E&PW-+WQ +.L. V$6ONNC2,>6B3
M,/A"Z &PWT<:-?H)KCN,AWUJ&.2UL_K39J.RXY(-]=IME>I5;]57F7KR,4SL
M71+^NO5U. HT:UL!<HH@Y*P^3)UITYP .)"V/P^0%$6"S]OQ0[%FHD$MF+.?
M"8RQ;-L_<I69DVQXDW(3HC[X@O<XP VH;%A[XH7B&618;2X-/*^U9=D0.@SS
M(CWVK/3NZ3$":=!ARTY*F#N,5K6MC%U"Z$_</FE]Z&]P%5Q$[IR"@I1L-*S>
MM2;S"KG02!II=JN9TY#J2YG!H\RGJD+[M!^3LAO .YBW,]0EG.7JLC9QW%@V
M>),TTT63;U-D0YV'(PF6A3? ?'T0 \0C&B& (V]@V7,?<BS=C! AF)>(KB3Y
M^TGRCYR(Z2!$ MA:8I;N@A,$;<MW)C"#NH=N0BDO#* TP:*J<LET$X1.$5@M
MA/Y93_\ ]/M2?<2G*>Q_FVE_YBT?ZH5I:GSI'_Q<C_25?>7"JTX1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X17D\-RYZWU]W.J&V;<.N8S7D;9VBQD)UF&*2%P-ZE
M].V!"A3C$,%;NB;[#TW(AJ:V#1NIFFCFHOEUBDEGEC3V_*3$]9,U*RK!$CQ#
M+.AL+VPP[<IN!&<+[R&MX$-U*G/#-6EBS,&4M*7F)AY9!8)@/>&N>6[I+1H3
M3=:"X\)[<AQY+D:HC=C437:.4?K2SF*]MP6.5]NT-FM[R*L[!CL.!SK:J#1V
M%QAN(AD=DT?NIS!8\-B*8RPRD:*12:OV,P+*P_!)T*;J/*"=LBU)^).6@86]
M8T2/8[H4E#F8$2*^#9D:)%B%\6)#?)B-$=%O0&Q&Q8+3!:(IH\AMQ*VG9\FR
M5DA$WQ"9!M-L6:?!C,AMBS\)D-@;#9$9,[DQL.[&=#,.*1$=N5"VI]L3NYK]
M-"MM5[L58M"R;7!"+U<- 1NHZSW'A<],%ZBH@K6U>GZ(F!F3OI$UDT?1=#H0
M9[V7D2L:D@<8@65&8=*ND5H=8\]!;*QY"7G8<^8DRY\2:F+*C0&MFIQL>/#G
M8+(;89AO(,9G:Z&(C'.++V1&3;3E(CIB#.1I1\D(<!K&2\&TH49QEY1T""^5
MBO>YX>P$0G;]>6/:T.NY@X2$;?ZUMMGM!-J2FPAH#%:5B.LE?V)K?W K-=NZ
M[7I:J'-?2B5!'@\8YKXU&WY=CD?CV ,BZE;KZ9$>B806X;OLW&<:RK0-FVW9
MC)%CXLW%M&/+S^[RX$<3<T(\.&\.<([(C6$,B7VB$-R;=>X%M,(5HR0GK)GW
M3;F0Y:')08TGN4<F#O:7,)\1I#3!<PN%YEPEYW0WFM-2<5X9NR46*G]:JGG,
MX-%K=-^*SK9=BSN4+%R&*]>16K[&@Q(P2EY7)9G@LR-24(R28/"'3SMHIDX2
M2\U:JYX3V06?$;#M"9@P6-E6=C4_*4AAC:1XDS+QFM;";0T+(;W%P;2N!-2L
M;$G89=)0(L5SIAUO24R3$+C6"R!&A.<Z(ZHJ'/:*%U:&HP!6W ]R]=XB/@U#
M%[ZD!S)A07B5UG)[](0RQ/0$5E6W;)@WK*/.!B3,O8I4)"2L94)R(D!CQ1LR
M-3%TK'4RS=N])J<;[)GXKHTZV28R]/=C\Q#D6QH%^+"LLN,P\.O-@-?&;$NL
M:][2606W[I(:.1EI2<-L*4=-/>1*6U ?-NAQKD.): ;N#"VCHQ;"=#)>YC'4
M?%-T. +EH,$V[URRUZA.MY.VWD#D#_1VS]<RMX(PR?OQ5?SA[N\0V#%I/6P,
M*K-W\*L>OF+469(Q@(7)#G1=@Q*!LL$2^#+GC67/[^C3[941F"V9>?;)F- #
MH\$6.V1?0O>((C2\=Q<QL1[&N#'%K\6UXH5H2>\X4DZ.83S9D>3=-;G&+8,4
MVFZ;;4,;NIAQH(#7.8UQ:7 .81> F([XE&N[NSALC!3B:#!8_P 2G0"Y3AKZ
M.21@3G5(ZRT*G4]J64::L.G"BSV8R80A+,8<^67D9),NBH]8+$V[WO#JP^Q^
M>$LZ'$@P7/=V/VW*,9ND-S8,Y:$[OF6EV%U.#"AN,/=0 QI;@0TA<[K9E#';
M$9%B-:+:LF9<ZY$#HLK)2@EX\9P%<8CVB)N9-\WA5MX%<#5PR /+;<M*51Y3
M)8!)K&F\@!JY-U&F2H<S)B9(8IDT5P35:Y9LG*&7;=5/!1'OOR>>&.6/?77L
MY1CX4K+0HF#X<O!8\5KPV0VM=B,#B#B,UY:8>V),1XC/F/C17LPIP7/<YN&C
M C#0HYYV%PIPB<(G")PB<(G")PB<(G")PB<(G")PBL/J5^DS1G[2XM]Y)<I>
MR/N%:WW&/[!5K8?=BSOO<'VEX]L/TEKQ_:7*OO-;D]CO<*R?N$M_3:HMONO:
M7WR/[95?.7*JTX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%8-G^BI(__J#A
M7_\ ;B?<IG?_ +# _P##3?YZ35JWN)%_\K+_ )2:5?.7*JDX1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A%8+83^64_P#_ $^U)]Q*<I['^;:7_F+1
M_JA6EJ?.D?\ Q<C_ $E7WEPJM.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X16'U*_29HS]I
M<6^\DN4O9'W"M;[C']@JUL/NQ9WWN#[2VG:2 3LAL9=3YA"9<]9.K&DZ[5VT
MC9ERU<H*$ELDUD'"++-)9+/'OK+!1//+#+KOY<>^^N=?L?G)1EB64U\U+M<V
M1EPYKH\)KFD0Q4$%P((T@XKFMF6F76M:+FR\=S73<<AS840@@O-""&T(.L*!
M?5I8_P!0)M\*G?W#EQOZ2\,E?2(7OJLWI->#3'X,3W4]6EC_ % FWPJ=_<.-
M_27ADKZ1"]]-Z37@TQ^#$]U/5I8_U FWPJ=_<.-_27ADKZ1"]]-Z37@TQ^#$
M]U/5I8_U FWPJ=_<.-_27ADKZ1"]]-Z37@TQ^#$]U/5I8_U FWPJ=_<.-_27
MADKZ1"]]-Z37@TQ^#$]U/5I8_P!0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=
M3U:6/]0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=3U:6/]0)M\*G?W#C?TEX9
M*^D0O?3>DUX-,?@Q/=3U:6/]0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=3U:
M6/\ 4";?"IW]PXW])>&2OI$+WTWI->#3'X,3W4]6EC_4";?"IW]PXW])>&2O
MI$+WTWI->#3'X,3W4]6EC_4";?"IW]PXW])>&2OI$+WTWI->#3'X,3W4]6EC
M_4";?"IW]PXW])>&2OI$+WTWI->#3'X,3W4]6EC_ % FWPJ=_<.-_27ADKZ1
M"]]-Z37@TQ^#$]U/5I8_U FWPJ=_<.-_27ADKZ1"]]-Z37@TQ^#$]U/5I8_U
M FWPJ=_<.-_27ADKZ1"]]-Z37@TQ^#$]U3TS@$[ZU?D+#N$R[I_G?4.>8,NX
MV9Z=YM$J]G2*KK%MYEY;)NFLLDDHOUAVE@JJFGEEUEGCUW4.G)3M_ ?OJ7N"
MR)II=N\*Z'&=DR&WKU+Q ) K4@$Z%:-EIGM+%;O>/>-J2[@W<HEZZ)29!-+M
M: D G*I TJ!?5I8_U FWPJ=_<.6^_I+PR5](A>^JO>DUX-,?@Q/=3U:6/]0)
MM\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=3U:6/]0)M\*G?W#C?TEX9*^D0O?3>
MDUX-,?@Q/=3U:6/]0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=3U:6/\ 4";?
M"IW]PXW])>&2OI$+WTWI->#3'X,3W4]6EC_4";?"IW]PXW])>&2OI$+WTWI-
M>#3'X,3W4]6EC_4";?"IW]PXW])>&2OI$+WTWI->#3'X,3W4]6EC_4";?"IW
M]PXW])>&2OI$+WTWI->#3'X,3W4]6EC_ % FWPJ=_<.-_27ADKZ1"]]-Z37@
MTQ^#$]U/5I8_U FWPJ=_<.-_27ADKZ1"]]-Z37@TQ^#$]U/5I8_U FWPJ=_<
M.-_27ADKZ1"]]-Z37@TQ^#$]U/5I8_U FWPJ=_<.-_27ADKZ1"]]-Z37@TQ^
M#$]U/5I8_P!0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=3U:6/]0)M\*G?W#C
M?TEX9*^D0O?3>DUX-,?@Q/=3U:6/]0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q
M/=3U:6/]0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=3U:6/\ 4";?"IW]PXW]
M)>&2OI$+WTWI->#3'X,3W4]6EC_4";?"IW]PXW])>&2OI$+WTWI->#3'X,3W
M4]6EC_4";?"IW]PXW])>&2OI$+WTWI->#3'X,3W5/5]P"=O'=2]M(3+G73:A
M:J9N.VT;,K](.VX13!PU6[299>2<(9_]*R&?S54LO^G/''O^+E39$Y*-;:-Z
M:EVWK6M!PO1X0JTQ11PJ[%IT$8'0K.TY:9<Z1NR\<TLR1::0HAHX0L0:-P(T
MC,*!?5I8_P!0)M\*G?W#EMOZ2\,E?2(7OJLWI->#3'X,3W4]6EC_ % FWPJ=
M_<.-_27ADKZ1"]]-Z37@TQ^#$]U/5I8_U FWPJ=_<.-_27ADKZ1"]]-Z37@T
MQ^#$]U/5I8_U FWPJ=_<.-_27ADKZ1"]]-Z37@TQ^#$]U/5I8_U FWPJ=_<.
M-_27ADKZ1"]]-Z37@TQ^#$]U/5I8_P!0)M\*G?W#C?TEX9*^D0O?3>DUX-,?
M@Q/=3U:6/]0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=3U:6/]0)M\*G?W#C?
MTEX9*^D0O?3>DUX-,?@Q/=3U:6/]0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/
M=3U:6/\ 4";?"IW]PXW])>&2OI$+WTWI->#3'X,3W4]6EC_4";?"IW]PXW])
M>&2OI$+WTWI->#3'X,3W4]6EC_4";?"IW]PXW])>&2OI$+WTWI->#3'X,3W4
M]6EC_4";?"IW]PXW])>&2OI$+WTWI->#3'X,3W4]6EC_ % FWPJ=_<.-_27A
MDKZ1"]]-Z37@TQ^#$]U/5I8_U FWPJ=_<.-_27ADKZ1"]]-Z37@TQ^#$]U/5
MI8_U FWPJ=_<.-_27ADKZ1"]]-Z37@TQ^#$]U/5I8_U FWPJ=_<.-_27ADKZ
M1"]]-Z37@TQ^#$]U/5I8_P!0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=3U:6
M/]0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=3U:6/]0)M\*G?W#C?TEX9*^D0
MO?3>DUX-,?@Q/=3U:6/]0)M\*G?W#C?TEX9*^D0O?3>DUX-,?@Q/=3U:6/\
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M0]O7G?I08-Q)8&$)?_ZBY/O!'_H7,5G7 C6*;;WK47@_#<J.+BHN C-D7,%
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M3*@2K>J'58Q.86Y-"5B3HQ&S3>KFEQ)-W\U.R4^.CQ2U"D:#.).79L!& I
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M^KH7] Z@:_1FY%[X#0THWL!21RJ:LTUI[83Z!@IY/ V4=G-A1:J'\J<U=%+
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MG+I5:<(G"+E(\+!NT@ME6]M(]F==P![K94AA[6DDM B18Q%&\K84[K"N.G^
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M-Z_9:;_W<7>4WI2]R7=">O=I[J;U^RTW_NXN\IO2E[DNZ$]>[3W4WK]EIO\
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M$U;3PBJ+,FUF+0##7$Q,7\9D5SQT19T=F<#;Y2!X@\/.XB'*"T!Q%<B1ISQ
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M_P"@Y/RE[(>Y$UY4K^<EU:6-W2E_)F/RL96DT6E,7CU$>(ZQD)2.MW<DU@A
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MR)KRI7\Y+JTL;NE+^3,?E8RKYRZ56G")PB<(G")PB<(G")PB<(G")PB[;_\
M!2?Y][J_JE1WWQ9W-8?Q+^@LC[6<]B76P.P+Z6TOLY7VHZ[G/-3+9"HKNC0N
MP5Z90D=3]ACXO$VT/N2.36-O[(M.K,'<LG 6,#:PL[(Q4C?([-V]3J,)CFO3
MYTG'HA.E9BV(EC[!]$Q'E2R! S%<NC2,=>&.8IEBM0D>IMFAJ>\/D%5O58KS
M+1DG!BJ,!F4BE RL)AT U<LG6UR/;3(+"3,B&+1C&QU)9$#CBO7?;Y4"F/?!
M JQ?$D$)45=RMF(/Z4STK%272FQIU=1FVI7+X3@C*=G-3+?/A!J1U;I.N-6*
MB=N(]"V"[MHGY4KWLZ4)SX:HYZ38MXDHDHLMZ?[49\)>H*<1%><X_P"G#^R@
MLOX9=JFJ/"UDZM"%)2%OI!M!K66.MVT@Q:96CNE:,$GFP=DC.O,L72;-RPBA
M)C&EU<$S7GAIQFY29I+N<\BF]C@.^:?\(( XLU->.K>S\'"[IP*EII5L)";$
M2N8VI6EK)FID-LZ%S22U]6<"'0XG'F$1>!A(*."H"J'!V2!EQ*1" RL?S'0=
M$E'NEWY14<&HR%*:-/ZFM*+0JNT M(19;><SD]#6@E[NU!MJSP1K9EMW(=SB
M-=::K4?"*L^GEL"&TID+J+WGDE:?<K.N\<38[MUDV"19RJW!LR7A3+O:5R[Z
MM:#BP4ZV1K7;TMW!@5^0=U7]4BX@AF-E5AQN<V6K8%S0)"N9T("4[:E-(AA5
M2R2/1NTILG8<;GAR42&3QEJ#]"Q8.!<R L6Z*,*'JRQUUU*I*?A[[1C*,UXK
MF,S"CPTQJ7P^-B]("9]Z=L$T-#2FXAE/LFNP<7[3A09[)9(<7I]J\D\7-(QC
M"..9226#R:3H,G#$^65X5).EP=YA6HXL\,='1*#3P_K""V)) 8.05RG0$@V=
MU'V34</EI(I9:8_4VJJ'@4-I7".H!4XHE&F$OH&-V:'F/4H5<)NBQ6-+PK!7
MK"6*E%[+70@\=2['H-*;5%, U#NU*O\ =XS$P9,%8.UMT["TS4+^8=L0>.O&
MM=HWA;$VGEPJ '[[I\X+RN;6/95KQX$%:KEYZCW0 >5L(^*%'#,8?'QCU*2<
MN( \Y 'Z #BQ7,E!H:!KJ$P^OHLUR91B"1:/PV.,\\_*Y- ,8$M @AKDI\F/
ME,D![%NEWG\W'Y_>'>7R=?+\G"P6T\(G")PB<(G")PB<(H*HC^26M^W6TOOO
M'F3N]\D+%O?>45.O,5DG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(H)V>_1ZN+]09!_D\^
M2,QSCUJ#D>8^I?+@VP_26O']I<J^\UN?1W8[W"LG[A+?TVK1EM]U[2^^1_;*
MKYRY56G")PBL'JQ_3K#/[I,_]!R?E+V0]R)KRI7\Y+JTL;NE+^3,?E8RKYRZ
M56G")PB<(G")PB<(G")PB<(G")PB[;_\%)_GWNK^J5'??%G<UA_$OZ"R/M9S
MV)=; [ OI;2^SE?:CKN<\U,MD)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G"*"J(_DEK?MUM+[[QYD[O?)"Q;WWE%3KS%9)PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G"*"=GOT>KB_4&0?Y//DC,<X]:@Y'F/J7RX-L/TEKQ_:7*OO-;GT=V.]P
MK)^X2W]-JT9;?=>TOOD?VRJ^<N55IPB<(K%:GMU7E_01HAUAVNZ3ES='I15)
M!/M5>#25)/K-=?--!'#O/+KK)591-)/KY<U,\<.N\NJ3LC<&V-...33+.- 2
M:";@$T !)PT $G0*JUL0%UIRS1FX1P*D#$RT8#$T YR0!I7@]EVY?[+A7VPT
MY^?N9=O[,^O-_P"66I_LU'::?^I+^GR'^Y3V7;E_LN%?;#3GY^X[?V9]>;_R
MRU/]FG::?^I+^GR'^Y3V7;E_LN%?;#3GY^X[?V9]>;_RRU/]FG::?^I+^GR'
M^Y3V7;E_LN%?;#3GY^X[?V9]>;_RRU/]FG::?^I+^GR'^Y3V7;E_LN%?;#3G
MY^X[?V9]>;_RRU/]FG::?^I+^GR'^Y3V7;E_LN%?;#3GY^X[?V9]>;_RRU/]
MFG::?^I+^GR'^Y3V7;E_LN%?;#3GY^X[?V9]>;_RRU/]FG::?^I+^GR'^Y3V
M7;E_LN%?;#3GY^X[?V9]>;_RRU/]FG::?^I+^GR'^Y3V7;E_LN%?;#3GY^X[
M?V9]>;_RRU/]FG::?^I+^GR'^Y3V7;E_LN%?;#3GY^X[?V9]>;_RRU/]FG::
M?^I+^GR'^Y3V7;E_LN%?;#3GY^X[?V9]>;_RRU/]FG::?^I+^GR'^Y3V7;E_
MLN%?;#3GY^X[?V9]>;_RRU/]FG::?^I+^GR'^Y79J_@VXYWKM,=LWEJXI#D)
M5&:@;!>XDZ:VDHJJ)*6$J^Z?(56M-%PV&&!!KV@J:3'I/<LE<&.;G-LZQ1U[
MV?S\M/PK,$L8SC#B31?NLK-2V#FP +IF8,$/R-;EZ[A>I45]MV&2<>3B3YF!
M#:(C)<-W./ CU+71JUW"+$NYBEZE<:5H:=K7VDJD_M*8?9/;7Y'YK2X[5M'6
MO>7VZ]AZD]I*I/[2F'V3VU^1^+CM6T=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T
M=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T
M=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T
M=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T
M=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T
M=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T
M=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T
M=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T
M=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T=:7VZ]AZD]I*I/[2F'V3VU^1^+CM6T
M=:7VZ]AZE#M-WW68AK9&+]_*,.R-Q6*7:^;UK9;[K)B0+XJM<UNV,0<]-7&6
M'\:K%UVB^:Y?]#ILCG_T\R+2:89- T+$. KCFXG2IB]I*I/[2F'V3VU^1^8W
M':MHZUE?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'XN.U;1UI?;KV'J3VDJD_M*8?9/;7Y'X
MN.U;1UI?;KV'J4.;"7U6<@I"T@@M_*%")2%FV3/!W6UEC&V3A9KEBGBN0*1%
MF.9I]]]_]3AXZ;MT^OXU%<>OX^2&NJ,-(TA07-H<=!T%?-#VP_26O']I<J^\
MUN?1G8[W"LG[A+?TVK1UM]U[2^^1_;*KYRY56G")PBL'JQ_3K#/[I,_]!R?E
M+V0]R)KRI7\Y+JTL;NE+^3,?E8RKYRZ56G")PB<(G")PB<(G")PB<(G")PB[
M;_\ !2?Y][J_JE1WWQ9W-8?Q+^@LC[6<]B76P.P+Z6TOLY7VHZYX]^]I)I2.
MP&JU6B]CZ\UA@UMUCM;,9//I_ PT]2)2JG76NZ$!BPL66-@5EU"F%FRQ9T*"
M.^CQOS-LU&=IN$L<^:F6RV@$.-"2" !SU]5.90K"_%W-L&U'Q6Y:?AL,M<K6
M&H4DV#@QJTG%?V?')EM070 XBZ5HDS#I+([$;5RBJA/+,$R::P8O"XB22%LU
MYC*A18:B2YF:X5-,*@TUFM!Q9^84)E+#Q.I*TP,R4YKR+8URYC_B .*[.,+F
M7*2^2ROP^YI,8C. LKAZM3C14+C]@8PHH0B,E&S:;D666/3,U%&^.3=XX)=X
M\>#7#ZP!%,<<\<ENLR\1E:.NC@D/2WITZT >',] M'=C8!&!<_XB5PS"FXN'
M)$L8065"#*V-1EH4-G$1YIP?&E%\60,8X&X)D2@-KC7#A?Z0';:J*/\ Q&;B
M.L#49E-"Q2JWQLANM20F:PZ]7UF/(_?>IL,L.4%7+"/F:-KUN5K0Z$@[HI&)
MD0*"Y/T<QQ"&ZO8L/)G'13=&@UR)%*8&FFN>(KHU$K 5OXE-MP.C8*E>='BC
MEM/:(T.LB'NHM<N!AG;X/;&Z(%K6M(Y82?U+#D*TG<9F\L92Z40X:)FL66&E
MV;(#/'.>+]4:2[4X'#A9C*Z*\==('-B%8>S-ZIQ2-HT+6ML5WKT/)VM+J:KR
M8QN%[8O);;D+EMVS56OXV7BM4%-?X@]G=7#Y(J*2)SP](*T?*LUS*XN)/UP"
MS1X4!M:G'"M#3 TQSK@::,= TK9+TLV])EMM M1Z2L<+2266O4UV,GMF/:^&
MV5(2*(RPXE6L+@D7"2 F/C@QDY?&)&?F)M\V+$NVPP ("IB<R3TJD0 4J<<:
M4RT'^RU]7>N0@+27AQ"LALCJ*&;+5AI3/;R2G*@*7.-B+&A,#.C24?H_&%%!
MJU6_2:R(=#2\A=6^/D8N0$R>0Z%FXX#Z/D27<,\:5I31CIUX5RRTJ+=--D)]
M;%V40%6EL\?U_,-.]@+&( I^8BDGD+R;0_;6.5V*/%Y)&(+ 6;M<='G10.*;
MCX\(:-@CAJU?H%"C10RZ(12O$1M!XRLO.]Y)D[\0+7FA:W,0A"B7=P6!0-Q%
M273)[(YG;HO6:W;L6CL.<Y/TLPHJK"D/KF/G#"#9\G)IO-Y+ .NQYBOBR#J-
M6WH2G!)IC0$<0K3'GT5Y](4(PG?N^0<5UIVBL0W')93.W;C9SH32(6#-P)NH
MAE24_>=]UDN(G6!5Z8E)4K!Z()1>R<9$.79.I;*VAB+MHJ)#YA",K*Z,1I%,
M==2!EHS%.;SJ=-7]BMC%[6U2BMZ3>'6&+W6U$G6S(=C%H"C"\:5FE>KZ_DC$
M "/4#11U+*^) -@6[,87E/G$L;%X1YVZ)N&TH]'!2Q(%"1H<!SU#L=BY6>%B
MG")PB<(G")PB@JB/Y):W[=;2^^\>9.[WR0L6]]Y17$':'B77E6E][:TX9;QE
MF*#7_15>ZL2Q2.?*@4[;S'4MELM6$B[[=Y(%90-KW9(%8,)(=]-7C@4XFRV+
M=9M7ZBV>*Y0T$ \3JXZ:.NGI%.C6I?(>+]#&\PND.)@$.DH*LD-R1H%J"NYH
M]MLE+M+@4W*S).RZG2KW/JI*_GSVM)P,KJ>J3*9NR6#..OB<0&=2L>V1)=RX
MZ'+#A94.G C5L4NSKQ%'47)R6/@Z3RDLA&H: -8\R<V.B!8G9'OW8,MK>+#"
M)+*%E,@(NOS<<9NC9I-D:<&1I-PJR#,7(U-J2**?KL%5^))O]/(1+Y$)E]"Q
M5"'TO8.KM+[/R^/W:2,O:YM_:92MF\;&U?&7U,@<K>K^%J7%6CN8S0\9J,[Z
M'/OGH" F7H-V*5)=X\P2,- KGT'*O'3,>2)>(DI-Q2Z0JLH;&9=$JIOJ<7,T
MM&[VE?P"E9C2E_Y:[LH1.+%<5Z5Z9B)U+8U;!@=.%HPT38QJLW1!&.F<SS%%
MN2[QZ0!3$D$5J!Q"F&LT4.X^+(JK"H:8RKJB0!DS>MLT/*IQ.=J"<6U.C\DK
M 1$3PS(/LLEKT:7,O+4%S@+E6HV1U1!43#X;+A[DHT7 LO3KF2[CI.%<L:<U
M=&G$T4V3/?"?@8=NK<T;H>*2.A-+P5]H'941NTC'['L&Q-?ZMQL&2Q^.UPVI
MJ0Q\9"7YOM6#MIR4L[TZD]9/C>%=.Q>++SX@;\T5Q=31AB:#&OZ+4K_W)F*D
M_&UA V;V"/8-M7X<\5D\D;E&);J;PC:&7]KRJ+9BW@'#H,V0##G(1V\1>NWA
M#![YVS4#JH]89DID=8=L'6L!*O%/0K\OL^*E%=51*\]?Z"LK88-ZB-E&MNJR
M&.53.1T%E4*L3)>IX4/J>S$GQT$X3C;,E8P]#MP48$3K%X'SQ=/C^WQL2[6E
M-) Q%,3JQQ''@K5W;M))-9=5Y%L)?E>PN*R@&>C$8P@D<MQ8]#.C5E6N JBL
M/3=M2&N81T #OR4OBY2P#BL$>LH$P5D"K+J8M0:#PN4 5-!\4%3@JHAO$^E,
MW& !-6T?6=@V25DFQ\7<="]D'WJ,=/-=(76MED"L,N@=1)HQ,HW+X-93#$24
M3JH0N+G(]Y#S#!NT0(28865T8U)H*:,<<,JCUJ(+1\22ZIQK_(C<,JX?3T\,
MUYX;FS5+/A-JHS7.7TUM[M;%ZX^B$_4*52 95M-G 4,>CLI8A$+/",1$L1)A
M)8[),%6R)3= -":TO@X9%K2:YXC3^BL@,\0.T#DT4UZ#Z[0E7;<;<]CU1(:Y
M?W^78TP.%5K2M67X0GS"[4J'>RPH)-P:[ZK'@A"E%#BO<PD!(46Q%A@#J1KE
M%T9U-VE:TQS(I2NL'3DJRG?$ D%CDYG:$9,V?%ZFD6J?A5V=%X%'3,+C<Q@\
M]V+WSO:F;(2<2,Q";!$N<U&49C,.G3/H638'XS%R3&)$HN3-H2]D0MH-9J\5
MU@-!'KJ-NI7#?[HW$'N?8^K3%,4&.C>O]9Y6$3MM]MD:#P($]D<C:-JKA-V%
MY-K6 $U+)IO NC5E'&L=,VUG 0 T3Z61?M9M"2ATHH* U.)RNCSTX6-.,"OF
M*A"+^(M<]ORK4P'5E6TMDI86WU\:XW?DE?1Z2PCS:G*%G5II$ZBG["A<'DR!
M'Q#,=-!YTK$(*_Z,QII7+D4F+F).?1 IN@7L\&@C#60,<<-6G8O7A?B$S097
M'FE>56?O"6QJ.;M7S9'K;NP)%#02H->=JK(J/L;%#\3HY43,)C(G8(@RJB"$
MHO!P0:)QML&G5MYE&B4FDK^^S! T',T^:!05Q(KCCT\^ T"2D?$F>&;):CXI
M2P\Q26-]:QT03M!_:3@1-?2&VM.5':M62<#56-:$AQ42P<VX*CLV:E;,CCX0
MV:X'0F$E4<NP@HHN\>-"<L,'$''S88'S*R,^V*L-ILL%UII^J(G/CHZL(Y=5
MKR2>6N3J\7#:YET^.0".]1!H%JNTGD^FQ-]#IP13CQ/N! $&4=13>3-LY,-4
MT2BF%2>(85J>D898X\RI)8?B5EG]063+GE5F(-65BT'O),];K0@%OCE;7DCG
M4N/294^X.1J14Z1BU-2&6"@A2:5*9Q?WF,;MA*:D\C(LEVG%GPX8J;O2"*BF
M&.6G'C"]5IM#8*-X2N,G)G9+R+=;<:"UG"1@8_"@[H6+M_6<-.90.ESYU6YG
M"41>02-5X5EHD0UB!DD]7P^C\FBC)+MDH4T% >)QTZ#SK--/%4D#.+O+ ENM
M*K.#F]:]KMAJLZA=KJ36=2OK3Z>06O;*B4OB;FKXL*@V)DK/Q9:(2(5+YXDM
M&F)4A)!4:?MTQ*I+FBO?-::C#A5H<^+%64UCW#E=\H;'/"M=5JJ-H!Z "M#N
MN]WDMBXQ:$B)5VTLTL'A$E<U!4HQZZ#!9#$0?;9#-Z24E[\T*(#@X\<$,RDL
M2*4SQUBAZ*E0U4'B:L)S!*8M&:Q6F -?6I;&=42TY6>Q;ZU'NO9M]3LHM"/!
M[\!&:4JXC YVN<C'5:R6$K8N>XU)9#&'*1PVS*]XMRDMQ(%<!JSQIA0FHTU7
M\J3Q')C<%EP*LFE,U55TCL*BX?=$6B5Y['F*\LR<X6%79JPHV,JF$-* D[6R
M!,:1; @5OF1\H''*V*NY3\V&25&)(=R0A;2N)-#2H%1@:&N.'%KJ,57R->+A
M-8EK+J3/+<KZC\;AV&U@D^TJ@DQL4K6D0(5U#P];N<!D;-&:7=+$+RL$I8[)
MC#Z;8!%XXW]#'U25NIM&+5V1*;F+L30.NY::GCRH,3S8*<S_ (E4[=3=R&JW
M7 #+H9A>%#Z_,Y1-;P(5S(7$VV5URK>_:O)NH6SI6=)#XFP6LAA$K'>9R=>0
MQE!IG(8U%YTZ56C+,EW6=!. K@"1K&I38+WI;)Z1S?;V65DX$F:]-7% C]4Q
M^7HR-%[:5/WG,-=7<8CL](QV+)OH_*+,B?D04M+1,$LC'RS0L6CK%PBZ&)E%
MWA4&FAK2F!%<N;CYE3#+Q%K?HVT]AHSL2%I\%-C6S],4A4T&.;#*@]?*T1,Z
M=,K[E1<_L,8H<#)FT>?,XU(26/3JF21MW8$D#0P4QS%NL3[8LBT$ BOS22:8
MGA4&%3KIGD"5.=3>)LUN&S]?Z_%0"MX RNFMHO.NBMPWNZ@I:3F2LULV"RN"
MZT"6M0R,#L:?K]_6#TV<2RF=7NW<3E<(D(X:JS-K=,"QNYYX:A75B<< :X8%
M5Z:^*D8JRDJR(,J\QL4L2I(W<[EWL!L0(A%@6$DK><MJD=75/YPG7D@RO"U6
M1$2U6(Q()#H*L$!GZ\'8*2([*6V2Q3<Q..FE *Z*U-3@/.<<%9MMXA\H'6D+
MC$WH^.1ZK^MF9[J-)[(%7$2D$C#VY!-?9;L2Y+C*Y5J$*V,U>^B\.(!.I(XG
M@:6M9 NWQ^@#D7UF2X47<,\;H=2FL@?KJ4(UQXQX.S(DW+1NIX2?E=@!-;R]
M&Q.&; LI@U*$=GK8$U+#()?TD85BV;T)8D/(22.R6RXX*'6\W"QMR5RC1:8&
M0V0AX4EE#35>KA]7.FL:CAQT4\ZW[![!$:+WHL6R L4-6A2&P&PP>+U[U/7K
MR!"!M=P2(2 +!!]EMJQ!GWT6P>N7^3:3/ZQ0/Y($,LW8%-9/IJD4$"K0,B!C
MSZ:5V542A/$<NZ.T17,IE-"P>?6-&=%(]O3LIA'KI(1X8'IU^S)9#GU8X/:4
M^;-+7FS")3:1)UD8;5W"XP^#+1?NVR:"XH\_BN%?/YE-T5SH"X@8>O'14:2>
M)<O@(T.D@0-(@Z_G0D\*'FA;GO#-+S@<4:(OF2_DU,<5$_*METE/F*8XYX?.
M^;ECUEUWUR5@LKPB@G9[]'JXOU!D'^3SY(S'./6H.1YCZE\N#;#]):\?VERK
M[S6Y]'=CO<*R?N$M_3:M&6WW7M+[Y']LJOG+E5:<(G"*P>K'].L,_NDS_P!!
MR?E+V0]R)KRI7\Y+JTL;NE+^3,?E8RKYRZ56G")PB<(G")PB<(G")PB<(G")
MPB[;_P#!2?Y][J_JE1WWQ9W-8?Q+^@LC[6<]B76P.P+Z6TOLY7VHZ[;LDI2%
MRJZ*JODIT6^GE.PRVH)#^VS_ !1#= KH>5H^F?10=VWSR?/.UZHBGHEQBY;]
M,,.B6.2;CSS'M'4RV34T(T&E?-6GK6B2#6".D[RROZ,V+:U9RPVP@ FR0< .
M1II#K?$5@6-%H2PL 1(XC)GN'8KZ1G!+DG""T+.'(Z_Z 'RA04/%-6!*X4SU
M<5?C3UK1L-"M?NP\=C[UA*282-O=NWB U](L_(D,-W)1*Y;>;(FHT:-72K-X
M2F9Q",XM5V;@ P4;HXN':J'3C(IO'U#_  TIZEJD6\.>E8^AEV8F5Q3\PH0U
M#>JR2;RX&Z,J(:.VH9MS7X5U@ B4=#(#0<@-+CI!BU$(/)2&02R+O%C[@F>(
M$O'B'SM'UA0[.A;B\T4HQ\LBX7ZF/E$+1V/MY/O"0I8]=2[:>)S*&6EWWUV-
M[Z[&=AIV=^CC+O\ C$._,UU%WO3?M-0H#B.@#H(/Z!:8*\..C&@MV*.22UIH
MFF.UJBT3<RF3@5'E>UQJ7;P:[Z7K&(*@XF"P^BPJ> V+J1E9,E); FC%-)G*
M9L4[8"5AY3>/K\Y<*$GS>8:!G78[0T2K.TK0.6F[GUNQ(C)II0]F2&-1 [$$
M8F7LW6R1AY#4D[<M)'!9(8P* \0; *_"-3C>%'A26"QB+/#K=F::D#J84!S&
M/'G\9K?KNU9BESS6$VBTGMITW;4!CTJA82SZ:D (%*7,!G#R/DY5 SS65Q::
MQ201DH8BD;-MTBL:<E !H0W*1@H$>+OE790#HS&HK1$M#ZCQM%C9B\IM5\VP
ML6$W8>K9_*QKBMYI?5>0,)7,3N^5CNX[C)7<]81V,1E=TW&RH5"#$FCH:9&8
M<_E;),QPE<*4'$=(&=/^:G16BVZFM.Z?HJ10B3P7J4]$Z_JV<U!'_3!M,@W^
MB%A6BTMZ0]/4L&#;MR4[ES)#MB]ZS2Q;#/GLNT%<LO+]$))KQX]"]>6:/:MS
M"X:KOA]3-?#;/J2QY#; 23 83#A)&03J21:3QAV<F[]"/]DY0\9JRI[+!3MX
M_P 7S"<L TJ2=]DQJ.?9*FA%30BF:U6!Z"TC IL'DZ!*P)/%H8[M<A5--S ^
M),5'3[^\<C&-HNH$ 1CK$[GC(V$CDX%DQF4FEXN'QB3'HO!6$8 $EAW93>)%
M-=*G2:9<6RITU69H/2>K]?)0"E8&56E.7L"J]2CJ>:6;*V$E8TI2ZY./EG5:
M5YVR !""@=\YA\*2(GIP0FD[(L(7%QKV6KL!*+?LH))\YJ::3\$Y88JX7"A.
M$3A$X1.$3A%!5$?R2UOVZVE]]X\R=WODA8M[[RBH;LGP_P#7>UT)%A,!DF</
M)#M)#]P<"[,]TS+@+EAD-@U>LW4=>8,<NQ\<+PB!,8S(@*V#M,J+,R)+-PDH
M_;J,L5F"1T$>8K*CM*:X&+7(&;S>V.ZAO3UP.9SKYG) /51>G+\S*N[<D05-
M**)6&*(3(Q()'(G0_"P58R.D4A,%PH :Z>=Y8$KEK%,=.&7%AS+38OX=U,@>
MNW)F97#8!Y0YJB=<RB;RT&Z-.EM+K"-6/1#'-*/Q*.A&XX,4-*BSR+ ,S7DP
MAJW5*.59 X*GB1+W-IVY_'Z+<9[I#4=AVV_M8P9L-BWDTOJ&Q+(JX/(1K6K+
M7L.@B DI3DUG@5R!>R%<Q!GT<B2J+6.2F. 9)A#8FVFH:3-0+%%,I#B!3#2*
MZ:',>>NJNI8N1Z Z_P B]IA?IO+097:F0UC+)\; GF[4E'Y)3T@PF]?E8'T[
M%/QX;(-8^9.REV!5@>$EYE() Z,#WXLJX$]E%3AQ?K\46LD?#WAQ*O[9K->_
M=C\(K?DIETJO!NB<J3%S9Z]AP2,U]88HTXSIM3T$(F(B+MW;G""IQ(A&R)(K
MC R,2$JLQ3%\?%%-[$&@PI3/1EI6P.=!J>5PN^.-)/:@FGMB8Y-@-KZ_C)0(
M2J4^[L.M&E32Z3M4UXRYL (>+P]BTZ71#SYE&NY EG+.X[W)7;THY**G#6,C
MISJO!'] *B%NLS$@F5O6'+'=@Z\V87F<XE01P>-2?5\J_)5+D]0CT4CD>:CA
MJ#U(288!@(I(XQ8-G3WO(ZY+&21+W-IVYJ-T_"PH/Z.FH8]GMXE(23I&U];Q
MT2?RJ&]BHM2-N26/3 O X^Z:UZU.^1CTCC;(A%Y(;,&IFFFJL,D,DD0= 8/'
ME-XUKA6H/G'QS*[%VTU"[_K.0U3/TROT=D"\>)8/@!-8+(8_)(=)@TVA,MC9
M=#'/,;)(;-(Y'Y5'WN2+E!N9#LE'31XVQ6:K% -#7XU'I"BQMJ;%7A"NI!/K
M(MJV)C68NW@P.9STU$L#;P==8(/'):V*,X5"8;&>DF@H&Q2 )"(\(1'+><.5
MTWJ[A7/(E?,#G\&JCEYX=6O+R(!X7EG/T!8"B]6]>A3EK*TT";2"Z?67E;-,
MNL'F(KOKN2LYCW@Y/E<DNT#3-)-GVP;8?/RS*;QK72;Q_P 0H5^._#ZK--%$
M\PM"\!%U=6I,;B(;(BY%!FMR&9C/Z^ 5-+<">/JZSJWN.E*RB$*AB$98UBQ"
MA6,)B98 T%2@&T/8DO'BI2E-&!KZ_65YL/#GUH:@4XN($2H)'T*IU5IIH,'2
M=?/!M#-.KFDM[U#_ .;)-B!%V<5GTL,.9J<)/'K^5LEL<':B+[)=^N2\3GQG
M_$ #ZL-2P^7AT5BH N:*.+;OYU%[NL!_;DE".)1 U,!-N*V7%+7!66$+>K7J
M1/)-"Y1"(JTB2,Q,RR/,(D#%PMZ"(Q8:/%-27LL!@*>;*AT<ZRH30"NP)4!)
MV=K7@K.(YL26V?83EV:KI8_G9LMJ=S3-CX.6G58IQC.+V5#7Y3&1Q]*.HHA"
M)-9>O%H.U:"60XHO'93S5J.A8D]X;5$E8V/C8.4W# $TPVP$-DA>"S,8+.SR
MLMG+4+7';U7RU^1C)?'N+%YL9>.@)6.(1V?PMHHNWB$V"J$3"Y)\=.)2OZ;,
M ?C#B4D*:/T1Z1./V0X^)3.7?K_?N8H472:"!LUUGB%=0:K6 AGYAGYE%F,>
MJV*-B@;RBN3]1)ZI@\:].<<$27CL(\Q)/K*VNQ=98W/+?C%YB9]:%6V*#BK>
MOSI6M#<>'MK%KEE)^IBP@DZ82B*2ULX#C9"L4>C"D;QC,O&X2"1,V,F;LC+Q
MNH2N%%!>?AK:_.6TZ"D3-IE81*H#L57$2KI_+!F4.I:/;7+.W-Z9U(W;QML9
M&D98X?.^ACF7FYHG!QSEU'8&WC,7>O0C@IO'U5XZ95^,<SBI)4TCI-66*3/+
MJ7>F5;7HZY<OD/I=-/IEKY7K>LJ_[Z0]'=]]"NHRV2Z-L?*?.)$/G.\'#7'O
MR/"BIRXB.E0K;GAPU\?HM6N*L*E <MB]$;/4A6I.7'"+@(W";5S*%SVS$Y(N
M :LS:;EX;@89G'Y&&RQ(0YJNZ?-1IITDBWS*;QKCK:3_ .O_ "5ONH&OMUT\
MVMQ"SIHZ91>;91A&O*O&WM:VR/56*#!IU"724;=EX1:)S@D0GI L,?9Q?.+-
M(S$E(PU<"^R#TZ;74(2#2G30"NK 8*,;K\-V.V91M[UCE8<OG\YV2F] $[0M
MFXB(3N3_ $0IN?0LBW8QY"K(9 8\-,1V!AY*RA;AK'63HA)RZ+F9G";'-SG@
M0.H0=5:#GY]O$K/S35V*V!:5:V+*)Q8SR/5')!$W@5+H/(:PJ4'.P$6.PX++
MTFS*$H6!D]&A9(5P0!]V#U#,WBJ3YS&%W+=+/$HK@108Z=.=?T4+QKP[:X@L
M1I6,U]<>P,"*Z]PV4535,_C4EKU.;Q^CY9E"\R%(/7!2L"D=D<#:*UW"7(8A
M)(V5L02^CS4DSG:9)P_=NRF\37 8XG//''/C*E(AIK3Y26R&;OU9>X/RC8&H
M-ES#C,^EVFXLZDJSAM40Q?%/T=\N 52+08)F;&_/[S(E>WKW!VVQ<]()%%3L
M(\Q)/K*]_P!D*F5->[%UC>,3[^KK/D-T2J2(KG7",@1/7K:TQNB6D@A\>FR=
MAW@F?S<H6A[IKCTYC_F8?I-9PLPZ75)4U!TBFP4&P*+'7A\UB\6*2=S9]Y*7
M(1M*)W2AL!C)H8C:@6RX=59*CATB"MV]?)5DU;/Z@,%*^/1A>MW40-!'[IP^
MCZAI7(KV4WCEA2E*8TI6NNN>.!6_R[4@+8)*HEI_<EX3*.U$=K6:-H.;-P'Z
M-3>QJCE7<W@EC3ET/KEA+U9,*E:0TPX9Q.51*(ELPHIB6B[T6W48KE%>(:=N
M'QI5#+=\-*SA1H*VU:F6,/!@*"85#7TO*;$WE4LUIR8M[$M^>K6D_CM3QDG$
M]DVK=Y:3-4#7%B.H$)#*QLJPS/OQL[+X#BR#AIUU.#37+#'YN68K74KTL=**
M@P=!29I:2R N,V3+;8OG3Y^Q39&[BD-+GZ*D#A^)1&]-.HF3A<F,9]QA+YJ2
M!1=)Q@\R01\US+&IV4\P(/K"U -H#6X>G^Z(4M2^3-8QY:J7%, C4QC#EUKL
MM1LJ%3.H5JA.-X,T.9.(&<C\=[&.K-(V2[("03"/2!<P S?#7I3>-:Z<:\=<
MZ\^.5%,]8:SU_5\&M*!M2,NES&ZI5+IM9YB9F6ST[*I3/HZ(C<S*JKA!@ <(
MQ/-A";S(9'Q@D,(=NG*$>'!Q*8\6Q**G#BR\V2K@3\-&G3,$A]?D;.OI45':
M/<:P2<@UEL.$F[9UH4<X*M*.LMX&KT<W>100S\Z#"9%$F<0LUH)+2!OW/559
M$<<$'Z*;QXLZ\QU_\U"Y#6C1J/:-6#%NBS9,FZ+1FT;)8(MVK5LGBBW;MT4^
ML4TD4$L,$DDL,<<$T\<<<>NL>NNN%BO8X103L]^CU<7Z@R#_ ">?)&8YQZU!
MR/,?4OEP;8?I+7C^TN5?>:W/H[L=[A63]PEOZ;5HRV^Z]I??(_ME5\Y<JK3A
M$X16#U8_IUAG]TF?^@Y/RE[(>Y$UY4K^<EU:6-W2E_)F/RL95\Y=*K3A$X1.
M$3A$X1.$3A$X1.$3A$X1=M_^"D_S[W5_5*COOBSN:P_B7]!9'VLY[$NM@=@7
MTMI?9ROM1UW.>:F6R$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%
M!5$?R2UOVZVE]]X\R=WODA8M[[RBN,M?:C;:#'=TBGTOIV8L17B::Z:?4O&Y
M!6LW'M*\!7?&]0 6)<P5'W Y5DHT"SNKT\\ L!4:<&IZUE\B2." ,O$0N#XZ
M^+_E<M ;N?S7$XYTO'##BX]6A;0KNSM"QVB)4 R@X:RTZ;LK5RG;I6K_ %DV
M 48S)_>$4@LKLBY8S:K*=2VK:$@U2@K'$RCNO++>V))3X:)RUK],V+EX!=JD
MNB@-:5O$5(P K04S-:4K@%6R^_$4V'4J?=AE65CU6<2!Z06[LO0-WQ+7*\*S
M'!6\$FZ$',CA+NR;4(#KL6=!#C(C!+J@64:@P^4-4SBD/FT=R;"'[X^,U( J
MW _. (J-.6C#C!!KQ+E"V5M^[*&INHG PC5LFMZP;SH*B"LH?026BJW:D;EL
M(/ 'TR'UVWLY_)TF0',RF9:1=S:3Q=]BSS%K2=OV[Q)M"Q !)SH 3Q\0K^M/
M,J!VAXC-^P6DK5(H26BN]@M=9!N$TFD-&:X; 64#O*,ZL]1<EU+HB*@EN^?:
MVQ D.F48!S><VE++-C4+F!QL.99R/R/F[DI#149T--(%*UUBARXJT6)N'8V]
MBF7B"R*3GH5)*7KD#I'C7M3MPMI0:1AGEP%:[EW9!Y:< NZ/%LLV*$H--)"B
M%" UI:[:Q?RS\9&@Y>*28@ X.LWJG#U$%24&\0S8*3VQ;R,9JGHO45?V9M_4
M+COU!WHR1@#O5V(V(J*M2:;(/#*5*2^/6-9%9NH7A645!!)4!PG<.5RE9%X/
M.M^$NC#', YC21@!S&M>(J#+)WHW2*5:2:,Y51$-F,IK7PLMB83)XO5%A*(1
M6%;P;5O*/E55R0>3O11>7%8ID&'DN[!$D(2WE$=(2&-80:*E'8N6B"FZWC[\
M9_5%:Y<>6/.K\U_LE=F&XQW7R[WD-K\"OY493 OK7BW&76Q2(*J8I,Y78$ V
M+5M8[4 AV-D;F<I/M>R44)V4 BL5R-*2@XQ3>&,2QH+M1Y\1ACAA2OGRZ%6F
M^/%%FVNVP\FJ6?0N&XQ"NKQP4L&4-6$CQ=,M4)3 =<@M?SUDKF?S9-YNYV2V
M2!5X3</6ZH%^$A,J]' F;Q; J-*0VHPKB/\ 4"<,LJ"O%50A)-E]LB"[U:/.
MJTI"]9A</A!QNUR#H%<%BQINZV!;C'\XAXJ"E;VCXB-!0AYS]&3'44[CA*<0
MCN0BY \PE)<3-(P4T:*5J11^5-%:8T/]LQJ,OUIL#L-6>SUNLGDH@\RINQ?%
M-2UD*Q,_'9NXG\:7D>C]4V&QD5>396S%XM%(:(DD>PS5K5Q6YW(@I(Y(62F0
MQ^MC@X*"!=&N[7GX9&/FTUT4HI;N^[9%4^Z.Q3E"SQ<%9,-)]-487C-HA8MN
MPEI9-F;9;*UV-]'4M6LBCLPG<VF[E6.1 *"AA(9)I,7QC(KM[FU:)))E &6&
MDZ0,@-)6C55O%M'<CRB*RCS:E8M94^M3=2L)K.IE3]LL(ZECJ;-HVQ%R,/21
M"VP$XB3V=Q4DY:%H7*[*)OH=(GJ)'(V9: 5X_("F@QSP#=.OCIZE&4L\2K:B
M(CKMMQ2O(2>J6CXKO7,IU"AE%W*P>0]#5Z426 4]&7VT9"R5*;FY.[S+%E+"
MA"OH 3=P@0!EL5[BY9XP+2J,/C_A+H-!I-T9C3GAQ<9QSKH7(#J5?ES6*/N3
M&^HYB"'UN\C3Z-VPM0=SZPQ.:QXU$>C$DP0KB_#D@F3-2NCX\N,+R3J1+A#@
MER$)H- KG)^Q2*"!A3HJ#3S@ *B([Q*KU91N_%OGU':;J&PG1:U*CGP^@[ZU
M\ALJANWFR,HHXBS<0VU["DTPE@H&)BW<EAEKQTH$C<NR-8=IQ7%L$5P+EE='
M!S%2X'$'( Z!AGDO=/>(;LM'99GKZ^9UN_N8=LI?=/O[6@VL&PUL0=_$J:HV
MDKE8$F.N-8VE)[08GI$XOV*Q1^^5MHF  -(W))4I@][>#HZBK\;5%!GC2@PJ
M :Y9TI2H)V+=5_$1OEI![+D$CIV-5U,() O"YD;ZN9D.E'T@B4KW;MK&N[DA
MLOZ]-"%UGE=)=.6T2R18!'#<PUS<2)J50S[&I$#032OUL?)%1TK9L-Q]F&D>
MLF]2K.D<J(JG=8YK/,(H/A,][L8=6$=V;=48?N56=+6?E'$UHU'S,=EQ^.XU
MXNV;CHG,#2)=7$X-CT9)08#&I;7BRK2E*Z->I:S&]\]@#1W6V<3,9!*<UDOY
M9G(XQ;#Z@;CMD%*@5D;!2"&T96QV=PZT $?URF4VI1S4LG9VA:8"15U)["M'
M".A@PW"-Y#C9+HQSJ-%0*4&.8X6-<!2E*XZ(Q[WTW:D2($Q%W6K(,38=9^(=
M/HD//5!;,A(1)70.ZP=9*CY$1'["QIM,D[A'&<7."PT9"<JW>)]NN\;!1Q]'
M*M-/C#_E+K0:8G%HS S',<CT\2LA36ZEN3[86K8O98^,TO5-TP.MY#2 LK2%
MJRE6^"LQUR87-)VD3VA&S]A3L%E4'D6,V"Y4W,*W>3F31"M#$Q!DU61Q+L 0
MM%,,2,\1AC3*E37#$&F-%DKRW-G=9;6UO6,2D=>36ORMW4]15HP)K1=RK3&O
MS5R1I<R$,E=EFTXPI(,>13?Q:1M:E>U^_E9.&&6Q14N+Q+AG2Q0!4'FJ#70.
M+/SUHJID?%"V$KZOU[IGT2IN40F6:V;_ -NP."0^-S>+2B-S#2.TX97 UA,)
MZ8L.7"9/%[/PEG98IV)@$0(0#!EVFD]F*?>:_197 333>:W,4X0)U84IQU5N
M-/"=[X;:[SQF^[!B4]D$;CFICICW6T6F4#KL4F=A5DO'Z4:@<QLJUGP9XY7;
M))&'Z$I4ZD:K%H358#<\L1S0L32C:#7Z^8*@EQ>(]MD\T_DUI"7M00U_LGX=
M>R&Y^N9**P2:J2RAAM0$*>0<0VQ7A&U70Z?S0M"+T".8]8@,3782%65'GF)2
MNYN%\W&.RR#0#K#7!IXZURPRPUXZPI7N>^=JM>-F]G9XVGE53,94FL?ALE;5
MAI6O;&81:8YV1L?MO )<[IH+A>+]O2L@*".V[UT=D:UQY$,XQ%Q!-D\:M,'K
M.-/1S9GXZ%  (I0U)=3$88 BN&.G4M@P\1[8<M+;[,Q6ID3-45C)]Y*\0Z6H
M*]AS& EM0P5EH1^Q9UL6\.-Z:G,=M"P*J)1=2MX:&CLJB_TTB;924D20P^GU
M*71AK-TYCOJ84SR(QXBITOJP;P*^$[MU<<]E,0&S^2:2[!6O!GU.!)= LJ\%
M&=<SLJB0CHP9G<N-&9M#R*JW:EAB%X8W++HL" V%Q==OFDH0 7VC1> QQKBM
M>SW2L"/;24)4(:3P"Q*IL"U NN\S#C*.N<?+ZQGBNJ$LO[%V9V8(3EW2,PD^
M3R(L4B=3A(&WE J+2]D8)R!$@*<LGY0!@3J%<QCP@,L].Q15'-Z=LS&ONHUQ
MGGE"1CK;UT@09DH[KU>UP)TR#%4W*YN0'E*Q@MT)V+;Q&:2R.-6@V01I2$!*
MS$E.Q\D:3%XF.-&(&(!UT2@J<\-9 KC350?\+7 _B(;IKGX5"2E%)*6E&Z6U
M<N.Z:HC^L6PLE.F7FRUB3YL6K@3)XO.)#&==2--5G"E7#F47-G+>K(FJ)ECC
M%:[;A"K)E*FZ*5KF2 :@94Q.NM<A2G'5<[/"P3A$X1.$4$[/?H]7%^H,@_R>
M?)&8YQZU!R/,?4OEP;8?I+7C^TN5?>:W/H[L=[A63]PEOZ;5HRV^Z]I??(_M
ME5\Y<JK3A$X16#U8_IUAG]TF?^@Y/RE[(>Y$UY4K^<EU:6-W2E_)F/RL95\Y
M=*K3A$X1.$3A$X1.$3A$X1.$3A$X1=M_^"D_S[W5_5*COOBSN:P_B7]!9'VL
MY[$NM@=@7TMI?9ROM1UW.>:F6R$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A%!5$?R2UOVZVE]]X\R=WODA8M[[RBL<^U3H,E,)=.GT"Z<2">6%6
M-MRS'*3S+&/%K1IQU#W=<6'E#<)#C#F<TCRE?PA+.2#P+0L:914&.D#HJ/'H
M-L<5G4^L>8Y^M>^:UHI<_;K*]7D5(-+0:)@$W1^/S6>11A)>HIF\SBRD[B<7
MDX>&V(XC/G[M./.9Y'Y&Y"H+=MAJK9OC@GB2II30HJ&>'SJ"):2(:TJ'#,/*
M:[L.H"X A.K++QOU3VDY9/9G60J-EID]!1ZOW9 >@3"0Z/CQ<>AQ11\3AH\
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M3"LO"TA<,N!Y8$HD5;RN+/"^P1&1 @E$CX5/;L'[%_31&6Q3:2Q$Y[( =WQ
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M'K/VQK.N,1J[-)^^9,5'23G-#!X\:MLL^EG"6&:HU#;UI0ZSLZE'ELRZ+T]
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M<:G%Y)PS;CY\:G7D*@J5[AU.VLN2S=A;@+0JP!]77%(/#O/VKJ@S/TN@SO.
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MLQ'0GQ-:/MJT%']8#6VX%O[)*BUJ?[ GA<O<&YCA,CPPM9I&0V@UC'4!)&4
M9%5H8,'FS$LKPJ#7"\PTH< !CT:A6OF"Y@=5JGL&OKOW.E<PCBP6/V?.-?BL
M$(J/A;K"0#X;JI3U>R5RD@P?.G3/$7,8T<"YX$D&2KA1AFZ9X.&"S9VM T\_
MZ!8'1S?J5>3DJ$X1.$3A%!5$?R2UOVZVE]]X\R=WODA8M[[RBN$;8[0390_;
M]W7Q5D.>KF[&WLJX=.(QU(HPUQM#4 4-TSG@2>,O2)M-DV+4K?-+2<@+&/\
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M.7X<>MHVB6B[U*;0:,8K$>A9Y\7C1 :4UM=>RSRP)KQ;5X2FG-\NY9;0E!M
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M9$NGBRK6HI2M,^?!9* ;W4;:YZM(Y6+.T9X0LB"0ZRE<H]5TN7:UO#9[+9E
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M6OJ7'UL[NKL%"K!V+@\6G#V)"(1OQI?KM&C,.J!"UYL K6[]<Z]L:?8A(0S
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MZA+QVN/^(4/J6RQC2&F8C; 2V@SRP$WD4MBT[MA4)6F+E6N899-X@IL&N,^
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M&,,L2[T:OD>T;BEHQLELBP<PJ,8A4F^I]@7M.W4=/'!KN#1(W;4YKAC! Y/
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MH])RNS<II=WMA([K&@;\E=VEX;HL>%N\+=(,-@#GOBLO7H;6-(<]S@ T$%U
M0NIO.;W.%%WK,;E'>V'!B;C$N17N-&LANNT>YQ!#0TDN((;4@T]!G0%ZD5V3
M8?3%K/W),K8((<W95]+'2Y W4HS$U:8=DB@)44=%*W#YX%9V/0Q4=Q(=EB]/
M),&V72G>1GI)H)=-RS0UL![B8\(!K)IUR6>278-F'\&"XX17<%A<<% E)HD
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M<_DU@FBQ>2R$7*JX3 +2&,VRS,PD63=SQ<9E'&V+N0@@XMR4-( &/UJC'$$
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M<EU:6-W2E_)F/RL95\Y=*K784HOQ/J&A=:P&F)W](WT-B.BSB*1PHVBV;QY
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MQ\H+*\(B^A3W^V3M-:/_ &8?I4I^^GLM7?\ 5@)]HM:?G#CY065X1%]"GO\
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M\!V%^5>+CM6T=:7VZ]AZD]I2G/K(7^ ["_*O%QVK:.M+[=>P]2>TI3GUD+_
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MUY]"K)'_  Q8#!'E7%*[M28 34 K;NG#QB2P6F+)=3^N6UG2^UPC4DTFU=%
M\=E$<DD^FJ(J1Q<6,:J#903;EP)11$,L)*;V=17&HS%#2E>OFT+99EX>X:3/
M[%=CKDF85K,-H8MM[' 3N*5[)P$/MT+%F<1-8NAIV.K]32(2,<R1?)Q^1JJK
M1L^@Q. ";5^-8J($O'933EYC\:5C*W\.M.FGT!/51L;:,1EL,'VS#RLGRBE2
M&W,VK&V;L(WT[B)T05@J\=9%HE-S)SZ(2L (%9LQL@-LB8<LDNPQ&$+B<P-&
M&.@4UZ@LP?\ #AJB21_J,D9Q9* [*P-Z+ 67%$ @PKY]OME:OK+9,R203-4>
ME#L+:-_0%XWP\_9*C1"YA<NHDY\X)>/%WO\ II3U8K107ABA!*9-RXOJ=*G7
MAG6.6#2(6!5%%1L>F&I;^0NZI*"(P$AB(+H2K@6&IRP"];.TS"PMRLQ>AT2>
M#0:_MLQ0NRPRKKTZ\=JV3OPRJ>.BG#"QIC.[!=RF/;E!+7)/NXZ#RLMQO$G$
MV5L$';0&%:MXWB!"PX-'*^91_IM@#"-&V!5<\41S*KDO'B%"TC/O:TT\9K^B
MLAKQKXZHV)F(J<L->T\"B0P=@0)5O5$ <=! XW,6V;%4:PAT40D11^FLNY,E
MC'3A-=VNKV)' VJR[18H..0IQ8_JJQ0SPSX3#Z5>Z\86M+7]3#<:=&5T,3@M
M/A)5"8K25H0^S8='B4]!0-A*)]DGG!H]$G165OG+IU'&?G3W!Y*U5I*H4EU3
M73C7/&OG4P(:25^WG0F>XRR8Y$A&Y4HW509Y9A?,E9]*M<Y1K8\BJO70KI?Z
M(-XK*GAUMC@MB:ZD+=MDJ44&]*L5&OC_ .%%<"-8IMO>M5ZC_A15FQKT'6DH
MN.UY@#K;7.*:S400<M:_#'Z<AL0G-96B*DPMZ)AZ3&53Q&QJ6J21)%Y6,(A^
MD*_"C',?>8O)$Z.%)?C6@Q))XR?TQ. U\U)CAVAT7"6!#[AEUH3FP+?";&F-
MF93-B(^(@D9M,7VK<GU#"QM>.Q\$S%@(3$ZFD#;T*+"^2)+203T;+F"2Q8NF
M[)>S%  13S7KW3582B_#\&:TDJI<TI>=E1(7"Z5H*A['"/ 5;R-M=$+UO[D2
M=>O#SDU$'+N(R9V,E\ECLK,PI03Z7C[]FBP;!C(40<:$+JUJ,R3IP)SIBIFD
M^M#QYL5AL=7UO3*K9%(H=7-=V[&PH&"2*.VM"*HE\RF,(&ONI=&S)&+EV"]C
M3\"[D,;>-7SR-RE=KCBW*B8^9$E%<*4KF1G@32OJ'Q6M4'?A0UB7KV3U+(+@
MM0S7"&O5XZP4A&U&D#9]T'4^P12.DYVQC9)C$T'LO.,6\-AT8B!N;YEU0,/C
MJ I9$F1)GC98IOG/#,./&1E7'CQ5Y*^HL+6TOV1FT?D1_HULK98BTI$HYQ$+
M)160!*.JBBF*4814&YHYLL -1 CN21U,OWF=?D^E.\QF39@@4$UIQ"FTG]5Q
MZ7+X8?TKH/8V A9MU*K2V>M?7R6R^<N 4,J(;%&E9SJ%-C,QC &LHHR'83AK
M7+28/GY1TW=E[$-NFD:+EQ,94:(ARD.Q!T '#/133\#1BK9SS3>.V%=='VD7
MF+IE%]>3 Z1UA7 :"UR/R %Q<)D4#;C6EDIQG*QFD&<"I,]>E(6R/-FA0DW9
M(.WV<=P<1]R45P(UYYZZ\R@,'X8D>B<*UVCL7O&8M9+K'64FH6N9M(*WI:;K
M.*%D64 S;P*21>6P0K%BAN-.*RB1&/SY$:RD")%,UT0P(AI 2"J%-[/#.AIQ
MBN.TX*:WVC->/YG(YLI+9C@0DNSE$[2NVB"<:;,&\PH*GH!3$;CS1LT MD6\
M8, :]&%#39!-)TF5>OL1+D:.Z:,6[7Q_\**^HCIQ63<Z60)SJ/>VGN4JE^,'
MOQ':]&22?',-]*PV.W%@VI8LU[!Y=B^Q'7<:*6P98Q;S\8\ZQ8#AG1;HDXZ=
MK."F\:AVD7?]( 'JQ6JVGH5#[0LJ43%:RYY&X3:9>AY!>E3!V</7C=LF];SX
M^05J]>'2L=>RZ+)O,@D< SYI&C+-"6Q:-"!*/0-?,N0*D#B*<5:<5?C2K%T1
M24?H*&GX5&RQ@RPD-O7M<;IV<[9=O$#M^7/.[LD@M#M@U9H^B0Q^?$A(3I1+
M-YT'9L>G[IX]Z7=+%!->@#H 'Z*9^%"<(G")PB<(H)V>_1ZN+]09!_D\^2,Q
MSCUJ#D>8^I?+@VP_26O']I<J^\UN?1W8[W"LG[A+?TVK1EM]U[2^^1_;*KYR
MY56G")PBL'JQ_3K#/[I,_P#0<GY2]D/<B:\J5_.2ZM+&[I2_DS'Y6,J^<NE5
MIPB<(G")PB<(G")PB<(G")PB<(NV_P#P4G^?>ZOZI4=]\6=S6'\2_H+(^UG/
M8EUL#L"^EM+[.5]J.NYSS4RV0G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(H*HC^26M^W6TOOO'F3N]\D+%O?>453(OO_.(];AX:;J*'-J&B>XC;
M3"13MM9)UU9C>;G:KCUE1F;M:[]7"<=<0W-Y* <3+M,;!R/HK/W1UJT5:B/,
M2F*Y+N&>-V]ELK7]/[5Z@/C!'YU5;^TQM$1XFQD$#UWL^MF FPYE@R;!+]OR
MNJ9;P2VI05I]B'BEEQP39T7FR[6%XV$#)=92 *S>=MXXF?/%-S&E=8RU"N&.
M(T5KU*4)[N#;M(VA=:$Q@ B0VC&:\\,\$O! ]X296B$Y1N1N'=VN#5[&%BM1
MMY#'EH]@P%R*7RW.,$B,R9M1 !.-B<8PV(F"@-J!C]?1CP6AVOH_NM#-[A[3
MSR]:2KR$1&N8U;E?WUM=15OUR]MB7HT?."D"UWKRXH=(TYFRJEY,'8S&)69%
MS[$2Z@35T-E:A(*N1S:,L#+DINBA-<* C#',@@BHU'UKU@WC%(R_NFB$3IIB
MLPF%'Z<W58,7?2V6/+$:M]NR2R'4:JL3&:P.@YBZIZ/M'4QEA66G8$SD@[)H
M*!HLW?I)X,)<SQTN%:8<'23H!5AA&ZUQ2&L;9M[J%:TUY"8O?=LZ\UN\M:_9
MX#>RZ5T_L;9-"FGYH>!H>09MB$H^@B)6!P.)*RX](";Y00N1&88X.\2B@&9.
M0)H-! .=>/'##C6F:U;?379C8K4J0XIO8/#[+TUW=DDUJ]B9?EXQW:-';5ZQ
M4PE(&KLJ C!<B@-4=S]*+O2\= %TP,I63*AAY!5PU0*2*!W$YN/.''6>+2O+
MUXFJKS9"85 #K$2;AD3N:R*">%&,CEZ]C#Y96M.G;,*6'(HRA6ZL)"U,\E<?
M=5.W>]V*YDJ1H@ DJPGT86S',2B[A7B!RPQ.O7YE#:/BG[!I0OJR2VM5.MX<
MGJQJYNL\2'W]-'TC2H_8^3R&+=1ENR<4*.&N;5C2D<=&,VV9-M$7**[<3@<4
M5\H4Q*;FBN-7#+"K:5T\>I;1!=UKFJ>VKHSMD("F.NI+Q";&UQ"S7N?G7%GU
MLKZE1$_BS)A7.4!QCCVN61,"]"*^;6'U($G\NR,)">V0M=J](0*"F=VIP_6O
MZ*/+B\1"ZI3K%,2;B$#*,E=L:?0G<K7:45]9)&8GQU9'+.JV-E([8.+^#1)I
M&;$##+/@J[S&-/I9&R/<B/#&)3K",IDCY T5SJ*D'1H./-AQ*89IN5;=3079
MR=5K!0=HE89NQ+Z("U]:]VRQM*9Y,RT8J1M6U>4&-C]129!LI+)#)UVS:&&7
M8X##D$3<S,3+$!V== 27:T%:85K3(8DUQT?VI52>?WCL.-;25CKD\B- &W%I
MR$O5;;J%77.91,*YN$7K1,MB<!UM#,*181.*1]_U S4<:C&DR+SS, 7A]AI1
MI<<9(A 91=P)U8XCC PQXQHXE42#^(I8\:HO5+:'94,X6<R#2S=K:0^$J2P7
MB45D,9IR/T9*1HV20@C @+$I.'V$H>AHLK@31%0?O%ZXS)R3N3OU1"N%?.IN
MUJ&_6:T5%,[W&<,//Q*R1[?V[(";D=2V#0U9MM@!4XT] "P$<NB2DJN?1W=&
M6V!7\#,$IT\IYC(QI"%3:L9F+F ]I C"3X0/%R (YR4.=A!2OZ;31108$$T-
M<P*U:*G"O&-/%HJ;A:G7M(=@:R/2691(-"IO!;BN^D)J$C,A?2J+9R>D+4E5
M9$C,8/% ,7*O0,B[C:1X>F4CXP@/3(]C'*;A1GYZY*"*'HXLQ7C5FN%"<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*"=GOT>KB_4&0?Y//D
MC,<X]:@Y'F/J7RX-L/TEKQ_:7*OO-;GT=V.]PK)^X2W]-JT9;?=>TOOD?VRJ
M^<N55IPB<(K!ZL?TZPS^Z3/_ $')^4O9#W(FO*E?SDNK2QNZ4OY,Q^5C*OG+
MI5:<(G")PB<(G")PB<(G")PB<(G"+MO_ ,%)_GWNK^J5'??%G<UA_$OZ"R/M
M9SV)=; [ OI;2^SE?:CKN<\U,MD)PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G"*"J(_DEK?MUM+[[QYD[O?)"Q;WWE%5WKW0B#AKHM6YK%.'YT_E.
MT1396OHAU*YFQKJ('W%.0BI1!(Q7GIW*'2*9 F@.3N1Y]T(R11Z/#G?FF1J.
MA28_%<A<:4X@./#CX_C2MGCNA%(1NM7U,(%[:*4_T\K1:(U@?M.4%X=6(RH;
M  67 (U70]RX[7!1X!(XP!;M&;IV3<)1L6SBJ+Q&/()#\"B\:UTZZ#&NM8S:
M;2");"-9N6#&2$,L&RY'I+C-I6B8D3?)Q --MH>MB@((!Z")BW\8DA#J06&(
M'RP(]9%&!(^')YKY= &F.)2'$<W"PXW-I7U8<2WZ"Z9477D@ATN!BI0\E\-F
MMIV.G+9)-9+)Y'))U<L:8P^>2:8EC9!ZZD3][&!0@"+2=Y],(\'#B!8)F/'C
M6;9$HJ<OC7YL=2U.#Z$4=5SVJWE6%+8K/JJZRJ6G,&4(M&3A1]A5M1BQ%>K(
MS:37!PKC,$XMD;/MTRBG;(X4%GBP(T3(@7/0Q,IO$UK0U).61.9&I;*8TOI<
MG7C"N1_TTBK('?TWV=B\DBTP)#9A%+GL2PYY9DLE(,ROT]2Q1)'[-G#/L&19
M$0:8 ^X#8C_-T6O:!14\^ 'F  'J"\M,Z9TG1$AA\G@K:79EX%&[TB$3<R68
MFI-F*C>Q=KQ.ZK.%YJE5UG)/HC8,,"EAS\NN0*C4?/F:3_-!\OUD2I/GIL%!
MZRO?8:F5L&LV=64 /6A'L+-)G)'/ZW"V+(&52RJ922%H0 U-"4$Q6R']'R$<
M9L/.L&BK8(Y/CVDP<!E9>GD<S)4TIASTQIJK\:LEIB^@>MCB%*U^I&C_ '&E
MM:J?U,S;=2TWTX[I:BS!@[787IWTY\OT6'$3I%1](/G>E"J:B:3U93!+#KHI
MO&M:Z2?.[/U+)I:047C:.%I+MYF0<8VM(KV4@Q.:&']9.KJDT4)P-]9KR%N5
M%&+F0-826=1L6Q55RC Y'%L90C_4I:HGL"B\=@'F&CK6B@_#9UA"1"503,=8
M)Z+2&M8[2@49*+*E9_JMJ5B<D;2R.U-6"[]\HXB4,'&V Q7M%%5T8?LPL>%%
M##X5&H^S&%-X_KSDX$GX]96=F&@5$RZ5,YPF0M.(2L?;MC7HP-0:RY#&W3*S
MK3AT;K^629G@@HLW:O<X=&48\)7;HIN0@HW+6 UPW:2LZB^*+QUZ ,AD,EYF
M6AE*C[1!VTT-6RG((W<2-_AQ.=E&W$3;7"O6#^FY1.5(^YZ6;O"D\KDJ5C\N
M1>J.![CLL6*!V88N5(OW)*FE-8IYJ@TZ1\8+U(YX>>LX"(1.OG@"3S""P:N+
MQIN*1.:S R?#AZ@V%'P\18M9I)**H.'$45$08$,"(O7#DD&:]/\ S<EDN_<+
MY%-X\V(.&L5H=I7O1C0NAXZGY<@K9$ZDF5B4E9"\XL2QI'+9JZ)ZY$%25*@7
M)Y^XZ54B,$=NRCAB!\EBB3>G9$7/JEC9\N2>%%3S9X#CS5AJNJ2%4Z+E0>#,
MG;%C,[,LFVSR;P@Z(YKS6V)B6G<T>HJ.\\\VS1[(C3]RT'I=XM1Z"F#5KA@B
MEACT4*3.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X103L]
M^CU<7Z@R#_)Y\D9CG'K4'(\Q]2^7!MA^DM>/[2Y5]YK<^CNQWN%9/W"6_IM6
MC+;[KVE]\C^V5 3=NL[<(-6^'E%W*R3=!/KO''M19;/%-+#K+/O''KYV>6./
MRY9=8]?+\O??77R]\N"0 2<@"3S#$JK J0!F<!YUM=AP"7U1/9I6%@!E([.J
M\E)Z%3$ LZ8/E0LGC)-R'."E'HIT^&.\V!)FY:Y.1[UVR6R2[4;.5D<L%,N.
M!'A3,"#,P'[I!CPV1H3P'-OPXC0]CJ.#7"\T@T< 17$ KDC0HDO%B0(S;D6#
M$?"B,)!+7L<6N;5I(-""*@D'02%IW.5<:L'JQ_3K#/[I,_\ 0<GY2]D/<B:\
MJ5_.2ZM+&[I2_DS'Y6,J^<NE5IPBY<]9_#6KK8*KM7B3_8"6P>Y=PI5L+#::
MB*--CI36[0YK\T$/B6-BS_&T@4CC R1HG!Z;0J%KR68"<O/7)%KTT9]*+^7M
M'L@F)&9M%K9&%&E++AR,:;BF:=#F"R=+FC>\#>SX<1T,L-6OCPKW!#34FGH)
M*Q8,W!D29N)"F;1?.0Y:&)81((=*!I=NT;=V/8UX<*.;!B7<2X4&-;T/#YOY
MQ6T<L9-:O?*2*.UG/,J_^F2&5D :ON*P&-85M:D@CJ;+-JSA$HF18(P:KMBS
MXZU9'@IH@!9A239_GWS;LB)B) _GT9$F(&[[D=[OF96"9B8EH<2M3&APFO<:
MM#"6/8UY>TM'3%D39@,CU@\-D"+N.Z#=F0)F,($&.]E*"$^(6@$.+P'M<Y@:
MX%;^5T DT C.SXB;/H9+[1HX;634@A5]S1HP&J682W8L=1I6,6J+1B9?([(,
MW:JJ&,>CLI"/(IV^8F3J[W)%W'TN%MMPX\2SG06QH,O..F"TS,I$8Z:A0I!T
MXV)+.W5MQET5W2)#>V)=<Q@%6O/*ZR7PF3S8AA1(\JV "($RQS9>)$G&RKF1
MVB&Z^^N%QD1IAW@Y]:%@F.HO"7GN6Q%85G>DGB3B!R&[K*UYLQ_2=DQLY**Q
MMF"5S,9XSA\G<%0;\.#?G6475+#W&3(PP5#LC+-\X#G6#IFRZLSV30=X3$Q)
M0XHC,DY>>EVS<O$9#F):-'A03%AAKVN>UAB77 .8X.<P@.8X$]F7L"+OR! F
MHD,PGS,>4CF5CL<^!,0H,2*(<0N86L+Q#O T<+H<"6O! KHOX=%VMRXGK.7T
MJI79.C5]B%[S;6'V[IH-63.>JU4]?E),U"K%<C#6S$\(-T %1XH4?&W+=04@
M_%=J$DN\+>DRUW\J;W=LX) 21@ 3;IAT#?+6MAEX9=,O6-?=$:UK 0XM?1IZ
M9L>:#F_S);<3*[\,T(U99L 1=P)=$#;U[=_Y5QK'.+CP014C%R_P^+SKJ(6I
M.+'.5%  %2SZ9U>45E%EAVCR63V(PB'V.TCE=#VJ3QW-'$WA<V#G80[%I=C2
M+3%QZ5>A,\Q^+_*%;DG'BRT&79-1WS4"%,MW*7<X0X$6-&@&)'<2!!$&+!<R
M,'<)I(NA_"NXQ+(FH,./%C.EX3)>-%@.OQV@Q(L*%#C!D%HJ8NZPHK7PBT77
M#YQ;5M9THGPSWLIO#6:.6-95?SFC[[L2P:P?6!K59@&:+1N;U[7R<Z,PYX8>
MQU^(9'T&):-D,%T1A\&2$/EE1A-?OK%9/I3O9"(<G:,27EX\&<D8$"9$"T)=
M\(1(,>/N+(H8(@>6$LB-^<Q[7-X31D>U*V(8DS),C1X,65FHT: 8TE&;$N18
M,'=G0BXL+0^CF$&Z]KFDEI.:XI>>F5"G")PB[;_\%)_GWNK^J5'??%G<UA_$
MOZ"R/M9SV)=; [ OI;2^SE?:CKN<\U,MD)PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G"*"J(_DEK?MUM+[[QYD[O?)"Q;WWE%3KS%9)PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G"*"=GOT>KB_4&0?Y//DC,<X]:@Y'F/J7RX-L/TEKQ_:7*OO-
M;GT=V.]PK)^X2W]-JT9;?=>TOOD?VRN=C5JJKU<P77)O:.LGA 47%[ @\"5J
M*;;'5FA);SNV-]1@<Y#V"+@,!G)^>2V0R08DA(21DR"AK$F0>+/LW#'%TCAW
MY>TIF2$:T-[6AV4SD2!&C[Z@R$P8<G)Q-T<'P'1X\%D&%#AN)AM8U\5S6MI1
MU%Z"0@31A28CR/8]*LC0H6]XL[ OS4TRXTMC-@P8KXL1[VB^7.9#:YQ)J*A<
M#>T,^PM?92_+-2E N<86%<=CS-.9!(J6@H:5XR:7%B^,B$PL^3,G(F-,^>>D
M&,<,ER10,V<)#R#YTZ;JK9^TLZ!O:SY*7,-T$P)67@[DZ(V,Z%N<)K-S=&8U
MC(KF4NNB,8UKR"YK0" O*ST;?$[-Q]T;%W:8C1-T;#=";$OQ'.OMA.<]T-KJ
MU#'.<YH-"215<E<[\+[7NNU)IE*-\!(-IKO/ ]4[8Y&*"GJ#^)6;(!$H) H;
M0XX89,*WD^+O8#/PZ+MUG7XQBA$W,F+O6(9ZCBEY^!V1S\P(.Y6*YYGX#YFR
M[L[!+8LO#=":^+.N<QHDVM$> X@;NXF*(;6EX-;J+8<I!W4OM5K1)Q6P)^]*
M10Z''>U[FPY5H<[?3G&%&:"3!:!#+W$--5QQZN])]7S$.DLLLDNF\VZ3RSQZ
MQSR3Z@LHZPRSQZ[[ZQR[Q^3O+'KOOKKOY>OE[_\ ?EGV05[3S5<[TK7GWY+J
MOL;NE \F8_+1E7GETJM.$5\L?$$NJ/:E4_JC54AF]1AJ_+7F\G4FA5@DQ65M
M"KF?19RD -!Q8T4X%,(PT!F!JF'T@,(2)I)WR+EJ/034;O*7M'*1+4FK3F8<
M&:?'9)M@PXT!KM[.E!$!>U[G.#G1"]KA_+889ABA<:%MKVWFF6?+R$!\679"
M=-&*^'%+=\-F3#-US6M:6B&&.;\]P>'G!N-9P->*'()'1])UH6$7BUD%-Q*D
M*XS&QG9!P UYG,'HF8@I#&5I50^=9$W+B:/@<=#QU\:PL?T'B1&#IAC&%"3;
MMBITV=CC(<Y.3#'R9AS<6<F+T20#Y^#'G83X<00YW?#0((?$<\,W"_=<Z%NE
MTWEV7VX]\K*P7-F@^6ART$MASI9)Q84K$:^&8DIN+JQ2UC6%V[7*M;$W,N%%
M&K/>QJ1GV\1XE7>(@=O/<,/L0FMU+%G_ *H683:(5L2Z:8)H13!>>?\ :8YQ
M?RZ:455^;WZ:39*J=8ALNPZQB(-CL;'O.L:5BP&C<@W?3GV:Z0!QBT@8NW2A
M,4=Y>[]<+;4!BVFXP;K;4F(<9QW0G>X;/-G",(=8N5RM(?UJ=ZKHVQXK=5P/
M:*>2O7NHR,SK-WNY;.UQR32*R2+)U<!R05[8U1PMW%QC^IH^2J:)LHY8I^2K
M1N0BIO(W98ATT=FA[9HW:MJF5[&IF-9T"'/338,P+'EK,9#9+@B58R/ FHPB
M.$R]LU$,2 R&(C'0888VH8XDDV4>WI>%/18DI+NB0#:<Q/N>^,09ASX,:7AE
MC3+L,O##(SWECVQ7EQH7  4K_1GBEEZ?A]8USU7TT9Q.(ZQ2K6J5G:PN52MK
M0*('-@C.P(:PH#->J_D;> 'X\8)(QI<01!3<3(07I=-]DV[+I)B^[.=C;9J+
M,S&[PC%BVC"M"$R9E-\2S2R1;(O@1X.[PS'9$8TQ YKX+H;[MVMTEW4E;<=+
M0X,'<8@APY&))1'0)G<([@^<?-MC0HNXOW%S'.N72V(U[:UI>P@^Y-XG-M5L
M[K<E#I=(DU-MRFSW4NN&UW%L3 T/=5=!*M85Y."RD-BBDI4:BH*U5>2Q+L.F
M\9N^@[6+C$&2+A3N2ECB5F!,-BPH?_XMMG;E*RPE83'"9C3+H\%HBQ-R!=&(
M$+A72+QB.)(76F;4,Q!W%T.(_P#_ "#I[=)F8,Q$>UT"# $&*XPV;I1L$5B<
M&H-T, %3=@WXQ\>=3>KIB(U^L+-O5&S4_P!BXI%)9L6./QN,C[-J]:NSE+0!
MBQHL$A ZKB*C<*1K0(-;N\(\V2D#0FF<=2!$@&J&=BCQ F8+IZ #-6? D(L2
M%(.9$B.EYC=V3<=QG'F/,Q07MF'NI?)86W PM?9.[(V&+!B-E(U($[%G&0XD
MXU[&"/ ,%\M!:)1@A0&<%T%K0;E'AP<7U;P7<]DO+IPB<(NU1_!?<;(RFVXO
MJ[5A"2W46I;TIW-&YYPEDEZ6LGS7T?T#=-L\5.L_+^<=N.\\>\>TO)]==]9_
M+K'^)5-QLBM?I9S+R)=>_P"P.NZVE2GT<KGY4==OOR>S/]<HK_#9_P#BO-3\
M#E;%L?A\G:GD]F?ZY17^&S_\5XX'*V)P^3M3R>S/]<HK_#9_^*\<#E;$X?)V
MK'E"6P@1IV0-']>A##IRQ9]O2B4W8-.G91\V%C&O;EV921Z<D2;QH.8H?/\
M*NWSILT;XJ.%TD\G Y6Q.'R=JR'D]F?ZY17^&S_\5XX'*V)P^3M3R>S/]<HK
M_#9_^*\<#E;$X?)VIY/9G^N45_AL_P#Q7C@<K8G#Y.U/)[,_URBO\-G_ .*\
M<#E;$X?)VK&N"NP+0F-".I#KPV,F42#D0(<839$F5;B>FO95<:P4-8NGR(SI
M\R[(*M4E<&73QKVYR3Z<)?/<#E;$X?)VK)>3V9_KE%?X;/\ \5XX'*V)P^3M
M3R>S/]<HK_#9_P#BO' Y6Q.'R=J>3V9_KE%?X;/_ ,5XX'*V)P^3M3R>S/\
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MRBO\-G_XKQP.5L3A\G:GD]F?ZY17^&S_ /%>.!RMB</D[4\GLS_7**_PV?\
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MMK5+ Z%AUG1(%+YR&K&15BRF86Q>Y>"57%0Y XXKG(#F6<YR(@H<Z(0*$TR
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M1D$AY!A->7/OM9\T.ONO 5O&M5V/X+<*T:FT1/W;M[X(!ZGPTE"$;.!55KB
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M[8N!D(HB#-BGN'E69,069K,"0]VE\O7E&SUDX6;+X?+U\])3/'Y?X^$7YCX
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MEUIP7',B9)I@*F6CG!5KY>*J3A$X1.$3A$X1.$3A$X1.$3A$X1=M_P#@I/\
M/O=7]4J.^^+.YK#^)?T%D?:SGL2ZV!V!?2VE]G*^U'7<YYJ9;(3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$4%41_)+6_;K:7WWCS)W>^2%BWOO*
M*G7F*R3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$4$[/?H]7%^H,@_R>?)&8YQZU!R/,?4
MOEP;8?I+7C^TN5?>:W/H[L=[A63]PEOZ;5HRV^Z]I??(_ME=C*)0;QE0=#P,
MCKM;]Z22J0NKFCARJ@@NB:N/MI>$M2L821E4(C<D6C:KK,31+?-NQP<DFTA?
MD6@MFH35:O,,W6?CHL;L4?.QVS\I)0YE]I6RR9>Z<F&&$^6F(K8<:)##Z7IT
MU-&F&&EQNU&"]1#A=DC)6"Z3F9M\NV1LQ\!C9:"X1&QX$,OA,?<)NRHHVI#R
M0!>H<5U\MY8T_AFZ.V$1*2DO-B48V,N4"0F1YJ'9')2\$V"?8N9$79QX>(!-
M29A9#,@];AA8T6BY7438L6K;%-'#W%C1&QK(LR*V$R"V)(2CVP6%Q9#:^ PB
M&TO<YY:T&Z"]SG$"KB34KR5J,,*TI^&Z(Z*YDY,M=%>&A\0MBO!>X,#6ASCB
M0UH;4X #!<U%0+[;V^R/8:QWWK_XJ<4[BIB&R&N=EJT-0C8UK#Y"*6&GXRM-
M[(QB<\9-B0#-1EVPKC::0-W../2+-FX60;89^1FA9<JYG;&2GNQN+NK8S)BS
MYAD:0,6&X.9$W&7W6"XM?B'3%FL(TN JO22_;"8#]Y34G;T/<W0WP9V Z%."
M&]MU[#%C;G&:"W"[!GW@BE :!<'^JZZ[#86%N4,>FCIEE,ET<>NNE.FJ[>$R
M=1/'KI;RO2G2*F'7772OE.L_F_\ 7\_KOOY?2=D30ZQ9MKN$';V:=%09N7!R
MI2HU4IH5%8A++4EG#!S=W(TT(EHQ&=0:$::KT_:IOOZ^Y?#,._+W,_D_9'@8
M_&F?WECVZM+PG_XR_P"TGM4WW]?<OAF'?E[CY/V1X&/QIG]Y.W5I>$__ !E_
MVD]JF^_K[E\,P[\O<?)^R/ Q^-,_O)VZM+PG_P",O^TGM4WW]?<OAF'?E[CY
M/V1X&/QIG]Y.W5I>$_\ QE_VD]JF^_K[E\,P[\O<?)^R/ Q^-,_O)VZM+PG_
M .,O^TGM4WW]?<OAF'?E[CY/V1X&/QIG]Y.W5I>$_P#QE_VD]JF^_K[E\,P[
M\O<?)^R/ Q^-,_O)VZM+PG_XR_[2>U3??U]R^&8=^7N/D_9'@8_&F?WD[=6E
MX3_\9?\ :3VJ;[^ON7PS#OR]Q\G[(\#'XTS^\G;JTO"?_C+_ +2>U3??U]R^
M&8=^7N/D_9'@8_&F?WD[=6EX3_\ &7_:3VJ;[^ON7PS#OR]Q\G[(\#'XTS^\
MG;JTO"?_ (R_[2>U3??U]R^&8=^7N/D_9'@8_&F?WD[=6EX3_P#&7_:79I_@
MW!)[L?,=LV=T+?3-M$XS4#F/IY)I1_T>N7*6$D1SZSBR83-UYPF/9X_->Y.,
M$O(_*ABGVHKWGKWL_L^3D(-F&4@[B8L2:#^'$?>#&P"WZ1[Z4O'*F>*]MV&3
MDS.Q+0$S$W00V2Y9P(;*%SHP/T;6UK09UXEV29Z(U(K2SZZJ>91Q4,?LR#W#
M8@0J[.R-M%!D4HM"#NK!)28^[E#=N$28-;! NFRBZ>;=5NF2677:ILN\E-:7
MW:]@ZE[VX*5II S.9K3U%885(/#I.QFQIJ$MJB3$/J!1DE:LJ&7PR?QZNE"6
M6:8S&:&6LY5'QOTFNDLV&]E7#7H@\0<,V?:SI!9'!?=KV#J3<QE=-3EFH;IN
MW-0KU,L>H%"HJ0@CRSK_ *Z3L7N^070<FTH4. ,$)M$1O<XQ*3J+'$#N.:[V
M*)$TX@S;=DY4JP8.6ZV:^[7L"&&!HT Z=*DP/8'AG2&/RF6 ;OUZ-1>#,&92
M:2(5L"-?A(F.)OV(P0^D91K.U609J<($QK, L06;X'ER#+ /V][=(?/7W:]@
M3<]%TURTK:9=AI/$*!D.SV:P.4TE'8<1G.4X@$LDL[&'00[RJ?RQ56,2$DG)
M'SY\GZ(',A:BZKHOG@/Z^:O\_'!?=KV#J00P32F/&2O%6(;76?IB&<II:;41
M,I(9/AXC6EXR!K&; FF$8!BI$;,0\+&[2F#:2!AHLN@L0<BB3EP+R;ODRK1C
MDT4XONU[ EQNJO-7:L9G*?#A3,B(]G<-!XG)!#GEA Q/K\']OBT#8!S<A>3(
M>WZG7:CN,H1^,R4[F;1ZS'=A8Z>*XN,F <BX;+[M>P=2;F/JG5I^-(Z5IL-N
M#PS9I35:7XA:E/1RL[:31PAAV97.VC.+PMV-:E2,9<^D)WB@UE,=9O$,Y0!R
M<9/HYWEET73:=8]Y<7W:]@0PP"1=-1GFMUFLE\.6MI:\@-A6_0D&G [)U@1B
M$MOL?'I*.491-E/7*1$(5G34BQ63@Y%A,/(NVZ*N<8=MSB>&8Q7%SVONU[ F
MYX5NFFO&BER"5+JS:$1!3^MD(O/H-*&71&.3"'3TS)(T=8^55;]NA1L1)G8Y
M\C@X17;*YMG"G23E!9NK\Q9%3#%?=KV#J47 ,"*'SK;?9HI'ZD8_$,K_ !WB
M^[7L'4EQNK:>M/9HI'ZD8_$,K_'>+[M>P=27&ZMIZT]FBD?J1C\0RO\ '>+[
MM>P=27&ZMIZT]FBD?J1C\0RO\=XONU[!U)<;JVGK3V:*1^I&/Q#*_P =XONU
M[!U)<;JVGK3V:*1^I&/Q#*_QWB^[7L'4EQNK:>M/9HI'ZD8_$,K_ !WB^[7L
M'4EQNK:>M/9HI'ZD8_$,K_'>+[M>P=27&ZMIZT]FBD?J1C\0RO\ '>+[M>P=
M27&ZMIZU#M-T!49AM9&1*(XN<AMQ6*'9=^G)(EY$<.+XHLVWR(&$NE/(I_\
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M\M!4VKLM+<1@UJNM@ONU[ FYC' U%,,=.7QIT+TR-G^%^(#M) 4O[6P<!(3
MY7S V]V,"MA+V;QA &ZDT5:$59_BS<G(TVDT<<2%@BMFN#0/!U2F+7 DSR67
MW:_4FYZ+IKY].2UB:VIHR!DM]UM$^H!,[@UVC<0DT]KEW>@2".&3&7F& G#%
MV=F4_'#0O0/LL"S//#73(<Q=R>*AL7BID\U8XK[M>P=2G<A@2" <CB5.*8C1
MM6T"=(I2^JU+D#"U31>JT[>SSL,8*0'-C#A^_A^,Q[/M&[<.]8EW&:[##S<2
M^8DUOF,7C9=5?=KV#J47!2MTTRKC3I7@JUEHE>!"0"J8F]26R2BC0*_DS&MK
MC^FSH"PDB;I6/ORJ,;F1+-BQ-8,7W0MXXZP;/LV+Y)LJHJS<X)+[M>P=2%@&
M;2.>JB<+8>B[O9&S=6),I"H%;,%DT#B\9C$OMOT1(;6>SNM@EDM<X!%WDO;G
MBW0]B9[%.$D&:ZK@@P=^:XYX8=]8K[L<<N(<Z;F*5IAKQUTQ6]"#OAUGU[/;
M [9HDNM2;%^3N' =?#%YZKA@ET^8%24_R0G.>,3'BB PD.)O3F3)L/(CG[!X
MJB\9N$4U]VO8.I-S&'!..6>-=2]5Y*?#B'0B*661M^AQU>3HJ3!PV;D+W9LH
MM)S(-99N=%A#CJ<)#B+\"NV<)G6K9PHL%R;K^E,&G22G>*^[7L";F/JG#//!
M:?=-B:+TO9=7TL04A4AN2SK1K2N&M4"+;^;8H-G9SITW%38G#EY?Z?[C31-M
MV\7638=9N&:F#AMWDC_W.+[M>P=2"&"";N !-<:8+)6E-M$ZHM!]1IY6-JW6
MC2\^O(=66%A/6DG,16 L%";IBQ&O9>B27-&AS,Z5#,VH]WY0)%)49=YM6(C)
M1=?=KV#J00P=&%:5QI5>C3UG^'9<E1(W"%GU.#0(L!6).R&[V]AZF51&[91&
M)1*'V._1G'F$9D1*0$\8B.9E56>9:3MG04=@N105:IK[M>P(88!I=/%GCS>;
M%;J-.^':8,5M'A5JT<0/W&*9G:G!M+R;+%[(#$G+YD-)PD;A-NWDE8DWHLHS
M&.!*+I(B[&$FK+)==@[317W:]@ZDW,8\$X9YX<ZUZ267X8<.+R2/RN^];XX>
MA^!S*5A36Q08<5CG<8D_<)DJ)H>ZGR;H:YCTP^2+G&CI))T)/Y8"GZ+=[G@C
MDONU[ FY\@_ZM*U?NVM F&PY;7:4EZZAD@5KZ@9_6QV3W0V%"[G1V#-VJ"BX
MBL$'<S1=2EZR<UFV[56$]/6Q%2<Q%J.S5<DFR;A?=KV!-S%*W3IUX4Q*G <(
MT<+S^552*E]5D;.@HUX8FE?,K>S<S**"AJ8Y8F1D4;1F.98.S%(F0RQ5=^T0
M3&(F0ZK_ ";IE6&3A?=KV#J2X,[IH>=04XOOPM.B=0BQ-TT;*,KOLTS4<"?Q
M2\QQ\4[FP&$NYV0'O2#&?YH-4^AWT<%MU,.W"CJ16#7 E!'/.:A%7"^[7L"G
M<L^"<,3GKI\<QU*8&2N@)$U9T<86-3#P_2@@V?N ,VNU!8E5P*,]J]24U8#-
M.;9+Q$3&\VZZ4A(G<&+,&NBJ@46:+)YX=+[M>P*-S&'!.. SQYEJH*?>&=*)
M((AL;O'78_+9!+W%?@HR&V%$DCIF<-D&3E:)BQ3.>K/7T@Z0)C%$Q;9%1VMT
M2'=(I*9/FN*J^[7L";GR3KTJ6H] M/I=E#L(J2@,ESL,%(91 < -GO2^<VC4
M2>AATJD$3Q82QQE(0L:(R( P/E!/3MD'>G!#4@LW7(LTUE]VO8.I1<;J]:T;
M,CX>Z<NED!5LZDTIO WP<9-HDK>#=.11,D?D\=A(4=(A&<VQ>B'Y.93")1-F
MR?(H.5I+*HV"Q2])G1;5TONU[!U*=S'U3KT_&@K]S9[X?=:DO0UA652L(,=2
M[. YBI7=R $DE-D@$8E:\468DYLV<H'VT8FT-D;L6LE@[: I;&2SE))@>%KN
ME]VO8.I-S'U3KT\WKP6D1>S/#?EF%[N1]B56T&:V3QG7%P&2]NXC1,3DA! 5
M@/P(.UIQ_P"2:$9"1=P<6N2P89EYQ'9+'!*+UV+R[57W:]@3<QAAGEFMBDDJ
M\."' (C*I9<= QJ,S\<R,08^=OX:*#S 01>9CV1:,D7L[1:G!:[U-5KT1&JN
M&>"R*^"BV':"OS%]VO8.I-S!R:33/-;Q7L<TFML))Y+5DEK.QX["BS\#,#L&
MMAQ*A$6-"V+<H0%R B$E[UH(>M!;MH46;OED%,1KMJ0^3MHX16S7W:]@ZE!8
M!F*<]54>B-F?#RN"F%;]E!VFJ<K,G:DOK&$FIOLI'O\ XB=17+M;K(KDC-46
M$6DC\+UA*U86Z(/RHJ(O!<C?N,1K_!9-?=KV!9&$ :4)- :8Z?7SJVBH+2%"
MR05-JRJK\+<DZ+MQ':P];:O=@&VS".X2YZY%Q#J8=GWK9K%E$Y$NX089HIA5
M$R>6?3-3!7M?=KV#J4;F*5NFFO&G2L>Z0T-8VDUHYY/*@:W.](9"&E3KW/BE
M8RY;&.,YAT*PAF<TZD/9-2)$&4G1']C^G:\><IF445!W?;CI?=KV!-S%*W33
M7C3I7I#G7A^EG-@-!EE4J_<U0Z196<BTN]NOG7SIP<6C"*,R\G-LNHYFI)VS
MJ-=>ENVO74A9O >7?11HY:)+[M>P)N8PX)QRSQYEI0.7Z.2(N_("35-/J;;5
MG%[$:7BSV1B[N'ONY/:4NJ) 7YBC8.15F,QF,44 CYLZ3PB1Z4N'D-#DG,E!
MEAZ"^[7L";F-1KJQU5^.E:3.;U\.N%MZ*DZ,HJZ2U-=UE3VL,+J"7<T7K"#G
MZ_JV>683PE$JZFF8E-PX[@V43;BTWF)+J0'1"&3?OR^.&:^[7L'4IW,8BZ00
M*TQKF!^JFXBMH 'RK#$K8],#N[L9"B5/>>7:BWZM(:=6&-@A*O\ )6;8XRT<
M9=FPC(2_!]OFA)^:#L6:RSLHP1<+[M>P=2C<QCP3AGGA36L.=D_AQQAW-V$C
MM^A03ZLVBCZQ696^F#!S!6R<QRKO/.7(.9TFI'LOI_AW",42N+5?.6]XQW!/
M(OG@TR7W:]@ZDW,?5..6>*QS OJ#);/U[@%?1X190#8^M[LLR#6?!;%?R."*
M!:2)58*,IHE14H=H%<RSRT6B+-8:NLBS7!E6S[M-?K!/I?=KV#J3<Q0DBE"!
M0UKB"?T5G/9HI'ZD8_$,K_'>+[M>P=2BXW5M/6GLT4C]2,?B&5_CO%]VO8.I
M+C=6T]:AS82@*CCU(6D<#Q'%F4%0LV]8.O3DD7\@Y0:Y9)*^1<F%FZOS<NOE
M^8LDHGE_[98=]?Q<D.=48Z1H"@M;0X:#I*^:'MA^DM>/[2Y5]YK<^C.QWN%9
M/W"6_IM6CK;[KVE]\C^V5SPC-0X'/M38I"JU%4%'SI34BF;4@^QQ/?(#&;8*
M;%2:/5[+II5\LJF1VTRB\6A Q Y,Z^:B7L/#Y@_HT-,>D^BRZOG'EG6I&@6G
M%C3#IZ(QMJ3<M&D&V*^)*MD(;X\*#,PYF'*NB1(SBR#'+FQ77]T<R[=Q'H6V
M="BR$.'!;*L<ZSY:/"G'6JQDP9Q[(,2+ B2[Y@0V0FWHD$-,-I9<#KUXX]<R
MPHN?A$\F4.E3T:2DT4E)V/2 @'D(V7"'QH.3<L";L;*0STB(D;!P\;K*M38P
M@]8%$,\'K1TX06P5R][ B0XT&%%A!S8<6&R(QKH;H3FL>T.:'0WAKH;@#0L<
MT.:<" 0O'1H;X46)#B%I?#B/8\M>V(TN:XAQ;$:7->"0:.:2'9@E69NOQ ]O
MK\"]Q"<73(AE;X)J-VE15LW%5-4+%CE_TIL$JTK5A%XBZ0;I?]E%8H+(/N\.
M\^UG:RBJRBE=*6'9<D_=8,I#=,8$S4P734T3KWQ,.B103F0US1J  "[TS:UH
M3;=SBS+VP<0)>"&R\N =&XP0R&>=S2=94<:L?TZPS^Z3/_0<GYQ]D/<B:\J5
M_.2ZRL;NE+^3,?E8RKYRZ56G"+F^U'\-6CMA:2U:/24ML**L/:63[-1A&?P]
MK$"M(TCC0S$0^&26TQC^,8'/HV=P+_(2=X3D'YHB-(NFV>?D^D.O'VIV03DA
M.6DR&R1? LZ'9T3<(IBMG)O?KG-=#EW")<OLN\$;B^I< :9KTUGV-*SDM(N>
MZ<;&GGSK!&AB&Z6EMZAI:^.TL#KC[V)W5M+KB%7=+PMKISIB)6WG+(HB[DT.
MIJT74,4!V'BJ#JB^+'"5E7TO5FV4/QKTL4<%Y/&#QB$A9,^DHB'R!@;7:Y*H
MDQX_O_*.4WW%E1"BD0XLW+"+?@4?,R4N^8CPMQW7=VM#846&V,^&(;HT-S <
M6N=U.T4SO:',;I#J^'+1S#N1JLEYN*V#!B&+N6XEQ<]CG0FO+VPWAQ&8&:+:
M&AH$!W(AJD[J>Y+(UZ2JR+3"01PE<<71I6R)!M*,HT]&AK _!(^&M CE@KBD
M;>9=JQ,6)*K/HV:+GAG3;/!MM/COLF+N$U*0)\S,2%#B-E8AFY=EG/G&1'.9
M&>^6;A5@^E<YH;$8QCKPR=9383;2A;K+S,:3W"'$>QTRP2T9\^V5<QH="8V.
M=#S]&UKKS'.>VBGBF_"<%"-EJ]A-IVE7MQ5VPV4L_5:]Q5<K6;&"4 M>(558
M=@@1BY*2P^+.2XDPRA;\DB=BG9)CTX!E ^6;C'R*[OIS79,Y]GQXLM+1Y6.Z
MSY>TI)TQO>(V/*Q9F! >Z[#C1 Q[71FM+(MTT>U^&(';EK :V=@PH\Q!F((G
M9B0FFP=W88,Q#EXT9H)?#AES7"&7!\.\. 6XZ:\B?"]F\D(1XU$KD@,QI@WK
MHZV44N.,0ZXB;5O$A]J/*2>QUE6_=?(6D7F&5F,\A0X8VBB;5X%SRD:SYBQ:
MOL&O==V1P8;7LBRD>%-LGQ9^](D65:3%=+"<$0S&[F6;"$N;SG&+4.&YAKG%
MM>FVPXL1S'0YF#$EG29G=\PX<PX"&V8,J6"!N(CNB;N+H:(="WAU ! U>U/#
MFE5%0NWYM<MUU7!FE7VQ-:2#"\Q=H'"]H6''ZS@5M11A$&X6 NTPXJ?PR?,'
MXTQ/EH@@!59K,Y(F.>KMFV?++6]#G(TK!E).9C&8EH,X]UZ68R6@/F8TK%=%
M+HXON@1H#@YD#=2\&L,N:"1QS%CQ)6%,19F9EX0@S$65:VD=[H\9D"#,,$,,
M@FZV+#C AT4PPP@A]TD!6+H?PQ8PYNO3Y],K(CMYZ\[#658U9%B<)C]TU8\1
MD\"K+">+-QV-JP&N)(7C)%L8#/0$TCS%<26[8EQZWF;AKF@IT)WLBB"3M408
M$23GI&7EYEC8SY29!AQY@P07;VCQX;(C2Q[8D%Y#VU:X5!!7=E;$89FSS$C,
MFI.;C1X#G0F3, [I!@;M0;O"@O<PAS2R(P%KKKA@11<+7/6KS2<(G"+MO_P4
MG^?>ZOZI4=]\6=S6'\2_H+(^UG/8EUL#L"^EM+[.5]J.NQ+N+K59]U7)54V@
M[8*N"B.K&^=2&,R9=,>YPF&P<6I<372+=OFDIDN/</(.>Z+ONLL<!:>#7-3!
M3ISCUCJ9;*! '_LT^87J^L*I,IT0V&P+PZ9 P<3,+5G0OA'C$X1E*V0U&P)O
MHQ?EVV7;$)Z?.&F8P=EG&YU'G==GR^.(-_+V0YN0<A1[5T79E-X<U2_&F(#@
M /UKQ56A6GJ%>PN%7);DVK86\"9X>*I;<BK8 7>SN3NX[LS0@ ?!(2U#0Q<
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M7&I9>FFX,EV-)[6@)13B9F-[GT[9D&K9[$#O=@N-?JYB"VN\FC#6\T[5:Q8
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MJD2;0*_"H6-C&HJ'Y8C]7_!MJ8BW4D37!NI*=)-V"]Y7BV[P[;=IKC6%>/\
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MJI@168S,^S8 WQ20QBJK3-U:!4D]?AK5C@F27&/AJ]5QR0&ZYD<;EPT";F#
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M [#K;M!SX,2_#$2#'AS)>V!":Z-,0F7(<:8(:#&>QE0+^&+B07.<3%H7=38
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MIF925;Y'K4G<I&])Q:0./+!CI3%T-<9]HL,^D5%4>OG9MU/FK)=_]*F&/?\
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G'K-!HUQ574PP[7<K)()_+\Y53##KO+J0UU1AIXE!>"",<OC2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>21
<FILENAME>filename21.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>New York</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Menlo Park</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Washington&nbsp;DC</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>S&atilde;o Paulo</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>London</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Paris</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Madrid</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Tokyo</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Beijing</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Hong&nbsp;Kong</B></P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g923792g95w47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Alan F. Denenberg </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Davis&nbsp;Polk&nbsp;&amp;&nbsp;Wardwell&nbsp;<SMALL>LLP</SMALL></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">1600 El Camino Real</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Menlo Park, CA 94025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">650 752 2004 tel</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">650 752 3604 fax</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">alan.denenberg@davispolk.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;31, 2015 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>VIA EDGAR </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street,
N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jay Mumford</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Russell Mancuso</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tara Harkins</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jay Webb</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Re:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Penumbra, Inc.</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Registration Statement on Form S-1</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Filed August 14, 2015</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>File No. 333-206412</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are submitting this letter on behalf of Penumbra, Inc. (the &#147;<B>Company</B>&#148;) in response to comments from the staff (the
&#147;<B>Staff</B>&#148;) of the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) received by letter dated August&nbsp;28, 2015 (the &#147;<B>Comment Letter</B>&#148;) relating to the registration statement on Form S-1 of the
Company, filed on August&nbsp;14, 2015 (the &#147;<B>Registration Statement</B>&#148;). The Company is concurrently filing Amendment No.&nbsp;1 to the Registration Statement (the &#147;<B>Amendment</B>&#148;), including changes in response to the
Staff&#146;s comments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For ease of review, we have set forth below in italics each of the comments numbered 1 through 7, as set forth in
the Comment Letter, together with the Company&#146;s responses thereto. All page references in the Company&#146;s responses are to the Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">******************************** </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">
 2
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">August&nbsp;31, 2015</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Overview, page 1 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We note your response to prior comment 1. If the cost of your device itself is higher than available alternatives, please clarify your disclosure about cost savings. Also, if you continue to offer previous generation
products that now have more cost-effective alternatives, please revise your disclosure to clarify. </I></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>RESPONSE: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company respectfully advises the Staff that while it believes that its statement on page 1 of the Registration Statement filed August&nbsp;14, 2015
regarding the cost-effectiveness of its Penumbra System ischemic stroke products, Penumbra Coil 400 neurovascular embolization products and Indigo peripheral thrombectomy products is accurate and supported by the available studies, it does not
believe that this disclosure is material to investors and has chosen to delete this statement from the Amendment. Similar statements regarding overall cost savings on pages 3, 12, 48, 66, 75, 77, 80 and 90 of the Amendment have also been removed.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Capitalization, page 42 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We note that you present $129,070,000 as your actual historical capitalization as of June&nbsp;30, 2015. We also note the same amount is recorded in your consolidated balance sheet on page F-3 as total assets as of
June&nbsp;30, 2015. Please revise the filing to present your actual historical capitalization as of June&nbsp;30, 2015 or tell us why no revisions are necessary. </I></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>RESPONSE: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has revised the disclosure on page
42 of the Amendment to correct the amount disclosed as its total capitalization as of June&nbsp;30, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management&#146;s Discussion and Analysis
fo[sic] Financial Condition and Results of Operations, page 48 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We will continue to evaluate your response to prior comment 3 when you file the subsequent amendment that you mention in that response. </I></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>RESPONSE: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company notes for the Staff that
&#147;prior comment 3&#148; relates to two prior comments from the Staff: (1)&nbsp;prior comment 5 of the Staff&#146;s comment letter dated July&nbsp;6, 2015 (&#147;<B>Prior Comment 5</B>&#148;) and (2)&nbsp;prior comment number 3 of the
Staff&#146;s comment letter dated July&nbsp;24, 2015 (&#147;<B>Prior Comment 3</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Prior Comment 5: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company notes for the Staff&#146;s reference that Prior Comment 5 reads as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>5.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>In an appropriate section of your prospectus, please describe the seasonal variations that you mention in the first bullet point of this risk factor. Include disclosure of when the cited major conferences occur.
</I></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">
 3
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">August&nbsp;31, 2015</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In response to the Staff&#146;s comment, the Company has revised the disclosure on pages 55 and 56 of the
Amendment to insert summary quarterly results of operations data for the six quarters ended June&nbsp;30, 2015, as well as disclosure with respect to significant factors affecting the Company&#146;s quarterly results. The Company supplementally
advises the Staff that, in the Company&#146;s response to the Staff&#146;s comments dated July&nbsp;20, 2015, the Company noted that it had modified the disclosure on page 32 of the Amendment to remove the word &#147;seasonal&#148; as some of the
factors described in that bullet are not seasonal in nature, but instead actually occur at irregular intervals. In particular, the timing of major conferences occurs irregularly during the year and from year to year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Prior Comment 3: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company notes for the Staff&#146;s
reference that Prior Comment 3 reads as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Please address that part of prior comment 8 that sought disclosure that indicates the extent of the impact of new product introductions during each of the periods presented. See Regulation S-K
Item&nbsp;303(a)(3)(iii). </I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company respectfully advises the Staff that the disclosure on pages 51 and 53 of the Amendment were
revised in response to the Staff&#146;s comment. Specifically, on page 51 of the Amendment (relating to the six months ended June&nbsp;30, 2015 and 2014), the Amendment notes that: &#147;Additionally, approximately 10.4% of the increase in revenue
for the six months ended June&nbsp;30, 2015 came from the sale of new products, including our Indigo peripheral thrombectomy product, our Apollo System and our Benchmark neuro access product.&#148; On page 53 of the Amendment (relating to the years
ended December&nbsp;31, 2014 and 2013), the Company notes that: &#147;With respect to the impact of the introduction of new products, 12.1% of the increase in 2014 revenues came from the sale of new products, including our Indigo peripheral
thrombectomy product, our Apollo System and our Benchmark neuro access product.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company respectively advises the Staff that such revisions to
the disclosure were made in prior confidential submissions or filings of the Registration Statement, and that the Company inadvertently referred to Prior Comment 3 as open in the Company&#146;s previous response to the Staff&#146;s comments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Revenue, page 51 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>4.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Please quantify the extent of the decrease in sales of your neuro embolization products during the period ended June&nbsp;30, 2015. Also discuss the reasons for the decrease. </I></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>RESPONSE: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has revised the disclosure on page
52 of the Amendment in response to the Staff&#146;s comment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Business, page 65 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>5.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>We note your response to prior comment 5; however, if you currently derive revenue from products that have been demonstrated by studies to have
limitations or to have performed at </I></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">
 4
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">August&nbsp;31, 2015</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>
rates lower than alternatives, it is unclear how your disclosure about studies presents a balanced presentation of your products. Please advise or revise your prospectus accordingly.
</I></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>RESPONSE: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Comment references
the discussion of studies on page 65 of the Registration Statement filed August 14, 2015. As noted in Response to the Staff&#146;s comment 1 above, the Company has removed this discussion of studies in relation to cost effectiveness from the
Amendment. In addition, the Company has revised its disclosure in the discussion of studies on page 80 of the Amendment to clarify that the studies indicate that the original Penumbra System showed lower rates of performance on certain metrics in
comparison to current competitive devices and current generations of the Penumbra System (including 5MAX and ACE). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Indigo System, page 86 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>6.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We note your response to prior comment 4; however, it is unclear how your disclosure added on page 87 addresses the significance and limitations of the initial results. For example, are results based on 38 patients
reasonably indicative of results to be expected from a complete study? Why or why not? </I></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>RESPONSE: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has revised the disclosure on page 88 of the Amendment in response to the Staff&#146;s comment by deleting references to the initial results from
the PRISM study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Underwriting Page 122 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>7.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We note your response to prior comment 8. Please disclose in your prospectus your prior relationships with Perella Weinberg. Also, it remains unclear why you believe that your agreement with Perella need not be filed
as an exhibit if it was not made in the ordinary course of your business; please expand your analysis of the materiality of the agreement to address the nature of the agreement, its significance to this offering, and the cost relative to your net
loss. </I></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>RESPONSE: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has
revised the disclosure on pages 127 and 128 of the Amendment in response to the Staff&#146;s comment to disclose its prior relationship with Perella Weinberg. In addition, the Company has filed the Company&#146;s engagement letter with Perella
Weinberg with the Amendment as exhibit 10.20 to the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">******************************** </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">
 5
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">August&nbsp;31, 2015</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company acknowledges the following and will also include acknowledgement of the following in any request
for acceleration of the effective date of the registration statement relating to this offering: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the
disclosure in the filing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">******************************** </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We appreciate your assistance in this matter. Please do not hesitate to call me at 650-752-2004 with any questions you may have respecting the foregoing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Alan F. Denenberg</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Alan F. Denenberg</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top">Adam Elsesser (Penumbra, Inc.) </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sri Kosaraju (Penumbra, Inc.) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bob Evans (Penumbra, Inc.) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Johanna Roberts (Penumbra, Inc.) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rezwan D. Pavri (Goodwin Procter LLP) </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
